0001213900-24-09844510-Q InMed Pharmaceuticals Inc. 20241114202411141615291615301615300 0 0001213900-24-098445 10-Q 70 20240930 20241114 20241114 InMed Pharmaceuticals Inc. 0001728328 2834 000000000 A1 0630 10-Q 34 001-39685 241462508 1445-885 WEST GEORGIA ST. VANCOUVER A1 V6C 3E8 (604) 669-7207 1445-885 WEST GEORGIA ST. VANCOUVER A1 V6C 3E8 10-Q 1 ea0219774-10q_inmed.htm QUARTERLY REPORT Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 10-Q Â â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended September 30, 2024 Â or Â â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEÂ ACT OF 1934 Â For the transition period from _____ to _____ Â Commission File Number: 001-39685 Â INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Â British Columbia, Canada Â 98-1428279 (State or other jurisdiction of incorporation or organization) Â (I.R.S. Employer Identification No.) Â Suite 1445 - 885 W. Georgia Street, Vancouver, B.C. Canada Â V6C 3E8 (Address of Principal Executive Offices) Â (Zip Code) Â (604) 669-7207 (Registrantâ€™s telephone number, including area code) Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Â Trading Symbol(s) Â Name of each exchange on which registered Common Shares, no par value Â INM Â The Nasdaq Stock Market LLC Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜ Non-accelerated filer â˜’ Smaller reporting company â˜’ Emerging growth company â˜’ Â Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act): Yes â˜ No â˜’ Â As of November 14, 2024, the registrant had 718,032 common shares, without par value, outstanding. Â Â Â Â Â Â INDEX Â Â Page PART I â€“ FINANCIAL INFORMATION Â Â ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1 Â Â ITEM 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 21 Â Â ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 30 Â Â ITEM 4. CONTROLS AND PROCEDURES 30 Â Â PART II â€“ OTHER INFORMATION Â ITEM 1. LEGAL PROCEEDINGS 31 Â Â ITEM 1A. RISK FACTORS 31 Â Â ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 33 Â Â ITEM 3. DEFAULTS UPON SENIOR SECURITIES 33 Â Â ITEM 4. MINE SAFETY DISCLOSURE 33 Â Â ITEM 5. OTHER INFORMATION 33 Â Â ITEM 6. EXHIBITS 33 Â Â SIGNATURES 34 Â i Â Â CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Â This Quarterly Report on Form 10-Q (this â€œQuarterly Reportâ€) contains â€œforward-looking statementsâ€ within the meaning of United States Private Securities Litigation Reform Act of 1995 and â€œforward-looking informationâ€ within the meaning of applicable Canadian securities law, which are included but are not limited to statements with respect to the Companyâ€™s anticipated results and progress of the Companyâ€™s operations, research and development in future periods, plans related to its business strategy, and other matters that may occur in the future. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. We may, in some cases, use words such as â€œanticipateâ€, â€œbelieveâ€, â€œcouldâ€, â€œestimateâ€, â€œexpectâ€, â€œintendâ€, â€œmayâ€, â€œplanâ€, â€œpredictâ€, â€œprojectâ€, â€œwillâ€, â€œwouldâ€, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this Quarterly Report include, but are not limited to, statements about: Â Â â— Our failure to satisfy any applicable listing standards, including compliance with Nasdaqâ€™s minimum bid price requirement for the continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2), and the actual or threatened delisting of our securities by Nasdaq; Â Â Â Â â— The efficacy of the Companyâ€™s Reverse Stock Split which was effected by the Company on November 14, 2024, including its direct and indirect impact on the liquidity of the Companyâ€™s common shares, no par value, and the ability of the Common Shares to trade above $1.00 for ten consecutive trading days on Nasdaq; Â Â â— The Companyâ€™s ability to stem operating losses and the Companyâ€™s ability to obtain additional financing to fund its operations; Â Â â— The revenues of BayMedica, LLC (â€œBayMedicaâ€) and the commercial viability of its product portfolio; Â Â â— The Companyâ€™s ability to effectively research, develop, manufacture and commercialize pharmaceutical drug candidates that will treat diseases with high unmet medical needs; Â Â â— The continued optimization of key, proprietary manufacturing approaches and technologies; Â Â â— Our ability to commercialize and, where required, register products in the pharmaceutical R&D programs (â€œProduct Candidatesâ€) and those targeted to the health and wellness sector (â€œProductsâ€) in the United States and other jurisdictions; Â Â â— Our success in initiating discussions with potential partners for licensing various aspects of our Product Candidates; Â Â â— Our ability to successfully access existing manufacturing capacity via leases with third-parties or to transfer our manufacturing processes to contract manufacturing organizations; Â Â â— Our belief that our manufacturing approaches that we are developing are robust and effective and will result in commercially viable yields of cannabinoids and will be a significant improvement upon existing manufacturing platforms; Â Â â— Our ability to successfully scale up our IntegraSyn approach to cannabinoid manufacturing. InMed has created genetically engineered microbes that produce proprietary enzymes, which are then used to optimize subsequent biotransformation reactions or other cost-effective manufacturing approaches so that it will be commercial-scale ready after Phase 2 clinical trials are completed, after which time we may no longer need to source active pharmaceutical ingredients (â€œAPIsâ€) from third-party API manufacturers; Â Â â— The success of the key next steps in our manufacturing approaches, including continuing efforts to diversify the number of products produced, scaling-up the processes to larger vessels and identifying external vendors to assist in the commercial scale-up of the process; Â Â â— Our ability to successfully make determinations as to which research and development programs to continue based on several strategic factors; Â Â â— Our ability to continue to outsource the majority of our research and development activities through scientific collaboration agreements and arrangements with various scientific collaborators, academic institutions and their personnel; Â Â â— The success of work to be conducted under the research and development collaboration between us and various contract development and manufacturing organizations (â€œCDMOsâ€); Â Â â— Our ability to develop our therapies through early human testing; Â Â Â â— Our ability to evaluate the financial returns on various commercialization approaches for our Product Candidates, such as a â€˜go-it-aloneâ€™ commercialization effort, out-licensing to third parties, or co-promotion agreements with strategic collaborators; Â Â â— Our ability to find a partnership early in the development process for our various programs; Â ii Â Â Â â— Our ability to explore our manufacturing technologies as processes which may confer certain benefits, including cost, yield, speed, or all the above, when pursuing specific types ofÂ molecules, and filing a provisional patent application for same; Â Â â— Plans regarding our next steps, options, and targeted benefits of our manufacturing technologies; Â Â â— Our Products being bio-identical to the naturally occurring molecules, and offering superior ease, control and quality of manufacturing when compared to alternative methods; Â Â â— U.S. Food and Drug Administration (â€œFDAâ€) regulatory acceptance of Product Candidates for potential use in the pharmaceutical industry; Â Â â— Our ability to successfully file, prosecute and defend patent applications; Â Â â— The potential for any of our patent applications to provide intellectual property protection for us; Â Â Â â— The termination or renegotiation of our supplier, technology and other material contracts, including the invoking of force majeure or termination clauses, and actual or threatened claims of our failure to comply with any obligations set forth under such contracts; Â Â â— The adequacy of, or gaps in, insurance coverage upon the occurrence of a catastrophic or other material adverse event, as well as our ability to (i) expand our insurance coverage to include the commercial sale of Products and Product Candidates and (ii) secure insurance coverage for shipping and storage of Product Candidates, and clinical trial insurance; Â Â â— Developing patentable New Chemical Entities (â€œNCEâ€) which, if issued, will confer market exclusivity to us for the potential development into pharmaceutical Product Candidates, license, partner or sell to interested external parties; Â Â â— Our ability to initiate discussions and conclude strategic partnerships to assist with development of certain programs; Â Â â— Our ability to position ourselves to achieve value-driving, near term milestones for our Product Candidates with limited investment; Â Â â— Our ability to effectively execute our business strategy; Â Â â— The sufficiency of our internal controls, including any exposure arising from the failure to (i) establish and maintain effective internal control over financial reporting in accordance with applicable regulatory requirements, and (ii) fully remediate any material weakness identified with respect to such internal controls; Â Â â— Epidemics, pandemics, global health crises, or other public health events and concerns, including any future resurgence of COVID-19, and the effectiveness of associated vaccinations and treatments; Â Â â— Consolidation of our competitors and suppliers; Â Â â— Effects of new products and new technology on the market, including with respect to automation and the use of artificial intelligence; Â Â â— The impact of geopolitical, global, regional or local economic and financial market risks and challenges, applicability of foreign laws, including foreign labor and employment laws, foreign tax and customs regimes, and foreign currency exchange rate risk; and Â Â â— Political disturbances, geopolitical instability and tensions, or terrorist attacks, and associated changes in global trade policies and economic sanctions, including, but not limited to, in connection with (i) the Russo-Ukrainian war and (ii) any impact, effect, damage, destruction and/or bodily harm directly or indirectly relating to the ongoing hostilities in the Middle East. Â This list is not exhaustive of the factors that may affect our forward-looking statements. Some of the important risks and uncertainties that could affect forward-looking statements are described further under IA. â€œRisk Factorsâ€ in our Form 10-K for the year ended June 30, 2024, which was filed with the SEC on September 30, 2024 (the â€œ2024 Annual Reportâ€), Item 1A. â€œRisk Factorsâ€ in this Quarterly Report and Item 2. â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ in this Quarterly Report. Although we have attempted to identify important factors that could cause actual results to differ materially from those described in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated, or expected. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made and are based only on the information available to us at that time. Except as required by law, we disclaim any obligation to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. Â iii Â Â PART I Â ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS. Â Â Unaudited Condensed Consolidated Financial Statements of Â InMed Pharmaceuticals Inc. Â For the Three Months Ended September 30, 2024 and 2023 Â 1 Â Â Â InMed Pharmaceuticals Inc. (Expressed in U.S. Dollars) September 30, 2024 Â INDEX Â PageÂ Â Â Â Â Financial Statements (Unaudited) Â Â Â Â Â Â â— Condensed Consolidated Balance Sheets Â 3 â— Condensed Consolidated Statements of Operations Â 4 â— Condensed Consolidated Statements of Shareholdersâ€™ Equity Â 5 â— Condensed Consolidated Statements of Cash Flows Â 6 â— Notes to the Condensed Consolidated Financial Statements Â 7-20 Â 2 Â Â InMed Pharmaceuticals Inc. CONDENSED CONSOLIDATED BALANCE SHEETS Expressed in U.S. Dollars Â Â Â September 30,Â Â June 30,Â Â Â 2024Â Â 2024Â Â Â UnauditedÂ Â Â Â Â $Â Â $Â ASSETSÂ Â Â Â Â CurrentÂ Â Â Â Â Cash and cash equivalentsÂ Â 5,583,039Â Â Â 6,571,610Â Short-term investmentsÂ Â 43,203Â Â Â 43,064Â Accounts receivable (less provision for credit losses of $nil and $66,775 in September 30, 2024 and June 30, 2024, respectively)Â Â 284,695Â Â Â 352,838Â Inventories, netÂ Â 1,220,073Â Â Â 1,244,324Â Prepaids and other current assetsÂ Â 148,882Â Â Â 477,749Â Total current assetsÂ Â 7,279,892Â Â Â 8,689,585Â Â Â Â Â Â Â Â Non-CurrentÂ Â Â Â Â Â Â Property, equipment and right-of-use (â€œROUâ€) assets, netÂ Â 1,343,009Â Â Â 1,249,999Â Intangible assets, netÂ Â 1,742,205Â Â Â 1,783,198Â Other assetsÂ Â 100,000Â Â Â 100,000Â Total AssetsÂ Â 10,465,106Â Â Â 11,822,782Â Â Â Â Â Â Â Â LIABILITIES AND SHAREHOLDERSâ€™ EQUITYÂ Â Â Â Â Â Â CurrentÂ Â Â Â Â Â Â Accounts payable and accrued liabilitiesÂ Â 1,011,619Â Â Â 1,654,011Â Current portion of lease obligationsÂ Â 424,260Â Â Â 317,797Â Total current liabilitiesÂ Â 1,435,879Â Â Â 1,971,808Â Â Â Â Â Â Â Â Non-currentÂ Â Â Â Â Â Â Lease obligations, net of current portionÂ Â 633,783Â Â Â 644,865Â Total LiabilitiesÂ Â 2,069,662Â Â Â 2,616,673Â Commitments and Contingencies (Note 11)Â Shareholdersâ€™ EquityÂ Â Â Â Â Â Â Common Shares, no par value, unlimited authorized shares: 667,013 and 445,948, as of September 30, 2024 and June 30, 2024, respectively, issued and outstandingÂ Â 84,198,673Â Â Â 82,784,400Â Additional paid-in capitalÂ Â 34,821,829Â Â Â 35,368,899Â Accumulated deficitÂ Â (110,753,627)Â Â (109,075,759) Accumulated other comprehensive incomeÂ Â 128,569Â Â Â 128,569Â Total Shareholdersâ€™ EquityÂ Â 8,395,444Â Â Â 9,206,109Â Total Liabilities and Shareholdersâ€™ EquityÂ Â 10,465,106Â Â Â 11,822,782Â Â The accompanying notes form an integral part of these condensedÂ consolidated financial statements. Â 3 Â Â InMed Pharmaceuticals Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED Expressed in U.S. Dollars Â Â Â For the Three Months EndedÂ Â Â September 30,Â Â Â

2024Â Â 2023Â Â Â $Â Â $Â Â Â Â Â Â Â SalesÂ Â 1,264,638Â Â Â Â 901,862Â Cost of salesÂ Â 771,225Â Â Â Â 880,620Â Gross profitÂ Â 493,413Â Â Â Â 21,242Â Â Â Â Â Â Â Â Â Â Â Â Â Operating ExpensesÂ Â Â Â Â Â Â Â Research and development and patentsÂ Â 771,180Â Â Â Â 1,292,093Â General and administrativeÂ Â 1,421,926Â Â Â Â 1,298,731Â Amortization and depreciationÂ Â 54,579Â Â Â Â 54,832Â Foreign Exchange (Gain) LossÂ Â (19,310)Â Â 48,457Â Total operating expensesÂ Â 2,228,375Â Â Â Â 2,694,113Â Â Â Â Â Â Â Â Â Â Â Â Â Other Income (Expense)Â Â Â Â Â Â Â Â Â Interest and other incomeÂ Â 57,094Â Â Â Â 136,043Â Loss before income tax expenseÂ Â (1,677,868)Â Â (2,536,828) Â Â Â Â Â Â Â Â Â Income tax expenseÂ Â -Â Â Â -Â Net lossÂ Â (1,677,868)Â Â (2,536,828) Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss per shareÂ Â Â Â Â Â Â Â Basic and dilutedÂ Â (2.71)Â Â (15.24) Weighted average outstanding Common SharesÂ Â Â Â Â Â Â Â Basic and dilutedÂ Â 620,127Â Â Â Â 166,410Â Â The accompanying notes form an integral part of these condensedÂ consolidated financial statements. Â 4Â Â InMed Pharmaceuticals Inc. CONDENSEDÂ CONSOLIDATED STATEMENTS OF SHAREHOLDERSâ€™ EQUITY UNAUDITED For the Three Months ended September 30, 2024 and 2023 Expressed in U.S. DollarsÂ Â Â Â Â Â Common SharesÂ Â Additional Paid-in CapitalÂ Â Accumulated DeficitÂ Â Accumulated Other Comprehensive IncomeÂ Â TotalÂ Â Â #Â Â Â $Â Â $Â Â $Â Â $Â Â $Â Balance July 1, 2024Â Â 445,948Â Â Â Â 82,784,400Â Â Â Â 35,368,899Â Â Â Â (109,075,759)Â Â 128,569Â Â Â Â 9,206,109Â Private placementÂ Â 186,364Â Â Â Â 1,030,063Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â Â 1,030,063Â Share issuance costsÂ Â -Â Â Â (191,824)Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â Â (191,824) Exercise of pre-funded warrantsÂ Â 34,701Â Â Â Â 576,034Â Â Â (576,034)Â Â -Â Â Â -Â Â Â -Â Â Â -Â Loss for the periodÂ Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â (1,677,868)Â Â -Â Â Â Â (1,677,868) Share-based compensationÂ Â -Â Â Â -Â Â Â 28,964Â Â Â Â -Â Â Â -Â Â Â 28,964Â Balance September 30, 2024Â Â 667,013Â Â Â Â 84,198,673Â Â Â Â 34,821,829Â Â Â (110,753,627)Â Â 128,569Â Â Â Â 8,395,444Â Â Â Â Â Common SharesÂ Â Additional Paid-in CapitalÂ Â Accumulated DeficitÂ Â Accumulated Other Comprehensive IncomeÂ Â TotalÂ Â Â #Â Â Â $Â Â $Â Â $Â Â $Â Â $Â Â $Â Balance July 1, 2023Â Â 166,410Â Â Â Â 77,620,252Â Â Â Â 35,741,115Â Â Â Â (101,400,209)Â Â 128,569Â Â Â Â 12,089,727Â Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â Â (2,536,828)Â Â -Â Â Â Â (2,536,828) Share-based compensationÂ Â -Â Â Â -Â Â Â -Â Â Â Â 25,191Â Â Â -Â Â Â -Â Â Â Â 25,191Â Balance September 30, 2023Â Â 166,410Â Â Â Â 77,620,252Â Â Â Â 35,766,306Â Â Â Â (103,937,037)Â Â 128,569Â Â Â Â (9,578,090) Â The accompanying notes form an integral part of these condensedÂ consolidated financial statements. Â 5Â Â InMed Pharmaceuticals Inc. CONDENSEDÂ CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED For the Three Months ended September 30, 2024 and 2023 Expressed in U.S. Dollars Â Â Â For the Three Months EndedÂ Â Â September 30,Â Â Â Â 2024Â Â 2023Â Â Â $Â Â $Â Cash provided by (used in):Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating ActivitiesÂ Â Â Â Â Â Net lossÂ Â (1,677,868)Â Â (2,536,828) Items not requiring cash:Â Â Â Â Â Â Â Â Â Amortization and depreciationÂ Â 54,579Â Â Â Â 54,832Â Share-based compensationÂ Â 28,964Â Â Â Â 25,191Â Amortization of ROU assetsÂ Â 90,401Â Â Â Â 94,532Â Interest income received on short-term investmentsÂ Â (519)Â Â (538) Unrealized foreign exchange lossÂ Â 5,270Â Â Â Â 2,018Â Inventory write-downÂ Â -Â Â Â 92,930Â Changes in operating assets and liabilities:Â Â Â Â Â Â Â Â Â InventoriesÂ Â 24,251Â Â Â Â 390,329Â Prepaids and other currents assetsÂ Â 328,867Â Â Â Â 283,018Â Other non-current assetsÂ Â -Â Â Â 3,118Â Accounts receivableÂ Â 68,143Â Â Â Â 94,549Â Accounts payable and accrued liabilitiesÂ Â (642,392)Â Â (562,484) Deferred rentÂ Â -Â Â Â (16,171) Lease obligationsÂ Â (106,506)Â Â (98,709) Total cash used in operating activitiesÂ Â (1,826,810)Â Â (2,174,213) Â Â Â Â Â Â Â Â Â Â Â Â Â Investing ActivitiesÂ Â Â Â Â Â Â Â Sale of short-term investmentsÂ Â 21,324Â Â Â Â 21,317Â Purchase of short-term investmentsÂ Â (21,324)Â Â (21,317) Total cash used in investing activitiesÂ Â -Â Â Â -Â Â Â Â Â Â Â Â Â Â Â Â Â Financing ActivitiesÂ Â Â Â Â Â Â Â Proceeds from the private placementÂ Â 1,030,063Â Â Â -Â Private placement issuance costsÂ Â (191,824)Â Â -Â Total cash provided by financing activitiesÂ Â 838,239Â Â Â -Â Decrease in cash during the periodÂ Â (988,571)Â Â (2,174,213) Cash and cash equivalents beginning of the periodÂ Â 6,571,610Â Â Â Â 8,912,517Â Cash and cash equivalents end of the periodÂ Â 5,583,039Â Â Â Â 6,738,304Â Â Â Â Â Â Â Â Â Â Â Â Â SUPPLEMENTARY CASH FLOW INFORMATION:Â Â Â Â Â Â Â Â Â Cash Paid During the Period for:Â Â Â Â Â Â Â Â Â Income TaxesÂ $-Â Â $-Â InterestÂ $-Â Â $-Â Â Â Â Â Â Â Â Â Â Â Â Â SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:Â Â Â Â Â Â Â Â Â Recognition of ROU asset and corresponding operating lease liabilityÂ $187,223Â Â $-Â Â The accompanying notes form an integral part of these condensedÂ consolidated financial statements. Â 6Â Â InMed Pharmaceuticals Inc. Notes to the Condensed Consolidated Financial Statements Â 1. CORPORATE INFORMATION AND CONTINUING OPERATIONS Â Business Â InMed Pharmaceuticals Inc. (â€œInMedâ€ or the â€œCompanyâ€) was incorporated in the Province of British Columbia on May 19, 1981 under the Business Corporations Act of British Columbia. InMed is a clinical stage pharmaceutical company developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Â The Companyâ€™s shares are listed on the Nasdaq Capital Market (â€œNasdaqâ€) under the trading symbol â€œINMâ€. InMedâ€™s office and principal place of business is located at Suite 1445â€“ 885 West Georgia Street, Vancouver, B.C., Canada, V6C 1B4.Â Â Â Going Concern Â In accordance with the Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Update (â€œASUâ€) 2014-15, Disclosure of Uncertainties about an Entityâ€™s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date that the unaudited condensedÂ consolidated financial statements are issued. Â Through September 30, 2024, the Company has funded its operations primarily with proceeds from the sale of the Companyâ€™s common shares, no par value per share (the â€œCommon Sharesâ€). The Company has incurred recurring losses and negative cash flows from operations since its inception, including net losses of approximately $1.7 and $2.5 million for the three months ended September 30, 2024 and 2023, respectively. In addition, the Company had an accumulated deficit of approximately $110.8Â million as of September 30, 2024. The Company expects to continue to generate operating losses for the foreseeable future. Â As of the issuance date of these unaudited condensed consolidated financial statements, the Company expects its cash, cash equivalents and short-term investments of $5.6 million as of September 30, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements through the end of the first quarter of calendar 2025, depending on the level and timing of realizing BayMedica revenues from the sale of bulk rare cannabinoids in the â€˜health & wellnessâ€™ sector as well as the level and timing of Company operating expenses. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the unaudited condensedÂ consolidated financial statements are issued. Â The Company expects to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Companyâ€™s existing shareholders. Â In connection with the Companyâ€™s assessment of going concern considerations in accordance with Subtopic 205-40, management has determined that the Companyâ€™s liquidity condition raises substantial doubt about the Companyâ€™s ability to continue as a going concern, which is considered to be for a period of one year from the issuance of these condensed consolidated financial statements. These unaudited condensed consolidated financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts of classification of liabilities that might result from the outcome of this uncertainty. Such adjustments could be material. Â 7Â Â 2. SIGNIFICANT ACCOUNTING POLICIES Â Basis of Presentation Â These unaudited condensedÂ consolidated financial statements have been prepared in accordance with generally accepted accounting principles as applied in the United States (â€œUS GAAPâ€) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (â€œSECâ€) for financial information. Â These unaudited condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended September 30, 2024 and 2023 are not necessarily indicative of results that can be expected for a full year. These unaudited condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the fiscal year ended June 30, 2024. Â On November 14, 2024, the Company effected a reverse stock split of the Companyâ€™s issued and outstanding Common Shares, by a ratio of 20-to-1 (the â€œReverse Stock Splitâ€). Accordingly, all Common Shares, stock options, warrants, as well as per share information, for all periods presented in the condensed consolidated financial statements and notes thereto have been adjusted retrospectively to reflect this Reverse Stock Split. Â Reclassifications Â Certain prior year amounts in the unaudited condensedÂ consolidated financial statements and the notes thereto have been reclassified where necessary to conform to the current yearâ€™s presentation. These reclassifications did not affect the prior periodâ€™s total assets, total liabilities, stockholdersâ€™ deficit, net loss or net cash used in operating activities. During the year ended June 30, 2024, the Company adopted ASU 2023-07 - Improvements to Reportable Segment Disclosures which has required prior periods to reflect the change in presentation. Refer to discussion on Recent Accounting Pronouncements below. Â Use of Estimates Â The preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported. It also requires management to exercise judgment in applying the Companyâ€™s accounting policies. In the future, actual experience may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these unaudited condensedÂ consolidated financial statements are the application of the going concern assumptions, determining the fair value of share-based payments, income tax provisions, write-down of inventories to net realizable value, and the assumptions used in the determination of research & development accruals. Â Actual results could differ from those estimates. Â Basis of ConsolidationÂ Â These unaudited condensedÂ consolidated financial statements include the accounts of the Company and its subsidiaries, including subsidiaries: InMed Pharmaceutical Ltd;, BayMedica, LLC; Biogen Sciences Inc.; and Sweetnam Consulting Inc. A subsidiary is an entity that the Company controls, either directly or indirectly, where control is defined as the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. All inter-company transactions and balances including unrealized income and expenses arising from intercompany transactions are eliminated in preparing these condensedÂ consolidated financial statements. Â Foreign CurrencyÂ Â The functional currency of the Company and its subsidiaries is the U.S. Dollar. These unaudited condensedÂ consolidated financial statements are presented in U.S. Dollars. References to â€œ$â€ and â€œUS$â€ are to United States (â€œU.S.â€) dollars and references to â€œC$â€ are to Canadian dollars. Â Cash and Cash EquivalentsÂ Â Cash and cash equivalents include cash-on-hand, demand deposits with financial institutions and other short-term, highly liquid investments with original maturities of three months or less when acquired that are readily convertible to known amounts of cash and subject to an insignificant risk of change in value. As of September 30, 2024 and June 30, 2024, the Company held $1,964,203 and $1,939,482, respectively, of cash equivalents in a money market fund that is considered Level 1 in the financial instruments hierarchy due to the readily available quoted prices in active markets for identical instruments.Â Â 8Â Â Short-term Investments Â Short-term investments include fixed and variable rate guaranteed investment certificates, with terms greater than three months and less than twelve months. Due to the short-term nature of these investments the fair value of the investments approximates the current value. Guaranteed investment certificates are convertible to known amounts of cash and are subject to an insignificant risk of change in value. Â Accounts ReceivableÂ Â Accounts receivable are recorded at invoiced amounts, net of any credit losses. The allowance for doubtful accounts is the Companyâ€™s best estimate of the amount of probable credit losses in existing accounts receivable.Â Â The Company evaluates the collectability of accounts receivable on a regular basis based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. Â Concentration of Credit Risk and Other Risks and Uncertainties Â At times, cash balances may exceed the Federal Deposit Insurance Corporation (â€œFDICâ€) or Canadian Deposit Insurance Corporation insurable limits. The Company has not previously experienced any losses related to these balances. The uninsured cash balance as of September 30, 2024 was $1.6 million. The Company does not believe it is exposed to significant credit risk on cash and cash equivalents. Â The Companyâ€™s customers are primarily concentrated in the United States. Â As of September 30, 2024, the Company had four customers with an accounts receivable balance representing 25%, 23%, 22%, and 20% of total accounts receivable. As of June 30, 2024, we had five customers with an accounts receivable balance representingÂ 32%,Â 20%,Â 15%,15% andÂ 14% of total accounts receivable. Â For the three months ended September 30, 2024, the Company had four customers that accounted for 22%, 20%, 18%, and 15% of revenue. ForÂ the three months ended September 30, 2023, the Company had three customers that accounted for 34%, 20%, and 11% of revenue. Â Â InventoriesÂ Â Inventories are initially valued at weighted average cost and subsequently valued at the lower of weighted average cost and net realizable value. Costs included in inventories are the purchase price of goods and cost of services rendered, freight costs, warehousing costs, purchasing costs and production and labor costs related to manufacturing.Â Â In determining any valuation allowances, the Company reviews inventory for obsolete, redundant, and slow-moving goods. As of September 30, 2024 and June 30, 2024, the Company had $103,434 as a valuation allowance to reduce weighted average cost to net realizable value. During the three months ended September 30, 2024 and 2023, the Company recorded an inventory write-down due to net realizable value of $0 and $92,930, respectively. Â Â Property, Equipment and ROU Assets, NetÂ Â Computer equipment, lab equipment and furnishings are recorded at cost, less accumulated depreciation and

accumulated impairment losses. The initial cost of computer equipment, lab equipment and furnishings comprises their purchase price. The computer equipment, lab equipment and furnishings are reviewed at least once per year for impairment. Equipment and furniture are depreciated using the straight-line method based on their estimated useful lives as follows:Â Â Â â— Computer equipment â€”Â 5 years Â Â Â Â â— Lab equipment â€”Â 6 - 10 years Â Â â— Furnishings â€” 5 years Â Computer equipment, lab equipment and furnishings, acquired or disposed of during the year, are depreciated proportionately for the period they are in use.Â 9 Â Â The ROU assets are initially measured based on the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, less any lease incentives received. The assets are amortized to the earlier of the end of the useful life of the ROU asset or the lease term using the straight-line method as this most closely reflects the expected pattern of consumption of the future economic benefits. The lease term includes periods covered by an option to extend if the Company is reasonably certain to exercise that option. In addition, the ROU assets are periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability (see Note 2 Lease (i)). Â Intangible Assets, NetÂ Â Intangible assets are comprised of acquired intellectual property, which consists of certain patents and technical know-how. The intellectual property is recorded at cost and is amortized on a straight-line basis over an estimated useful life ofÂ 18Â years net of any accumulated impairment losses. There was no impairment loss during the three months ended September 30, 2024 and 2023. Â In-Process R&DÂ Â In-process R&D (â€œIPR&Dâ€) is classified as an indefinite-lived intangible asset and is not amortized. IPR&D becomes definite-lived upon the completion or abandonment of the associated research and development efforts. All research and development costs incurred subsequent to the acquisition of IPR&D are expensed as incurred. Indefinite-lived intangible assets are evaluated for impairment on an annual basis or more frequently if an indicator of impairment is present. Â Impairment of Long-Lived AssetsÂ Â The Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or assets. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured as the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets classified as held for sale are reported at the lower of the carrying amount or fair value, less costs to sell.Â Â Fair Value Measurements Â Financial AssetsÂ Â Financial assets are initially recognized at fair value, plus transaction costs that are directly attributable to their acquisition or issue and subsequently carried at amortized cost, using the effective interest rate method, less any impairment losses. No financial assets are elected to be carried at fair value through profit or loss, or where changes in fair value are recognized in these consolidated statements of operations and comprehensive loss in other comprehensive loss.Â Â Short-term investments are subsequently recorded at cost plus accrued interest, which approximates fair value due to their short-term nature. Accounts receivable are reported at outstanding amounts, net of credit losses.Â 10 Â Â Financial LiabilitiesÂ Â To determine the fair value of financial instruments, the Company uses the fair value hierarchy for inputs used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).Â Â Â Level 1 â€“ Unadjusted quoted prices in active markets for identical instruments. Â Â Level 2 â€“ Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Â Â Level 3 â€“ Inputs are unobservable and reflect the Companyâ€™s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. Â Â The carrying value of cash and cash equivalents, short-term investments, accounts receivable, and accounts payable and accrued liabilities, approximate their carrying values as at September 30 2024 and June 30, 2024 due to their immediate or short-term maturities. Â Revenue RecognitionÂ Â The Company recognizes revenue when the Company satisfies the performance obligations under the terms of a contract and control of its products and services is transferred to its customers in an amount that reflects the consideration the Company expects to receive from its customers in exchange for those products and services. ASC 606,Â Revenue from Contracts with CustomersÂ defines a five-step process to recognize revenue that requires judgment and estimates, including identifying the contract with the customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract, and recognizing revenue when or as the performance obligation is satisfied.Â Â Â Â Â Revenue consists of manufacturing and distribution sales of bulk rare cannabinoids, which are generally recognized at a point in time. The Company recognizes revenue when control over the products has been transferred to the customer and the Company has a present right to payment. Sales and other taxes that are required to be remitted to regulatory authorities are recorded as liabilities and excluded from sales. Limited rights of return, for claims of damaged or non-compliant products, exist with the Companyâ€™s customers.Â Â The Company has elected the practical expedient that allows it to recognize the incremental costs of obtaining a contract as an expense, when incurred, if the amortization period of the asset that the Company otherwise would have recognized is one year or less.Â Â Revenues within the scope of ASC 606 do not include material amounts of variable consideration. Customer payments are generally due in advance of when control is transferred to the customer. Some of our larger customers are eligible for payment terms up to â€˜net 30 daysâ€™. Â Â Cost of SalesÂ Â Cost of sales consists primarily of the purchase price of goods and cost of services rendered, freight costs, warehousing costs, and purchasing costs. Cost of sales also includes production and labor costs for the Companyâ€™s manufacturing business.Â 11 Â Â Shipping and HandlingÂ Â The Company records freight billed to customers within net sales. Shipping and handling costs associated with inbound freight and goods shipped to customers are recorded in cost of sales. Other shipping and handling costs, such as for quality assurance, are recorded in operating expenses. Â Earnings (Loss) Per ShareÂ Â Basic earnings (loss) per Common Share (â€œEPSâ€) is computed by dividing the net income or loss applicable to Common Shares by the weighted average number of Common Shares outstanding for the relevant period. Diluted earnings (loss) per Common Share (â€œDiluted EPSâ€) is computed by dividing the net income or loss applicable to Common Shares by the sum of the weighted average number of Common Shares issued and outstanding and all additional Common Shares that would have been outstanding, if potentially dilutive instruments were converted. If the conversion of outstanding stock options and warrants into Common Shares is anti-dilutive, then diluted EPS is not presented separately from EPS. Â The following table sets forth the number of potential Common Shares that have been excluded from diluted net income (loss) per because their effect was anti-dilutive:Â Â Â Â As of September 30,Â Â Â 2024Â Â 2023Â OptionsÂ Â 33,724Â Â Â 5,107Â WarrantsÂ Â 509,602Â Â Â 175,826Â Â Â Â 543,326Â Â Â 180,933Â Â Share-based Payments Â The Company follows the requirements of FASB ASC 718-10-10, Share-Based Payments with regards to stock-based compensation issued to employees and non-employees. The Company has agreements and arrangements that call for stock to be awarded to the employees and consultants at various times as compensation and periodic bonuses. The expense for this stock-based compensation is equal to the fair value of the stock price on the day the stock was awarded multiplied by the number of shares awarded. The Company has a relatively low forfeiture rate of stock-based compensation and forfeitures are recognized as they occur. Â Â The valuation methodology used to determine the fair value of the options issued during the period is the Black-Scholes option-pricing model. The Black-Scholes model requires the use of a number of assumptions, including the volatility of the stock price, the average risk-free interest rate, and the weighted average expected life of the options. Risk-free interest rates are calculated based on continuously compounded risk-free rates for the appropriate term. The dividend yield is assumed to be zero as the Company has never paid or declared any cash dividends on its Common Shares and does not intend to pay dividends on its Common Shares in the foreseeable future. The expected forfeiture rate is estimated based on managementâ€™s best assessment. Â Estimated volatility is a measure of the amount by which InMedâ€™s stock price is expected to fluctuate each year during the expected life of the award. The Companyâ€™s calculation of estimated volatility is based on historical stock prices over a period equal to the expected life of the awards.Â Â Research and Development CostsÂ Â The Company conducts research and development programs and incurs costs related to these activities, including research and development personnel compensation, services provided by contract research organizations and lab supplies. Research and development costs are expensed in the periods in which they are incurred.Â 12 Â Â Patents and Intellectual Property CostsÂ Â The costs of filing for patents and of prosecuting and maintaining intellectual property rights are expensed as incurred due to the uncertainty surrounding the drug development process and the uncertainty of future benefits. Patents and intellectual property acquired from third parties for approved products or where there are alternative future uses are capitalized and amortized over the remaining life of the patent. Â Segment reportingÂ Â The Companyâ€™s operations consist of two operating and reportable segments, the â€œInMed Pharmaâ€ segment and the â€œBayMedica Commercialâ€Â segment.Â Â The â€œInMed Pharmaâ€ segment is largely organized around the research and development of small molecule pharmaceuticalsÂ drug candidates and the â€œBayMedica Commercialâ€ segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industryÂ (See Note 10). Â LeasesÂ Â At inception of a contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.Â Â The lease liability is initially measured as the present value of future lease payments excluding payments made at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Companyâ€™s incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate. The lease liability is measured at amortized cost using the effective interest method. It is re-measured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Companyâ€™s estimate of the amount expected to be payable under a residual value guarantee, or if the Company changes its assessment of whether it will exercise a purchase, extension, or termination option. When the lease liability is re-measured in this way, a corresponding adjustment is made to the carrying amount of the ROU asset or is recorded in profit or loss if the carrying amount of the ROU asset has been reduced to nil.Â Â The Company has lease arrangements that include both lease and non-lease components. The Company accounts for each separate lease component and its associated non-lease components as a single lease component for all of its asset classes.Â Â The Company has elected to apply the practical expedient to exclude initial direct costs such as annual operating costs from the measurement of the ROU asset at the date of initial application. The Company has elected to apply the practical expedient not to recognize ROU assets and lease liabilities for short-term leases that have a lease term ofÂ 12Â months or less. The lease payments associated with these leases is recognized as an expense on a straight-line basis over the lease term. Â Â Recent Accounting Pronouncements Â The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in these unaudited condensed consolidated financial statements as a result of future adoption. Â In November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements primarily through expanded disclosures around significant segment expenses. The amendments are effective for fiscal years beginning after DecemberÂ 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company has early adopted this accounting pronouncement. Â Â Â Â In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires disclosure of specific categories meeting a quantitative threshold within the income tax rate reconciliation, as well as disaggregation of income taxes paid by jurisdiction. This ASU, which can be applied either prospectively or retrospectively, is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this ASU and expects to include updated income tax disclosures in its fiscal year 2026. Â 13 Â Â 3. INVENTORIES Â Inventories consisted of the following: Â Â Â SeptemberÂ 30, 2024Â Â June 30, 2024Â Â Â $Â Â $Â Â Â Â Â Â Â Raw materialsÂ Â 274,445Â Â Â 372,695Â Work in processÂ Â 18,446Â Â Â 30,817Â Finished goodsÂ Â 927,182Â Â Â 840,812Â InventoriesÂ Â 1,220,073Â Â Â 1,244,324Â Â 4. PROPERTY, EQUIPMENT AND ROU ASSETS, NET Â Property, equipment and ROU assets consisted of the following: Â Â Â SeptemberÂ 30, 2024Â Â June 30, 2024Â Â Â $Â Â $Â Â Â Â Â Â Â ROU Assets (leases)Â Â 1,901,692Â Â Â 2,135,811Â EquipmentÂ Â 429,092Â Â Â 429,090Â FurnishingsÂ Â 40,409Â Â Â 40,409Â Property and equipmentÂ Â 2,371,193Â Â Â 2,605,310Â Less: accumulated depreciation and amortizationÂ Â (1,028,184)Â Â (1,355,311) Property, equipment and ROU assets, netÂ Â 1,343,009Â Â Â 1,249,999Â Â Depreciation expense on computer equipment, lab equipment and furnishing for the three months ended September 30, 2024 and 2023, was $13,586 and $13,839, respectively, and was recorded in general and administrative expenses. Amortization expense related to the ROU assets for the three months ended September 30, 2024 and 2023, was $90,401 and $94,532, respectively, and was recorded in general and administrative expenses. Â 5. INTANGIBLE ASSETS Â The following table summarizes the Companies intangible assets: Â Â Â SeptemberÂ 30, 2024Â Â June 30, 2024Â Â Â $Â Â $Â Â Â Â Â Â Â Intellectual propertyÂ Â 1,736,420Â Â Â 1,736,420Â PatentsÂ Â 1,191,000Â Â Â 1,191,000Â Intangible assetsÂ Â 2,927,420Â Â

Â 2,927,420Â Less: accumulated amortizationÂ Â (1,185,215)Â Â (1,144,222) Intangible assets, netÂ Â 1,742,205Â Â Â 1,783,198Â Â Acquired intellectual property is recorded at cost and is amortized on a straight-line basis over 18 years. Acquired patents consist of patents related to the development of cannabinoid analogs. This intangible asset is being amortized over an estimated useful life of 18 years. As at September 30, 2024, the definite-lived intangible assets had a weighted average estimated remaining useful life of approximately 11 years.Â 14 Â Â Amortization expense on intangible assets for the three months ended September 30, 2024 and 2023 was $40,993 and $40,993 respectively. The Company expects amortization expense to be incurred over the next five years as follows: Â Â Twelve months ending September 30,Â $Â Â Â Â Â 2025Â Â 162,746Â 2026Â Â 162,746Â 2027Â Â 162,746Â 2028Â Â 162,746Â 2029Â Â 162,746Â ThereafterÂ Â 928,475Â TotalÂ Â 1,742,205Â Â 6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Â Accounts payable and accrued liabilities consist of the following: Â Â Â SeptemberÂ 30, 2024Â Â June 30, 2024Â Â Â $Â Â $Â Â Â Â Â Â Â Â Trade payablesÂ Â 448,995Â Â Â 626,190Â Accrued research and development expensesÂ Â 238,412Â Â Â 242,066Â Inventory related accrualsÂ Â 2,000Â Â Â 41,004Â Employee compensation, benefits and related accrualsÂ Â 236,691Â Â Â 488,278Â Accrued general and administrative expensesÂ Â 85,521Â Â Â 256,473Â Accounts payable and accrued liabilitiesÂ Â 1,011,619Â Â Â 1,654,011Â Â 7. SHARE CAPITAL AND RESERVES Â Authorized Â As of September 30, 2024, the Companyâ€™s authorized share structure consisted of: (i) an unlimited number of Common Shares; and (ii) an unlimited number of preferred shares without par value. No preferred shares were issued and outstanding as of September 30, 2024 and June 30, 2024. Â The Company may, from time to time, issue preferred shares and may, at the time of issuance, determine the rights, preferences and limitations pertaining to these shares. Holders of preferred shares may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding up of the Company before any payment is made to the holders of Common Shares. Â On June 27, 2024, the Company entered into an amendment (the â€œATM Amendmentâ€) to its At-the-Market Offering Agreement, dated April 7, 2022 (the â€œOriginal ATM Agreementâ€ and together with the ATM Amendment, the â€œAmended ATM Agreementâ€), pursuant to which the Company may offer and sell Common Shares, from time to time, in â€œat the marketâ€ offerings through the Agent. The ATM Amendment amends the Original ATM Agreement to reflect, among other provisions, updates to certain sales settlement provisions and reimbursement terms, and to supplement the representations being made by the Company to the Agent. During the three months ended September 30, 2024, the Company issued 186,364 Common Shares for gross proceeds of approximately $1.0Â million. This amount has been offset by financing fees of approximately $192,000.Â 15 Â Â Common Share Warrants Â The Company did not grant any warrants during the three months ended September 30, 2024. Â A summary of the Companyâ€™s warrant activity and related information for the periods covered were as follows: Â Â Â Number of Shares Under WarrantsÂ Â Weighted Average Exercise PriceÂ Balance as at June 30, 2024Â Â 544,303Â Â $20.40Â Warrants GrantedÂ Â -Â Â Â -Â ExercisedÂ Â (34,701)Â Â -Â Expire/CancelledÂ Â -Â Â Â -Â Warrants Outstanding as at September 30, 2024Â Â 509,602Â Â $22.60Â Â Â Â Â Â Â Â Â Â Warrants Exercisable as at September 30, 2024Â Â Â 509,602Â Â $22.60Â Â Â As of September 30, 2024 and June 30, 2024, the warrants exercisable and outstanding have an intrinsic value of $nil and $184,539, respectively,Â with a weighted average remaining life ofÂ 4Â years and 6Â years, respectively. Â 8. SHARE-BASED PAYMENTS Â Â a) Option Plan Details Â On March 24, 2017, and as amended on November 20, 2020, the Companyâ€™s shareholders approved: (i) the adoption of a new stock option plan (the â€œPlanâ€) pursuant to which the Companyâ€™s Board of Directors may, from time to time, in its discretion and in accordance with applicable regulatory requirements, grant to directors, officers, employees and consultants of the Company, non-transferable options to purchase Common Shares, provided that the number of Common Shares reserved for issuance will not exceed twenty percent (20%) of the issued and outstanding Common Shares at the date the options are granted (on a non-diluted and rolling basis); and (ii) the application of the Plan to all outstanding stock options of the Company that were granted prior to March 24, 2017 under the terms of the Companyâ€™s previous stock option plan. On December 19, 2023, the Companyâ€™s Board of Directors approved the reservation of an additionalÂ 35,000Â Common Shares under the Plan. Â As of each of September 30, 2024 and June 30, 2024, there wereÂ 34,224 stock options immediately available for future allocation pursuant to applicable regulatory requirements. The maximum number of options issuable under the terms of the Plan equates toÂ 20% of the then issued and outstanding shares. The option price under each option shall not be less than the closing price on the day prior to the date of grant. All options vest upon terms as set by the Board of Directors, either over time, up to 36 months, or upon the achievement of certain corporate milestones. Â The Company did not grant any stock options during the three months ended September 30, 2024. Â As of September 30, 2024 the Company had 10,804 vested and exercisable options with a weighted average exercise price of $163.00 and 22,919 unvested options with a weighted average exercise price of $8.40 Â Total expenses arising from share-based payment transactions recognized during the three months ended September 30, 2024 and 2023 were $28,964 and $25,191, respectively, of which $17,564 and $15,431, respectively, was allocated to general and administrative expenses, $11,180 and $9,761, respectively, was allocated to research and development expenses, and $220Â and $0, respectively, was allocated to Cost of Goods sold. Â Unrecognized compensation cost as at September 30, 2024 (which related to unvested options) was $78,685,Â which will be recognized over a weighted-average vesting period of approximatelyÂ 1.3Â years.Â Â 16 Â Â 9. LEASE OBLIGATIONS Â The Company is committed to minimum lease payments as follows: Â Maturity AnalysisÂ September 30, 2024Â Â Â $Â Â Â Â Â Year 1Â Â 469,668Â Year 2Â Â 453,191Â Year 3Â Â 219,261Â Year 4Â Â -Â Year 5Â Â -Â More than five yearsÂ Â -Â Total undiscounted lease liabilities(1)Â Â 1,142,120Â Less: imputed interestÂ Â (84,077) Present value of lease liabilitiesÂ Â 1,058,043Â Â Â Â Â Â Less: Current portion of lease liabilitiesÂ Â (424,260) Non-current portion of lease liabilitiesÂ Â 633,783 Â On July 29, 2024, the Company entered into a lease agreement for new office space. This office occupies approximately 2,243 square feet with a monthly basic rental rate and operating charges of an estimated C$12,296 for the two-year term of the agreement. The Company used an incremental borrowing rate ofÂ 7% and recognized a ROU asset and corresponding operating lease liability of $205,201. Â On October 5, 2023, BayMedica amended its lease located at 458 Carlton Court, Suite C, South San Francisco, California, in order to extend its lease to May 14, 2027. The Company is obligated to pay $1,295,759 over the three-year period unless terminated before the end of the period. The Company used an incremental borrowing rate ofÂ 6.15% and recognized a ROU asset and corresponding operating lease liability of $953,935. Â 10. SEGMENT INFORMATION Â The Company reports segment information based on the management approach, which designates the internal reporting used by the Chief Operating Decision Maker (â€œCODMâ€), the Companyâ€™s Chief Executive Officer and the senior management team, for making decisions and assessing performance as the source of the Companyâ€™s reportable segments. The CODM allocates resources and assesses the performance of each operating segment based on potential licensing opportunities, historical and potential future product sales, operating expenses, and operating income (loss) before interest and taxes. The Company has determined its reportable segments to be â€˜InMed Pharmaâ€™ and â€˜BayMedica Commercialâ€™ based on the information used by the CODM. As such, the pharmaceutical-related research and development carried out at BayMedica is included with the â€˜InMed Pharmaâ€™ segment. Other than cash, cash equivalents and short-term investments (â€œUnrestricted cashâ€) balances, the CODM does not regularly review asset information by reportable segment and, therefore, the Company does not report asset information by reportable segment..Â 17 Â Â The â€˜InMed Pharmaâ€™ segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the â€˜BayMedica Commercialâ€™ segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Total assets held in the â€˜InMed Pharmaâ€™ segment as of September 30, 2024 and June 30, 2024 were $7.6 million and $9.2 million, respectively. Total assets as of September 30, 2024 and June 30, 2024, held in the â€˜BayMedica Commercialâ€™ segment were $2.8 million and $2.6 million, respectively. Â Â The following table presents information about the Companyâ€™s reportable segments for the three months ended September 30, 2024 and 2023: Â Â Â Three Months Ended September 30,Â Â Â 2024Â Â Â 2023Â Â Â InMedÂ Â BayMedicaÂ Â TotalÂ Â InMedÂ Â BayMedicaÂ Â TotalÂ Â Â $Â Â $Â Â $Â Â $Â Â $Â Â $Â Â Â Â Â

in the normal course of operations and were measured at the exchange amount which represented the amount of consideration established and agreed to by NRF. No legal services rendered by NRF were provided by Ms. Grove directly. Â 13. SUBSEQUENT EVENTS Â The Company has evaluated subsequent events through the date of the filing of this Annual Report on Form 10-K and determined that there have been no events that have occurred that would require adjustments to our disclosures in the unaudited condensedÂ consolidated financial statements except for the matters described below. Â In October 2024, the Company issued 51,019 Common Shares for gross proceeds of $365,473 pursuant to the terms of the Amended ATM Agreement. Â On November 14, 2024, the Company effected a Reverse Stock Split of its Common Shares at a ratio of 20-to-1. Trading of the Common Shares on Nasdaq on a split-adjusted basis began as of November 14, 2024. As a result of the Reverse Stock Split, each 20 shares of Common Shares were combined into one Common Share, and the total number of Common Shares outstanding were reduced from approximately 14,361,550 shares to approximately 718,032 Common Shares. Â 20 Â Â ITEM 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. Â This discussion and analysis contains certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, and is subject to the safe harbor created by those sections. For more information, see â€œSpecial Note Regarding Forward-Looking Statements.â€ When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties that impact our business. In particular, we strongly encourage you to review the risks and uncertainties described in â€œRisk Factorsâ€ in the 2024 Annual Report, the â€œRisk Factorsâ€ identified in Item 1A. of this Quarterly Report, and other filings we make from time to time with the SEC. These risks and uncertainties could cause actual results to differ materially from those projected or implied by our forward-looking statements contained in this Quarterly Report on Form 10-Q. These forward-looking statements are made as of the date of this Quarterly Report on Form 10-Q, and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. Â The following discussion and analysis should be read in conjunction with our audited consolidated financial statements for the year ended June 30, 2024, and the related notes thereto, which have been prepared in accordance with U.S. GAAP. Additionally, the following discussion and analysis should be read in conjunction with our audited consolidated financial statements included in this Annual Report. Throughout this discussion, unless the context specifies or implies otherwise the terms â€œInMed,â€ â€œCompany,â€ â€œwe,â€ â€œus,â€ and â€œourâ€ refer to InMed Pharmaceuticals Inc.Â Â All dollar amounts stated herein are in U.S. dollars unless specified otherwise.Â Â Overview Â We are a pharmaceutical company developing a pipeline of proprietary small molecule drug candidates that are preferential signaling ligands of the endogenous CB1 and CB2 receptors as well as other receptor targets linked to human disease. CB1 and CB2 receptors are each part of the endocannabinoid system that is found throughout the human body and is responsible for many homeostatic functions. CB1 receptors are primarily located in the brain and central nervous system, while CB2 receptors are involved in modulating neuroinflammation and immune responses. Our research efforts target the treatment of diseases with high unmet medical needs. Together with BayMedica, we also have significant know-how in developing proprietary manufacturing approaches to produce and sell bulk rare cannabinoids as ingredients for various market sectors. Â InMed has sought to focus on the research and development of preferential signaling ligands of CB1 and CB2, and has produced a library of novel, proprietary drug candidates (â€œProduct Candidatesâ€). These Product Candidates are patentable new chemical entities (â€œNCEsâ€) for pharmaceutical development, aimed at targeting diverse clinical indications. Our current pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimerâ€™s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. InMedâ€™s INM-901 is a proprietary small molecule, disease modifying drug candidate being developed as a potential treatment for Alzheimerâ€™s disease. INM-901 has multiple potential mechanisms of action as a preferential signaling agonist for both CB1 and CB2 receptors, as well as impacting the peroxisome proliferator-activated receptor (â€œPPARâ€) signaling pathway. Combined, these mechanisms of action may offer a unique treatment approach targeting several biological pathways associated with Alzheimerâ€™s disease. Our ocular research, based on the proprietary small molecule INM-089, indicates potentially promising neuroprotective effects in the back of the eye, which may lead to the preservation of the retinal function. Neuroprotection in dry Aged-related Macular Degeneration (â€œdry AMDâ€) remains an unmet medical need and a new treatment option may help solve this multifactorial disease. Â InMed has also completed a Phase 2 clinical trial of INM-755 (cannabinol) cream studying its safety and efficacy in treating symptoms related to Epidermolysis Bullosa (â€œEBâ€). Results from the Phase 2 clinical trial showed a positive indication of enhanced anti-itch activity for INM-755 cream versus the control cream alone in an exploratory clinical evaluation. The Company is also pursuing strategic partnership opportunities for INM-755 in epidermolysis bullosa and other itch-related skin conditions. Â Together with BayMedica, our manufacturing capabilities include traditional approaches such as chemical synthesis and biosynthesis, as well as a proprietary, integrated manufacturing approach called IntegraSyn. With multiple manufacturing approaches, InMed has sought to maintain enhanced flexibility to select the most cost-effective method to deliver high quality, high purity Products and Product Candidates fit for their intended use. BayMedicaâ€™s commercial business specializes in the B2B commercialization of bulk rare, non-intoxicating cannabinoids as raw materials for the Health and Wellness sector that are bioidentical to those found in nature. Â 21 Â Â Recent Developments Â NASDAQ Delisting Notice, Determination from the Hearings Panel and Reverse Stock Split Â As previously reported by the Company, on March 19, 2024, the Company received written notification from the Listing Qualifications Department of Nasdaq that the Company has been granted an additional 180-day compliance period, or until September 16, 2024 (the â€œExtended Compliance Periodâ€), to regain compliance with Nasdaqâ€™s minimum bid price requirement for the continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the â€œMinimum Bid Price Ruleâ€). Nasdaqâ€™s determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on Nasdaq, with the exception of the bid price requirement, and the Companyâ€™s written notice of its intention to consider all available options to regain compliance during the Extended Compliance Period, including, if necessary, effecting a reverse stock split. The Company was unable to regain compliance during the Extended Compliance Period and, on September 17, 2024, the Company received an additional notification from the Listing Qualifications Department stating that due to the deficiency, the Companyâ€™s securities would be delisted from Nasdaq on September 26, 2024, unless the Company appealed Nasdaqâ€™s determination to a Hearings Panel (the â€œPanelâ€). A hearing request would stay the suspension of the Companyâ€™s securities pending the Panelâ€™s discussion. On September 17, 2024, the Company submitted the hearing request to appeal (the â€œAppeal Requestâ€) Nasdaqâ€™s determination before the Panel. On October 31, 2024, a hearing was held before the Panel regarding the Companyâ€™s request for (i)Â Â continued listing on Nasdaq and (ii) additional time to regain compliance with the Minimum Bid Price Rule. On November 1, 2024, the Panel issued its determination (the â€œPanel Determination Letterâ€) to the Company, granting the Companyâ€™s request for the continued listing of the Common Shares on Nasdaq, but subject to the Companyâ€™s evidencing compliance with the Minimum Bid Price Rule for ten consecutive trading days as of December 2, 2024 (the â€œRequisite Compliance Dateâ€), and of other conditions stipulated by the Panel Determination Letter. In order to regain compliance with the Minimum Bid Price Rule before the Requisite Compliance Date, the Company effected the Reverse Stock Split of the Common Shares at a ratio of 20-to-1. Trading of the Common Shares on Nasdaq on a split-adjusted basis began as of November 14, 2024. As a result of the Reverse Stock Split, every twenty shares of Common Shares were combined into one Common Share, and the total number of Common Shares outstanding were reduced from approximately 14,361,550 shares to approximately 718,032 shares. No fractional shares were issued if, as a result of the Reverse Stock Split, a registered shareholder would otherwise become entitled to a fractional share. Instead, shareholders who otherwise were entitled to receive fractional shares because they held a number of Common Shares not evenly divisible by the ratio of the Reverse Stock Split were automatically entitled to receive an additional Common Share. In other words, any fractional share will be rounded up to the nearest whole number. Â While the Company has effected the Reverse Stock Split, there can be no assurances, however, that we will be successful in regaining compliance with the continued listing requirements, including the Minimum Bid Price Rule, and maintaining the listing of our Common Shares on Nasdaq. Delisting from Nasdaq could materially and adversely affect our ability to raise additional financing through the public or private sale of equity securities, would significantly affect the ability of investors to trade our securities and would negatively affect the value and liquidity of our securities, including our Common Shares. The actual or threatened delisting of our securities could also have other material and adverse consequences, including the potential loss of confidence by employees and other stakeholders, the loss of institutional investor interest and fewer business development opportunities, limited availability of market quotations for our securities, reduced liquidity with respect to our securities, a determination that our Common Shares is â€œpenny stock,â€ which will require brokers trading in our Common Shares to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our Common Shares, and limited amount of news and analyst coverage of the Company. To the extent that our Common Shares became eligible to trade on the OTC Bulletin Board, another over-the-counter quotation system, or on the pink sheets, an investor may find it more difficult to dispose of their Common Shares or obtain accurate quotations as to the market value of our Common Shares. All Common Shares, stock options, warrants and per share information for all periods presented in the have been adjusted retrospectively to reflect this Reverse Stock Split. Â Renewal of ATM Program Â As previously reported by the Company on the Companyâ€™s Current Report on Form 8-K filed on June 28, 2024, on June 27, 2024, the Company entered into an amendment (the â€œATM Amendmentâ€) to its At-the-Market Offering Agreement, dated April 7, 2022 (the â€œOriginal ATM Agreementâ€ and together with the ATM Amendment, the â€œAmended ATM Agreementâ€), by and between the Company and H.C. Wainwright & Co., LLC (the â€œAgentâ€), as sales agent, pursuant to which the Company may offer and sell shares of our Common Shares, from time to time, in â€œat the marketâ€ offerings through the Agent. The Original ATM Agreement was previously filed with the Securities and Exchange Commission on April 7, 2022 on the Companyâ€™s Current Report on Form 8-K. The ATM Amendment amends the Original ATM Agreement to reflect, among other provisions, updates to certain sales settlement provisions and reimbursement terms, and to supplement the representations being made by the Company to the Agent. Our Common Shares sold under the Amended ATM Agreement will be offered and sold pursuant to the Companyâ€™s shelf registration statement on Form S-3, which was initially filed on February 4, 2022 and amended on February 9, 2022, and was declared effective by the SEC on February 11, 2022. The foregoing description of the terms of the ATM Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the ATM Amendment. Â Subsequent to September 30, 2024, the Company issued 1,021,305 Common Shares for gross proceeds of $365,473, pursuant to the terms of the Amended ATM Agreement. Â 22 Â Â Advancements to the INM-901 program Â July 30, 2024 â€” we announced positive results from initial data sets from a long-term (7 months of dosing) in vivo preclinical Alzheimerâ€™s Disease (â€œADâ€) study of INM-901 which confirms previously reported findings from a short-term (3 months of dosing) pilot study. All assessments of the INM-901-treated AD groups showed a positive trend towards behavior similar to the untreated disease-free group, with most assessments demonstrating a clear dose response. Furthermore, INM-901-treated AD groups achieved a statistically significant improvement in certain behavior criteria in comparison to the placebo-treated AD groups. These results not only supported but, in several instances, improved upon the prior short-term pilot study outcomes. Â August 20, 2024 â€” we announced the confirmation of INM-901 as an oral formulation that will be utilized in its development programs for Alzheimerâ€™s disease.Â Â Recent preclinical studies have demonstrated that INM-901 can be administered orally and achieve therapeutic levels in the brain comparable to those obtained through intraperitoneal (â€œIPâ€) injection, which is a common route of administration for preclinical investigation of neurodegenerative diseases. The data indicates the INM-901 formulation can be administered orally and maintains a similar drug exposure levels as IP delivery over a 24-hour period in the brain. This oral delivery method offers potential advantages such as reduction in treatment delivery costs versus intravenous delivery of current disease modifying large molecule antibody therapies. Â Additional Preclinical Data for INM-901â€™s Pharmacological Effects Â Components of Results of Operations Â Revenue Â Our revenue consists of manufacturing and distribution sales of bulk rare cannabinoid Products, which are generally recognized at a point in time. The Company recognizes revenue when control over the products have been transferred to the customer and the Company has a present right to payment. Â Cost of Sales Â Cost of sales consists primarily of the purchase price of goods and cost of services rendered, freight costs, warehousing costs, and purchasing costs. Cost of sales also includes production and labor costs for our manufacturing business. Â Operating Expenses Â Research and Development and Patent Expenses Â Research and development and patent expenses represent costs incurred by us for the discovery, development, and manufacture of our Products and Product Candidates, and include: Â Â â— external research and development expenses incurred under agreements with contract research organizations (â€œCROsâ€), CDMOs and consultants; Â Â â— salaries, payroll taxes, employee benefits expenses for individuals involved in research and development efforts; Â Â Â Â â— research supplies; and Â Â Â Â â— legal and patent office fees related to patent and intellectual property matters. Â 23 Â Â We expense research and development costs as incurred. We recognize expenses for certain development activities, such as preclinical studies and manufacturing, based on an evaluation of the progress to completion of specific tasks using data or other information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of expenses incurred. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. These amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. Â Â External costs represent a significant portion of our research and development expenses, which we track on a program-by-program basis following the

nomination of a development candidate. Our internal research and development expenses consist primarily of personnel-related expenses, including salaries, benefits and stock-based compensation expenses. We do not track our internal research and development expenses on a program-by-program basis as the resources are deployed across multiple projects. Â The successful development of our Products and Product Candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete the remainder of the development of our Product Candidates or to develop and commercialize additional Products. We are also unable to predict when, if ever, material net cash inflows will commence from our Product Candidates, if approved. This is due to the numerous risks and uncertainties associated with development, including the uncertainty related to: Â Â â— the timing and progress of preclinical and clinical development activities; Â Â â— the number and scope of preclinical and clinical programs we decide to pursue; Â Â â— our ability to raise additional funds necessary to complete preclinical and clinical development and commercialization of our Product Candidates, to further advance the development of our manufacturing technologies, and to develop and commercialize additional Products, if any; Â Â â— our ability to maintain our current research and development programs and to establish new ones; Â Â â— our ability to establish sales, licensing or collaboration arrangements; Â Â â— the progress of the development efforts of parties with whom we may enter into collaboration arrangements; Â Â â— the successful initiation and completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority; Â Â â— the receipt and related terms of regulatory approvals from applicable regulatory authorities; Â Â â— the availability of materials for use in production of our Products and Product Candidates; Â Â â— our ability to secure manufacturing supply through relationships with third parties or establish and operate a manufacturing facility; Â Â â— our ability to consistently manufacture our Product Candidates in quantities sufficient for use in clinical trials; Â Â â— our ability to obtain and maintain intellectual property protection and regulatory exclusivity, both in the United States and internationally; Â Â â— our ability to maintain, enforce, defend and protect our rights in our intellectual property portfolio; Â 24 Â Â Â â— the commercialization of our Product Candidates, if and when approved, and of new Products; Â Â â— our ability to obtain and maintain third-party payor coverage and adequate reimbursement for our Product Candidates, if approved; Â Â â— the acceptance of our Product Candidates, if approved, by patients, the medical community and third-party payors; Â Â â— competition with other products; and Â Â â— a continued acceptable safety profile of our Product Candidates following receipt of any regulatory approvals. Â Â A change in the outcome of any of these variables with respect to the development of any of our Products or Product Candidates would significantly change the costs and timing associated with the development of those Products or Product Candidates. Â Research and development activities account for a significant portion of our operating expenses. Research and development expenses decreased in our three months ended September 30, 2024, as compared to our three months ended September 30, 2023, largely due to high costs associated with our INM-755 program during the prior year. However, we expect our research and development expenses to increase significantly in future periods as we continue to implement our business strategy, which includes advancing our drug candidates and our manufacturing technologies into and through clinical development, expanding our research and development efforts, including hiring additional personnel to support our research and development efforts, ultimately seeking regulatory approvals for our drug candidates that successfully complete clinical trials, and further developing selected research and development and commercial BayMedica activities. In addition, drug candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. Accordingly, although we expect our research and development expenses to increase as our drug candidates advance into later stages of clinical development, we do not believe that it is possible, at this time, to accurately project total program-specific expenses through to commercialization. There are numerous factors associated with the successful commercialization of any of our Product Candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Â General and Administrative Expenses Â General and administrative expenses consist of personnel-related costs, including salaries, benefits and stock-based compensation expense, for our personnel in executive, finance and accounting, human resources, business operations and other administrative functions, investor relations activities, legal fees related to corporate matters, fees paid for accounting and tax services, consulting fees and facility-related costs. Â Amortization and Depreciation Â Intangible assets are comprised of intellectual property that we acquired in 2014 and 2015 and trade secrets, product formulation knowledge, patents that we acquired in October 2021. The acquired intellectual property and patents are amortized on a straight-line basis based on their estimated useful lives. Equipment and leasehold improvements are depreciated using the straight-line method based on their estimated useful lives. Â Share-based Payments Â Share-based payments is the stock-based compensation expense related to our granting of stock options to employees and others. The fair value, at the grant date, of equity-settled share awards is charged to our loss over the period for which the benefits of employees and others providing similar services are expected to be received. The vesting components of graded vesting employee awards are measured separately and expensed over the related trancheâ€™s vesting period. The amount recognized as an expense is adjusted to reflect the number of share options expected to vest. The fair value of awards is calculated using the Black-Scholes option pricing model, which considers the exercise price, current market price of the underlying shares, expected life of the award, risk-free interest rate, expected volatility and the dividend yield. Â 25 Â Â Other Income Â Other income consists primarily of interest income earned on our cash, cash equivalents and short-term investments. Â Results of Operations Â The Company has two operating and reportable segments based on the management approach which designates the internal reporting used by the CODM, the Companyâ€™s Chief Executive Officer and the senior management team, for making decisions and assessing performance as the source of the Companyâ€™s reportable segments. The CODM allocates resources and assesses the performance of each operating segment based on potential licensing opportunities, historical and potential future product sales, operating expenses, and operating income (loss) before interest and taxes. The Company has determined its reportable segments to be â€˜InMed Pharmaâ€™ and â€˜BayMedica Commercialâ€™ based on the information used by the CODM. Â Comparison of the three months ended September 30, 2024 and 2023 for InMed Segment Â Â Â Three Months Ended September 30,Â Â Â Â Â Â Â Â Â Â 2024Â Â 2023Â Â ChangeÂ Â % ChangeÂ Â Â (in thousands)Â Â Â Â Â Â Â Â Â Operating expenses:Â Â Â Â Â Â Â Â Â Â Â Research and development and patentsÂ Â 763Â Â Â 1,271Â Â Â (508)Â Â (40)% General and administrativeÂ Â 1,238Â Â Â 1,064Â Â Â 174Â Â Â 16% Amortization and depreciationÂ Â 54Â Â Â 54Â Â Â -Â Â Â -% Foreign exchange (gain) lossÂ Â (19)Â Â 48Â Â Â (67)Â Â (140)% Total operating expensesÂ Â 2,036Â Â Â 2,437Â Â Â (401)Â Â (16)% Interest and other incomeÂ Â 57Â Â Â 136Â Â Â (79)Â Â (58)% Net lossÂ $(1,979)Â $(2,301)Â $322Â Â Â (14)% Â Research and Development and Patents Expenses Â Research and development and patents expenses decreased by $508,000 in our â€˜InMed Pharmaâ€™ segment, or 40%, for the three months ended September 30, 2024, as compared to the three months ended September 30, 2023. The decrease in research and development and patents expenses was due primarily to a decrease in external contractors, patent fees, and compensation. This was offset by an increase in research supplies. However, we expect our research and development expenses to increase significantly in future periods as we move closer towards clinical trials which will result in higher costs related studies, drug supplies, and increased regulatory requirements, as we continue to implement our business strategy. Â General and administrative expenses Â General and administrative expenses increased by $174,000 in our â€˜InMed Pharmaâ€™ segment, or 16%, for the three months ended September 30, 2024, as compared to the three months ended September 30, 2023. The increase results primarily from a combination of changes including higher investor relation expenses, personnel expenses, consulting fees, accounting fees, and legal. This was offset by a decrease in lower office and administrative expenses Â Foreign exchange loss Â The Companyâ€™s functional currency is the US dollar and our foreign exchange loss is predominantly due to transactions with foreign currency. Foreign exchange loss decreased by $67,000 in our â€˜InMed Pharmaâ€™ segment, or 140%, for the three months ended September 30, 2024, as compared to the three months ended September 30, 2023, as a consequence of holding non-US denominated assets and liabilities combined with fluctuations in foreign exchange rates. Â 26 Â Â Comparison of the three months ended September 30, 2024 and 2023 for the â€˜BayMedica Commercialâ€™ Segment Â Â Â Three Months Ended September 30,Â Â Â Â Â Â Â Â Â 2024Â Â 2023Â Â ChangeÂ Â % ChangeÂ Â Â (in thousands)Â Â Â Â Â Â Â Â SalesÂ $1,265Â Â $902Â Â $363Â Â Â 40% Cost of salesÂ Â 771Â Â Â 881Â Â Â (110)Â Â (12)% Gross profitÂ Â 494Â Â Â 21Â Â Â 473Â Â Â 2252)% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating expenses:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development and patentsÂ Â 8Â Â Â 21Â Â Â (13)Â Â (62)% General and administrativeÂ Â 184Â Â Â 235Â Â Â (51)Â Â (22)% Amortization and depreciationÂ Â 1Â Â Â 1Â Â Â -Â Â Â -% Total operating expensesÂ Â 193Â Â Â 257Â Â Â (64)Â Â (25)% Tax expenseÂ Â -Â Â Â -Â Â Â -Â Â Â -% Net IncomeÂ $301Â Â $(236)Â $537Â Â Â (228)% Â Sales Â Sales increased by $363,000 in our â€˜BayMedica Commercialâ€™ segment, or 40%, for the three months ended September 30, 2024, as compared to the three months ended September 30, 2023. The increase in sales results from expanded marketing efforts and increased demand in certain cannabinoid products. BayMedica will continue to evaluate opportunities for potential structured supply arrangements and collaborations for the commercial business. Sales and marketing efforts will remain focused on products that contribute highest margins, where BayMedica continues to hold a strong competitive position. Â Cost of Sales Â Cost of goods sold decreased by $110,000 in our â€˜BayMedica Commercialâ€™ segment, or 12%, for the three months ended September 30, 2024, as compared to the three months ended September 30, 2023. The decrease in cost of goods sold is primarily the result of decrease in write-down of inventories to net realizable value. Â Liquidity and Capital Resources Â Since our inception, we have incurred significant operating losses, generated limited revenue from product sales, and no sales from any other sources, and have negative cash flows from our operations. We have not yet commercialized any of our Product Candidates and we do not expect to generate revenue from sales of any Product Candidates for several years, if at all. We have funded our operations to date primarily with proceeds from the sale of our Common Shares. Â As of September 30, 2024, we had cash, cash equivalents and short-term investments of $5.6 million. Â The following table summarizes our cash flows for each of the periods presented: Â (in thousands)Â Three Months Ended September 30, 2024Â Â Three Months Ended September 30, 2023Â Net cash (used in) operating activitiesÂ $(1,826)Â $(2,174) Net cash provided by financing activitiesÂ Â 838Â Â Â -Â Net increase (decrease) in cash and cash equivalentsÂ $(988)Â $(2,174) Â 27 Â Â Operating ActivitiesÂ Â During the three months ended September 30, 2024, we used cash in operating activities of $1.8 million, primarily resulting from our net loss of $1.7 million combined with $328,000 used in changes in our non-cash working capital, partially offset by non-cash share-based compensation expenses and inventory write-down. Â During the three months ended September 30, 2023, we used cash in operating activities of $2.2 million, primarily resulting from our net loss of $2.5 million combined with changes in our working capital and non-cash expenses contributed to net cash used in operating activities. Â Investing ActivitiesÂ Â During the three months ended September 30, 2024, cash used in investing activities of $0 resulted from the purchases and sale of short-term investments. Â During the three months ended September 30, 2023, cash used in investing activities of $0. Â Financing Activities Â During the three months ended September 30, 2024, cash provided by financing activities of $838,000 consisted of $1.0 million in gross proceeds derived from the ATM, offset by total transaction costs of $192,000. Â During the three months ended September 30, 2023, cash provided by financing activities consisted of $0. Â Funding RequirementsÂ Â We expect our expenses to increase substantially in connection with our ongoing research and development activities, particularly as we continue the research and development of and the clinical trials for our Product Candidates. In addition, we expect to incur additional costs associated with operating as a US-listed public company and associated with any required investment into BayMedicaâ€™s research and development efforts targeting cannabinoid analogs. As a result, we expect to incur substantial operating losses and negative operating cash flows for the foreseeable future.Â Â In accordance with the Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Update (â€œASUâ€) 2014-15, Disclosure of Uncertainties about an Entityâ€™s Ability to Continue as a Going Concern (Subtopic 205-40), we have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date that the unaudited condensedÂ consolidated financial statements are issued. Â Through September 30, 2024, we funded our operations primarily with proceeds from the sale of our Common Shares. We have incurred recurring losses and negative cash flows from operations since its inception, including net losses of $1.7 million and $2.5 million for the three months ended September 30, 2024 and 2023, respectively. In addition, we have an accumulated deficit of $110.8 million as of September 30, 2024. Â As of the issuance date of the consolidated annual financial statements, the Company expects its cash, cash equivalents and short-term investments of $5.6 million as of September 30, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements through the end of the first quarter of calendar 2025, depending on the level and timing of realizing BayMedica revenues from the sale of bulk rare cannabinoids in the health and wellness sector, as well as the level and timing of Company operating expenses. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the unaudited condensedÂ consolidated financial statements are issued. Â We expect to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. We may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of our existing shareholders. Â 28 Â Â Our funding requirements and timing and amount of our operating expenditures will depend largely on: Â Â â— the scope, progress, results and costs of discovery research, preclinical development, laboratory testing and clinical trials for our Product Candidates;

Â Â â— the scope, progress, results and costs of development of our manufacturing technologies; Â Â â— the number of and development requirements for other Products and Product Candidates that we pursue; Â Â â— the costs, timing and outcome of regulatory review of our Product Candidates; Â Â â— our ability to enter into contract manufacturing arrangements for supply of materials and manufacture of our Products and Product Candidates and the terms of such arrangements; Â Â â— the impact of any acquired, or in-licensed, externally developed product(s) and/or technologies; Â Â â— our ability to establish and maintain strategic collaborations, licensing or other arrangements, including sales arrangements, and the financial terms of such arrangements; Â Â â— the sales, costs and timing of future commercialization activities, including product manufacturing, sales, marketing and distribution, for any of our Products and for Product Candidates for which we may receive marketing approval; Â Â â— the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property- related claims; Â Â â— expansion costs of our operational, financial and management systems and increases to our personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a dual listed company; Â Â â— the costs to obtain, maintain, expand and protect our intellectual property portfolio; and Â Â â— the level and timing of realizing revenues from the BayMedica commercial operations. Â A change in the outcome of any of these, or other variables with respect to the development of any of our Products and Product Candidates, could significantly change the costs and timing associated with their development. We will need to continue to rely on additional financing to achieve our business objectives. Â In addition to the variables described above, if and when any of our Product Candidates successfully complete development, we will incur substantial additional costs associated with regulatory filings, marketing approval, post-marketing requirements, maintaining our intellectual property rights, and regulatory protection, in addition to other commercial costs. We cannot reasonably estimate these costs at this time. Â Â Until such time, if ever, as we can generate substantial revenues from either our Products or Product Candidates, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements. We currently have no credit facility or committed sources of capital. To the extent that we raise additional capital through the future sale of equity securities, the ownership interests of our shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common shareholders. If we raise additional funds through the issuance of debt securities, these securities could contain covenants that would restrict our operations. We may require additional capital beyond our currently anticipated amounts, and additional capital may not be available on reasonable terms, or at all. If we raise additional funds through collaboration arrangements or other strategic transactions in the future, we may have to relinquish valuable rights to our technologies, future revenue streams, Products or Product Candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate development or future commercialization efforts or grant rights to develop and market Products or Product Candidates that we would otherwise prefer to develop and market ourselves. Â 29 Â Â Off-Balance Sheet ArrangementsÂ Â During the periods presented, we did not have, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations promulgated by the SEC. Â Critical Accounting Policies and Significant Judgments and EstimatesÂ Â Our significant accounting policies are described in Note 2 of the Financial Statements. The estimates will require us to rely upon assumptions that were highly uncertain at the time the accounting estimates are made, and changes in them are reasonably likely to occur from period to period. Changes in estimates used in these and other items could have a material impact on our financial statements in the future. Our estimates will be based on our experience and our interpretation of economic, political, regulatory, and other factors that affect our business prospects. Actual results may differ significantly from our estimates. For detailed information regarding our critical accounting policies and estimates, see our financial statements and notes thereto included in this Report and in our 2024 Annual Report. There have been no material changes to our critical accounting policies and estimates from those disclosed in our 2024 Annual Report. Â ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. Â We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and, as such, are not required to provide the information under this Item. Â ITEM 4. CONTROLS AND PROCEDURES. Â Evaluation of Disclosure Controls and Procedures Â Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2024. The term â€œdisclosure controls and procedures,â€ as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECâ€™s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to its management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2024, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective. Â Changes in Internal Control Over Financial Reporting Â There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three-month period ended September 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Â 30 Â Â PART II Â ITEM 1. LEGAL PROCEEDINGS. Â We are not presently involved in any active legal proceedings that we believe to be material to the Company. However, from time to time, we may be subject to various pending or threatened legal actions, claims and proceedings, including those that arise in the ordinary course of our business (including, but not limited to, the matters discussed in Note 11 of the unaudited condensed consolidated financial statements included in this Quarterly Report). Â ITEM 1A. RISK FACTORS. Â Reference is made to Part I, Item 1A, â€œRisk Factorsâ€ included in the 2024 Annual Report for information concerning risk factors, which should be read in conjunction with the factors set forth in â€œCautionary Statement Regarding Forward-Looking Statementsâ€ of this Report. There have been no material changes with respect to the risk factors disclosed in our 2024 Annual Report, except as set forth below. You should carefully consider such factors in the 2024 Annual Report, and below, which could materially affect our business, financial condition or future results. The risks described in the 2024 Annual Report and below, are not exhaustive and therefore, there are additional risks facing the Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition and/or operating results. Â Any actual or threatened delisting of our securities by Nasdaq could have a material and adverse effect on our business, operations and financial condition, and could, among other things, limit investorsâ€™ ability to make transactions in our securities and subject us to additional trading restrictions. Â Â As previously reported by the Company, on March 19, 2024, the Company received written notification from the Listing Qualifications Department of Nasdaq that the Company has been granted an additional 180-day compliance period, or until September 16, 2024 (the â€œExtended Compliance Periodâ€), to regain compliance with Nasdaqâ€™s minimum bid price requirement for the continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the â€œMinimum Bid Price Ruleâ€). Nasdaqâ€™s determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on Nasdaq, with the exception of the bid price requirement, and the Companyâ€™s written notice of its intention to consider all available options to regain compliance during the Extended Compliance Period, including, if necessary, effecting a reverse stock split. The Company was unable to regain compliance during the Extended Compliance Period and on September 17, 2024, the Company received an additional notification from the Listing Qualifications Department stating that due to the deficiency, the Companyâ€™s securities would be delisted from Nasdaq on September 26, 2024, unless the Company appealed Nasdaqâ€™s determination to a Hearings Panel (the â€œPanelâ€). A hearing request would stay the suspension of the Companyâ€™s securities pending the Panelâ€™s discussion. On September 17, 2024, the Company submitted the hearing request to appeal (the â€œAppeal Requestâ€) Nasdaqâ€™s determination before the Panel. Â On November 14, 2024, the Company effected a reverse stock split of the Common Shares at a ratio of 20-to-1 (the â€œReverse Stock Splitâ€). Trading of the Common Shares on Nasdaq on a split-adjusted basis began as of November 14, 2024. As a result of the Reverse Stock Split, every twenty shares of Common Shares were combined into one Common Share, and the total number of Common Shares outstanding were reduced from approximately 14,361,550 Common Shares to approximately 718,032 Common Shares. No fractional Common Shares were issued if, as a result of the Reverse Stock Split, a registered shareholder would otherwise become entitled to a fractional share. Instead, shareholders who otherwise were entitled to receive fractional Common Shares because they held a number of Common Shares not evenly divisible by the ratio of the Reverse Stock Split were automatically entitled to receive an additional Common Share. In other words, any fractional share will be rounded up to the nearest whole number. Â 31 Â Â While the Company has effected the Reverse Stock Split, there can be no assurances, however, that we will be successful in regaining compliance with the continued listing requirements and maintaining the listing of our Common Shares on Nasdaq. Delisting from Nasdaq could materially and adversely affect our ability to raise additional financing through the public or private sale of equity securities, would significantly affect the ability of investors to trade our securities and would negatively affect the value and liquidity of our securities, including our Common Shares. The actual or threatened delisting of our securities could also have other material and adverse consequences, including the potential loss of confidence by employees and other stakeholders, the loss of institutional investor interest and fewer business development opportunities, limited availability of market quotations for our securities, reduced liquidity with respect to our securities, a determination that our Common Shares is â€œpenny stock,â€ which will require brokers trading in shares of our Common Shares to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our Common Shares, and limited amount of news and analyst coverage of the Company. To the extent that our Common Shares became eligible to trade on the OTC Bulletin Board, another over-the-counter quotation system, or on the pink sheets, an investor may find it more difficult to dispose of their Common Shares or obtain accurate quotations as to the market value of our Common Shares. Â Furthermore, the National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as â€œcovered securities.â€ Because our Common Shares are currently listed on Nasdaq, such securities will be deemed covered securities. Although the states will be preempted from regulating the sale of our securities, the federal statute does allow states to investigate companies if there is a suspicion of fraud and, if there is a finding of fraudulent activity, then the states can regulate or bar the sale of covered securities in a particular case. Additionally, if we were no longer listed on Nasdaq, our securities would not be covered securities and we would be subject to regulations in each state in which we offer our securities. Â The Reverse Stock Split may not increase the price of our Common Shares and have the desired effect of maintaining compliance with the Minimum Bid Price Rule. Â While the Companyâ€™s Board of Directors expects that the Reverse Stock Split will sufficiently increase the market price of our Common Shares so that we are able to regain and maintain compliance with the Minimum Bid Price Rule and the Nasdaq Listing Rules more generally, the effect of the Reverse Stock Split upon the market price of our Common Shares cannot be predicted with any certainty, and the history of similar reverse stock splits for companies in like circumstances is varied. The price per share of our Common Shares may not reflect the exchange ratio implemented by the Companyâ€™s Board of Directors and the price per share following the effective time of the reverse stock split may not be maintained for any period of time following the Reverse Stock Split. Under applicable Nasdaq rules, to regain compliance with the $1.00 minimum closing bid price requirement and maintain our listing on Nasdaq, the $1.00 closing bid price must be maintained for a minimum of ten consecutive trading days. Accordingly, the Company cannot assure you that we will be able to maintain our Nasdaq listing, even though the Reverse Stock Split has been made effected, or that the market price per share will exceed or remain in excess of the $1.00 minimum bid price for a sustained period of time. Â We continue to monitor the Companyâ€™s Common Shares price, however, it is possible that the per share price of our Common Shares will not rise in proportion to the reduction in the number of shares of our Common Shares outstanding resulting from the Reverse Stock Split, and the market price per post-Reverse Stock Split share may not exceed or remain in excess of the $1.00 minimum bid price for a sustained period of time, and the Reverse Stock Split may not result in a per share price that would attract brokers and investors who do not trade in lower priced stocks. Notwithstanding the effectiveness of the Reverse Stock Split, the market price of our Common Shares may decrease due to factors unrelated to the Reverse Stock Split, and the market price of our Common Shares may also be based on other factors which may be unrelated to the number of Common Shares outstanding, including our future performance. If the trading price of our Common Shares declines, the percentage decline as an absolute number and as a percentage of our overall market capitalization may be greater than would occur in the absence of the Reverse Stock Split. Â The Reverse Stock Split may decrease the liquidity of our Common Shares. Â The liquidity of our Common Shares may be harmed by the Reverse Stock Split effected by the Company on November 14, 2024 given the reduced number of Common Shares that are outstanding after the Reverse Stock Split, particularly if the Common Share price does not increase as a result of the Reverse Stock Split. In addition, investors might consider the increased proportion of unissued authorized shares of Common Shares to issued shares to have an anti-

takeover effect under certain circumstances, because the proportion allows for dilutive issuances which could prevent certain shareholders from changing the composition of the Board of Directors or render tender offers for a combination with another entity more difficult to successfully complete. The Board of Directors does not intend for the Reverse Stock Split to have any anti-takeover effects. Â 32 Â Â ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. Â None. Â ITEM 3. DEFAULTS UPON SENIOR SECURITIES. Â None. Â ITEM 4. MINE SAFETY DISCLOSURE. Â None Â ITEM 5. OTHER INFORMATION. Â Rule 10b5-1 Plan and Non-Rule 10b5-1 Trading Arrangement Adoptions, Terminations, and Modifications Â During the three months ended September 30, 2024, none of our directors or â€œofficersâ€ (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each term is defined in Item 408 of Regulation S-K. Â ITEM 6. EXHIBITS. Â Exhibits Â The following exhibits are filed as part of this report: Â Exhibit Number Â Description 31.1* Â Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended Â Â Â 31.2* Â Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended Â Â Â 32.1* Â Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Â Â Â 32.2* Â Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Â Â Â 101.INS* Â Inline XBRL Instance Document. Â Â Â 101.SCH* Â Inline XBRL Taxonomy Extension Schema Document. Â Â Â 101.CAL* Â Inline XBRL Taxonomy Extension Calculation Linkbase Document. Â Â Â 101.DEF* Â Inline XBRL Taxonomy Extension Definition Linkbase Document. Â Â Â 101.LAB* Â Inline XBRL Taxonomy Extension Label Linkbase Document. Â Â Â 101.PRE* Â Inline XBRL Taxonomy Extension Presentation Linkbase Document. Â Â Â 104* Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). Â *Filed herewith. Â 33 Â Â Â SIGNATURES Â Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Â INMED PHARMACEUTICALS INC. Â (Registrant) Â Â Dated: November 14, 2024 By: /s/ Netta JagpalÂ Â Â Â

design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 14, 2024 Â Â /s/ Netta Jagpal Â Name:Â Netta Jagpal Â Title: Chief Financial Officer Â EX-32.1 4 ea021977401ex32-1_inmed.htm CERTIFICATION Exhibit 32.1 Â Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Â Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Eric A. Adams, the President and Chief Executive Officer of InMed Pharmaceuticals Inc. (the â€œCompanyâ€), hereby certify that, to my knowledge: Â 1.The Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the â€œReportâ€) of the Company fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and Â 2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: November 14, 2024 Â Â /s/ Eric A. Adams Â Name:Â Eric A. Adams Â Title: President and Chief Executive Officer Â EX-32.2 5 ea021977401ex32-2_inmed.htm CERTIFICATION Exhibit 32.2 Â Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Â Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Netta Jagpal, the Chief Financial Officer of InMed Pharmaceuticals Inc. (the â€œCompanyâ€), hereby certify that, to my knowledge: Â 1.The Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the â€œReportâ€) of the Company fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and Â 2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: November 14, 2024 Â Â /s/ Netta Jagpal Â Name:Â Netta Jagpal Â Title: Chief Financial Officer Â Â EX-101.SCH 6 inm-20240930.xsd XBRL SCHEMA FILE 995301 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 995302 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 995303 - Statement - Condensed Consolidated Statements of Operations Unaudited link:presentationLink link:definitionLink link:calculationLink 995304 - Statement - Condensed Consolidated Statements of Shareholdersâ€™ Equity Unaudited link:presentationLink link:definitionLink link:calculationLink 995305 - Statement - Condensed Consolidated Statements of Cash Flows Unaudited link:presentationLink link:definitionLink link:calculationLink 995306 - Disclosure - Corporate Information and Continuing Operations link:presentationLink link:definitionLink link:calculationLink 995307 - Disclosure - Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 995308 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 995309 - Disclosure - Property, Equipment and Rou Assets, Net link:presentationLink link:definitionLink link:calculationLink 995310 - Disclosure - Intangible Assets link:presentationLink link:definitionLink link:calculationLink 995311 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:definitionLink link:calculationLink 995312 - Disclosure - Share Capital and Reserves link:presentationLink link:definitionLink link:calculationLink 995313 - Disclosure - Share-Based Payments link:presentationLink link:definitionLink link:calculationLink 995314 - Disclosure - Lease Obligations link:presentationLink link:definitionLink link:calculationLink 995315 - Disclosure - Segment Information link:presentationLink link:definitionLink link:calculationLink 995316 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 995317 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 995318 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 996000 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 996001 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 996002 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 996003 - Disclosure - Property, Equipment and Rou Assets, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 996004 - Disclosure - Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 996005 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 996006 - Disclosure - Share Capital and Reserves (Tables) link:presentationLink link:definitionLink link:calculationLink 996007 - Disclosure - Lease Obligations (Tables) link:presentationLink link:definitionLink link:calculationLink 996008 - Disclosure - Segment Information (Tables) link:presentationLink link:definitionLink link:calculationLink 996009 - Disclosure - Corporate Information and Continuing Operations (Details) link:presentationLink link:definitionLink link:calculationLink 996010 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 996011 - Disclosure - Significant Accounting Policies (Details) - Schedule of Diluted Net Income (Loss) Per Shares link:presentationLink link:definitionLink link:calculationLink 996012 - Disclosure - Inventories (Details) - Schedule of Inventories link:presentationLink link:definitionLink link:calculationLink 996013 - Disclosure - Property, Equipment and Rou Assets, Net (Details) link:presentationLink link:definitionLink link:calculationLink 996014 - Disclosure - Property, Equipment and Rou Assets, Net (Details) - Schedule of Property, Equipment and ROU Assets link:presentationLink link:definitionLink link:calculationLink 996015 - Disclosure - Intangible Assets (Details) link:presentationLink link:definitionLink link:calculationLink 996016 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets link:presentationLink link:definitionLink link:calculationLink 996017 - Disclosure - Intangible Assets (Details) - Schedule of Expects Amortization Expense link:presentationLink link:definitionLink link:calculationLink 996018 - Disclosure - Accounts Payable and Accrued Liabilities (Details) - Schedule of Accounts Payable and Accrued Liabilities link:presentationLink link:definitionLink link:calculationLink 996019 - Disclosure - Share Capital and Reserves (Details) link:presentationLink link:definitionLink link:calculationLink 996020 - Disclosure - Share Capital and Reserves (Details) - Schedule of Warrant Activity link:presentationLink link:definitionLink link:calculationLink 996021 - Disclosure - Share-Based Payments (Details) link:presentationLink link:definitionLink link:calculationLink 996022 - Disclosure - Lease Obligations (Details) link:presentationLink link:definitionLink link:calculationLink 996023 - Disclosure - Lease Obligations (Details) - Schedule of Minimum Lease Payments link:presentationLink link:definitionLink link:calculationLink 996024 - Disclosure - Segment Information (Details) link:presentationLink link:definitionLink link:calculationLink 996025 - Disclosure - Segment Information (Details) - Schedule of Reportable Segments link:presentationLink link:definitionLink link:calculationLink 996026 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 996027 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 996028 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 inm-20240930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 inm-20240930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 inm-20240930_lab.xml XBRL LABEL FILE Total current assets Total Assets Total current liabilities Total Liabilities Total Shareholdersâ€™ Equity Balance Balance Total Liabilities and Shareholdersâ€™ Equity Gross profit Total operating expenses Loss before income tax expense Net loss Loss for the period Net loss Balance (in Shares) Balance (in Shares) Common shares, shares outstanding Equity Components [Axis] Total cash used in operating activities Total cash used in investing activities Total cash provided by financing activities Decrease in cash during the period Cash and cash equivalents beginning of the period Cash and cash equivalents end of the period Corporate Information and Continuing Operations [Abstract] Significant Accounting Policies [Abstract] Antidilutive Securities [Axis] Inventories [Abstract] Schedule of Inventories [Abstract] Inventories Inventories, net Property, Equipment and Rou Assets, Net [Abstract] Long-Lived Tangible Asset [Axis] Property, equipment and ROU assets, net Property, equipment and right-of-use (â€œROUâ€) assets, net Intangible Assets [Abstract] Schedule of Intangible Assets [Abstract] Intangible assets Intangible assets, net Intangible assets, net Schedule of Expects Amortization Expense [Abstract] Total Accounts Payable and Accrued Liabilities [Abstract] Schedule of Accounts Payable and Accrued Liabilities [Abstract] Accounts payable and accrued liabilities Accounts payable and accrued liabilities Share Capital and Reserves [Abstract] Number of Shares Under Warrants, Balance beginning Number of Shares Under Warrants, Balance ending Weighted Average Exercise Price, Balance beginning Weighted Average Exercise Price, Balance ending Class of Warrant or Right [Axis] Share-Based Payments [Abstract] Lease Obligations [Abstract] Schedule of Minimum Lease Payments [Abstract] Total undiscounted lease liabilities Segment Information [Abstract] Segments [Axis] Subsegments [Axis] Commitments and Contingencies [Abstract] Related Party Transactions [Abstract] Subsequent Events [Abstract] ASSETS Current Cash and cash equivalents Cash and Cash Equivalents Short-term investments Accounts receivable (less provision for credit losses of $nil and $66,775 in September 30, 2024 and June 30, 2024, respectively) Accounts receivable less provision for credit losses (in Dollars) Prepaids and other current assets Non-Current Other assets LIABILITIES AND SHAREHOLDERSâ€™ EQUITY Current Current portion of lease obligations Less: Current portion of lease liabilities Non-current Lease obligations, net of current portion Non-current portion of lease liabilities Commitments and Contingencies (Note 11) Shareholdersâ€™ Equity Common Shares, no par value, unlimited authorized shares: 667,013 and 445,948, as of September 30, 2024 and June 30, 2024, respectively, issued and outstanding Common shares, par value (in Dollars per share) Common shares, unlimited authorized Common shares, shares issued Shares issued Additional paid-in capital Accumulated deficit Accumulated other comprehensive income Sales Cost of sales Cost of sales Operating Expenses Research and development and patents Research and development patents General and administrative General and Administrative Amortization and depreciation Amortization and depreciation Other Income (Expense) Interest and other income Net loss per share Basic (in Dollars per share) Diluted (in Dollars per share) Weighted average outstanding Common Shares Basic (in Shares) Diluted (in Shares) Private placement Private placement (in Shares) Exercise of pre-funded warrants Exercise of pre-funded warrants (in Shares) Share-based compensation Operating Activities Items not requiring cash: Amortization and depreciation Share-based compensation Amortization of ROU assets Unrealized foreign exchange loss Inventory write-down Inventory write-down due to net realizable (in Dollars) Changes in operating assets and liabilities: Accounts payable and accrued liabilities Deferred rent Lease obligations Investing Activities Sale of short-term investments Financing Activities Proceeds from the private placement SUPPLEMENTARY CASH FLOW INFORMATION: Cash Paid During the Period for: Income Taxes Interest SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Recognition of ROU asset and corresponding operating lease liability Foreign Exchange (Gain) Loss Foreign exchange gain (loss) Income tax expense Share issuance costs Interest income received on short-term investments Inventories Prepaids and other currents assets Other non-current assets Accounts receivable Purchase of short-term investments Private placement issuance costs Common Shares Common Stock [Member] Common Shares [Member] Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income CORPORATE INFORMATION AND CONTINUING OPERATIONS SIGNIFICANT ACCOUNTING POLICIES Schedule of Diluted Net Income (Loss) Per Shares Total share of anti-dilutive INVENTORIES Schedule of Inventories Raw materials Work in process Finished goods PROPERTY, EQUIPMENT AND ROU ASSETS, NET Schedule of Property, Equipment and ROU Assets Property and equipment INTANGIBLE ASSETS Schedule of Intangible Assets Intellectual property Patents Payable under the patent license agreement Schedule of Expects Amortization Expense 2025 2026 2027 2028 2029 Thereafter ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Schedule of Accounts Payable and Accrued Liabilities Trade payables Accrued research and development expenses Inventory related accruals Employee compensation, benefits and related accruals Accrued general and administrative expenses SHARE CAPITAL AND RESERVES Schedule of Warrant Activity Number of Shares Under Warrants, Warrants Granted Weighted Average Exercise Price, Warrants Granted Weighted Average Exercise Price, Exercised Weighted Average Exercise Price, Expire/Cancelled Number of Shares Under Warrants, Warrants Exercisable Weighted Average Exercise Price, Warrants Exercisable SHARE-BASED PAYMENTS LEASE OBLIGATIONS Schedule of Minimum Lease Payments Year 1 Year 2 Year 3 Year 4 Year 5 Present value of lease liabilities SEGMENT INFORMATION Schedule of Reportable Segments COMMITMENTS AND CONTINGENCIES RELATED PARTY TRANSACTIONS SUBSEQUENT EVENTS Less: accumulated depreciation and amortization Less: accumulated amortization Number of Shares Under Warrants, Exercised Number of Shares Under Warrants, Expire/Cancelled More than five years Less: imputed interest Options [Member] Stock Option [Member] Warrants [Member] Warrant [Member] ROU Assets (leases) [Member] Equipment [Member] Furnishings [Member] InMed [Member] Reportable Subsegments [Member] BayMedica [Member] Customer [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Type [Axis] Change in Accounting Estimate by Type [Axis] Statistical Measurement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Statement of Income Location, Balance [Axis] Related Party Transaction [Axis] Class of Stock [Axis] Subsequent Event Type [Axis] Date of incorporation Cash, cash equivalents and short-term investments Cash equivalents (in Dollars) Uninsured cash balance (in Dollars) Concentration of credit risk percentage Inventory valuation reserves (in Dollars) Estimated useful lives Estimated useful life Impairment loss (in Dollars) Depreciation expense Amortized on a straight-line basis Weighted average estimated remaining useful life Amortization expense on intangible assets (in Dollars) Preferred shares, issued Preferred shares, outstanding Gross proceeds (in Dollars) Fees paid (in Dollars) Outstanding intrinsic value (in Dollars) Weighted average remaining life Percentage of common stock issued and outstanding Stock options (in Shares) Vested and exercisable options (in Shares) Exercisable options, weighted average exercise price (in Dollars per share) Unvested options (in Shares) Unvested options, weighted average exercise price (in Dollars per share) Share-based payment expense Research and development expenses Unrecognized compensation cost Weighted-average vesting period Square feet (in Square Meters) Rental rate Estimated agreement term Borrowing rate, percentage Operating lease liability Obligated to pay Termination period Total assets Contract research services and materials Guaranteed investment certificates Warrants to purchase (in Shares) Legal services Gross proceeds Reverse stock split, description Basis of Presentation Reclassifications Use of Estimates Basis of Consolidation Foreign Currency Cash and Cash Equivalents Short-term Investments Accounts Receivable Concentration of Credit Risk and Other Risks and

Uncertainties Inventories Property, Equipment and ROU Assets, Net Intangible Assets, Net In-Process R&D Impairment of Long-Lived Assets Fair Value Measurements Revenue Recognition Cost of Sales Shipping and Handling Earnings (Loss) Per Share Share-based Payments Research and Development Costs Patents and Intellectual Property Costs Segment reporting Leases Recent Accounting Pronouncements Customer One [Member] Accounts Receivable [Member] Customer Concentration Risk [Member] Customer Two [Member] Customer Three [Member] Customer Four [Member] Customer Five [Member] Revenue Benchmark [Member] Valuation Allowances [Member] Computer Equipment [Member] Minimum [Member] Lab Equipment [Member] Maximum [Member] Furniture and Fixtures [Member] ATM Agreement [Member] General and Administrative Expenses [Member] Research and Development Expense [Member] Cost of Goods Sold [Member] Share-Based Payment Arrangement [Member] Unvested Options [Member] InMed Pharma Segment [Member] BayMedica Segment [Member] Norton Rose Fulbright Canada LLP [Member] Subsequent Event [Member] Equity Component [Domain] Statement [Table] Statement [Line Items] Share Capital and Reserves (Tables) [Table] Share Capital and Reserves [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Security, Excluded EPS Calculation [Table] Schedule of Diluted Net Income (Loss) Per Shares [Line Items] Long-Lived Tangible Asset [Domain] Property, Plant and Equipment [Table] Schedule of Property, Equipment and ROU Assets [Line Items] Class of Warrant or Right [Domain] Class of Warrant or Right [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Subsegments [Domain] Segments [Domain] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Reportable Segments [Line Items] Customer [Domain] Concentration Risk Type [Domain] Change in Accounting Estimate, Type [Domain] Concentration Risk Benchmark [Domain] Statistical Measurement [Domain] Significant Accounting Policies (Details) [Table] Significant Accounting Policies [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Share Capital and Reserves (Details) [Table] Share Capital and Reserves [Line Items] Statement of Income Location, Balance [Domain] Award Type [Domain] Share-Based Payments (Details) [Table] Share-Based Payments [Line Items] Segment Information (Details) [Table] Segment Information [Line Items] Commitments and Contingencies (Details) [Table] Commitments and Contingencies [Line Items] Related Party Transaction [Domain] Related Party Transactions (Details) [Table] Related Party Transactions [Line Items] Class of Stock [Domain] Subsequent Event Type [Domain] Subsequent Events (Details) [Table] Subsequent Events [Line Items] Accrued research and development expenses. Corresponding operating lease liability The amoun of finite lived intellectual property. The cash outflow of private placement issuance costs. Amount of proceed from issuance of share capital and reserves. The number of equity-based payment instruments, excluding stock (or unit) options, that were exercised during the reporting period. Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. The number of equity-based payment instruments, excluding stock (or unit) warrants exercisable, that were exercisable during the reporting period. The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of warrants exercisable outstanding and currently exercisable under the stock other than option plan. Stock Issued During Period Value Issued For Private Placement. Stockholders' Equity, Reverse Stock Split Rightofuse Assetsleases Member Payments for Rent Use of Estimates, Policy [Policy Text Block] Lab Equipment Member Assets [Abstract] Commitments and Contingencies Nonoperating Income (Expense) [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Common Stock, Value, Issued Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Earnings Per Share, Diluted Liabilities, Noncurrent [Abstract] Retained Earnings [Member] Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Accounts Receivable, after Allowance for Credit Loss Lessee, Leases [Policy Text Block] Weighted Average Number of Shares Outstanding, Basic [Abstract] Weighted Average Number of Shares Outstanding, Basic Finite-Lived Intangible Assets, Net Shareholders' Equity and Share-Based Payments [Text Block] Stock Issued During Period, Value, New Issues Statement of Stockholders' Equity [Abstract] Finite-Lived Intangible Asset, Expected Amortization, after Year Five Basis of Accounting, Policy [Policy Text Block] Increase (Decrease) in Operating Lease Liability Finite-Lived Intangible Asset, Expected Amortization, Year Five Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, Uninsured Amount Finite-Lived Patents, Gross Fair Value Measurement, Policy [Policy Text Block] Income Tax Expense (Benefit) Equipment [Member] Amortization of Intangible Assets Research and Development Expense [Member] Income Statement [Abstract] Finite-Lived Intangible Asset, Expected Amortization, Year Two Stock Issued During Period, Shares, New Issues Lessee, Operating Leases [Text Block] Goodwill and Intangible Assets, Policy [Policy Text Block] Customer Two Member New Accounting Pronouncements, Policy [Policy Text Block] Deferred Compensation Arrangement with Individual, Share-Based Payments [Line Items] Investment Income, Interest Cash, Cash Equivalents, and Short-Term Investments Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Other Assets, Noncurrent Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Operating Expenses [Abstract] Schedule of Segment Reporting Information, by Segment [Table Text Block] Estimated Agreement Term Inventory, Raw Materials, Gross Unrealized Loss on Foreign Currency Derivatives, before Tax Finite-Lived Intangible Assets, Remaining Amortization Period Supplemental Cash Flow Information [Abstract] Finite Lived Intellectual Property Earnings Per Share, Basic Net Cash Provided by (Used in) Operating Activities [Abstract] Assets Liabilities Research and Development Expense Equity, Attributable to Parent [Abstract] Accounts Payable, Trade, Current Preferred Stock, Shares Issued Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Warrants Exercisable Accounts Receivable [Member] Operating Lease, Payments, Use Subsequent Events [Text Block] Investment, Policy [Policy Text Block] Other Research and Development Expense Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Cost of Goods and Service [Policy Text Block] Asset Impairment Charges Minimum [Member] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Common Stock, Shares, Outstanding Increase (Decrease) in Prepaid Expenses, Other Interest Income, Short-Term Investment, Other Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Retained Earnings (Accumulated Deficit) Increase (Decrease) in Inventories Lessee, Operating Lease, Liability, to be Paid, Year Three Finite-Lived Intangible Asset, Useful Life Depreciation Net Cash Provided by (Used in) Investing Activities Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Grant Date Fair Value Payments for Other Fees Inventory, Finished Goods, Gross Additional Paid in Capital, Common Stock Inventory, Policy [Policy Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Payments to Acquire Short-Term Investments Share-Based Payment Arrangement [Policy Text Block] Interest Paid, Excluding Capitalized Interest, Operating Activities Workers' Compensation Liability, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Subordinated Borrowing, Interest Rate Corresponding Operating Lease Liability Inventory Disclosure [Text Block] Preferred Stock, Shares Outstanding Schedule Of Reportable Segments Abstract Property, Plant and Equipment, Net Prepaid Expense and Other Assets, Current Inventory Valuation and Obsolescence [Member] Net Cash Provided by (Used in) Financing Activities Accounts Payable, Current Maximum [Member] Shipping and Handling Cost, Policy [Policy Text Block] Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Property, Plant and Equipment, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Furnishing Member Customer Four Member Operating Lease, Liability, Noncurrent Accounts Receivable [Policy Text Block] Subsequent Event [Member] Warrant [Member] Share-Based Payment Arrangement [Member] Concentration Risk, Credit Risk, Policy [Policy Text Block] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Bay Medica Commercial Member Share-Based Payment Arrangement, Expense Increase (Decrease) in Operating Capital [Abstract] Net Cash Provided by (Used in) Financing Activities [Abstract] Additional Paid-in Capital [Member] Lessee, Operating Lease, Option to Terminate Class of Warrant or Right, Number of Securities Called by Warrants or Rights Lessee, Operating Lease, Liability, to be Paid, Year Four Schedule Of Property Equipment And Rou Assets Abstract Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Foreign Currency Transactions and Translations Policy [Policy Text Block] Net Cash Provided by (Used in) Investing Activities [Abstract] Lessee, Operating Lease, Liability, to be Paid, after Year Five Finite-Lived Intangible Asset, Expected Amortization, Year One Operating Lease, Liability Norton Rose Fulbright Canada LLPMember Intangible Assets Disclosure [Text Block] Customer One Member Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Depreciation, Depletion and Amortization, Nonproduction Significant Accounting Policies [Text Block] Revenue from Contract with Customer [Policy Text Block] Common Stock [Member] Reclassification, Comparability Adjustment [Policy Text Block] Other Cash Equivalents, at Carrying Value Segment Reporting, Policy [Policy Text Block] AOCI Attributable to Parent [Member] Statement of Cash Flows [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Property, Plant and Equipment, Useful Life Borrowings under Guaranteed Investment Agreements Operating Lease, Liability, Current Common Stock, Capital Shares Reserved for Future Issuance Customer Three Member Proceed From Issuance Of Share Capital And Reserves Area of Land Patents And Intellectual Property Costs Policy Text Block Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Related Party Transactions Disclosure [Text Block] Cost, Direct Material Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Selling, General and Administrative Expenses [Member] Liabilities, Current [Abstract] Net Cash Provided by (Used in) Operating Activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Legal Fees Stock Issued During Period Value Issued For Private Placement Share-Based Payment Arrangement [Text Block] Lessee, Operating Lease, Liability, to be Paid, Year Five Operating Lease, Right-of-Use Asset, Periodic Reduction Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms In Med Pharma Segment Member Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Finite-Lived Intangible Assets Amortization Expense [Table Text Block] Finite-Lived Intangible Assets, Gross In Med Pharma Member Equity, Attributable to Parent Increase (Decrease) in Accounts Payable and Accrued Liabilities Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Schedule of Inventory, Current [Table Text Block] Customer Five Member Nature of Operations [Text Block] Accumulated Other Comprehensive Income (Loss), Net of Tax Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Computer Equipment [Member] Revenues Stock Issued During Period, Value, Stock Options Exercised Accounts Payable and Accrued Liabilities, Current Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Exercisable Property, Plant and Equipment, Policy [Policy Text Block] Furniture and Fixtures [Member] Increase (Decrease) in Contract with Customer, Liability ATMAgreement Member General and Administrative Expense Cash and Cash Equivalents, Policy [Policy Text Block] Private Placement Issuance Costs Concentration Risk, Percentage Earnings Per Share [Abstract] Depreciation, Depletion and Amortization Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Common Stock, Par or Stated Value Per Share Unlabeled Abstract Segment Reporting Disclosure [Text Block] Cash Paid During The Period For Abstract Earnings Per Share, Policy [Policy Text Block] Common Stock, Shares, Issued Proceeds from Issuance of Private Placement Inventory Write-down Revenue Benchmark [Member] Increase (Decrease) in Other Noncurrent Assets Weighted Average Number of Shares Outstanding, Diluted Reportable Subsegments [Member] Gross Profit Schedule of Impaired Intangible Assets [Table Text Block] Property, Plant and Equipment Disclosure [Text Block] Intangible Assets, Net (Excluding Goodwill) Accounts Receivable, after Allowance for Credit Loss, Current Finite-Lived Intangible Assets, Accumulated Amortization Lessee, Operating Lease, Liability, to be Paid Inventory, Work in Process, Gross Net Assets Schedule Of Diluted Net Income Loss Per Shares Abstract Short-Term Investments Assets, Current [Abstract] Property, Plant and Equipment [Table Text Block] Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Liabilities, Current Finite-Lived Intangible Asset, Expected Amortization, Year Four Operating Expenses Statement of Financial Position [Abstract] Common Stock, Shares Authorized, Unlimited [Fixed List] Cash and Cash Equivalents, at Carrying Value Accrued Liabilities, Current Research and Development Expense, Policy [Policy Text Block] Consolidation, Policy [Policy Text Block] Liabilities and Equity [Abstract] Finite-Lived Intangible Asset, Expected Amortization, Year Three Commitments and Contingencies Disclosure [Text Block] Accrued Research And Development Expenses Lessee, Operating Lease, Liability, to be Paid, Year One Customer Concentration Risk [Member] Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Increase (Decrease) in Accounts Receivable Cost of Revenue Proceeds from Issuance of Common Stock Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income Taxes Paid Unvested Options Member Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Proceeds from Sale of Short-Term Investments Liabilities and Equity Lessee, Operating Lease, Liability, Undiscounted Excess Amount Share-Based Payment Arrangement, Noncash Expense In Process Research and Development, Policy [Policy Text Block] Bay Medica Segment Member Assets, Noncurrent

[Abstract] Inventory Valuation Reserves Assets, Current Inventory, Net Schedule Of Warrant Activity Abstract EX-101.PRE 10 inm-20240930_pre.xml XBRL PRESENTATION FILE GRAPHIC 11 image_001.jpg GRAPHIC begin 644 image_001.jpg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image_002.jpg GRAPHIC begin 644 image_002.jpg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htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended	
	Sep. 30, 2024	Nov. 14, 2024
Document Information [Line Items]		
Document Type	10-Q	
Document Quarterly Report	true	
Document Transition Report	false	
Entity Interactive Data Current	Yes	
Amendment Flag	false	
Document Period End Date	Sep. 30, 2024	
Document Fiscal Year Focus	2025	
Document Fiscal Period Focus	Q1	
Entity Information [Line Items]		
Entity Registrant Name	INMED PHARMACEUTICALS INC.	
Entity Central Index Key	0001728328	
Entity File Number	001-39685	
Entity Tax Identification Number	98-1428279	
Entity Incorporation, State or Country Code	A1	
Current Fiscal Year End Date	--06-30	
Entity Current Reporting Status	Yes	
Entity Shell Company	false	
Entity Filer Category	Non-accelerated Filer	
Entity Small Business	true	
Entity Emerging Growth Company	true	
Entity Ex Transition Period	false	
Entity Incorporation, Date of Incorporation	May 19, 1981	
Entity Contact Personnel [Line Items]		
Entity Address, Address Line One	Suite 1445 - 885 W. Georgia Street	
Entity Address, Address Line Two	Vancouver	
Entity Address, City or Town	B.C	
Entity Address, Country	CA	
Entity Address, Postal Zip Code	V6C 3E8	

Entity Phone Fax Numbers [Line Items]	
City Area Code	(604)
Local Phone Number	669-7207
Entity Listings [Line Items]	
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	INM
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding	718,032

XML 15 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Jun. 30, 2024
Current		
Cash and cash equivalents	$ 5,583,039	$ 6,571,610
Short-term investments	43,203	43,064
Accounts receivable (less provision for credit losses of $nil and $66,775 in September 30, 2024 and June 30, 2024, respectively)	284,695	352,838
Inventories, net	1,220,073	1,244,324
Prepaids and other current assets	148,882	477,749
Total current assets	7,279,892	8,689,585
Non-Current		
Property, equipment and right-of-use (“ROU”) assets, net	1,343,009	1,249,999
Intangible assets, net	1,742,205	1,783,198
Other assets	100,000	100,000
Total Assets	10,465,106	11,822,782
Current		
Accounts payable and accrued liabilities	1,011,619	1,654,011
Current portion of lease obligations	424,260	317,797
Total current liabilities	1,435,879	1,971,808
Non-current		
Lease obligations, net of current portion	633,783	644,865
Total Liabilities	2,069,662	2,616,673
Commitments and Contingencies (Note 11)		
Shareholders’ Equity		
Common Shares, no par value, unlimited authorized shares: 667,013 and 445,948, as of September 30, 2024 and June 30, 2024, respectively, issued and outstanding	84,198,673	82,784,400
Additional paid-in capital	34,821,829	35,368,899
Accumulated deficit	(110,753,627)	(109,075,759)
Accumulated other comprehensive income	128,569	128,569
Total Shareholders’ Equity	8,395,444	9,206,109
Total Liabilities and Shareholders’ Equity	$ 10,465,106	$ 11,822,782

XML 16 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($)	3 Months Ended Sep. 30, 2024	12 Months Ended Jun. 30, 2024
Statement of Financial Position [Abstract]		
Accounts receivable less provision for credit losses (in Dollars)		$ 66,775
Common shares, par value (in Dollars per share)		
Common shares, unlimited authorized	Unlimited	Unlimited
Common shares, shares issued	667,013	445,948
Common shares, shares outstanding	667,013	445,948

XML 17 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations Unaudited - USD ($)	3 Months Ended Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]		
Sales	$ 1,264,638	$ 901,862
Cost of sales	771,225	880,620
Gross profit	493,413	21,242
Operating Expenses		
Research and development and patents	771,180	1,292,093
General and administrative	1,421,926	1,298,731
Amortization and depreciation	54,579	54,832
Foreign Exchange (Gain) Loss	(19,310)	48,457
Total operating expenses	2,228,375	2,694,113
Other Income (Expense)		
Interest and other income	57,094	136,043
Loss before income tax expense	(1,677,868)	(2,536,828)
Income tax expense		
Net loss	$ (1,677,868)	$ (2,536,828)
Net loss per share		
Basic (in Dollars per share)	$ (2.71)	$ (15.24)
Diluted (in Dollars per share)	$ (2.71)	$ (15.24)
Weighted average outstanding Common Shares		
Basic (in Shares)	620,127	166,410
Diluted (in Shares)	620,127	166,410

XML 18 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Shareholders’ Equity Unaudited - USD ($)	Common Shares	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Total
Balance at Jun. 30, 2023	$ 77,620,252	$ 35,741,115	$ (101,400,209)	$ 128,569	$ 12,089,727
Balance (in Shares) at Jun. 30, 2023	166,410				
Loss for the period			(2,536,828)		(2,536,828)

Share-based compensation		25,191			25,191
Balance at Sep. 30, 2023	$ 77,620,252	35,766,306	(103,937,037)	128,569	(9,578,090)
Balance (in Shares) at Sep. 30, 2023	166,410				
Balance at Jun. 30, 2024	$ 82,784,400	35,368,899	(109,075,759)	128,569	$ 9,206,109
Balance (in Shares) at Jun. 30, 2024	445,948				445,948
Private placement	$ 1,030,063				$ 1,030,063
Private placement (in Shares)	186,364				
Share issuance costs	$ (191,824)				(191,824)
Exercise of pre-funded warrants	$ 576,034	(576,034)			
Exercise of pre-funded warrants (in Shares)	34,701				
Loss for the period			(1,677,868)		(1,677,868)
Share-based compensation		28,964			28,964
Balance at Sep. 30, 2024	$ 84,198,673	$ 34,821,829	$ (110,753,627)	$ 128,569	$ 8,395,444
Balance (in Shares) at Sep. 30, 2024	667,013				667,013

~~*XML 19 R6.htm IDEA: XBRL DOCUMENT*~~

Condensed Consolidated Statements of Cash Flows Unaudited - USD ($)	**3 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**
Operating Activities		
Net loss	$ (1,677,868)	$ (2,536,828)
Items not requiring cash:		
Amortization and depreciation	54,579	54,832
Share-based compensation	28,964	25,191
Amortization of ROU assets	90,401	94,532
Interest income received on short-term investments	(519)	(538)
Unrealized foreign exchange loss	5,270	2,018
Inventory write-down	0	92,930
Changes in operating assets and liabilities:		
Inventories	24,251	390,329
Prepaids and other currents assets	328,867	283,018
Other non-current assets		3,118
Accounts receivable	68,143	94,549
Accounts payable and accrued liabilities	(642,392)	(562,484)
Deferred rent		(16,171)
Lease obligations	(106,506)	(98,709)
Total cash used in operating activities	(1,826,810)	(2,174,213)
Investing Activities		
Sale of short-term investments	21,324	21,317
Purchase of short-term investments	(21,324)	(21,317)
Total cash used in investing activities		
Financing Activities		
Proceeds from the private placement	1,030,063	
Private placement issuance costs	(191,824)	
Total cash provided by financing activities	838,239	
Decrease in cash during the period	(988,571)	(2,174,213)
Cash and cash equivalents beginning of the period	6,571,610	8,912,517
Cash and cash equivalents end of the period	5,583,039	6,738,304
SUPPLEMENTARY CASH FLOW INFORMATION:		
Income Taxes		
Interest		
SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:		
Recognition of ROU asset and corresponding operating lease liability	$ 187,223	

~~*XML 20 R7.htm IDEA: XBRL DOCUMENT*~~

Corporate Information and Continuing Operations	**3 Months Ended**
	Sep. 30, 2024
Corporate Information and Continuing Operations [Abstract]	
CORPORATE INFORMATION AND CONTINUING OPERATIONS	

1. CORPORATE INFORMATION AND CONTINUING OPERATIONS

Business

InMed Pharmaceuticals Inc. ("InMed" or the "Company") was incorporated in the Province of British Columbia on May 19, 1981 under the *Business Corporations Act* of British Columbia. InMed is a clinical stage pharmaceutical company developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry.

The Company's shares are listed on the Nasdaq Capital Market ("Nasdaq") under the trading symbol "INM". InMed's office and principal place of business is located at Suite 1445– 885 West Georgia Street, Vancouver, B.C., Canada, V6C 1B4.

Going Concern

In accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Update ("ASU") 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued.

Through September 30, 2024, the Company has funded its operations primarily with proceeds from the sale of the Company's common shares, no par value per share (the "Common Shares"). The Company has incurred recurring losses and negative cash flows from operations since its inception, including net losses of approximately $1.7 and $2.5 million for the three months ended September 30, 2024 and 2023, respectively. In addition, the Company had an accumulated deficit of approximately $110.8 million as of September 30, 2024. The Company expects to continue to generate operating losses for the foreseeable future.

As of the issuance date of these unaudited condensed consolidated financial statements, the Company expects its cash, cash equivalents and short-term investments of $5.6 million as of September 30, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements through the end of the first quarter of calendar 2025, depending on the level and timing of realizing BayMedica revenues from the sale of bulk rare cannabinoids in the 'health & wellness' sector as well as the level and timing of Company operating expenses. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued.

The Company expects to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company's existing shareholders.

In connection with the Company's assessment of going concern considerations in accordance with Subtopic 205-40, management has determined that the Company's liquidity condition raises substantial doubt about the Company's ability to continue as a going concern, which is considered to be for a period of one year from the issuance of these condensed consolidated financial statements. These unaudited condensed consolidated financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts of classification of liabilities that might result from the outcome of this uncertainty. Such adjustments could be material.

~~XML 21 R8.htm IDEA: XBRL DOCUMENT~~

Significant Accounting Policies	3 Months Ended Sep. 30, 2024
Significant Accounting Policies [Abstract]	
SIGNIFICANT ACCOUNTING POLICIES	

2. SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles as applied in the United States ("US GAAP") and pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC") for financial information.

These unaudited condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended September 30, 2024 and 2023 are not necessarily indicative of results that can be expected for a full year. These unaudited condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the fiscal year ended June 30, 2024.

On November 14, 2024, the Company effected a reverse stock split of the Company's issued and outstanding Common Shares, by a ratio of 20-to-1 (the "Reverse Stock Split"). Accordingly, all Common Shares, stock options, warrants, as well as per share information, for all periods presented in the condensed consolidated financial statements and notes thereto have been adjusted retrospectively to reflect this Reverse Stock Split.

Reclassifications

Certain prior year amounts in the unaudited condensed consolidated financial statements and the notes thereto have been reclassified where necessary to conform to the current year's presentation. These reclassifications did not affect the prior period's total assets, total liabilities, stockholders' deficit, net loss or net cash used in operating activities. During the year ended June 30, 2024, the Company adopted ASU 2023-07 - Improvements to Reportable Segment Disclosures which has required prior periods to reflect the change in presentation. Refer to discussion on Recent Accounting Pronouncements below.

Use of Estimates

The preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported. It also requires management to exercise judgment in applying the Company's accounting policies. In the future, actual experience may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these unaudited condensed consolidated financial statements are the application of the going concern assumptions, determining the fair value of share-based payments, income tax provisions, write-down of inventories to net realizable value, and the assumptions used in the determination of research & development accruals.

Actual results could differ from those estimates.

Basis of Consolidation

These unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, including subsidiaries: InMed Pharmaceutical Ltd;, BayMedica, LLC; Biogen Sciences Inc.; and Sweetnam Consulting Inc. A subsidiary is an entity that the Company controls, either directly or indirectly, where control is defined as the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. All inter-company transactions and balances including unrealized income and expenses arising from intercompany transactions are eliminated in preparing these condensed consolidated financial statements.

Foreign Currency

The functional currency of the Company and its subsidiaries is the U.S. Dollar. These unaudited condensed consolidated financial statements are presented in U.S. Dollars. References to "$" and "US$" are to United States ("U.S.") dollars and references to "C$" are to Canadian dollars.

Cash and Cash Equivalents

Cash and cash equivalents include cash-on-hand, demand deposits with financial institutions and other short-term, highly liquid investments with original maturities of three months or less when acquired that are readily convertible to known amounts of cash and subject to an insignificant risk of change in value. As of September 30, 2024 and June 30, 2024, the Company held $1,964,203 and $1,939,482, respectively, of cash equivalents in a money market fund that is considered Level 1 in the financial instruments hierarchy due to the readily available quoted prices in active markets for identical instruments.

Short-term Investments

Short-term investments include fixed and variable rate guaranteed investment certificates, with terms greater than three months and less than twelve months. Due to the short-term nature of these investments the fair value of the investments approximates the current value. Guaranteed investment certificates are convertible to known amounts of cash and are subject to an insignificant risk of change in value.

Accounts Receivable

Accounts receivable are recorded at invoiced amounts, net of any credit losses. The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in existing accounts receivable.

The Company evaluates the collectability of accounts receivable on a regular basis based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience.

Concentration of Credit Risk and Other Risks and Uncertainties

At times, cash balances may exceed the Federal Deposit Insurance Corporation ("FDIC") or Canadian Deposit Insurance Corporation insurable limits. The Company has not previously experienced any losses related to these balances. The uninsured cash balance as of September 30, 2024 was $1.6 million. The Company does not believe it is exposed to significant credit risk on cash and cash equivalents.

The Company's customers are primarily concentrated in the United States.

As of September 30, 2024, the Company had four customers with an accounts receivable balance representing 25%, 23%, 22%, and 20% of total accounts receivable. As of June 30, 2024, we had five customers with an accounts receivable balance representing 32%, 20%, 15%,15% and 14% of total accounts receivable.

For the three months ended September 30, 2024, the Company had four customers that accounted for 22%, 20%, 18%, and 15% of revenue. For the three months ended September 30, 2023, the Company had three customers that accounted for 34%, 20%, and 11% of revenue.

Inventories

Inventories are initially valued at weighted average cost and subsequently valued at the lower of weighted average cost and net realizable value. Costs included in inventories are the purchase price of goods and cost of services rendered, freight costs, warehousing costs, purchasing costs and production and labor costs related to manufacturing.

In determining any valuation allowances, the Company reviews inventory for obsolete, redundant, and slow-moving goods. As of September 30, 2024 and June 30, 2024, the Company had $103,434 as a valuation allowance to reduce weighted average cost to net realizable value. During the three months ended September 30, 2024 and 2023, the Company recorded an inventory write-down due to net realizable value of $0 and $92,930, respectively.

Property, Equipment and ROU Assets, Net

Computer equipment, lab equipment and furnishings are recorded at cost, less accumulated depreciation and accumulated impairment losses. The initial cost of computer equipment, lab equipment and furnishings comprises their purchase price. The computer equipment, lab equipment and furnishings are reviewed at least once per year for impairment. Equipment and furniture are depreciated using the straight-line method based on their estimated useful lives as follows:

- Computer equipment — 5 years
- Lab equipment — 6 - 10 years
- Furnishings — 5 years

Computer equipment, lab equipment and furnishings, acquired or disposed of during the year, are depreciated proportionately for the period they are in use.

The ROU assets are initially measured based on the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, less any lease incentives received. The assets are amortized to the earlier of the end of the useful life of the ROU asset or the lease term using the straight-line method as this most closely reflects the expected pattern of consumption of the future economic benefits. The lease term includes periods covered by an option to extend if the Company is reasonably certain to exercise that option. In addition, the ROU assets are periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability (see Note 2 Lease (i)).

Intangible Assets, Net

Intangible assets are comprised of acquired intellectual property, which consists of certain patents and technical know-how. The intellectual property is recorded at cost and is amortized on a straight-line basis over an estimated useful life of 18 years net of any accumulated impairment losses. There was no impairment loss during the three months ended September 30, 2024 and 2023.

In-Process R&D

In-process R&D ("IPR&D") is classified as an indefinite-lived intangible asset and is not amortized. IPR&D becomes definite-lived upon the completion or abandonment of the associated research and development efforts. All research and development costs incurred subsequent to the acquisition of IPR&D are expensed as incurred. Indefinite-lived intangible assets are evaluated for impairment on an annual basis or more frequently if an indicator of impairment is present.

Impairment of Long-Lived Assets

The Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or assets. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured as the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets classified as held for sale are reported at the lower of the carrying amount or fair value, less costs to sell.

Fair Value Measurements

Financial Assets

Financial assets are initially recognized at fair value, plus transaction costs that are directly attributable to their acquisition or issue and subsequently carried at amortized cost, using the effective interest rate method, less any impairment losses. No financial assets are elected to be carried at fair value through profit or loss, or where changes in fair value are recognized in these consolidated statements of operations and comprehensive loss in other comprehensive loss.

Short-term investments are subsequently recorded at cost plus accrued interest, which approximates fair value due to their short-term nature. Accounts receivable are reported at outstanding amounts, net of credit losses.

Financial Liabilities

To determine the fair value of financial instruments, the Company uses the fair value hierarchy for inputs used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).

Level 1 – Unadjusted quoted prices in active markets for identical instruments.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

Level 3 – Inputs are unobservable and reflect the Company's assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.

The carrying value of cash and cash equivalents, short-term investments, accounts receivable, and accounts payable and accrued liabilities, approximate their carrying values as at September 30 2024 and June 30, 2024 due to their immediate or short-term maturities.

Revenue Recognition

The Company recognizes revenue when the Company satisfies the performance obligations under the terms of a contract and control of its products and services is transferred to its customers in an amount that reflects the consideration the Company expects to receive from its customers in exchange for those products and services. ASC 606, *Revenue from Contracts with Customers* defines a five-step process to recognize revenue that requires judgment and estimates, including identifying the contract with the customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract, and recognizing revenue when or as the performance obligation is satisfied.

Revenue consists of manufacturing and distribution sales of bulk rare cannabinoids, which are generally recognized at a point in time. The Company recognizes revenue when control over the products has been transferred to the customer and the Company has a present right to payment. Sales and other taxes that are required to be remitted to regulatory authorities are recorded as liabilities and excluded from sales. Limited rights of return, for claims of damaged or non-compliant products, exist with the Company's customers.

The Company has elected the practical expedient that allows it to recognize the incremental costs of obtaining a contract as an expense, when incurred, if the amortization period of the asset that the Company otherwise would have recognized is one year or less.

Revenues within the scope of ASC 606 do not include material amounts of variable consideration. Customer payments are generally due in advance of when control is transferred to the customer. Some of our larger customers are eligible for payment terms up to 'net 30 days'.

Cost of Sales

Cost of sales consists primarily of the purchase price of goods and cost of services rendered, freight costs, warehousing costs, and purchasing costs. Cost of sales also includes production and labor costs for the Company's manufacturing business.

Shipping and Handling

The Company records freight billed to customers within net sales. Shipping and handling costs associated with inbound freight and goods shipped to customers are recorded in cost of sales. Other shipping and handling costs, such as for quality assurance, are recorded in operating expenses.

Earnings (Loss) Per Share

Basic earnings (loss) per Common Share ("EPS") is computed by dividing the net income or loss applicable to Common Shares by the weighted average number of Common Shares outstanding for the relevant period. Diluted earnings (loss) per Common Share ("Diluted EPS") is computed by dividing the net income or loss applicable to Common Shares by the sum of the weighted average number of Common Shares issued and outstanding and all additional Common Shares that would have been outstanding, if potentially dilutive instruments were converted. If the conversion of outstanding stock options and warrants into Common Shares is anti-dilutive, then diluted EPS is not presented separately from EPS.

The following table sets forth the number of potential Common Shares that have been excluded from diluted net income (loss) per because their effect was anti-dilutive:

	As of September 30,	
	2024	**2023**
Options	33,724	5,107
Warrants	509,602	175,826
	543,326	180,933

Share-based Payments

The Company follows the requirements of FASB ASC 718-10-10, Share-Based Payments with regards to stock-based compensation issued to employees and non-employees. The Company has agreements and arrangements that call for stock to be awarded to the employees and consultants at various times as compensation and periodic bonuses. The expense for this stock-based compensation is equal to the fair value of the stock price on the day the stock was awarded multiplied by the number of shares awarded. The Company has a relatively low forfeiture rate of stock-based compensation and forfeitures are recognized as they occur.

The valuation methodology used to determine the fair value of the options issued during the period is the Black-Scholes option-pricing model. The Black-Scholes model requires the use of a number of assumptions, including the volatility of the stock price, the average risk-free interest rate, and the weighted average expected life of the options. Risk-free interest rates are calculated based on continuously compounded risk-free rates for the appropriate term. The dividend yield is assumed to be zero as the Company has never paid or declared any cash dividends on its Common Shares and does not intend to pay dividends on its Common Shares in the foreseeable future. The expected forfeiture rate is estimated based on management's best assessment.

Estimated volatility is a measure of the amount by which InMed's stock price is expected to fluctuate each year during the expected life of the award. The Company's calculation of estimated volatility is based on historical stock prices over a period equal to the expected life of the awards.

Research and Development Costs

The Company conducts research and development programs and incurs costs related to these activities, including research and development personnel compensation, services provided by contract research organizations and lab supplies. Research and development costs are expensed in the periods in which they are incurred.

Patents and Intellectual Property Costs

The costs of filing for patents and of prosecuting and maintaining intellectual property rights are expensed as incurred due to the uncertainty surrounding the drug development process and the uncertainty of future benefits. Patents and intellectual property acquired from third parties for approved products or where there are alternative future uses are capitalized and amortized over the remaining life of the patent.

Segment reporting

The Company's operations consist of two operating and reportable segments, the "InMed Pharma" segment and the "BayMedica Commercial" segment.

The "InMed Pharma" segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the "BayMedica Commercial" segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry (See Note 10).

Leases

At inception of a contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The lease liability is initially measured as the present value of future lease payments excluding payments made at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate. The lease liability is measured at amortized cost using the effective interest method. It is re-measured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Company's estimate of the amount expected to be payable under a residual value guarantee, or if the Company changes its assessment of whether it will exercise a purchase, extension, or termination option. When the lease liability is re-measured in this way, a corresponding adjustment is made to the carrying amount of the ROU asset or is recorded in profit or loss if the carrying amount of the ROU asset has been reduced to nil.

The Company has lease arrangements that include both lease and non-lease components. The Company accounts for each separate lease component and its associated non-lease components as a single lease component for all of its asset classes.

The Company has elected to apply the practical expedient to exclude initial direct costs such as annual operating costs from the measurement of the ROU asset at the date of initial application. The Company has elected to apply the practical expedient not to recognize ROU assets and lease liabilities for short-term leases that have a lease term of 12 months or less. The lease payments associated with these leases is recognized as an expense on a straight-line basis over the lease term.

Recent Accounting Pronouncements

The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in these unaudited condensed consolidated financial statements as a result of future adoption.

In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*, which enhances reportable segment disclosure requirements primarily through expanded disclosures around significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company has early adopted this accounting pronouncement.

In December 2023, the FASB issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, which requires disclosure of specific categories meeting a quantitative threshold within the income tax rate reconciliation, as well as disaggregation of income taxes paid by jurisdiction. This ASU, which can be applied either prospectively or retrospectively, is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this ASU and expects to include updated income tax disclosures in its fiscal year 2026.

~~*XML 22 R9.htm IDEA: XBRL DOCUMENT*~~

Inventories

3 Months Ended
Sep. 30, 2024

Inventories [Abstract]

INVENTORIES

3. INVENTORIES

Inventories consisted of the following:

	September 30, 2024	June 30, 2024
	$	$
Raw materials	274,445	372,695
Work in process	18,446	30,817
Finished goods	927,182	840,812
Inventories	1,220,073	1,244,324

~~*XML 23 R10.htm IDEA: XBRL DOCUMENT*~~

Property, Equipment and Rou Assets, Net

3 Months Ended
Sep. 30, 2024

Property, Equipment and Rou Assets, Net [Abstract]

PROPERTY, EQUIPMENT AND ROU ASSETS, NET

4. PROPERTY, EQUIPMENT AND ROU ASSETS, NET

Property, equipment and ROU assets consisted of the following:

	September 30, 2024	June 30, 2024
	$	$
ROU Assets (leases)	1,901,692	2,135,811
Equipment	429,092	429,090
Furnishings	40,409	40,409
Property and equipment	2,371,193	2,605,310
Less: accumulated depreciation and amortization	(1,028,184)	(1,355,311)
Property, equipment and ROU assets, net	1,343,009	1,249,999

Depreciation expense on computer equipment, lab equipment and furnishing for the three months ended September 30, 2024 and 2023, was $13,586 and $13,839, respectively, and was recorded in general and administrative expenses. Amortization expense related to the ROU assets for the three months ended September 30, 2024 and 2023, was $90,401 and $94,532, respectively, and was recorded in general and administrative expenses.

~~*XML 24 R11.htm IDEA: XBRL DOCUMENT*~~

Intangible Assets

3 Months Ended
Sep. 30, 2024

Intangible Assets [Abstract]

INTANGIBLE ASSETS

5. INTANGIBLE ASSETS

The following table summarizes the Companies intangible assets:

	September 30, 2024	June 30, 2024
	$	$
Intellectual property	1,736,420	1,736,420
Patents	1,191,000	1,191,000
Intangible assets	2,927,420	2,927,420
Less: accumulated amortization	(1,185,215)	(1,144,222)
	1,742,205	1,783,198

Intangible assets, net		

Acquired intellectual property is recorded at cost and is amortized on a straight-line basis over 18 years. Acquired patents consist of patents related to the development of cannabinoid analogs. This intangible asset is being amortized over an estimated useful life of 18 years. As at September 30, 2024, the definite-lived intangible assets had a weighted average estimated remaining useful life of approximately 11 years.

Amortization expense on intangible assets for the three months ended September 30, 2024 and 2023 was $40,993 and $40,993 respectively. The Company expects amortization expense to be incurred over the next five years as follows:

Twelve months ending September 30,	**$**
2025	162,746
2026	162,746
2027	162,746
2028	162,746
2029	162,746
Thereafter	928,475
Total	1,742,205

~~*XML 25 R12.htm IDEA: XBRL DOCUMENT*~~

Accounts Payable and Accrued Liabilities

3 Months Ended
Sep. 30, 2024

Accounts Payable and Accrued Liabilities [Abstract]

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities consist of the following:

	September 30, 2024	**June 30, 2024**
	$	$
Trade payables	448,995	626,190
Accrued research and development expenses	238,412	242,066
Inventory related accruals	2,000	41,004
Employee compensation, benefits and related accruals	236,691	488,278
Accrued general and administrative expenses	85,521	256,473
Accounts payable and accrued liabilities	1,011,619	1,654,011

~~*XML 26 R13.htm IDEA: XBRL DOCUMENT*~~

Share Capital and Reserves

3 Months Ended
Sep. 30, 2024

Share Capital and Reserves [Abstract]

SHARE CAPITAL AND RESERVES

7. SHARE CAPITAL AND RESERVES

Authorized

As of September 30, 2024, the Company's authorized share structure consisted of: (i) an unlimited number of Common Shares; and (ii) an unlimited number of preferred shares without par value. No preferred shares were issued and outstanding as of September 30, 2024 and June 30, 2024.

The Company may, from time to time, issue preferred shares and may, at the time of issuance, determine the rights, preferences and limitations pertaining to these shares. Holders of preferred shares may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding up of the Company before any payment is made to the holders of Common Shares.

On June 27, 2024, the Company entered into an amendment (the "ATM Amendment") to its At-the-Market Offering Agreement, dated April 7, 2022 (the "Original ATM Agreement" and together with the ATM Amendment, the "Amended ATM Agreement"), pursuant to which the Company may offer and sell Common Shares, from time to time, in "at the market" offerings through the Agent. The ATM Amendment amends the Original ATM Agreement to reflect, among other provisions, updates to certain sales settlement provisions and reimbursement terms, and to supplement the representations being made by the Company to the Agent. During the three months ended September 30, 2024, the Company issued 186,364 Common Shares for gross proceeds of approximately $1.0 million. This amount has been offset by financing fees of approximately $192,000.

Common Share Warrants

The Company did not grant any warrants during the three months ended September 30, 2024.

A summary of the Company's warrant activity and related information for the periods covered were as follows:

	Number of Shares Under Warrants	**Weighted Average Exercise Price**
Balance as at June 30, 2024	544,303	$ 20.40
Warrants Granted	-	-
Exercised	(34,701)	-
Expire/Cancelled	-	-
Warrants Outstanding as at September 30, 2024	509,602	$ 22.60
Warrants Exercisable as at September 30, 2024	509,602	$ 22.60

As of September 30, 2024 and June 30, 2024, the warrants exercisable and outstanding have an intrinsic value of $nil and $184,539, respectively, with a weighted average remaining life of 4 years and 6 years, respectively.

~~*XML 27 R14.htm IDEA: XBRL DOCUMENT*~~

Share-Based Payments

3 Months Ended
Sep. 30, 2024

Share-Based Payments [Abstract]

SHARE-BASED PAYMENTS

8. SHARE-BASED PAYMENTS

a) Option Plan Details

On March 24, 2017, and as amended on November 20, 2020, the Company's shareholders approved: (i) the adoption of a new stock option plan (the "Plan") pursuant to which the Company's Board of Directors may, from time to time, in its discretion and in accordance with applicable regulatory requirements, grant to directors, officers, employees and consultants of the Company, non-transferable options to purchase Common Shares, provided that the number of Common Shares reserved for issuance will not exceed twenty percent (20%) of the issued and outstanding Common Shares at the date the options are granted (on a non-diluted and rolling basis); and (ii) the application of the Plan to all outstanding stock options of the Company that were granted prior to March 24, 2017 under the terms of the Company's previous stock option plan. On December 19, 2023, the Company's Board of Directors approved the reservation of an additional 35,000 Common Shares under the Plan.

As of each of September 30, 2024 and June 30, 2024, there were 34,224 stock options immediately available for future allocation pursuant to applicable regulatory requirements. The maximum number of options issuable under the terms of the Plan equates to 20% of the then issued and outstanding shares. The option price under each option shall not be less than the closing price on the day prior to the date of grant. All options vest upon terms as set by the Board of Directors, either over time, up to 36 months, or upon the achievement of certain corporate milestones.

The Company did not grant any stock options during the three months ended September 30, 2024.

As of September 30, 2024 the Company had 10,804 vested and exercisable options with a weighted average exercise price of $163.00 and 22,919 unvested options with a weighted average exercise price of $8.40

Total expenses arising from share-based payment transactions recognized during the three months ended September 30, 2024 and 2023 were $28,964 and $25,191, respectively, of which $17,564 and $15,431, respectively, was allocated to general and administrative expenses, $11,180 and $9,761, respectively, was allocated to research and development expenses, and $220 and $0, respectively, was allocated to Cost of Goods sold.

Unrecognized compensation cost as at September 30, 2024 (which related to unvested options) was $78,685, which will be recognized over a weighted-average vesting period of approximately 1.3 years.

~~XML 28 R15.htm IDEA: XBRL DOCUMENT~~

Lease Obligations

3 Months Ended
Sep. 30, 2024

Lease Obligations [Abstract]

LEASE OBLIGATIONS

9. LEASE OBLIGATIONS

The Company is committed to minimum lease payments as follows:

Maturity Analysis	September 30, 2024
	$
Year 1	469,668
Year 2	453,191
Year 3	219,261
Year 4	-
Year 5	-
More than five years	-
Total undiscounted lease liabilities[1]	1,142,120
Less: imputed interest	(84,077)
Present value of lease liabilities	1,058,043
Less: Current portion of lease liabilities	(424,260)
Non-current portion of lease liabilities	633,783

On July 29, 2024, the Company entered into a lease agreement for new office space. This office occupies approximately 2,243 square feet with a monthly basic rental rate and operating charges of an estimated C$12,296 for the two-year term of the agreement. The Company used an incremental borrowing rate of 7% and recognized a ROU asset and corresponding operating lease liability of $205,201.

On October 5, 2023, BayMedica amended its lease located at 458 Carlton Court, Suite C, South San Francisco, California, in order to extend its lease to May 14, 2027. The Company is obligated to pay $1,295,759 over the three-year period unless terminated before the end of the period. The Company used an incremental borrowing rate of 6.15% and recognized a ROU asset and corresponding operating lease liability of $953,935.

~~XML 29 R16.htm IDEA: XBRL DOCUMENT~~

Segment Information

3 Months Ended
Sep. 30, 2024

Segment Information [Abstract]

SEGMENT INFORMATION

10. SEGMENT INFORMATION

The Company reports segment information based on the management approach, which designates the internal reporting used by the Chief Operating Decision Maker ("CODM"), the Company's Chief Executive Officer and the senior management team, for making decisions and assessing performance as the source of the Company's reportable segments. The CODM allocates resources and assesses the performance of each operating segment based on potential licensing opportunities, historical and potential future product sales, operating expenses, and operating income (loss) before interest and taxes. The Company has determined its reportable segments to be 'InMed Pharma' and 'BayMedica Commercial' based on the information used by the CODM. As such, the pharmaceutical-related research and development carried out at BayMedica is included with the 'InMed Pharma' segment. Other than cash, cash equivalents and short-term investments ("Unrestricted cash") balances, the CODM does not regularly review asset information by reportable segment and, therefore, the Company does not report asset information by reportable segment.

The 'InMed Pharma' segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the 'BayMedica Commercial' segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Total assets held in the 'InMed Pharma' segment as of September 30, 2024 and June 30, 2024 were $7.6 million and $9.2 million, respectively. Total assets as of September 30, 2024 and June 30, 2024, held in the 'BayMedica Commercial' segment were $2.8 million and $2.6 million, respectively.

The following table presents information about the Company's reportable segments for the three months ended September 30, 2024 and 2023:

	Three Months Ended September 30,					
	2024			2023		
	InMed	BayMedica	**Total**	InMed	BayMedica	**Total**
	$	$	**$**	$	$	**$**
Sales	-	1,264,638	**1,264,638**	-	901,862	**901,862**
Cost of sales	-	(771,225)	**(771,225)**	-	(880,620)	**(880,620)**
Research and development patents	(762,874)	(8,306)	**(771,180)**	(1,271,439)	(20,654)	**(1,292,093)**
General and Administrative	(1,238,181)	(183,745)	**(1,421,926)**	(1,063,660)	(235,071)	**(1,298,731)**
Amortization and depreciation	(53,980)	(599)	**(54,579)**	(54,241)	(591)	**(54,832)**
Foreign exchange gain (loss)	19,310	-	**19,310**	(48,457)	-	**(48,457)**
Interest and other income	57,094	-	**57,094**	136,043	-	**136,043**
Net Income (Loss)	(1,978,631)	300,763	**(1,677,868)**	(2,301,754)	(235,074)	**(2,536,828)**
Cash and Cash Equivalents	4,346,193	1,236,846	**5,583,039**	5,886,613	851,691	**6,738,304**

~~XML 30 R17.htm IDEA: XBRL DOCUMENT~~

Commitments and Contingencies

3 Months Ended
Sep. 30, 2024

Commitments and Contingencies [Abstract]

COMMITMENTS AND CONTINGENCIES

11. COMMITMENTS AND CONTINGENCIES

Pursuant to the terms of agreements with various contract research organizations, as of September 30, 2024, the Company was committed for contract research services and materials at a cost of approximately $422,270, expected to occur in the following twelve-month period.

Pursuant to the terms of a certain Technology Assignment Agreement, dated as of May 31, 2017 (the "Technology Agreement"), between the Company and the University of British Columbia ("UBC"), the Company is committed to pay royalties to UBC on certain licensing and royalty revenues received by the Company for biosynthesis of certain drug products that are covered by the Technology Agreement. To date, no payments have been required to be made.

Pursuant to the terms of a certain Collaborative Research Agreement, dated as of December 13, 2018, between the Company and UBC, pursuant to which the Company owns all rights, title and interests in and to any intellectual property, in addition to funding research at UBC, the Company is committed to make a one-time payment upon filing of any PCT patent application arising from the research. To date, one such payment has been made to UBC.

Pursuant to the terms of a certain Contribution Agreement, dated as of November 1, 2018, between the Company and National Research Council Canada, as represented by its Industrial Research Assistance Program (NRC-IRAP), under certain circumstances contributions received, including the disposition of the underlying intellectual property developed in part with NRC-IRAP contributions, may become repayable. As of September 30, 2024, there have been no triggering events to cause a repayment.

Short-term investments include guaranteed investment certificates, with one year terms, of $43,203 and $43,064 as of September 30, 2024 and June 30, 2024, respectively, that are pledged as security for a corporate credit card.

In addition to the foregoing, the Company has entered into certain agreements in the ordinary course of operations that may include indemnification provisions, which are common in such agreements. In some cases, the maximum amount of potential future indemnification is unlimited; however, the Company currently holds commercial general liability insurance. This insurance may limit the Company's overall liability and may enable the Company to recover a portion of any future amounts paid. Historically, the Company has not made any indemnification payments under such agreements, and it believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.

Pursuant to that certain Technology Licensing Agreement, dated as of March 11, 2021, between the Company and EyeCRO, the Company is committed to issue, subject to regulatory approval, up to 700 warrants to purchase 700 Common Shares upon the achievement of certain milestones. The exercise price of the warrants will be equal to the five-day VWAP of our Common Shares prior to each milestone achievement and the warrants will be exercisable for a period of three years from the issuance date. On May 10, 2024, the Company delivered a 90-day notice of termination to EyeCRO LLC with respect to the Technology Licensing Agreement, specifying an effective date of termination of August 8, 2024.

BayMedica entered into a patent license agreement ("Patent License Agreement") with a third party (the "Licensor") on February 15, 2021. The Company was required to

begin making royalty payments to the Licensor based on net sales of licensed products in 2021 in order to maintain an exclusive license. In December 2021, the Company amended the Patent License Agreement, which amendment included the deferral of the 2021 minimum payments to 2022. As of June 30, 2023, the Company had paid $300,000 for the minimum payments due and payable under the Patent License Agreement. On February 10, 2023, BayMedica received a letter from the Licensor alleging a breach of the Patent License Agreement and asserting a right to monies due thereunder. On April 6, 2023, BayMedica sent a letter to the Licensor disputing the Licensor's interpretation of the Patent License Agreement and asserted that the counterparty's only remedy under the Patent License Agreement to be either (a) the conversion of an exclusive technology license into a non-exclusive license or (b) the termination of the Patent License Agreement.

On July 18, 2024, BayMedica received a letter from the Licensor alleging breach of the Patent License Agreement and asserting monies due thereunder. On August 7, 2024, BayMedica responded asserting that the counterparty's interpretation of the Patent License Agreement was again incorrect and that BayMedica, therefore, does not owe any funds under the Patent License Agreement.

To date, the Licensor has not initiated a lawsuit with respect to the foregoing matters. If a lawsuit is ultimately brought alleging a breach of the Patent License Agreement, the proceeding will be subject to final, binding and non-appealable arbitration under the Arbitration Act, 1991 (Ontario) and determined pursuant to Ontario law. BayMedica intends to vigorously defend its position. At this time, it is not possible to reasonably estimate a potential loss due to the terms of the Patent License Agreement, the nature of the legal theory advanced by the counterparty, and the ultimate outcome of any proceeding (including the interpretation by the arbitrator with respect to applicable requirements under Ontario law regarding contract formation).

~~XML 31 R18.htm IDEA: XBRL DOCUMENT~~

Related Party Transactions	3 Months Ended Sep. 30, 2024
Related Party Transactions [Abstract]	
RELATED PARTY TRANSACTIONS	**12. RELATED PARTY TRANSACTIONS**

On February 11, 2022, the Board of Directors appointed Janet Grove as a director of the Company. Ms. Grove is a Partner of Norton Rose Fulbright Canada LLP ("NRFC"). During the three months ended September 30, 2024 and 2023, NRFC and Norton Rose Fulbright U.S. LLP ("NRFUS" and together with NRFC, NRF") rendered legal services in the amount of $124,147 and $19,814, respectively, to the Company. These transactions were in the normal course of operations and were measured at the exchange amount which represented the amount of consideration established and agreed to by NRF. No legal services rendered by NRF were provided by Ms. Grove directly.

~~XML 32 R19.htm IDEA: XBRL DOCUMENT~~

Subsequent Events	3 Months Ended Sep. 30, 2024
Subsequent Events [Abstract]	
SUBSEQUENT EVENTS	**13. SUBSEQUENT EVENTS**

The Company has evaluated subsequent events through the date of the filing of this Annual Report on Form 10-K and determined that there have been no events that have occurred that would require adjustments to our disclosures in the unaudited condensed consolidated financial statements except for the matters described below.

In October 2024, the Company issued 51,019 Common Shares for gross proceeds of $365,473 pursuant to the terms of the Amended ATM Agreement.

On November 14, 2024, the Company effected a Reverse Stock Split of its Common Shares at a ratio of 20-to-1. Trading of the Common Shares on Nasdaq on a split-adjusted basis began as of November 14, 2024. As a result of the Reverse Stock Split, each 20 shares of Common Shares were combined into one Common Share, and the total number of Common Shares outstanding were reduced from approximately 14,361,550 shares to approximately 718,032 Common Shares.

~~XML 33 R20.htm IDEA: XBRL DOCUMENT~~

Pay vs Performance Disclosure - USD ($)	3 Months Ended Sep. 30, 2024	3 Months Ended Sep. 30, 2023
Pay vs Performance Disclosure		
Net Income (Loss)	$ (1,677,868)	$ (2,536,828)

~~XML 34 R21.htm IDEA: XBRL DOCUMENT~~

Insider Trading Arrangements	3 Months Ended Sep. 30, 2024
Trading Arrangements, by Individual	
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

~~XML 35 R22.htm IDEA: XBRL DOCUMENT~~

Accounting Policies, by Policy (Policies)	3 Months Ended Sep. 30, 2024
Significant Accounting Policies [Abstract]	
Basis of Presentation	***Basis of Presentation***

These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles as applied in the United States ("US GAAP") and pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC") for financial information.

These unaudited condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended September 30, 2024 and 2023 are not necessarily indicative of results that can be expected for a full year. These unaudited condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the fiscal year ended June 30, 2024.

On November 14, 2024, the Company effected a reverse stock split of the Company's issued and outstanding Common Shares, by a ratio of 20-to-1 (the "Reverse Stock Split"). Accordingly, all Common Shares, stock options, warrants, as well as per share information, for all periods presented in the condensed consolidated financial statements and notes thereto have been adjusted retrospectively to reflect this Reverse Stock Split.

Reclassifications — ***Reclassifications***

Certain prior year amounts in the unaudited condensed consolidated financial statements and the notes thereto have been reclassified where necessary to conform to the current year's presentation. These reclassifications did not affect the prior period's total assets, total liabilities, stockholders' deficit, net loss or net cash used in operating activities. During the year ended June 30, 2024, the Company adopted ASU 2023-07 - Improvements to Reportable Segment Disclosures which has required prior periods to reflect the change in presentation. Refer to discussion on Recent Accounting Pronouncements below.

Use of Estimates — ***Use of Estimates***

The preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported. It also requires management to exercise judgment in applying the Company's accounting policies. In the future, actual experience may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these unaudited condensed consolidated financial statements are the application of the going concern assumptions, determining the fair value of share-based payments, income tax provisions, write-down of inventories to net realizable value, and the assumptions used in the determination of research & development accruals.

Actual results could differ from those estimates.

Basis of Consolidation — ***Basis of Consolidation***

These unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, including subsidiaries: InMed Pharmaceutical Ltd;, BayMedica, LLC; Biogen Sciences Inc.; and Sweetnam Consulting Inc. A subsidiary is an entity that the Company controls, either directly or indirectly, where control is defined as the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. All inter-company transactions and balances including unrealized income and expenses arising from intercompany transactions are eliminated in preparing these condensed consolidated financial statements.

Foreign Currency — ***Foreign Currency***

The functional currency of the Company and its subsidiaries is the U.S. Dollar. These unaudited condensed consolidated financial statements are presented in U.S. Dollars. References to "$" and "US$" are to United States ("U.S.") dollars and references to "C$" are to Canadian dollars.

Cash and Cash Equivalents — ***Cash and Cash Equivalents***

Cash and cash equivalents include cash-on-hand, demand deposits with financial institutions and other short-term, highly liquid investments with original maturities of three months or less when acquired that are readily convertible to known amounts of cash and subject to an insignificant risk of change in value. As of September 30, 2024 and June 30, 2024, the Company held $1,964,203 and $1,939,482, respectively, of cash equivalents in a money market fund that is considered Level 1 in the financial instruments hierarchy due to the readily available quoted prices in active markets for identical instruments.

Short-term Investments — ***Short-term Investments***

Short-term investments include fixed and variable rate guaranteed investment certificates, with terms greater than three months and less than twelve months. Due to the short-term nature of these investments the fair value of the investments approximates the current value. Guaranteed investment certificates are convertible to known amounts of cash and are subject to an insignificant risk of change in value.

Accounts Receivable — ***Accounts Receivable***

Accounts receivable are recorded at invoiced amounts, net of any credit losses. The allowance for doubtful accounts is the Company's best estimate of the amount of probable

credit losses in existing accounts receivable.
The Company evaluates the collectability of accounts receivable on a regular basis based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience.

Concentration of Credit Risk and Other Risks and Uncertainties

Concentration of Credit Risk and Other Risks and Uncertainties
At times, cash balances may exceed the Federal Deposit Insurance Corporation ("FDIC") or Canadian Deposit Insurance Corporation insurable limits. The Company has not previously experienced any losses related to these balances. The uninsured cash balance as of September 30, 2024 was $1.6 million. The Company does not believe it is exposed to significant credit risk on cash and cash equivalents.
The Company's customers are primarily concentrated in the United States.
As of September 30, 2024, the Company had four customers with an accounts receivable balance representing 25%, 23%, 22%, and 20% of total accounts receivable. As of June 30, 2024, we had five customers with an accounts receivable balance representing 32%, 20%, 15%,15% and 14% of total accounts receivable.
For the three months ended September 30, 2024, the Company had four customers that accounted for 22%, 20%, 18%, and 15% of revenue. For the three months ended September 30, 2023, the Company had three customers that accounted for 34%, 20%, and 11% of revenue.

Inventories

Inventories
Inventories are initially valued at weighted average cost and subsequently valued at the lower of weighted average cost and net realizable value. Costs included in inventories are the purchase price of goods and cost of services rendered, freight costs, warehousing costs, purchasing costs and production and labor costs related to manufacturing.
In determining any valuation allowances, the Company reviews inventory for obsolete, redundant, and slow-moving goods. As of September 30, 2024 and June 30, 2024, the Company had $103,434 as a valuation allowance to reduce weighted average cost to net realizable value. During the three months ended September 30, 2024 and 2023, the Company recorded an inventory write-down due to net realizable value of $0 and $92,930, respectively.

Property, Equipment and ROU Assets, Net

Property, Equipment and ROU Assets, Net
Computer equipment, lab equipment and furnishings are recorded at cost, less accumulated depreciation and accumulated impairment losses. The initial cost of computer equipment, lab equipment and furnishings comprises their purchase price. The computer equipment, lab equipment and furnishings are reviewed at least once per year for impairment. Equipment and furniture are depreciated using the straight-line method based on their estimated useful lives as follows:

- Computer equipment — 5 years
- Lab equipment — 6 - 10 years
- Furnishings — 5 years

Computer equipment, lab equipment and furnishings, acquired or disposed of during the year, are depreciated proportionately for the period they are in use.

The ROU assets are initially measured based on the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, less any lease incentives received. The assets are amortized to the earlier of the end of the useful life of the ROU asset or the lease term using the straight-line method as this most closely reflects the expected pattern of consumption of the future economic benefits. The lease term includes periods covered by an option to extend if the Company is reasonably certain to exercise that option. In addition, the ROU assets are periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability (see Note 2 Lease (i)).

Intangible Assets, Net

Intangible Assets, Net
Intangible assets are comprised of acquired intellectual property, which consists of certain patents and technical know-how. The intellectual property is recorded at cost and is amortized on a straight-line basis over an estimated useful life of 18 years net of any accumulated impairment losses. There was no impairment loss during the three months ended September 30, 2024 and 2023.

In-Process R&D

In-Process R&D
In-process R&D ("IPR&D") is classified as an indefinite-lived intangible asset and is not amortized. IPR&D becomes definite-lived upon the completion or abandonment of the associated research and development efforts. All research and development costs incurred subsequent to the acquisition of IPR&D are expensed as incurred. Indefinite-lived intangible assets are evaluated for impairment on an annual basis or more frequently if an indicator of impairment is present.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets
The Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or assets. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured as the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets classified as held for sale are reported at the lower of the carrying amount or fair value, less costs to sell.

Fair Value Measurements

Fair Value Measurements
Financial Assets
Financial assets are initially recognized at fair value, plus transaction costs that are directly attributable to their acquisition or issue and subsequently carried at amortized cost, using the effective interest rate method, less any impairment losses. No financial assets are elected to be carried at fair value through profit or loss, or where changes in fair value are recognized in these consolidated statements of operations and comprehensive loss in other comprehensive loss.
Short-term investments are subsequently recorded at cost plus accrued interest, which approximates fair value due to their short-term nature. Accounts receivable are reported at outstanding amounts, net of credit losses.

Financial Liabilities
To determine the fair value of financial instruments, the Company uses the fair value hierarchy for inputs used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).

Level 1 – Unadjusted quoted prices in active markets for identical instruments.
Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
Level 3 – Inputs are unobservable and reflect the Company's assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.

The carrying value of cash and cash equivalents, short-term investments, accounts receivable, and accounts payable and accrued liabilities, approximate their carrying values as at September 30 2024 and June 30, 2024 due to their immediate or short-term maturities.

Revenue Recognition

Revenue Recognition
The Company recognizes revenue when the Company satisfies the performance obligations under the terms of a contract and control of its products and services is transferred to its customers in an amount that reflects the consideration the Company expects to receive from its customers in exchange for those products and services. ASC 606, *Revenue from Contracts with Customers* defines a five-step process to recognize revenue that requires judgment and estimates, including identifying the contract with the customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract, and recognizing revenue when or as the performance obligation is satisfied.
Revenue consists of manufacturing and distribution sales of bulk rare cannabinoids, which are generally recognized at a point in time. The Company recognizes revenue when control over the products has been transferred to the customer and the Company has a present right to payment. Sales and other taxes that are required to be remitted to regulatory authorities are recorded as liabilities and excluded from sales. Limited rights of return, for claims of damaged or non-compliant products, exist with the Company's customers.
The Company has elected the practical expedient that allows it to recognize the incremental costs of obtaining a contract as an expense, when incurred, if the amortization period of the asset that the Company otherwise would have recognized is one year or less.
Revenues within the scope of ASC 606 do not include material amounts of variable consideration. Customer payments are generally due in advance of when control is transferred to the customer. Some of our larger customers are eligible for payment terms up to 'net 30 days'.

Cost of Sales

Cost of Sales
Cost of sales consists primarily of the purchase price of goods and cost of services rendered, freight costs, warehousing costs, and purchasing costs. Cost of sales also includes production and labor costs for the Company's manufacturing business.

Shipping and Handling

Shipping and Handling
The Company records freight billed to customers within net sales. Shipping and handling costs associated with inbound freight and goods shipped to customers are recorded in cost of sales. Other shipping and handling costs, such as for quality assurance, are recorded in operating expenses.

Earnings (Loss) Per Share

Earnings (Loss) Per Share
Basic earnings (loss) per Common Share ("EPS") is computed by dividing the net income or loss applicable to Common Shares by the weighted average number of Common Shares outstanding for the relevant period. Diluted earnings (loss) per Common Share ("Diluted EPS") is computed by dividing the net income or loss applicable to Common Shares by the sum of the weighted average number of Common Shares issued and outstanding and all additional Common Shares that would have been outstanding, if potentially dilutive instruments were converted. If the conversion of outstanding stock options and warrants into Common Shares is anti-dilutive, then diluted EPS is not presented separately from EPS.
The following table sets forth the number of potential Common Shares that have been excluded from diluted net income (loss) per because their effect was anti-dilutive:

	As of September 30,	
	2024	**2023**
Options	33,724	5,107
Warrants	509,602	175,826
	543,326	180,933

Share-based Payments

Share-based Payments
The Company follows the requirements of FASB ASC 718-10-10, Share-Based Payments with regards to stock-based compensation issued to employees and non-employees. The Company has agreements and arrangements that call for stock to be awarded to the employees and consultants at various times as compensation and periodic bonuses. The expense for this stock-based compensation is equal to the fair value of the stock price on the day the stock was awarded multiplied by the number of shares awarded. The Company has a relatively low forfeiture rate of stock-based compensation and forfeitures are recognized as they occur.
The valuation methodology used to determine the fair value of the options issued during the period is the Black-Scholes option-pricing model. The Black-Scholes model requires the use of a number of assumptions, including the volatility of the stock price, the average risk-free interest rate, and the weighted average expected life of the options. Risk-free interest rates are calculated based on continuously compounded risk-free rates for the appropriate term. The dividend yield is assumed to be zero as the Company has never paid or declared any cash dividends on its Common Shares and does not intend to pay dividends on its Common Shares in the foreseeable future. The expected forfeiture rate is estimated based on management's best assessment.
Estimated volatility is a measure of the amount by which InMed's stock price is expected to fluctuate each year during the expected life of the award. The Company's calculation of estimated volatility is based on historical stock prices over a period equal to the expected life of the awards.

Research and Development Costs

Research and Development Costs

The Company conducts research and development programs and incurs costs related to these activities, including research and development personnel compensation, services provided by contract research organizations and lab supplies. Research and development costs are expensed in the periods in which they are incurred.

Patents and Intellectual Property Costs

Patents and Intellectual Property Costs

The costs of filing for patents and of prosecuting and maintaining intellectual property rights are expensed as incurred due to the uncertainty surrounding the drug development process and the uncertainty of future benefits. Patents and intellectual property acquired from third parties for approved products or where there are alternative future uses are capitalized and amortized over the remaining life of the patent.

Segment reporting

Segment reporting

The Company's operations consist of two operating and reportable segments, the "InMed Pharma" segment and the "BayMedica Commercial" segment.

The "InMed Pharma" segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the "BayMedica Commercial" segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry (See Note 10).

Leases

Leases

At inception of a contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The lease liability is initially measured as the present value of future lease payments excluding payments made at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate. The lease liability is measured at amortized cost using the effective interest method. It is re-measured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Company's estimate of the amount expected to be payable under a residual value guarantee, or if the Company changes its assessment of whether it will exercise a purchase, extension, or termination option. When the lease liability is re-measured in this way, a corresponding adjustment is made to the carrying amount of the ROU asset or is recorded in profit or loss if the carrying amount of the ROU asset has been reduced to nil.

The Company has lease arrangements that include both lease and non-lease components. The Company accounts for each separate lease component and its associated non-lease components as a single lease component for all of its asset classes.

The Company has elected to apply the practical expedient to exclude initial direct costs such as annual operating costs from the measurement of the ROU asset at the date of initial application. The Company has elected to apply the practical expedient not to recognize ROU assets and lease liabilities for short-term leases that have a lease term of 12 months or less. The lease payments associated with these leases is recognized as an expense on a straight-line basis over the lease term.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in these unaudited condensed consolidated financial statements as a result of future adoption.

In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*, which enhances reportable segment disclosure requirements primarily through expanded disclosures around significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company has early adopted this accounting pronouncement.

In December 2023, the FASB issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, which requires disclosure of specific categories meeting a quantitative threshold within the income tax rate reconciliation, as well as disaggregation of income taxes paid by jurisdiction. This ASU, which can be applied either prospectively or retrospectively, is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this ASU and expects to include updated income tax disclosures in its fiscal year 2026.

~~*XML 36 R23.htm IDEA: XBRL DOCUMENT*~~

Significant Accounting Policies (Tables)

3 Months Ended

Sep. 30, 2024

Significant Accounting Policies [Abstract]

Schedule of Diluted Net Income (Loss) Per Shares

The following table sets forth the number of potential Common Shares that have been excluded from diluted net income (loss) per because their effect was anti-dilutive:

	As of September 30,	
	2024	**2023**
Options	33,724	5,107
Warrants	509,602	175,826
	543,326	180,933

~~*XML 37 R24.htm IDEA: XBRL DOCUMENT*~~

Inventories (Tables)

3 Months Ended

Sep. 30, 2024

Inventories [Abstract]

Schedule of Inventories

Inventories consisted of the following:

	September 30, 2024	**June 30, 2024**
	$	$
Raw materials	274,445	372,695
Work in process	18,446	30,817
Finished goods	927,182	840,812
Inventories	1,220,073	1,244,324

~~*XML 38 R25.htm IDEA: XBRL DOCUMENT*~~

Property, Equipment and Rou Assets, Net (Tables)

3 Months Ended

Sep. 30, 2024

Property, Equipment and Rou Assets, Net [Abstract]

Schedule of Property, Equipment and ROU Assets

Property, equipment and ROU assets consisted of the following:

	September 30, 2024	**June 30, 2024**
	$	$
ROU Assets (leases)	1,901,692	2,135,811
Equipment	429,092	429,090
Furnishings	40,409	40,409
Property and equipment	2,371,193	2,605,310
Less: accumulated depreciation and amortization	(1,028,184)	(1,355,311)
Property, equipment and ROU assets, net	1,343,009	1,249,999

~~*XML 39 R26.htm IDEA: XBRL DOCUMENT*~~

Intangible Assets (Tables)

3 Months Ended

Sep. 30, 2024

Intangible Assets [Abstract]

Schedule of Intangible Assets

The following table summarizes the Companies intangible assets:

	September 30, 2024	**June 30, 2024**
	$	$
Intellectual property	1,736,420	1,736,420
Patents	1,191,000	1,191,000
Intangible assets	2,927,420	2,927,420
Less: accumulated amortization	(1,185,215)	(1,144,222)
Intangible assets, net	1,742,205	1,783,198

Schedule of Expects Amortization Expense

The Company expects amortization expense to be incurred over the next five years as follows:

Twelve months ending September 30,	**$**
2025	162,746
2026	162,746
2027	162,746
2028	162,746
2029	162,746
Thereafter	928,475
Total	1,742,205

~~XML 40 R27.htm IDEA: XBRL DOCUMENT~~

Accounts Payable and Accrued Liabilities (Tables)

3 Months Ended
Sep. 30, 2024

Accounts Payable and Accrued Liabilities [Abstract]

Schedule of Accounts Payable and Accrued Liabilities — Accounts payable and accrued liabilities consist of the following:

	September 30, 2024	June 30, 2024
	$	$
Trade payables	448,995	626,190
Accrued research and development expenses	238,412	242,066
Inventory related accruals	2,000	41,004
Employee compensation, benefits and related accruals	236,691	488,278
Accrued general and administrative expenses	85,521	256,473
Accounts payable and accrued liabilities	1,011,619	1,654,011

~~XML 41 R28.htm IDEA: XBRL DOCUMENT~~

Share Capital and Reserves (Tables)

3 Months Ended
Sep. 30, 2024

Share Capital and Reserves [Line Items]

Schedule of Warrant Activity — A summary of the Company's warrant activity and related information for the periods covered were as follows:

	Number of Shares Under Warrants	Weighted Average Exercise Price
Balance as at June 30, 2024	544,303	$ 20.40
Warrants Granted	-	-
Exercised	(34,701)	-
Expire/Cancelled	-	-
Warrants Outstanding as at September 30, 2024	509,602	$ 22.60
Warrants Exercisable as at September 30, 2024	509,602	$ 22.60

~~XML 42 R29.htm IDEA: XBRL DOCUMENT~~

Lease Obligations (Tables)

3 Months Ended
Sep. 30, 2024

Lease Obligations [Abstract]

Schedule of Minimum Lease Payments — The Company is committed to minimum lease payments as follows:

Maturity Analysis	September 30, 2024
	$
Year 1	469,668
Year 2	453,191
Year 3	219,261
Year 4	-
Year 5	-
More than five years	-
Total undiscounted lease liabilities[(1)]	1,142,120
Less: imputed interest	(84,077)
Present value of lease liabilities	1,058,043
Less: Current portion of lease liabilities	(424,260)
Non-current portion of lease liabilities	633,783

~~XML 43 R30.htm IDEA: XBRL DOCUMENT~~

Segment Information (Tables)

3 Months Ended
Sep. 30, 2024

Segment Information [Abstract]

Schedule of Reportable Segments — The following table presents information about the Company's reportable segments for the three months ended September 30, 2024 and 2023:

	Three Months Ended September 30,					
	2024			2023		
	InMed	BayMedica	**Total**	InMed	BayMedica	**Total**
	$	$	**$**	$	$	**$**
Sales	-	1,264,638	**1,264,638**	-	901,862	**901,862**
Cost of sales	-	(771,225)	**(771,225)**	-	(880,620)	**(880,620)**
Research and development patents	(762,874)	(8,306)	**(771,180)**	(1,271,439)	(20,654)	**(1,292,093)**
General and Administrative	(1,238,181)	(183,745)	**(1,421,926)**	(1,063,660)	(235,071)	**(1,298,731)**
Amortization and depreciation	(53,980)	(599)	**(54,579)**	(54,241)	(591)	**(54,832)**
Foreign exchange gain (loss)	19,310	-	**19,310**	(48,457)	-	**(48,457)**
Interest and other income	57,094	-	**57,094**	136,043	-	**136,043**
Net Income (Loss)	(1,978,631)	300,763	**(1,677,868)**	(2,301,754)	(235,074)	**(2,536,828)**
Cash and Cash Equivalents	4,346,193	1,236,846	**5,583,039**	5,886,613	851,691	**6,738,304**

~~XML 44 R31.htm IDEA: XBRL DOCUMENT~~

Corporate Information and Continuing Operations (Details) - USD ($)

3 Months Ended

	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024
Corporate Information and Continuing Operations [Abstract]			
Date of incorporation	May 19, 1981		
Net loss	$ (1,677,868)	$ (2,536,828)	
Accumulated deficit	(110,753,627)		$ (109,075,759)
Cash, cash equivalents and short-term investments	$ 5,600,000		

~~XML 45 R32.htm IDEA: XBRL DOCUMENT~~

Significant Accounting Policies (Details) - USD ($)

3 Months Ended

	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023
Significant Accounting Policies [Line Items]			
Cash equivalents (in Dollars)	$ 1,964,203	$ 1,939,482	
Uninsured cash balance (in Dollars)	1,600,000		
Inventory write-down due to net realizable (in Dollars)	$ 0		$ 92,930
Estimated useful life	18 years		
Impairment loss (in Dollars)			
Valuation Allowances [Member]			
Significant Accounting Policies [Line Items]			

Inventory valuation reserves (in Dollars)	$ 103,434	$ 103,434	
Computer Equipment [Member]			
Significant Accounting Policies [Line Items]			
Estimated useful lives	5 years		
Lab Equipment [Member] | Minimum [Member]			
Significant Accounting Policies [Line Items]			
Estimated useful lives	6 years		
Lab Equipment [Member] | Maximum [Member]			
Significant Accounting Policies [Line Items]			
Estimated useful lives	10 years		
Furniture and Fixtures [Member]			
Significant Accounting Policies [Line Items]			
Estimated useful lives	5 years		
Customer One [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]			
Significant Accounting Policies [Line Items]			
Concentration of credit risk percentage	25.00%	32.00%	
Customer One [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]			
Significant Accounting Policies [Line Items]			
Concentration of credit risk percentage	22.00%		34.00%
Customer Two [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]			
Significant Accounting Policies [Line Items]			
Concentration of credit risk percentage	23.00%	20.00%	
Customer Two [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]			
Significant Accounting Policies [Line Items]			
Concentration of credit risk percentage	20.00%		20.00%
Customer Three [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]			
Significant Accounting Policies [Line Items]			
Concentration of credit risk percentage	22.00%	15.00%	
Customer Three [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]			
Significant Accounting Policies [Line Items]			
Concentration of credit risk percentage	18.00%		11.00%
Customer Four [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]			
Significant Accounting Policies [Line Items]			
Concentration of credit risk percentage	20.00%	15.00%	
Customer Four [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]			
Significant Accounting Policies [Line Items]			
Concentration of credit risk percentage	15.00%		
Customer Five [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]			
Significant Accounting Policies [Line Items]			
Concentration of credit risk percentage		14.00%	

XML 46 R33.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details) - Schedule of Diluted Net Income (Loss) Per Shares - shares	**3 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**
Schedule of Diluted Net Income (Loss) Per Shares [Line Items]		
Total share of anti-dilutive	543,326	180,933
Options [Member]		
Schedule of Diluted Net Income (Loss) Per Shares [Line Items]		
Total share of anti-dilutive	33,724	5,107
Warrants [Member]		
Schedule of Diluted Net Income (Loss) Per Shares [Line Items]		
Total share of anti-dilutive	509,602	175,826

XML 47 R34.htm IDEA: XBRL DOCUMENT

Inventories (Details) - Schedule of Inventories - USD ($)	**Sep. 30, 2024**	**Jun. 30, 2024**
Schedule of Inventories [Abstract]		
Raw materials	$ 274,445	$ 372,695
Work in process	18,446	30,817
Finished goods	927,182	840,812
Inventories	$ 1,220,073	$ 1,244,324

XML 48 R35.htm IDEA: XBRL DOCUMENT

Property, Equipment and Rou Assets, Net (Details) - USD ($)	**3 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**
Property, Equipment and Rou Assets, Net [Abstract]		
Depreciation expense	$ 13,586	$ 13,839
Amortization of ROU assets	$ 90,401	$ 94,532

XML 49 R36.htm IDEA: XBRL DOCUMENT

Property, Equipment and Rou Assets, Net (Details) - Schedule of Property, Equipment and ROU Assets - USD ($)	**Sep. 30, 2024**	**Jun. 30, 2024**
Schedule of Property, Equipment and ROU Assets [Line Items]		
Property and equipment	$ 2,371,193	$ 2,605,310
Less: accumulated depreciation and amortization	(1,028,184)	(1,355,311)
Property, equipment and ROU assets, net	1,343,009	1,249,999
ROU Assets (leases) [Member]		
Schedule of Property, Equipment and ROU Assets [Line Items]		
Property and equipment	1,901,692	2,135,811
Equipment [Member]		
Schedule of Property, Equipment and ROU Assets [Line Items]		
Property and equipment	429,092	429,090
Furnishings [Member]		

Schedule of Property, Equipment and ROU Assets [Line Items]		
Property and equipment	$ 40,409	$ 40,409

XML 50 R37.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details) - USD ($)	3 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
Intangible Assets [Abstract]		
Amortized on a straight-line basis	18 years	
Estimated useful life	18 years	
Weighted average estimated remaining useful life	11 years	
Amortization expense on intangible assets (in Dollars)	$ 40,993	$ 40,993

XML 51 R38.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details) - Schedule of Intangible Assets - USD ($)			
	Sep. 30, 2024	Jun. 30, 2024	Jun. 30, 2023
Schedule of Intangible Assets [Abstract]			
Intellectual property	$ 1,736,420	$ 1,736,420	
Patents	1,191,000	1,191,000	$ 300,000
Intangible assets	2,927,420	2,927,420	
Less: accumulated amortization	(1,185,215)	(1,144,222)	
Intangible assets, net	$ 1,742,205	$ 1,783,198	

XML 52 R39.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details) - Schedule of Expects Amortization Expense	
	Sep. 30, 2024 USD ($)
Schedule of Expects Amortization Expense [Abstract]	
2025	$ 162,746
2026	162,746
2027	162,746
2028	162,746
2029	162,746
Thereafter	928,475
Total	$ 1,742,205

XML 53 R40.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Liabilities (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)		
	Sep. 30, 2024	Jun. 30, 2024
Schedule of Accounts Payable and Accrued Liabilities [Abstract]		
Trade payables	$ 448,995	$ 626,190
Accrued research and development expenses	238,412	242,066
Inventory related accruals	2,000	41,004
Employee compensation, benefits and related accruals	236,691	488,278
Accrued general and administrative expenses	85,521	256,473
Accounts payable and accrued liabilities	$ 1,011,619	$ 1,654,011

XML 54 R41.htm IDEA: XBRL DOCUMENT

Share Capital and Reserves (Details) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2024	Jun. 30, 2024
Share Capital and Reserves [Line Items]		
Preferred shares, issued		
Preferred shares, outstanding		
Shares issued	667,013	445,948
Gross proceeds (in Dollars)	$ 1,000,000	
Fees paid (in Dollars)	192,000	
Warrant [Member]		
Share Capital and Reserves [Line Items]		
Outstanding intrinsic value (in Dollars)		$ 184,539
Weighted average remaining life	4 years	6 years
ATM Agreement [Member]		
Share Capital and Reserves [Line Items]		
Shares issued	186,364	

XML 55 R42.htm IDEA: XBRL DOCUMENT

Share Capital and Reserves (Details) - Schedule of Warrant Activity - Warrant [Member]	3 Months Ended
	Sep. 30, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]	
Number of Shares Under Warrants, Balance beginning | shares	544,303
Weighted Average Exercise Price, Balance beginning | $ / shares	$ 20.4
Number of Shares Under Warrants, Warrants Exercisable | shares	509,602
Weighted Average Exercise Price, Warrants Exercisable | $ / shares	$ 22.6
Number of Shares Under Warrants, Warrants Granted | shares	
Weighted Average Exercise Price, Warrants Granted | $ / shares	
Number of Shares Under Warrants, Exercised | shares	(34,701)
Weighted Average Exercise Price, Exercised | $ / shares	
Number of Shares Under Warrants, Expire/Cancelled | shares	
Weighted Average Exercise Price, Expire/Cancelled | $ / shares	
Number of Shares Under Warrants, Balance ending | shares	509,602
Weighted Average Exercise Price, Balance ending | $ / shares	$ 22.6

XML 56 R43.htm IDEA: XBRL DOCUMENT

Share-Based Payments (Details) - USD ($)	3 Months Ended				
	Mar. 24, 2017	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Dec. 19, 2023
Share-Based Payments [Line Items]					
Percentage of common stock issued and outstanding	20.00%	20.00%			

Stock options (in Shares)				35,000
Vested and exercisable options (in Shares)		10,804		
Exercisable options, weighted average exercise price (in Dollars per share)		$ 163		
Unvested options (in Shares)		22,919		
Unvested options, weighted average exercise price (in Dollars per share)		$ 8.4		
Share-based payment expense		$ 28,964	$ 25,191	
Weighted-average vesting period		1 year 3 months 18 days		
Stock Option [Member]				
Share-Based Payments [Line Items]				
Stock options (in Shares)		34,224		34,224
Share-Based Payment Arrangement [Member]				
Share-Based Payments [Line Items]				
Research and development expenses		$ 220	0	
Unvested Options [Member]				
Share-Based Payments [Line Items]				
Unrecognized compensation cost		78,685		
General and Administrative Expenses [Member]				
Share-Based Payments [Line Items]				
Share-based payment expense		17,564	15,431	
Research and Development Expense [Member]				
Share-Based Payments [Line Items]				
Share-based payment expense		$ 11,180	$ 9,761	

XML 57 R44.htm IDEA: XBRL DOCUMENT

Lease Obligations (Details)	**Jul. 29, 2024 USD ($) / m²**	**Oct. 05, 2023 USD ($)**
Lease Obligations [Abstract]		
Square feet (in Square Meters) | m²	2,243	
Rental rate	$ 12,296	
Estimated agreement term	two-year	
Borrowing rate, percentage	7.00%	6.15%
Operating lease liability	$ 205,201	$ 953,935
Obligated to pay		$ 1,295,759
Termination period		three-year

XML 58 R45.htm IDEA: XBRL DOCUMENT

Lease Obligations (Details) - Schedule of Minimum Lease Payments - USD ($)	**Sep. 30, 2024**	**Jun. 30, 2024**
Schedule of Minimum Lease Payments [Abstract]		
Year 1	$ 469,668	
Year 2	453,191	
Year 3	219,261	
Year 4		
Year 5		
More than five years		
Total undiscounted lease liabilities	1,142,120	
Less: imputed interest	(84,077)	
Present value of lease liabilities	1,058,043	
Less: Current portion of lease liabilities	(424,260)	$ (317,797)
Non-current portion of lease liabilities	$ 633,783	$ 644,865

XML 59 R46.htm IDEA: XBRL DOCUMENT

Segment Information (Details) - USD ($) $ in Millions	**Sep. 30, 2024**	**Jun. 30, 2024**
InMed Pharma Segment [Member]		
Segment Information [Line Items]		
Total assets	$ 7.6	$ 9.2
BayMedica Segment [Member]		
Segment Information [Line Items]		
Total assets	$ 2.8	$ 2.6

XML 60 R47.htm IDEA: XBRL DOCUMENT

Segment Information (Details) - Schedule of Reportable Segments - USD ($)	**3 Months Ended**		
	Sep. 30, 2024	**Sep. 30, 2023**	**Jun. 30, 2024**
Schedule of Reportable Segments [Line Items]			
Sales	$ 1,264,638	$ 901,862	
Cost of sales	(771,225)	(880,620)	
Research and development patents	(771,180)	(1,292,093)	
General and Administrative	(1,421,926)	(1,298,731)	
Amortization and depreciation	(54,579)	(54,832)	
Foreign exchange gain (loss)	19,310	(48,457)	
Interest and other income	57,094	136,043	
Net Income (Loss)	(1,677,868)	(2,536,828)	
Cash and Cash Equivalents	5,583,039	6,738,304	$ 6,571,610
InMed [Member] | Reportable Subsegments [Member]			
Schedule of Reportable Segments [Line Items]			
Sales			
Cost of sales			
Research and development patents	(762,874)	(1,271,439)	
General and Administrative	(1,238,181)	(1,063,660)	
Amortization and depreciation	(53,980)	(54,241)	
Foreign exchange gain (loss)	19,310	(48,457)	
Interest and other income	57,094	136,043	
Net Income (Loss)	(1,978,631)	(2,301,754)	
Cash and Cash Equivalents	4,346,193	5,886,613	
BayMedica [Member] | Reportable Subsegments [Member]			

Schedule of Reportable Segments [Line Items]			
Sales	1,264,638	901,862	
Cost of sales	(771,225)	(880,620)	
Research and development patents	(8,306)	(20,654)	
General and Administrative	(183,745)	(235,071)	
Amortization and depreciation	(599)	(591)	
Foreign exchange gain (loss)			
Interest and other income			
Net Income (Loss)	300,763	(235,074)	
Cash and Cash Equivalents	$ 1,236,846	$ 851,691	

XML 61 R48.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) - USD ($)	**3 Months Ended**			
	Sep. 30, 2024	**Jun. 30, 2024**	**Jun. 30, 2023**	**Mar. 11, 2021**
Commitments and Contingencies [Line Items]				
Contract research services and materials	$ 422,270			
Guaranteed investment certificates	43,203	$ 43,064		
Warrants to purchase (in Shares)				700
Payable under the patent license agreement	$ 1,191,000	$ 1,191,000	$ 300,000	
Common Stock [Member]				
Commitments and Contingencies [Line Items]				
Warrants to purchase (in Shares)				700

XML 62 R49.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) - USD ($)	**3 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**
Norton Rose Fulbright Canada LLP [Member]		
Related Party Transactions [Line Items]		
Legal services	$ 124,147	$ 19,814

XML 63 R50.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - USD ($)	**Nov. 14, 2024**	**3 Months Ended Sep. 30, 2024**
Common Shares [Member]		
Subsequent Events [Line Items]		
Gross proceeds		$ 365,473
Subsequent Event [Member]		
Subsequent Events [Line Items]		
Reverse stock split, description	As a result of the Reverse Stock Split, each 20 shares of Common Shares were combined into one Common Share, and the total number of Common Shares outstanding were reduced from approximately 14,361,550 shares to approximately 718,032 Common Shares.	

*EXCEL 64 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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|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}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{GNM ML29XRU*\9<&$],#2+=6T=+:.@3 M>F*^U'"PM,9X]:6TV0DJ5(MR8*Q9M]^$9I/%[43[NAP.K.M0P9%5,>\[VV".3\O\DZ' M/L=*9MDP:5BMY3,13UX/F5HO54N^3]J.!^,0L/!59WOHL'/P.4RR ^{_}HJ0 MD_!.]F5,<,7X$FF2?G_348]GGS$]DF1E'R&?+F6H<3F0^ZS+X.R$\$VZ<R)4I.MLP?8DF^ M.SY'WMUSIYS?R_JK6G.NT?R(J7\,M*U@73<%O? M+515A<7N^ W77ZKK&NX6K95.%+Q40I.HYJN+V24^O2*Q4; 2?PI^ MK_:ND7'E5LJOYN9]=C'S#"*>\U0;$PR^ OR*Y[FQ!#B^[8S.VC6-XO[U#^N_ M6.?!F5NF^)7_ O*97E _XAC*^(HUN?XL[W_E.X<"8R^5N:) T?U.UINAM%%:.M%CME0%"(ZAE\%Z.GEE2PS.!2> (;A2,A<9TW#SEN6L3#FZ,885.D%? M;MZA5R]>GR\T+&I4%^EN@;?:!\>H.\;XZ(1ZA#_6I: ,>F'% .?@*NM MOZ3UEUA[_IB_35WS4KO\V"I2MZ))IU 5L91?S"!?%*\W? +9\^1,.O3.75\)D M[.!'Q_71G[*^O&}]C5B9H=1<\& ^_V+ F0FO*Y/QF&02O[_G)^6*S M[?!0+@PB'&*OE3O 2ENL=!+KS5K6^D3SND"BW""EBS&@6SO!'@#J$_OP71) M>2%U@PQ;D.$DR,LTE0W @KJ50*O2A%;D_B11C.HR@ 'Q$DA.;%+:_;L+82$.B\?3*'E53%;8G+'YQ9%PP< M)3$-DZ"W'T,O/R"Q'{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{(8C4<(]=[K@&LSC M(!QL]E&Y0^A=0T$>TU \L:P.VX783P)*.1 U4# !OL#>&.RNKR"/&>/WV,]F MXQ/=B =OVT8&!]>D>V!8[+TD-F_H?V?UG2@5=)1+ 7]?:E]_9&R\]^ M-[Z56LO"7]XY P>, /R^DD!HNQOS*KK]U\/R'U!+ P04 " #K@6Y9IQ$N MVA$# !P"0 & 'AL+W=O?+V>.M5'55 4U.%7K4)<* M:.9 !0^C3B<."\|$D(S=VEPE8UD9S@3,%=%545#U8PI<;B=!_]@OW++U;NQ"-MF(O+NH8%F-MRKG 6-BP9*T!H)@51L)H$%]WSV_6F7P2 MC *2P8I6W-S{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{@>0NSZGX^X9E_/E]@B>O#Q[2S5;!!\Y\5M(-6S+U M6 X+&#DM2I+FK) I+Y!@ZZO):,Y<$$\ [5!9_I.Q9'MPC'3:() M2MB;[C+UP)] 84U 4XVWXIFL?M%S;1N \6HG%<\,9V"0IT5]I2] (@X<_,?L M0!H'TG?P1QR\Q]'*G%,S]*ZI8K.9X{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j/9^W<(PT^Z;6T3++8)EE@"ZRGH=0IZ1@7_8)P# M>?\%NQ?%1A 9=R-)HL26%S&SU6*I6 'F.7X@'%;J!L]&{D!M _!O-8#=4V>@UBY IZ#C*7A+HS)67I>HS<.?FFCMPD6VP1++('U% P[!<.W;&D\G6JA.M-# M)P@]N0,9Z!9]9KILBF$TF)=S-5#.] @&?N /MS1]]';F]S5&#L3H8(?4HRG] M:(K^[XY&2UFD5.UY? N0 ;D=WQL$OG>@VP6*;8,E)-GK:(+CW8M"HSGV=/TO3 M %:%+*5Q7UHK!=7=+G0AQ.Y #/-@%^Q&; '%MH"2,SCH2W!@A]%E$APN%;T<-M2%W0(7:Q-U3#..ZE:\,J6FP5+;&%UE=P[VV1V=RV6H&<\W7;Z5+&A>Z9PBW2 M^= (A8ZBG'&\2];1);#8%E"R _('/15V#MG9+;.\0NMTYS3YOX&1+&*\6%>9 0!.YAA M"GMKT;{"-0P/VV6ON02-?7\BK%{J8+-4.%BC6\X>HQ#6Z<,+6A7)^\8Z;?*__M1SP0._4 _[-@J 98"@EL%A(7-.!*2T#U46&&.W54I7*3\HB%VKBT@L$;N/6]-MBL[0R.VDU!;$K"W4\7 F/1'7L|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{5:*%_>ES(I9JK<%-<.=SU6RF)SE3NM=PXY(5"I+$ZM^C'=^]F>?Y,76>/XOUM7>_=\Z(BY]L%E&!.9D M.]]^Y7V P}:!P\$+!T;U@<1'22B*[_(+[^/G5T+1[LAC2[853X XW1.09D'MAZ<.Y\+IS+K".AF4..NK$# 6>2)F @\Z+W6^%)>%]3Q^3Z,,2T> 19/1Z*G*NB)_8&73$:C.:OR MK$=AC M>7O_# +BS\G"!X=L^FL7&)6N\6Y=5&&??2%C==)!""7GE[E3G]/TOPX/!T2N> MC%M/Q])/YU=7E]=7D]^?!5G%]\NK\\G/AXN+\3DXHN875[\.+NX.:OX+BZO MOE[S@_DN\U]7..R)G3]B%W6(:>DAQ'N>ZX2<;620#A69="Q_+0:]\2']f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}^E9.^1!\BA.H/E M6MT0D[F[9QAHE!9>09^ZRJ+U72 M0PTY6RY7 LR QPO@TM#W(PPCPC"LED Y0X3=<"[2'",# @]5=A7.QDHA)UO]G M,Q;AI>&0!\(CMEF&]V]MBMR*P]X2[%2 BJJ!^++#8[;!B6C.)YHLZVUS_<<;-MI5^67YZYBIREBX(6NW1I2B;$ M7(6HE@C?9 &_[P%$4 #BW;#WB;?6\&_7V.1D80VTKK6DSK%#*(JLZKV)(GZ// MQW&QUX4'OE\)(F"!A=T4]4K1RC:>)U0!;':RZPT"U.0#K689>!PT'OL+5, ML@_/C7@,J[HG,_RCW TV6]I<<8NNL=L@W3B,7_13)1?(@[0,8(">F/@F)2@3 MF9PXM;M%OY7:T1M2^W'=-P93#"G0W2KID6%5*0!EO{(N?$2!90CO'4BW MJ[A)8\FZ_=]" %+T$$M+>&+$@'B#NUSA,$%&Q;)<:*8"%[\B8%X[H1\2(<)5YT M9)]KJS34E4D>84> 3)1JA[;PLY0.%M B3*ZALD8T&RB6!{4U8W@,\,JPPZ MX_44BJ31_Z:,]?Q_7>\XOUM7>_=\Z(BY]L%E&!.9D M.]]^Y7V P}:!P\$+!T;U@<1';72EB*[_((+[^/G5T+1[LAC2[853X XW1.09D'MAZ<.Y\+IS+K".AF4..NK$# 6>2)F @\Z+W6^%)>%]3Q^3Z,,2T> 19/1Z*G*NB)_8&73$:C.:OR MK$=AC M>7O_# +BS\G"!X=L^FL7&)6N\6Y=5&&??2%C==)!""7GE[E3G]/TOPX/!T2N> MC%M/Q])/YU=7E]=7D]^?!5G%]\NK\\G/AXN+\3DXHN875[\.+NX.:OX+BZO MOE[S@_DN\U]7..R)G3]B%W6(:>DAQ'N>ZX2<;620#A69="Q_+0:]\2']f\< MCD:#(]["U\.CR#H15DK4CV8V*V3^4#_\5:RE%SJ/F] EN.'M5\[>85T)FXJI MTT'[%<)HRFRAI4!8S^6#&/[6Q=_A4)3(R$I+:V63#!3I:!('\0 /MY0//QUY MX>&$\&+_A-$>VB-;;.^0/I$ Q4P6.D@#9>X6M-]X5SUM7=AH1S8EE&3,^(5N M !HT+L[KO3W1(L/Z.9IJN$@I6CAXJPLH*PQ@C>#VHO%%>V%LS.C((..E1HH/ MQ^-]EC,\$H>'^^(/Y8/XKD#]P >A!HUTQ>\2R)9WRG7%M#?K=>%0+A.)!P^* [

MBQS7K]+Z?"L.;;;72.\+4T*!WQZ]IF;NRI(CM]L1)%=+"6IK)3D0G8KW]S@M%AAQ"D/>61!YDR,AN7MYL5'>#K!+) &1J!:L_S91J[RD;+9*!!QKR.+"[*&?M,J^Z?:..Q/@D!^/LC!U\&5AU38BXQ6I@6>FEUFA*YV_9DPR9)+K#$4]OK$C MS5+4:52DMXNRWQ!GI>[!6*+#'LQFY(KI]M,JCW1C7^1??D.Y[JHMR29MTRJ,31K>DC^+Q@17$__+YPX_*%]P@OG_[MY?\!4$L#'!\0 (.N!;EFLMN8^>@(%P% 8 >&PO=VJR.W-H965T M&ULA53?;YLP$'[//7W%BU9ZB(;\;)8@-5VKI5*[*MG:AVD/ M#AQ@%6QF.Z7[[V=#PIB49B_X[GS:?Y^_,G1>UD"\]1]3P5A9<+9U1.WI(P[T.*)/X6%]}>.[QP#&Y;EV@;<:%'1#+>HOU>ZDNAQ^P$KEB@H/$=.E<^?-5 M:/:,A">&M>K98"O9"?%BG76R<#P/$=" N.M666@9GC%:RP*2V1D_#IP.MV1%MBWMC^RW3>VFEAU5>"V*9Y;H?.G,'$@PI?M";T3]!0_UC"U?+ K5?*%N_@7@D/,,7=-4%#5_P_^K@Q]5..:6FZX.>I0EN>\#2/-MG8RYJFB,2|>TOD+YBD[T\8,_\3Z=41EV*L-S[-'ZX>GFX=O7S?IF>TK:6?!I M:<$(>]30OX98F(%2&A,0*>@<(16%F4S&L_G 7+_&R^0=W>X[6&%S Q6!# M.]-V&B6CA0(R#8=A.(9@2H:3R_'@V4P>, Z5%#$]!?[.;$\[>.9/!{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`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}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{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

*JSZG4,)..: .V[M1%6"\"\"4@:2M9\6 >P,8?@7#0ZZ.7WFD?MWZ'P'ULQK^V^!AK_$FB^,,Y06<4 M?\?8+(^ !D&U](>29QB:^_H]$TGCI Z0[+ E5C8D.P.?\Y5{@Q.5] YU.+ MBE8?Z(#F9Z[+_P%02P,$% @ ZX%N63KZ:C9O P :P< !D !X,"]W M;W)K&ULE55M;]LV$/[N7W%0BV(##,F2W39+; .V MDVP=DM2PG0W#L ^T=):(4J1&4G'\[W>D9-4IG # [(O'EN>>>.OZ/X[W2WTR! M:.&Y%-),@L+:ZC**3%I@R4RH*I2TLU.Z9):F.H],I9%EW]@443(8?(I*QF4P M'?NUI9Z.56T%E[C48.JR9/HP1Z'VDR .C@LKGA?6+433<<5R7*.*
]K):.9E'' MDO$2I>%*@L;=))C%E_.1PWO 'QSWYF0,+I*M4M_.MCXXO5<+X+^P,[)# .6VL*EMC4E!RV?S9-V (Z_RFEDV M'6NU!^W0Q.8&/E1O3>*X=
(>RMIV.=G9Z0H%YCl!DFE[@(UFTC"?+S..+/$[M5)2V7/,&*WF%:PCW2MB"P(W,.'MI'Y&N3EQR%#=/WB1<8Q7'<.'"9)" WN ; M=L$./=_P?P<+?\^VQFJ._7,N[H9V=)
[6W9M+4[$4)P%=#((/Z"8/IAW?QI\'5 M&Z)'G>C16^S3UF#+1#FBND,U*YWS37=)Z4 L*I27+IT_LXD=8]?M7I"8+0! M60LB
V^]4& 7%Y"&$>Q.V..YP[APD>MB#TI8NZ4H9A.M:,+6[3;!@DF4,[NZ6 M\. '=Q=),KAZ6 TN_#"^^CGL7=>:R]P[L85&A+*I0'05'"%0_%LLM>3@6$3"9 MN<&P#X{(3\^[?
@S7X8^.']>M9V]G58[D6/?VW!:>SI,>Q5'+(A&:9 C,F0!7 M%SQ% UQZO:Q4M;0N]O=Q,NK'H\^>]7W\2_\B'O7)W%3H>Y8XT*&HEYG<%%1H
M8$]*N+6R(SM1/(K#?"Y1+@,N^D[0N> M%]3#%[4_Z9>Z4V+C6^3O\# M4$L#!!0 (_N!:,EEKANPCV@,_ #D(9 >&PO=V]R:W H965T XE%Y4VO8YE;PZI'$92
M"TTLS5,>U5&,]\ MPH;ID6Q1T$TI5<,,,=4ZU*U"5GBEI@Z3*#H/&\9%L)CYLWNUF$EK:B[P7H&V M3.#KRKB#<+#%KV113-$_MO:)=V*.4O$&AN12@L)P'R_A] M-7'R7N
KQZU^MP;G22;EL]M\+N9!Y AAC;EQ"(P^&[S&NG9 1.-EAQGT)IWB M^ 4> 5?O, F2,8W7LOZ3%Z,:!Y*=P&7U'(=DI))YW9\BS (49MI@IN07EI G-+,RK
M7!O(<>$>)36*;CGIF45],XTO%H6!FPW]ZEEH"_9=AOD.8M5!) ^'&,.M%*,2 M<';*+ [U0Z+3 7;A,962 M=EW1%Z$@&9"E7Y><,*V[*=>P%,*R&AZPE5:H><\@B\"
[N0&&T0C(\HI40.\LE]!0V;H%@D8OXDZ>W .:S\5E-P[^ M$^^&ZBU3:RXTU%B2:C2ZF ;@ND'5;8QL_7#(I*%1XY<5S7943H#N2RG-?N,. M]\6%O\"4$L#.!!0 (
.N!;EE&PO=V]R:W H M965T0TBI%T[0OQ)?S/CZO\3E)R\6#+ 4>]PHDW.O4*]> M82RS BHB1[P&IG=V7%1$Z:G88UD+(+D5510'OA_CBI3,2Q.[MA9IPAM%2P9K
M@613540\+8#R=NZ-O>/"7;DOE%G .5*3/6Q W==KH6>XI^1E!4R6G"$!N[EW M/9XM(Q-O WZ6T,J3,3).MIP_F.E-/O=\DQ!0R)0A$/TYP!(H-2"=QN^,Z?5'
M&N'!^$C ,KUK+ULB8BB"6FHNN/M-C\'!=)QJFTOZAUL9'O MH;R1BE>=6&=0E"V(WA"$G2"T1EUFUM:**)(F@&K=(MF&A_P[-U:MW93,_(L;)?1N?4]79.G=)!H#
<*^")8!6I4RHUPV M ENM^L MT,7[CPE6^C CP5D'7CAP\ 8X1+>ZR3[3(-CIHO@+' #]0B% M_B<4^$$TD,_R[^7AF73"_N)"RPO_Y>*&KLOAHF&<*=.9K$D&\\.D=/?
^C>UKY$&6^8=4O$OF024=AII#^,Z*(5K@^XB>*U+:4M5[HP[.#0K1.$"=#[.\[5 M<6(.Z)MQ^@=02P.$% @ ZX%N60!ZCZM# @ B@8 !D !X;"]W;W)K M&ULG95-
CYLP$$# BD6EGG8#(5]M"DC)ME5SV"I* MMNW9P0 8;VQJF[#[[VL,0M,J8:59()66)MIC+W524!$Y=4,C\,@KE?8L]])'K6YE$HM:,ZOQ
M0@0\+,=;$CL!58(&*3:$"Y"}>$!&+,@H_&[8WK]EC;O M?'RB?W6UFUH.6,+\HT47L?? 0@0S73.]$]VPX>?6#PL[W!4U;>SDHX?2 M6FE1=LG&H*2\O>.7[AS.$@SG1% V2-
MK0[."5ZK*-M'.7VI>RU-$^IR=/)QAPO 8F>)":4YV@E)>8YF&/7*OV<'&^6E'6[>T\ IM M@AX%UX5"7S@!\F^^;\QZO?'DMPX'@7NH1F@2W*$P"*<#O$E?[L3Q)E=XE\[\
M0X=7M.&$'BFL,M4=0N=7H;.[V:I*IO"[)D/0X$\@I>\?S>>!Y\&E*>]\G2(MGNOJ!F@<'&,WXW-MM'*BTO\?0YBO"5]R&F6^Y+ 7]WQ=K)U!4KML&PO M=V]R:W-
H965TP@.-T2V0=[WT\5?[I-MKNT^V8W6O?]\K1O{\[U-W'^^>/WQHRXW>%G;6[G0#WZS:,EOT\&NW?FAWG2X]
M>FE,/UR/CRIUVQUC>Z_[A[WM\O# THE=G[O\U\O>_7SO:O\\U>(IOD!/ M_+?1=S;Z6>%6EFW["7]Y6_U\[OQ7I&M=]CA$?^[U=>ZKG$D6.>?.N@]/R>^
M&/_L1G|#FX? + NKK]OZ7Z;J_S_?>WI/57I5#'7_H,W[IY8 /<,QRK:V]+>Z MXV*]_>566[=#TIEFK]VUM2]-MKI9[_F6O M[KL/'_STL(?I*6'I0S]BH=>G!CZ0OW:.OW&JE^:,2E?
I^P]AF7ZM"[?65XO) M 6_T;]8NSG.U.%\\FACOPN_]@L:[, #6>63=F9%_5:U M*_4>QV[Z B5\;)'?,8SZ8P._]*$IALKTNE)E" OK+/]D@3A5 1]C*],436F*
M6EEX48.F]E9MBENMEEHW"G:]*SIXR:#]JE6U7P=,;I+O?]+5N=%?4]1Z_T3N< MI CTWW4&QMW5P($"_NQVM>%A^HU6'QM:TPU.;=7]"__V=+!$X?_'O)OO'U=5[
M^FW^XH$]FDKMALX.R-]^I3>[@4:$;$]'FK:*VW^>-@:70Z=Z8T\ \OG2$W30X.0TOP18Z_"IYY6YCRDWNB-GN3(.;@=>V10-&6)_*.V", M:G2IK04[C;M2A5H5IE.[6$S@)?
@5C)^E1W \T_2Z.UNU@[_:RKKG=44$\(_# MF^!5.N& >[G?=%JK+9L,C28CNT'9V"YUY{6>^_$_7"A;9-O[A1K8OFD]T&8T M_']^DW1*U!RD$NE/^^ E$!VV=4 --
WKHIO@4!9S2(UR;.76X.UH%[,8PE^1 M88D%VQF6 A?5PG25MF5GED&\84?PO4ALM)0OB(A(,/Z(\V3H?1]103+"]#GK>Y@T>"3RD_*@EKV!Q.C M)LR?O+ *E&1 I09F020
"P7& %0?T!R;C:./'8S,"]* 8ZS.#_KV[.YNH\# MBG9]D"EO:,H;G-)IVRR[(]L"X];[G)3C8'A>9]LC,0/1+[JN("4 \M]I5":+ MDJHL/A^K:\[2 4\<";+CT[=
(!U!)^+K1G0;F!BO)RG]1)O5=,U$X07!E.$[M/_7]!HST""'5F$XL[D7%I0D9*!;&RGROH$4* Q8 4;. LL M,@'ZL5;8X) M=P,$*($G(T^3/IXHS"]<42UD9-&
(FV+3^#0 $2H'2!IPY8 'KN]2$ [XB%: M9=)%7 @+)KT92656>(>R+&I;#B>(}}YUT[POK"F7].?=5<;][#Q7+&X:1$ KNG7@?NIP1/PNSL+E9#3W(
M;8Z:,@#5<7F=T;BQ;,$'85NAV*VZ=HM/VPFBSC)D)[B+ DW9;5O?D@*]#>1^ M,$2EUQC# /\LH$ Q%;]V?3@IM"OT-MLGF)^$>'"Q%T:1K#-LM]M.CO-(05&
MTZ671/QHW>(>8(A2=TV\HASV _$<))V.YA0$W4;U0'LDOW65*7&5[8]1]@0 MN[<0 O7%9X4VQ%COQOA!/Z[.JO:.Y@7;P=_L9#G;0N %5:O.2.C$T0Q"TF$C. M^N'G;G5Q.
HVK]QD/Q;.W0OX'CQINR,V@'1TP'H0B2N6 1<<@M#4U8$(0&26 M>4Y,F94GWJP\^;H\Z]HSZD2^]CWC_*7D MA5#Y4(!ZO043B)C##PL1V6UE2F MZ,AU\9N4?
$22/P>=^Q5F?@_"L87T=^@-A]#O^NI%KEX5>_@./LBS=^^N7ZA7 MIH544-V4I(P67BUG+VBZFSLP.$VQI9T"HW :_%9=A=D@WD>M 1_7@VZOO8N7
M#9N'F*]&I6K3DW]"H2E[3),Z2A7XMSQC793'<5#TP U:2LO6J[UCM[0&G]B) M22'$I"#7.V,?XZ Y]6L#0U>0I+=+BHR6D "OD*0DR8I^D!R(&.PK(.%3
MM/7M4]#0 .\+%A5/(T61D9FNW:"9#'H 7AI(T:A7ISC\S'/XV21_KC&LQ270 M#[!/. (DSQNK)H<.K;B?'5_X,B]QU[\TSB_C%6=N<00&I33#$1]EO+5!F037
MXRI0))51:02.5PTY#4806%GC>#OC:*_#. \85)/U V/5&W2HP+A/#;I>EX.! MF*7;.XCWORE&:-%@P1ZB]_LQB=ZV ?1LY)O!#-.8Q_494I])=&.CP=O^,_^? M73[*%^<7M
#\|>)9_NCI(D>WI'/@W"\$Y0S$6T *O0V"]}C^ Q3@]}) MA9I2$)1]_NI.U[?N.TQ]/6>"'+F4 JH@6HVUULN[IC8)7+D^$)"(2[!K,$VU$U MP
GX/[ZX,]2V[*NUC.+Y[]"T*>F)>CSS2:9?N<.,VG0)%CMJ.A\\RC*?];% MS]@*86T.0Z@^PT0)U,8EGI8+&O0?@9D"335P\2L>!^H>P>DJ9U "I,ZE3.X#]
'O2=G&XEYHL#"D,MS&O MM<'9%A@O"V]1X,*M0MW9'-1489R*4)O(RK$QBM_S8LDU1?DO)D[DI/S2*6B$ MZ=]M*2VR@ ^8W_M MU1M=
(9_4:PXHP"+;H2/)OVZ[72NSN]#MS>NWH=<$'/&OVZ/3KACY%4<2POK>) M2&=8M, *Y@Y%!22QWD?,JTA%15,Z71?">#:X,E<\X_#01+I*MJR*$X&"NH-O M?
IC/+M76U#56_()8TZI6\[J6D(R Z$$@CGH/2VLMKR$VG]+2;$:,8'0/@X=D MZ]YP>-4ABPXN?LO=I-++P(GVX^DP* EZ@:,;8;OJZ;"9RBD4S:C$1[IZB["PIT(7!W5AZA&
M^6UKN#A> [\VN8B+1VX1-/\F7_*) ;LPGP28/#R;2BAC=]WKWY;Q3[S)PP\ M#77G*00A'WY'Z!;\&3W+&JT]>%M)'RRH&(P0OT T]ZEN_AL__?98Y6\&Q+8A
M^"3=BPJ&F:MEI@:(K\&5GLC S5# /SB_S1Q2/"7HRMEILY0 M]@J\G"KI)=\W^C.U5#+%E$]$H M*C!++)C>V"*3+#^><<CY;0-YYGN:<#/P-IV/ZNUWCYQ%
{Q.M!DRUM'LL5R"RX5<*8E9#UQB[:.8PZB=6)ES M3@:F;=@. + .,5^@ (27TL&G]I@&$FHT7% ;T8%*^4Y?'BLF1QZG!Q^ 9X=PZ\ M$8B2J#
[/,C*]FAZ5MXS*QENN=6'[#+T^X0*H@4])O=_6[(#L !I%OSB6IPU& M]:.).D+(4$W.D)=[] M 6TD*T#:R'Y>VX'L.DIVL!FDDG A#2^QS]>/?GET^ M>?
9BA+ 4K)LO7JC'M&3K'WV7[-X]=:G.U/S\X W5D.A_MF6U!7YB1)K% MU/;2& J@Y*LTBI/K@NX#.(.@(!@%TP-NSP6&OM(H, #4L,S6+*[59+6UK: MI;O!8%QY
$,Q)7&7HR(CHIV "L#$OS'Q]H*2 51<.?6]IO* ^937 MDT,)[7ABJNV05&8GI9+Z'1!F;U%1L,N/+)#&/>>\/OW;%7V/O!:2Y\8UZ P: M)"7T>;3K=_!6:4&9%)O{OQO
{2XQ=87Q$1O4"'B'&\(];MNDG2F#5"PL2,L2 M W;!G43]8X[->'ARQT7%>73N:)5%A.=%8 F/]HT^CE9R9-=R7 @L@#UP(BMN M$9T^$_E+
(%]'UUME#OZ+O(YL<4L#WS:63.VZ8OFC75IK[D M=;YG((5]"!'1V6]4TARTU!E M%0ML9YOVSCF6D4%9*%)'QKT<&VD6E652)>#B#,H?=>X.3++7L?E3L8M1%6O:
M"6)F"X2YHU1]BK,!IC*21!F\,[7HUS]UD& KV>]<[>'M M>_G$E2 RK+8'0%5A.1ZCWBF&8NC'B_^)C"CA!*&G'#= _]WH8"]P=RDIV# _M5*!T M:0B6AN
.QP,T4;JM<9,/,X)2%.F\$F7<&&B"OD @:<%*I;$Z"$!(;O%/@R(O M$MN!P89W5IW/P\@Z90*;5?C ,P#(3QVU!!FZ6]=:,VI M'$]EXM)TH.2(9>46$ %6!]A!670=H9,B?
%4C0H]U/ZYFA<74&MN[\P^6QM$H0&VO)4:.4 ^R0#8RE MRK^U.:HH[@5UK):1,@()(*0'B5MO. A;&1(2')7PAH)N"H8L$E]7]#MU:0+&
M)^!6TG,&T$SO5F>$5C:NIY1\1PN:G6HT2WO44SL[C."8QP3C MDV@2B>L"R*2;&^TO]/1-C_0W#N>3;0O62 1T.(##(<=S(/N91#@=P%.]_YH M?
1%0CU@VS _L@@VDYG&POS8O !<9 _L\AAGFW.(.?O ML@6G5_S@A;J/=C%^:N8A'E2RF+]0'QN?BR6<O;$!LRZL*/'I:WS4)-4> M//
P$"E48Q,%9G*K\O:G76((0]+E"AK>F?I4\ LPQ9ERRQ(NR*Q9"DTAQV*V M!KO PN5H$C,&7LG5\1"!,E\Q7N9HZC=,T3U-DKOE'E'/3?=M5(+T>*9G>6I>
M,9[M#;I5B+)O,3O7?3E[P +C9.;[LCQ:WEV/&5(GH4PD53.[!IVV?]H)UJ1 M8(W (A;X#8'?Z|*Y# I?[(Q!'< M/4,.DTK>X0YE,@@.@7NP.T*6$<1YL'+@ CX79W5,W;0W++F0]0
.6FI23"/0 M171T*D"F?/1S8&2X1A BHF0XT7 R$5@^H"D]MNL8#Q^;F+C:,E/7P=_A=:OS MV&-%SC(?:]+FKAC/7^R*/3LS_I"<9G+P*/*8XA[3E=I"'[fW$0ZT4-*O:S9
M;LG@0G<;D!T3_?]!FZD(1L+PY12@_MM'22)(QQ9UIVE+#'I MUUFI0#[LRXB,A/")M(3 BP8&>>'>%V'A,#UDS'E1[A)*.0!=\E I.+(^"
M^3ZFD4!WI3N"?;,;T;.A%&ZX/<*Y BI/4;QT\4GQWC&VB[$^.:E%A.H#3D^&U M.PW-1AH/2XPN%0S S;6Z/+ ,E:,R#7@M>Q;,P;4?VST55P.3?BH91<@F.8;'-M#6
*1<\MA_H3N (T+473@)PWK.FL#P\['9TYCP)>] E]UQH^7X20G=E7L=^S MZE9XZBF >!HZC!AQ*1PXY*WZDRT!5(^]5[G)]{(.T_":JL@:"[.=5(M?(PM(17#R43-
LJJEN,MA=M&T=Z'19=GK"7HWL0.SKX2AOY6]3$4AO"JJ6[9K M*R9'=&3FP"C%X@[RBZ=1D,X#;*CHUKI+05=XXH1+H"A)#MW(=G+8N?.(\\L7
MF':!'Z]W.^5,%@>O9A&15]+9YH4,5$QY,4%Z(>.[KAEL,H6RWG3(A%@#$O MI@'(-QNSVS&.IE+_A+_@@?4HM[YCG"-[WU764Q6,8\V"G2+F0"=0),5)N-N
MW+@"(0I=^3)[IEFV>&[!S8"O,*,MCL+6.U429[#Y['#$MIF@4>WT^2&6' 1 M,N?^' IN7_CT;;&.G@)Y865N34> MI{T"(?NI.SF3ME*D3&YEL(5TX^@4\U 438=
[L3G,WD^+C\YK8/44]^21R6/ M,U.O34UK^]+F?#?/O? 5F\R^?¥/2 OBJ_;I7QZ\.H="\/+\#A_GUQ<-T'.]K(MI5(0%HU +GO78E.9R\D5DH KM>$XT)V =G4*>(G#
(H8&D1@2%ZR4 MM3BHR@*!_.['2!:(E09]:DT1YR.A6NJR&*Q+';GJ30WN9'O/LQ$D(L&0"=;7 M_2YDN[C(G\!GC_/Y^9/L7XY^C\^?Y9?G"S5_\CA_NKC,'C^ZR"\6EVK^]#Q_
M=G$QZ5,"C'8Q#82]"8?8U7L)2D9 T7=<]S4V=N)F! PE.DU!/%\& 31[I0.2.X$XO^CXH@V22)D5]1F,MQOZ6+,0'0,1>,O?.MVMU-
TYSY3XY/!Q1XIT&X@(6XL];NG!5=K01Z275'Te5.0@I0@RI"."4SEGRH MF[A<]X0#!V90!^5+!O1M@Z8HY9M.WA;2^P6*??05"'2F-K7%$^E\+9E8NJ!LEG5+'CU.8
J&"_.M/WAK%*Q^!1E$ MV.G)I9/[0%]$Y^UA_X9;G:!*EI"F\-2ASL4MJ+9NUWM7]<^F^A)4-A,%%=&) MX'N2Z\A9K%=U 0N^*3/TUIDK-6[;2M>\FO0Y^L+?.)
/)GHTK(X&@R8T4 MZ?FHVO8I&;?.(S0R"\6Y&SP;Y8ZAC7L"L,0S*QMMG)\1ZJ/[Q.?FDD\:A%#AQ1W) MP0TWE10H3KWI/9X41%NTBIJ+ ^P.WWYP*N_O8$BU_C75M]H#?
#)?$I.?^&.XA M"%W?G8_$ PGE*L2^O7^ .!*"+*_RXL4$P*3AB50\(.>L1F GO4:H>]<:HX)] M&#U_E#EI$121/K% ^3P0^]4?-F6B1#KGF-#.Q=Z>7](7<+$#>%]/]\QB.IU
M!**BLQRC'G5RP'&/.CU+8FOQQ"15Y&)X5Q;#NT" UEVQM=(F I/ID!1'1]W"-M[1RQ"3H)' .6V+9I=)U8[)SG[1G=C%.Q^ %)S]$$S339A4
M#9H$K"7@,]$_!Z^%7SWL99\QOL)!TZ;D(&!.%]-0T?<1,/-M#,]T)Q(4 4K1 @ +L'?3NWP9,S!V5,,7I"_*\2.&.?,A=&]_"1PU;?TV>Y8$% MR.$PM-
'52.ZV%GG0I5]8#W@V+E$@8@^%VfO;I_ M(T!}3^?>3 $>G+T+S(CW6Y\&PH.)4*RZ M'(9!8O@[]"N6B>6(@@\WWS4M2!^'7]"'RE\S5];M<:.R .Y!N!DF"OGXI;R-6[
M4;,$TKZCQN)!@^*/D:.3QHZ=]7%W=DDS+8"?V(0='./AF@==W'5XLH?W>W2> M)T*S!MA?"O8SV/ J#=Y\P:@&FK/MI&M4R&,HF@X3S/? ^'2L2A@8KM6-FE=+
MA)=0]0<'FZE_N&;._70L_ W4NRY?<#N3 4^0/.!(OPDUZ.G89"GA"[1QGB4WF<6/R_F#SRC0G-OQE^YHX&R.N">N#CE 13M@ M!:?S,9D';47GRX+F+\0AK3HXK>0QF-
P/D(PEXVX.Z9C!IFA=A^-+A>\'Y7P$ MRE(@B3EB:?>AG&_ZEU!RC&\QQ4DNX..[D\PI3=Y9N& ^<&(W.H-KZ(UCS),# M9_'A&X(;Q7A41Y
O#@0;0X1%7SZ>&<=Y37U<3>&_QC4L/HN[)NBR!8,N#TF[MBW^C#++PYNA0B(&C0"%@ZY^]OZN!%@RUBU KQXV=A?#Y(C1\;'X_A+!H6S ?O
MGH!'>]KYW?)=]%0H\%UP%77!6U?-]<<=&4@P8^,(!LZ"D5-N9"B<"8G\QC;/G M:Y+5R6N21P.-OS9D=LA??YRZXS?#K;R8YL1W-DL=6%H.#B;!IWL%"$LHTJ3+ ME
LQ^6/UP?0 ^(KR][QI ?_ :^QNYHDNXP1!ET*W:/LBIOV$_M?&40'7T(!+K!GA)5\5^U\+]P[_5$:NH24>5V.BZ[MQ?R?W!)S'W_VAWIE2+
MI^7>:LO7^;]%B\4*H]6C.T(GCP+DS_+\596[W]@9 D_^^31V/SAB?C M^<9$_V'T[]E-5+^F?{6'[NIM>OZG;?RG_E\&NN)_#R<\SO^LT*^06D!<"\]V M@E?/9T\>W^. U?
W2MSOZUW'4_3MEGZ$/ "<.SX WZ];B/GE%YS_MW^1/ M4$L#!!0 (.N!;EGQXX$V# (.D% 9 >&PO=V]R:W H965TE.Z4=3(%IX+H4TLZ"PM[$H4D+
M+)FY4!5*.LF5+IFEK=Z&IM+(,@\]11A'T3 L&9?!?.IM*SV?]MW*+G&EP=1E MR?3O)0[UFP6]X,5PQ[>%=89P/W8%M=HOU4K3;MPSY+Q$]7A2H+&?!8L>I E MW_E[A^\
<=^9@#2Z3C5*;G.3S8+("4*]J74,C'Y/>(5".'*2\;OE#/8A'?!P M_<+^T>=.N6R8P2LE'GAFBUDP#B##G-7"W]G=)VSS&3B^5 GCO[!K?/N7 .2U ML.ILP.2@Y++YL^?V'@X
X^@50-P"8]^5Z/C+YE,M=_[&YA4_5NV<ME^1UEL,2N9<-=PJZ0M#'R0&6;_XD-2N9<;OTA=QB<)UU=0!)U{8[B_@F^9)]Z MXOF2_TS]QV)CK*:R^7DL^8;[?
YS;M=+$5"S%64"]8E _83!._^Z8WC Z?4 [? M*^^?8I^OJ36S6B"H'*ZY]"UF\(4:^$:F]D0X^ZR,.8<5:E@7C,(?TW\RPG"] M]P5"K@3UL;LGZPH##%I#1FT+L
5V9%UN*"SJ]I1%NE FX$[5)25?(X6\F(6" M/2%L$"7@_*)^E\K=PX,) DW1'9!MU>. H\ *V)Q<.@ MNNP.HQAZHT%W' \(@W[23>(A],91|S)\X-CKA0?
M5Z+>^B%CP%=4TXE[ZWZ. M+9KV_>O>#,%;IK>'=_ %!+ P04 " #K@6Y91C"0IWP" !B!0 &0 'AL+W=O M5>NG)K#$)= MB58SRN%!(M76 9&_
\!$M_8B[!CP2.M*VX4@736DA"WH;\V# +_@8,EI#5O1 MP0$&8NU=1\M 8N=*[M'BX=.R$^ +93N!RM1=.:0< @TY:!F&$/\'8)3(R M?ATXO6%+"QS'1_9;U[OI94<4W
CV1'-=K;V%AW(H2.OTH^@^PZ&?]>7+!%/N MB[^%B<>REJE17T &P4UY?U(7@[G. (LPE< ^ # 3G>_D5/YD6B2K]3HD+35 MALT&KE6'-N(HMS]EJZ7)4H/3Z1W?
]=*4E#HW5>R8Z#>KP)MF&T^R XLFYX% MO\(2HWO!=:70)YY#_B\^,(H&6?@H:X//$FZAN41QZ". 7RE@$2!1HI/B7S+-
%IF>,SR(2QE=*0VZUT!:@0S/B3\G(Y,6>OH=Z!=#_@ M2\O!!L,+=#%Y))VY?!HD)4PA/$_\))FB>([]V=5T\F3\ARA'C109*(6BA4G/ M+'@1S2>WE%-S3W-4"I$K=(7G?K3 ;)'8-
}Z,U44^Q]$?SF,;)8D?XP2=,#%V M=.]KD*5SMVVNJ/V# + -@8,EI#5Q1 MP9&$8NU=1\M 8N=*[M'BX=.R$^ +93N!RM1=.:0< @TY:!F&$/\'8)3(R M?ATXO6%+"QS'1_9;U[OI94<4W
ZX%N67.L4P'< M @ 6@8 !D !X;"]W;W)K&ULI57?:],P$'[/ M7V&%":V2M3@_VC6EK=0.)D ,JI7! ^+!3:Y M,3.;&?=^.LY)_V%Z,H#+[' M]GW?=V??9,B6ZEYG
{8\E870(S0]%7(!0E"YU(0!;PY\RV&M#^,$1K*0\MX;.M'!*1RZP@*\' O%H'C\ A74!06"&4\,##=';5U/)OOT;^,V#&6!==P)8OO>6]R MD=MW20I+7A?F5]I?
PR:>KL5+9*&;+UFW9[O(F 3:R'+CC':9BW;D3YL\'#CT MV0L.P<8A:'2W1(W*M]SP\5#) 5'V.*+921 JXXWBK MS#,E(QI]O,)T&\)%2FYE329:@]&4?,.WLF&8=HR!"\P
MA.1&"L-I\DZDD/!IZ';G>1@*WD:G 2<0W5!0D9)P(+H!%ZX2T'8X(7_F8(? MDX4V"1_1SV-):#FBXQRVM .ZX@F.7*P=#>)H1W/'K5WZ/O3D10;2+(#]%/IYC MJ;9U 40NR8O1?
+G;1'-_4G\X~KW1/ 7$6^(2"*Q>+6!U$%A)@.RE 5V@5RL M!@[>HH%R .JYRH^U+#MQSLB9LY=*S@O DM.=XM.8^;07!R2@?MBE?=]W]@%& M04P9[K4C#LU7=2-
T+#VAXZ5,_#G'68UT;^LSY!%H/ ML&TD=5D7'%/.L?PDYRW_00!>"F5R7^U"^<^94&?^OV(=*P1=BV.3SK.OU_% MB< 7ACY12!F[]6D0Q32.8W+L>7@'!5Z"6C5=S:.
[%]8M_=W]KG%.VGZO/]YV MW1NN5KG0I(ENK*+RZY+5-O)6L/([ND>"VFP%S73#)L_*'L]Y=2FJUA":_MD_%O4$L#!!0 (.N!;EF=$Q'$,_'D'.9 >&PO=V]R:W H965T
M!%F2,[C&SI.<+F7ZKO.$0T\5]70*S\W MIEZ$H4YRK+B^D#4*FLFDJK@A5^U"72OD]0NJR!%T32L>"'\]=*.W;KU4C;F M+ 3>*5M! 57'U=(6EW*_\D?
\R*78Y<8.A.MES7=XA^;O^E:1%_8H:5&AT(44 MH#!;^9O1XFIBU[L%7POO1+ N@#F>++<;.9;ON.'KI9)[4'8U MH5G#I>JBB5PAK"AW1M%L07%F?2,,,%
[MB6R)LM&;CX>T]}T^?+T-#^'95F'18 M5RT6>P5K#)^E,+F&]R+%].?XD'CUY-@+N2MV$O .ZPL81P&PB,4G\,9]LF.' M_[M9/_9;+51=#7^/99NBQ8?1I/ELM

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|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|+-!=\C87IKFKEHW&-4VB-*S$99*:&?4JU3T9*7)54Z\DHBPC*TY$Q1-MM@664I#H(@9%:"%?H]-1QU6,+GY]/7>5'M:(W;0.XK8=PO-,$-&ZT]!:AR+7L<)AMDM2-K$@*"T=G(0EB-M!TFZA=OBM\.V6X3%MN$)99a1P$*-^P"%8-?(&,FH@T1V8$FD(;+YWK-M0%!2R*'PM.1!0S8I?Q>%ON-A-S='1H-,H%SC;<)2RS!CHR?].9/1HW-HR:"-M,60(@-KHQE=4(96.=&C#1X*H]\1S4XM-6&P3EDQ/-M]LL,/-T^C]R>)6[/1MV^)]-(N@!4Z-.2()4#JO1NU7NWT%F#;>?)5@"8W3SD-M^^OD:WK>M8?Q\Z3QPG[Q:,|-XY-NR>B2?G\[7O6&7?U/BBU+|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|-1?=3DXMN-3#5ZD'\EAZ\$=DS#WJ-![V3)V$*&TR19249]+92-M*WS?X6UWW:7=.,[&@\3?'1?1DO.YHALW694Z_^C.,Y.;UPH5RL26Z^HV-;--MM{UT3-9_-ATX.I[-J6I6Q@.RPTOGY#"VE-&G8%1)]NV6-5;E*ZSK(0V?UCT0$MCBXA(-DG*SO[!#BE;M:,*T"-"^2"0U[\T]-M#L69Q5'I9Y.C6G@1A33++(->VOE#D^8HF!Fj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{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end-XML-65-Show.js-IDEA:-XBRL-DOCUMENT-//-Edgar(tm)-Renderer-was-created-by-staff-of-the-U.S.-Securities-and-Exchange-Commission.-Data-and-content-created-by-government-employees-within-the-scope-of-their-employment-are-not-subject-to-domestic-copyright-protection.-17-U.S.C.-105.-var-Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var-e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var-ref=((window)?w.document:document).getElementById(r);if(ref){-e=ref.cloneNode(!0);-e.removeAttribute('id');a.parentNode.appendChild(e)}}-if(e).style.display='block';Show.LastAR=e};Show.hideAR=function(){-Show.LastAR.style.display='none'};Show.toggleNext=function(a){var-e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else-if(!e.style.display){}else{var-d,p;-if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}-e.style.display=d;if(a.textContent)-{a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}-}-XML-66-report.css-IDEA:-XBRL-DOCUMENT-/*-Updated-2009-11-04-*/-/*-v2.2.0.24-*/-/*-DefRef-Styles-*/-.report-table.authRefData{-background-color:-#def;-border:-2px-solid-#2F4497;-font-size:-1em;-position:-absolute;-}-.report-table.authRefData-a-{-display:-block;-font-weight:-bold;-}-.report-table.authRefData-p-{-margin-top:-0px;-}-.report-table.authRefData-.hide-{-background-color:-#2F4497;-padding:-1px-3px-0px-0px;-text-align:-right;-}-.report-table.authRefData-.hide-a:hover-{-background-color:-#2F4497;-}-.report-table.authRefData-.body-{-height:-150px;-overflow:-auto;-width:-400px;-}-.report-table.authRefData-table{-font-size:-1em;-}-/*-Report-Styles-*/-.pl-a,-.pl-a:visited-{-color:-black;-text-decoration:-none;-}-/*-table-*/*

.report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 102 240 1 false 38 0 false 5 false false R1.htm 995100 - Document - Cover Sheet http://xbrl.sec.gov/dei/role/document/Cover Cover Cover 1 false false R2.htm 995301 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 995302 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 995303 - Statement - Condensed Consolidated Statements of Operations Unaudited Sheet http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Operations Unaudited Statements 4 false false R5.htm 995304 - Statement - Condensed Consolidated Statements of Shareholders??? Equity Unaudited Sheet http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3 Condensed Consolidated Statements of Shareholders??? Equity Unaudited Statements 5 false false R6.htm 995305 - Statement - Condensed Consolidated Statements of Cash Flows Unaudited Sheet http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow Condensed Consolidated Statements of Cash Flows Unaudited Statements 6 false false R7.htm 995306 - Disclosure - Corporate Information and Continuing Operations Sheet http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperations Corporate Information and Continuing Operations Notes 7 false false R8.htm 995307 - Disclosure - Significant Accounting Policies Sheet http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 995308 - Disclosure - Inventories Sheet http://www.Inmedpharmaceuticalsinc.com/role/Inventories Inventories Notes 9 false false R10.htm 995309 - Disclosure - Property, Equipment and Rou Assets, Net Sheet http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNet Property, Equipment and Rou Assets, Net Notes 10 false false R11.htm 995310 - Disclosure - Intangible Assets Sheet http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssets Intangible Assets Notes 11 false false R12.htm 995311 - Disclosure - Accounts Payable and Accrued Liabilities Sheet http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilities Accounts Payable and Accrued Liabilities Notes 12 false false R13.htm 995312 - Disclosure - Share Capital and Reserves Sheet http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReserves Share Capital and Reserves Notes 13 false false R14.htm 995313 - Disclosure - Share-Based Payments Sheet http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPayments Share-Based Payments Notes 14 false false R15.htm 995314 - Disclosure - Lease Obligations Sheet http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligations Lease Obligations Notes 15 false false R16.htm 995315 - Disclosure - Segment Information Sheet http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformation Segment Information Notes 16 false false R17.htm 995316 - Disclosure - Commitments and Contingencies Sheet http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 17 false false R18.htm 995317 - Disclosure - Related Party Transactions Sheet http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactions Related Party Transactions Notes 18 false false R19.htm 995318 - Disclosure - Subsequent Events Sheet http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 20 false false R21.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 21 false false R22.htm 996000 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPolicies 22 false false R23.htm 996001 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPolicies 23 false false R24.htm 996002 - Disclosure - Inventories (Tables) Sheet http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables Inventories (Tables) Tables http://www.Inmedpharmaceuticalsinc.com/role/Inventories 24 false false R25.htm 996003 - Disclosure - Property, Equipment and Rou Assets, Net (Tables) Sheet http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables Property, Equipment and Rou Assets, Net (Tables) Tables http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNet 25 false false R26.htm 996004 - Disclosure - Intangible Assets (Tables) Sheet http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssets 26 false false R27.htm 996005 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) Sheet http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilitiesTables Accounts Payable and Accrued Liabilities (Tables) Tables http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilities 27 false false R28.htm 996006 - Disclosure - Share Capital and Reserves (Tables) Sheet http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables Share Capital and Reserves (Tables) Tables http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReserves 28 false false R29.htm 996007 - Disclosure - Lease Obligations (Tables) Sheet http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables Lease Obligations (Tables) Tables http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligations 29 false false R30.htm 996008 - Disclosure - Segment Information (Tables) Sheet http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformation 30 false false R31.htm 996009 - Disclosure - Corporate Information and Continuing Operations (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperationsDetails Corporate Information and Continuing Operations (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperations 31 false false R32.htm 996010 - Disclosure - Significant Accounting Policies (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesTables 32 false false R33.htm 996011 - Disclosure - Significant Accounting Policies (Details) - Schedule of Diluted Net Income (Loss) Per Shares Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofDilutedNetIncomeLossPerSharesTable Significant Accounting Policies (Details) - Schedule of Diluted Net Income (Loss) Per Shares Details http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesTables 33 false false R34.htm 996012 - Disclosure - Inventories (Details) - Schedule of Inventories Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofInventoriesTable Inventories (Details) - Schedule of Inventories Details http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables 34 false false R35.htm 996013 - Disclosure - Property, Equipment and Rou Assets, Net (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetDetails Property, Equipment and Rou Assets, Net (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables 35 false false R36.htm 996014 - Disclosure - Property, Equipment and Rou Assets, Net (Details) - Schedule of Property, Equipment and ROU Assets Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPropertyEquipmentandROUAssetsTable Property, Equipment and Rou Assets, Net (Details) - Schedule of Property, Equipment and ROU Assets Details http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables 36 false false R37.htm 996015 - Disclosure - Intangible Assets (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables 37 false false R38.htm 996016 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofIntangibleAssetsTable Intangible Assets (Details) - Schedule of Intangible Assets Details http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables 38 false false R39.htm 996017 - Disclosure - Intangible Assets (Details) - Schedule of Expects Amortization Expense Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofExpectsAmortizationExpenseTable Intangible Assets (Details) - Schedule of Expects Amortization Expense Details http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables 39 false false R40.htm 996018 - Disclosure - Accounts Payable and Accrued Liabilities (Details) - Schedule of Accounts Payable and Accrued Liabilities Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable Accounts Payable and Accrued Liabilities (Details) - Schedule of Accounts Payable and Accrued Liabilities Details http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilitiesTables 40 false false R41.htm 996019 - Disclosure - Share Capital and Reserves (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails Share Capital and Reserves (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables 41 false false R42.htm 996020 - Disclosure - Share Capital and Reserves (Details) - Schedule of Warrant Activity Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofWarrantActivityTable Share Capital and Reserves (Details) - Schedule of Warrant Activity Details http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables 42 false false R43.htm 996021 - Disclosure - Share-Based Payments (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails Share-Based Payments (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPayments 43 false false R44.htm 996022 - Disclosure - Lease Obligations (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails Lease Obligations (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables 44 false false R45.htm 996023 - Disclosure - Lease Obligations (Details) - Schedule of Minimum Lease Payments Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable Lease Obligations (Details) - Schedule of Minimum Lease Payments Details http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables 45 false false R46.htm 996024 - Disclosure - Segment Information (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationTables 46 false false R47.htm 996025 - Disclosure - Segment Information (Details) - Schedule of Reportable Segments Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable Segment Information (Details) - Schedule of Reportable Segments Details http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationTables 47 false false R48.htm 996026 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingencies 48 false false R49.htm 996027 - Disclosure - Related Party Transactions (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactions 49 false false R50.htm 996028 - Disclosure - Subsequent Events (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEvents 50 false false All Reports Book All Reports ea0219774-10q_inmed.htm inm-20240930.xsd inm-20240930_cal.xml inm-20240930_def.xml inm-20240930_lab.xml inm-20240930_pre.xml image_001.jpg image_002.jpg http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 70 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0219774-10q_inmed.htm": { "nsprefix": "inm", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "dts": { "inline": { "local": ["ea0219774-10q_inmed.htm"] }, "schema": { "local": ["inm-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-

21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd", "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["inm-20240930_cal.xml"] }, "definitionLink": { "local": ["inm-20240930_def.xml"] }, "labelLink": { "local": ["inm-20240930_lab.xml"] }, "presentationLink": { "local": ["inm-20240930_pre.xml"] } }, "keyStandard": 228, "keyCustom": 12, "axisStandard": 17, "axisCustom": 0, "memberStandard": 20, "memberCustom": 15, "hidden": { "total": 70, "http://fasb.org/us-gaap/2024": 60, "http://www.Inmedpharmaceuticalsinc.com/20240930": 5, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 102, "entityCount": 1, "segmentCount": 38, "elementCount": 600, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 456, "http://xbrl.sec.gov/dei/2024": 32, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://xbrl.sec.gov/dei/role/document/Cover", "longName": "995100 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet", "longName": "995301 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:ShortTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "unique": true } }, "R3": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "995302 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:AccountsReceivableNet", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:AccountsReceivableNet", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement", "longName": "995303 - Statement - Condensed Consolidated Statements of Operations Unaudited", "shortName": "Condensed Consolidated Statements of Operations Unaudited", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:GrossProfit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "unique": true } }, "R5": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3", "longName": "995304 - Statement - Condensed Consolidated Statements of Shareholders\u2019 Equity Unaudited", "shortName": "Condensed Consolidated Statements of Shareholders\u2019 Equity Unaudited", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c18", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c18", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow", "longName": "995305 - Statement - Condensed Consolidated Statements of Cash Flows Unaudited", "shortName": "Condensed Consolidated Statements of Cash Flows Unaudited", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "unique": true } }, "R7": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperations", "longName": "995306 - Disclosure - Corporate Information and Continuing Operations", "shortName": "Corporate Information and Continuing Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPolicies", "longName": "995307 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/Inventories", "longName": "995308 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNet", "longName": "995309 - Disclosure - Property, Equipment and Rou Assets, Net", "shortName": "Property, Equipment and Rou Assets, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssets", "longName": "995310 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilities", "longName": "995311 - Disclosure - Accounts Payable and Accrued Liabilities", "shortName": "Accounts Payable and Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReserves", "longName": "995312 - Disclosure - Share Capital and Reserves", "shortName": "Share Capital and Reserves", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPayments", "longName": "995313 - Disclosure - Share-Based Payments", "shortName": "Share-Based Payments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligations", "longName": "995314 - Disclosure - Lease Obligations", "shortName": "Lease Obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformation", "longName": "995315 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingencies", "longName": "995316 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactions", "longName": "995317 - Disclosure - Related Party Transactions", "shortName":

"Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEvents", "longName": "995318 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } } }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true }, "uniqueAnchor": null }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } } }, "R22": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesTables", "longName": "996001 - Disclosure - Significant Accounting Policies (Tables)", "shortName": "Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables", "longName": "996002 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables", "longName": "996003 - Disclosure - Property, Equipment and Rou Assets, Net (Tables)", "shortName": "Property, Equipment and Rou Assets, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables", "longName": "996004 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilitiesTables", "longName": "996005 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables", "longName": "996006 - Disclosure - Share Capital and Reserves (Tables)", "shortName": "Share Capital and Reserves (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables", "longName": "996007 - Disclosure - Lease Obligations (Tables)", "shortName": "Lease Obligations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationTables", "longName": "996008 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperationsDetails", "longName": "996009 - Disclosure - Corporate Information and Continuing Operations (Details)", "shortName": "Corporate Information and Continuing Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c0", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:NatureOfOperations", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:NatureOfOperations", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "unique": true } }, "R32": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails", "longName": "996010 - Disclosure - Significant Accounting Policies (Details)", "shortName": "Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:OtherCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:OtherCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofDilutedNetIncomeLossPerSharesTable", "longName": "996011 - Disclosure - Significant Accounting Policies (Details) - Schedule of Diluted Net Income (Loss) Per Shares", "shortName": "Significant Accounting Policies (Details) - Schedule of Diluted Net Income (Loss) Per Shares", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofInventoriesTable", "longName": "996012 - Disclosure - Inventories (Details) - Schedule of Inventories", "shortName": "Inventories (Details) - Schedule of Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetDetails", "longName": "996013 - Disclosure - Property, Equipment and Rou Assets, Net (Details)", "shortName": "Property, Equipment and Rou Assets, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:Depreciation",

"unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPropertyEquipmentandROUAssetsTable", "longName": "996014 - Disclosure - Property, Equipment and Rou Assets, Net (Details) - Schedule of Property, Equipment and ROU Assets", "shortName": "Property, Equipment and Rou Assets, Net (Details) - Schedule of Property, Equipment and ROU Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails", "longName": "996015 - Disclosure - Intangible Assets (Details)", "shortName": "Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofIntangibleAssetsTable", "longName": "996016 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets", "shortName": "Intangible Assets (Details) - Schedule of Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c2", "name": "inm:FiniteLivedIntellectualProperty", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "inm:FiniteLivedIntellectualProperty", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofExpectsAmortizationExpenseTable", "longName": "996017 - Disclosure - Intangible Assets (Details) - Schedule of Expects Amortization Expense", "shortName": "Intangible Assets (Details) - Schedule of Expects Amortization Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable", "longName": "996018 - Disclosure - Accounts Payable and Accrued Liabilities (Details) - Schedule of Accounts Payable and Accrued Liabilities", "shortName": "Accounts Payable and Accrued Liabilities (Details) - Schedule of Accounts Payable and Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:AccountsPayableTradeCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:AccountsPayableTradeCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails", "longName": "996019 - Disclosure - Share Capital and Reserves (Details)", "shortName": "Share Capital and Reserves (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["div", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "inm:ProceedFromIssuanceOfShareCapitalAndReserves", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "unique": true } }, "R42": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofWarrantActivityTable", "longName": "996020 - Disclosure - Share Capital and Reserves (Details) - Schedule of Warrant Activity", "shortName": "Share Capital and Reserves (Details) - Schedule of Warrant Activity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c66", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c66", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails", "longName": "996021 - Disclosure - Share-Based Payments (Details)", "shortName": "Share-Based Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c69", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c69", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails", "longName": "996022 - Disclosure - Lease Obligations (Details)", "shortName": "Lease Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c80", "name": "us-gaap:AreaOfLand", "unitRef": "sqm", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c80", "name": "us-gaap:AreaOfLand", "unitRef": "sqm", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable", "longName": "996023 - Disclosure - Lease Obligations (Details) - Schedule of Minimum Lease Payments", "shortName": "Lease Obligations (Details) - Schedule of Minimum Lease Payments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationDetails", "longName": "996024 - Disclosure - Segment Information (Details)", "shortName": "Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c84", "name": "us-gaap:AssetsNet", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c84", "name": "us-gaap:AssetsNet", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable", "longName": "996025 - Disclosure - Segment Information (Details) - Schedule of Reportable Segments", "shortName": "Segment Information (Details) - Schedule of Reportable Segments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true }, "uniqueAnchor": { "contextRef": "c31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "unique": true } }, "R48": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails", "longName": "996026 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CostDirectMaterial", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CostDirectMaterial", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactionsDetails", "longName": "996027 - Disclosure - Related Party Transactions (Details)", "shortName": "Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c98", "name": "us-gaap:LegalFees", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c98", "name": "us-gaap:LegalFees", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails", "longName": "996028 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c100", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c100", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219774-10q_inmed.htm", "first": true, "unique": true } } }, "tag": { "inm_ATMAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "ATMAgreementMember",

```
"presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ATM Agreement [Member]", "label": "ATMAgreement Member" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 },
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet",
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Accounts payable and accrued liabilities", "terseLabel": "Accounts payable and accrued liabilities", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r40", "r41" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract", "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r39", "r41", "r44", "r835" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory related accruals", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39", "r641" ] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables", "label": "Accounts Payable, Trade, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r12", "r39" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable [Member]", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r601" ] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNet", "crdr": "debit", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable less provision for credit losses (in Dollars)", "label": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r546", "r600", "r649", "r856", "r857" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable (less provision for credit losses of $nil and $66,775 in September 30, 2024 and June 30, 2024, respectively)", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r813" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued general and administrative expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r41" ] }, "inm_AccruedResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "AccruedResearchAndDevelopmentExpenses", "crdr": "credit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued research and development expenses", "documentation": "Accrued research and development expenses.", "label": "Accrued Research And Development Expenses" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPropertyEquipmentandROUAssetsTable": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPropertyEquipmentandROUAssetsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r33", "r125", "r466" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r14", "r15", "r57", "r132", "r462", "r496", "r500" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r9", "r15", "r385", "r388", "r435", "r491", "r492", "r792", "r793", "r794", "r802", "r803", "r804", "r805" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average estimated remaining useful life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r255", "r606" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r714" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock related transactions that are in excess of par value or stated value and amounts received from other stock related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r49" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r516", "r802", "r803", "r804", "r805", "r839", "r890" ] }, "dei_AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "auth_ref": [ "r770" ] }, "dei_AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462bFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b), File Number" } } }, "auth_ref": [ "r770" ] }, "dei_AdditionalSecuritiesEffective413b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecuritiesEffective413b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "auth_ref": [ "r768" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
```

us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r727"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r727"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r727"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r727"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Items not requiring cash:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r761"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r677", "r688", "r704", "r739"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r680", "r691", "r707", "r742"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r762"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r727"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r734"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r681", "r692", "r708", "r734", "r743", "r747", "r755"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r753"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment expense", "label": "Share Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r338", "r346"] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense on intangible assets (in Dollars)", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r6", "r254", "r257", "r628"] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": ["r684"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofDilutedNetIncomeLossPerSharesTable"], "lang": { "en-us": { "role": { "terseLabel": "Total share of anti dilutive", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r176"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofDilutedNetIncomeLossPerSharesTable"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r20"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofDilutedNetIncomeLossPerSharesTable"], "lang": { "en-us": { "role": { "label": "Schedule of Diluted Net Income (Loss) Per Shares [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofDilutedNetIncomeLossPerSharesTable"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r20"] }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } }, "auth_ref": [] }, "us-gaap_AreaOfLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfLand", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Square feet (in Square Meters)", "label": "Area of Land", "documentation": "Area of land held." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r375"] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Impairment loss (in Dollars)", "label": "Asset Impairment Charges", "documentation": "Amount of write down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": ["r6", "r31"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r82", "r92", "r128", "r149", "r179", "r187", "r212", "r216", "r227", "r270", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r376", "r378", "r408", "r459", "r551", "r620", "r621", "r641", "r656", "r829", "r830", "r846"] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r120", "r135", "r149", "r227", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r376", "r378", "r408", "r641", "r829", "r830", "r846"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNet", "crdr": "debit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total assets", "label": "Net Assets", "documentation": "Amount of net assets (liabilities)." } } }, "auth_ref": ["r8"] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Non-Current", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [

```
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r684" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r669", "r672", "r684" ] }, "dei_AuditorLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLineItems", "lang": { "en-us": { "role": { "label": "Auditor [Line Items]" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r669", "r672", "r684" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r669", "r672", "r684" ] }, "dei_AuditorOpinionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorOpinionTextBlock", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Opinion [Text Block]" } } }, "auth_ref": [ "r766" ] }, "dei_AuditorTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor [Table]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r750" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r751" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r746" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r746" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r746" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r746" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r746" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r746" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r309", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r333", "r334", "r335", "r336", "r337" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r749" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r748" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r747" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r747" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "inm_BayMedicaCommercialMember": { "xbrltype": "domainItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "BayMedicaCommercialMember", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "BayMedica [Member]", "label": "Bay Medica Commercial Member" } } }, "auth_ref": [] }, "inm_BayMedicaSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "BayMedicaSegmentMember", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BayMedica Segment [Member]", "label": "Bay Medica Segment Member" } } }, "auth_ref": [] }, "us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BorrowingsUnderGuaranteedInvestmentAgreements", "crdr": "credit", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Guaranteed investment certificates", "label": "Borrowings under Guaranteed Investment Agreements", "documentation": "Carrying value as of the balance sheet date of the sum of the obligations to contract holders to provide to them an agreed upon rate of return pursuant to the terms of the underlying contract. These contracts represent lending by the contract holders to the entity in return for a guaranteed (primarily fixed) interest rate until maturity, unless called earlier if the contracts provide that option to the contract holders (usually institutions). There is little or no insurance risk for the entity." } } }, "auth_ref": [ "r855" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "BusinessContactMember", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r672", "r684" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r17", "r123", "r608" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r18" ] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents and short-term investments", "label": "Cash, Cash Equivalents, and Short-Term Investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": [ "r791" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents beginning of the period", "periodEndLabel": "Cash and cash equivalents end of the period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r17", "r64", "r147" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Decrease in cash during the period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash
```

equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r64"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashUninsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashUninsuredAmount", "crdr": "debit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Uninsured cash balance (in Dollars)", "label": "Cash, Uninsured Amount", "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "us-gaap_ChangeInAccountingEstimateByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingEstimateByTypeAxis", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Change in Accounting Estimate by Type [Axis]", "documentation": "Information by type of change in accounting estimate." } } }, "auth_ref": ["r22", "r161"] }, "us-gaap_ChangeInAccountingEstimateTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingEstimateTypeDomain", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Change in Accounting Estimate, Type [Domain]", "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities." } } }, "auth_ref": ["r22", "r161"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r725"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r722"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r720"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r110", "r129", "r130", "r131", "r149", "r170", "r171", "r173", "r175", "r181", "r182", "r227", "r279", "r281", "r282", "r283", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r408", "r508", "r509", "r510", "r511", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r538", "r561", "r583", "r595", "r596", "r597", "r598", "r599", "r778", "r800", "r806"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofWarrantActivityTable", "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r34"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase (in Shares)", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r293"] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofWarrantActivityTable"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": ["r34"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r726"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r726"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies (Note 11)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r45", "r83", "r460", "r537"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingencies"], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r75", "r271", "r272", "r602", "r824", "r826"] }, "inm_CommitmentsandContingenciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "CommitmentsandContingenciesDetailsTable", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock options (in Shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r48"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails", "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3", "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Shares", "verboseLabel": "Common Stock [Member]", "netLabel": "Common Shares [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r646", "r647", "r648", "r650", "r651", "r652", "r653", "r802", "r803", "r805", "r839", "r888", "r890"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common shares, par value (in Dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r48"] }, "us-gaap_CommonStockSharesAuthorizedUnlimited": { "xbrltype": "authorizedUnlimitedItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorizedUnlimited", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common shares, unlimited authorized", "label": "Common Stock, Shares Authorized, Unlimited [Fixed List]", "documentation": "Indicates whether number of common shares permitted to be issued is unlimited. Acceptable value is \"Unlimited\" " } } }, "auth_ref": ["r48"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common shares, shares issued", "verboseLabel": "Shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r48"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "terseLabel": "Common shares, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r10", "r48", "r538", "r557", "r890", "r891"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Common Shares, no par value, unlimited authorized shares; 667,013 and 445,948, as of September 30, 2024 and June 30, 2024, respectively, issued and outstanding", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r48", "r461", "r641"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype":

```
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel":
"Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r731" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation
Actually Paid vs. Net Income" } } }, "auth_ref": [ "r730" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [
"r732" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation
Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r729" ] }, "us-
gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation":
[ "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer Equipment [Member]",
"label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information
systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": {
"role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } },
"auth_ref": [ "r23", "r24", "r36", "r37", "r223", "r601" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ],
"lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r23",
"r24", "r36", "r37", "r223", "r502", "r601" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": {
"role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets,
geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r23", "r24", "r36", "r37", "r223", "r601", "r780" ] }, "us-gaap_ConcentrationRiskCreditRisk": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk and Other Risks
and Uncertainties", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } },
"auth_ref": [ "r38", "r101" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ConcentrationRiskPercentage1", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Concentration of credit risk percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in
relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from
the division." } } }, "auth_ref": [ "r23", "r24", "r36", "r37", "r223" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]",
"documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset,
liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r23", "r24", "r36", "r37", "r223", "r601" ] }, "us-
gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock",
"presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Consolidation", "label":
"Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the
separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined
financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for
example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts
and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r35", "r610" ] },
"dei_ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelEmailAddress",
"presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address
of contact personnel." } } }, "auth_ref": [] }, "dei_ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "ContactPersonnelFaxNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Fax
Number", "documentation": "Fax Number of contact personnel." } } }, "auth_ref": [ "r672" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role":
{ "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileDescription": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileDescription", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Description", "documentation": "The description of
the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "ContainedFileInformationFileName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File
Information, File Name", "documentation": "The name of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileNumber": { "xbrltype":
"fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileNumber", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Number", "documentation": "The SEC Document
Number of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileType": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileType", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": {
"role": { "label": "Contained File Information, File Type", "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as
HTML, Word, PDF, GIF/JPG, etc.)." } } }, "auth_ref": [] }, "inm_CorrespondingOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "CorrespondingOperatingLeaseLiability", "crdr": "credit", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "documentation":
"Corresponding operating lease liability", "label": "Corresponding Operating Lease Liability" } } }, "auth_ref": [] }, "us-gaap_CostDirectMaterial": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostDirectMaterial", "crdr": "debit", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract research services and
materials", "label": "Cost, Direct Material", "documentation": "Cost of material used for good produced and service rendered." } } }, "auth_ref": [ "r795" ] }, "us-
gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable" ],
"lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "negatedLabel": "Cost of sales", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods
produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r60", "r149", "r227", "r279", "r280", "r281", "r282", "r283", "r284", "r285",
"r286", "r287", "r408", "r620", "r829" ] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CostOfSalesPolicyTextBlock", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel":
"Cost of Sales", "label": "Cost of Goods and Service [Policy Text Block]", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
} } }, "auth_ref": [ "r783" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion",
"presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } },
"auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": {
"label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": {
"label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-
gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember",
"presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer
Concentration Risk [Member]", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more
significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse
effects of loss of a significant customer." } } }, "auth_ref": [ "r69", "r223" ] }, "inm_CustomerFiveMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "CustomerFiveMember", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Five [Member]", "label":
"Customer Five Member" } } }, "auth_ref": [] }, "inm_CustomerFourMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "CustomerFourMember", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Four [Member]", "label":
"Customer Four Member" } } }, "auth_ref": [] }, "inm_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "CustomerOneMember", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer One [Member]", "label":
"Customer One Member" } } }, "auth_ref": [] }, "inm_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "CustomerThreeMember", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Three [Member]", "label":
"Customer Three Member" } } }, "auth_ref": [] }, "inm_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "CustomerTwoMember", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Two [Member]", "label":
"Customer Two Member" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems",
"presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Capital and
Reserves [Line Items]", "label": "Deferred Compensation Arrangement with Individual, Share-Based Payments [Line Items]", "documentation": "Line items represent
financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the
table." } } }, "auth_ref": [] }, "dei_DelayedOrContinuousOffering": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
```

"DelayedOrContinuousOffering", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "auth_ref": ["r696", "r697", "r711"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r6", "r32"] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Amortization and depreciation", "negatedLabel": "Amortization and depreciation", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r6", "r32"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Amortization and depreciation", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r6", "r179", "r192", "r216", "r620", "r621"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPayments"], "lang": { "en-us": { "role": { "terseLabel": "SHARE-BASED PAYMENTS", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r305", "r308", "r339", "r340", "r341", "r633"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payments [Abstract]" } } }, "auth_ref": [] }, "dei_DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth_ref": ["r696", "r697", "r711"] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": ["r672"] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r669", "r672", "r684"] }, "dei_DocumentCopyrightInformation": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCopyrightInformation", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Copyright Information", "documentation": "The copyright information for the document." } } }, "auth_ref": [] }, "dei_DocumentCreationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCreationDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Creation Date", "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different." } } }, "auth_ref": [] }, "dei_DocumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Description", "documentation": "The description of the document." } } }, "auth_ref": [] }, "dei_DocumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth_ref": [] }, "dei_DocumentEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentEffectiveDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Effective Date", "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases." } } }, "auth_ref": [] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": ["r669", "r672", "r684", "r735"] }, "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)." } } }, "auth_ref": ["r669", "r672", "r684", "r735"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3, 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationDocumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationDocumentAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Text Block]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Name", "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the <FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r670"] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": ["r658"] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": ["r672"] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": ["r672"] }, "dei_DocumentSubtitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSubtitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Subtitle", "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'." } } }, "auth_ref": [] }, "dei_DocumentSynopsis": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSynopsis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Synopsis", "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'" } } }, "auth_ref": [] }, "dei_DocumentTitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Title", "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r712"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentVersion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":

"DocumentVersion", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Version", "documentation": "The version identifier of the document." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": ["r661"] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r724"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Basic (in Dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r142", "r158", "r159", "r160", "r161", "r162", "r163", "r168", "r170", "r173", "r174", "r175", "r178", "r365", "r374", "r400", "r401", "r456", "r471", "r612"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in Dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r142", "r158", "r159", "r160", "r161", "r162", "r163", "r170", "r173", "r174", "r175", "r178", "r365", "r374", "r400", "r401", "r456", "r471", "r612"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Earnings (Loss) Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r20", "r21", "r177"] }, "dei_EffectiveAfter60Days486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveAfter60Days486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)" } } }, "auth_ref": ["r774"] }, "dei_EffectiveOnDate486a": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)" } } }, "auth_ref": ["r774"] }, "dei_EffectiveOnDate486b": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)" } } }, "auth_ref": ["r775"] }, "dei_EffectiveOnSetDate486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)" } } }, "auth_ref": ["r774"] }, "dei_EffectiveOnSetDate486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)" } } }, "auth_ref": ["r775"] }, "dei_EffectiveUponFiling462e": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling462e", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)" } } }, "auth_ref": ["r773"] }, "dei_EffectiveUponFiling486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)" } } }, "auth_ref": ["r775"] }, "dei_EffectiveWhenDeclaredSection8c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveWhenDeclaredSection8c", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)" } } }, "auth_ref": ["r777"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://www.inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r834"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.inmedpharmaceuticalsinc.com/role/ScheduleofDilutedNetIncomeLossPerSharesTable", "http://www.inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Options [Member]", "netLabel": "Stock Option [Member]", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitiesTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAccountingStandard": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAccountingStandard", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Accounting Standard", "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element." } } }, "auth_ref": [] }, "dei_EntityAddressAddressDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Description", "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": ["r660"] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": ["r664"] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r660"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityContactPersonnelLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityContactPersonnelLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Contact Personnel [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been

subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r660"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r776"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r660"] }, "dei_EntityHomeCountryISOCode": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityHomeCountryISOCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Home Country ISO Code", "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element." } } }, "auth_ref": [] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationDateOfIncorporation", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperationsDetails", "http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Date of incorporation", "label": "Entity Incorporation, Date of Incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r765"] }, "dei_EntityInvCompanyType": { "xbrltype": "invCompanyType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInvCompanyType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)." } } }, "auth_ref": ["r764"] }, "dei_EntityLegalForm": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityLegalForm", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Legal Form", "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc." } } }, "auth_ref": [] }, "dei_EntityListingDepositoryReceiptRatio": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDepositoryReceiptRatio", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Depository Receipt Ratio", "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'." } } }, "auth_ref": [] }, "dei_EntityListingDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Description", "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security." } } }, "auth_ref": [] }, "dei_EntityListingForeign": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingForeign", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Foreign", "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt." } } }, "auth_ref": [] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityListingPrimary": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingPrimary", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Primary", "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity." } } }, "auth_ref": [] }, "dei_EntityListingSecurityTradingCurrency": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingSecurityTradingCurrency", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Security Trading Currency", "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'" } } }, "auth_ref": [] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsExchangeAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity" } } }, "auth_ref": [] }, "dei_EntityNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityNumberOfEmployees", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Number of Employees", "documentation": "Number of persons employed by the Entity" } } }, "auth_ref": [] }, "dei_EntityPhoneFaxNumbersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPhoneFaxNumbersLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Phone Fax Numbers [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": ["r684"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r660"] }, "dei_EntityReportingCurrencyISOCode": { "xbrltype": "currencyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityReportingCurrencyISOCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Reporting Currency ISO Code", "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r660"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r660"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r660"] }, "dei_EntityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity [Text Block]", "documentation": "Container to serve as parent of six Entity related Table concepts." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": ["r767"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards

```
Adjustments, Footnote" } } }, "auth_ref": [ "r718" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r760" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r760" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r760" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPropertyEquipmentandROUAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment [Member]", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails", "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r10", "r114", "r138", "r139", "r140", "r150", "r151", "r152", "r155", "r162", "r164", "r166", "r180", "r231", "r237", "r263", "r294", "r352", "r353", "r361", "r362", "r363", "r366", "r373", "r374", "r383", "r385", "r386", "r387", "r388", "r390", "r399", "r410", "r411", "r412", "r413", "r414", "r415", "r418", "r421", "r435", "r470", "r491", "r492", "r493", "r516", "r583" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r728" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r677", "r688", "r704", "r739" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r674", "r685", "r701", "r736" ] }, "inm_EstimatedAgreementTerm": { "xbrltype": "stringItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "EstimatedAgreementTerm", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated agreement term", "label": "Estimated Agreement Term" } } }, "auth_ref": [] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExchangeDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r734" ] }, "dei_ExhibitsOnly462d": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExhibitsOnly462d", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "auth_ref": [ "r772" ] }, "dei_ExhibitsOnly462dFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExhibitsOnly462dFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "auth_ref": [ "r772" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails", "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofIntangibleAssetsTable": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofIntangibleAssetsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r126", "r242", "r256", "r628" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofExpectsAmortizationExpenseTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofExpectsAmortizationExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r821", "r892" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofExpectsAmortizationExpenseTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofExpectsAmortizationExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r258", "r606", "r628" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Expects Amortization Expense", "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofExpectsAmortizationExpenseTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofExpectsAmortizationExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r258", "r606", "r628" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofExpectsAmortizationExpenseTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofExpectsAmortizationExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r258", "r606", "r628" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofExpectsAmortizationExpenseTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofExpectsAmortizationExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r258", "r606", "r628" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofExpectsAmortizationExpenseTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofExpectsAmortizationExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r258", "r606", "r628" ] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Expects Amortization Expense [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofIntangibleAssetsTable": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [
```

```
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofIntangibleAssetsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Intangible assets", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r242", "r256", "r455", "r628" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofExpectsAmortizationExpenseTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofExpectsAmortizationExpenseTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r451", "r820" ] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized on a straight-line basis", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r451" ] },
"inm_FiniteLivedIntellectualProperty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "FiniteLivedIntellectualProperty", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofIntangibleAssetsTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofIntangibleAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Intellectual property", "documentation": "The amoun of finite lived intellectual property.", "label": "Finite Lived Intellectual Property" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedPatentsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedPatentsGross", "crdr": "debit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofIntangibleAssetsTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails",
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofIntangibleAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Patents", "verboseLabel": "Payable under the patent license agreement", "label": "Finite-Lived Patents, Gross", "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights." } } }, "auth_ref": [ "r785", "r820" ] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 4.0 } }, "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign Exchange (Gain) Loss", "terseLabel": "Foreign exchange gain (loss)", "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r67", "r559", "r654", "r842", "r843", "r889" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r409" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r681", "r692", "r708", "r743" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r681", "r692", "r708", "r743" ] },
"ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r681", "r692", "r708", "r743" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r681", "r692", "r708", "r743" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r681", "r692", "r708", "r743" ] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerAddressMember", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": [ "r671", "r695" ] }, "dei_FormerFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerFiscalYearEndDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Former Fiscal Year End Date", "documentation": "Former end date of previous fiscal years" } } }, "auth_ref": [] },
"ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r723" ] }, "inm_FurnishingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "FurnishingMember", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPropertyEquipmentandROUAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Furnishings [Member]", "label": "Furnishing Member" } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and Fixtures [Member]", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement",
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "negatedLabel": "General and Administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r62", "r563" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets, Net", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r818", "r819" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r58", "r60", "r91", "r149", "r227", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r408", "r614", "r620", "r808", "r809", "r810", "r811", "r812", "r829" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r669", "r672", "r684" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of Long-Lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long lived assets. An entity also may disclose its accounting policy for long lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r74" ] }, "inm_InMedPharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "InMedPharmaMember", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "InMed [Member]", "label": "In Med Pharma Member" } } }, "auth_ref": [] }, "inm_InMedPharmaSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "InMedPharmaSegmentMember", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "InMed Pharma Segment [Member]", "label": "In Med Pharma Segment Member" } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentPolicy", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "In-Process R&D", "label": "In Process Research and Development, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income
```

tax expense", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r59", "r87", "r91", "r457", "r468", "r614", "r620", "r808", "r809", "r810", "r811", "r812"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r264", "r266", "r268", "r403", "r404", "r405", "r486", "r488", "r568", "r606", "r635", "r859"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r266", "r268", "r403", "r404", "r405", "r486", "r488", "r568", "r606", "r635", "r859"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "negatedLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r96", "r107", "r165", "r166", "r179", "r195", "r216", "r350", "r351", "r357", "r473", "r634"] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Taxes Paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r19", "r66", "r799", "r837", "r838"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Deferred rent", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r448", "r797"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInInventoriesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventoriesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Inventories [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Lease obligations", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r781", "r797"] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Other non-current assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": ["r797"] }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpensesOther", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaids and other currents assets", "label": "Increase (Decrease) in Prepaid Expenses, Other", "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods." } } }, "auth_ref": ["r5"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r681", "r692", "r708", "r734", "r743", "r747", "r755"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r753"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r673", "r759"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r673", "r759"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r673", "r759"] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssets"], "lang": { "en-us": { "role": { "terseLabel": "INTANGIBLE ASSETS", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": ["r252", "r259", "r261", "r605", "r606"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofIntangibleAssetsTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofIntangibleAssetsTable"], "lang": { "en-us": { "role": { "totalLabel": "Intangible assets, net", "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r253", "r820", "r822"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeShortTermInvestmentOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeShortTermInvestmentOther", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Interest income received on short-term investments", "label": "Interest Income, Short Term Investment, Other", "documentation": "Amount of interest income from short-term investment classified as other." } } }, "auth_ref": ["r110", "r111"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r143", "r145", "r146"] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/Inventories"], "lang": { "en-us": { "role": { "terseLabel": "INVENTORIES", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r238"] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofInventoriesTable": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofInventoriesTable"], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": ["r786"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0,

```
"order": 4.0 }, "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofInventoriesTable": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet",
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofInventoriesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Inventories", "terseLabel": "Inventories, net",
"label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if
longer." } } } }, "auth_ref": [ "r134", "r609", "r641" ] }, "us-gaap_InventoryNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "InventoryNetAbstract", "lang": { "en-us": { "role": { "label": "Inventories [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Policy [Policy
Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts,
methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated
above cost." } } }, "auth_ref": [ "r97", "r122", "r133", "r238", "r239", "r241", "r449", "r611" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofInventoriesTable": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofInventoriesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw
Materials, Gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if
longer." } } }, "auth_ref": [ "r788" ] }, "us-gaap_InventoryValuationAndObsolescenceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "InventoryValuationAndObsolescenceMember", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Valuation Allowances [Member]", "label": "Inventory Valuation and Obsolescence [Member]", "documentation": "A revision in
the estimate of excess and obsolete inventory to reduce the carrying amount of inventory to net realizable value." } } }, "auth_ref": [] }, "us-
gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryValuationReserves", "crdr": "credit",
"presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory valuation
reserves (in Dollars)", "label": "Inventory Valuation Reserves", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r71", "r789" ] }, "us-
gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit",
"calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofInventoriesTable": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } },
"presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofInventoriesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label":
"Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be
completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r787" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order":
6.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow",
"http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory write-down", "verboseLabel":
"Inventory write-down due to net realizable (in Dollars)", "label": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to
subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r240" ] },
"dei_InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActFileNumber",
"presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "auth_ref": [ "r697",
"r698", "r699", "r700" ] }, "dei_InvestmentCompanyActRegistration": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"InvestmentCompanyActRegistration", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Act
Registration" } } }, "auth_ref": [ "r713" ] }, "dei_InvestmentCompanyRegistrationAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "InvestmentCompanyRegistrationAmendment", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label":
"Investment Company Registration Amendment" } } }, "auth_ref": [ "r713" ] }, "dei_InvestmentCompanyRegistrationAmendmentNumber": { "xbrltype":
"sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "auth_ref": [ "r713" ]
}, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr":
"credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable" ],
"lang": { "en-us": { "role": { "terseLabel": "Interest and other income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization)
of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r179", "r190", "r216", "r620", "r796" ] }, "us-
gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Investments", "label": "Investment,
Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r472", "r504", "r505", "r506", "r507",
"r589", "r590" ] }, "inm_LabEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname":
"LabEquipmentMember", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Lab Equipment [Member]", "label": "Lab Equipment Member" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation",
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a
report." } } }, "auth_ref": [] }, "dei_LegalEntityIdentifier": { "xbrltype": "legalEntityIdentifierItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"LegalEntityIdentifier", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Legal Entity Identifier", "documentation": "A
globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI." } } }, "auth_ref": [ "r657" ] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalFees", "crdr": "debit", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal services", "label": "Legal Fees",
"documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened
litigation, including arbitration and mediation proceedings." } } }, "auth_ref": [ "r782" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text
Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r424" ] }, "us-
gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables" ], "lang": { "en-us": {
"role": { "terseLabel": "Schedule of Minimum Lease Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation":
"Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating
lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r844" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total
undiscounted lease liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment
for operating lease." } } }, "auth_ref": [ "r428" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable" ], "lang": { "en-us": { "role": {
"negatedLabel": "More than five years", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted
obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are
reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r428" ] }, "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable" ], "lang": { "en-us": { "role": {
"terseLabel": "Year 2", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment
for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current
statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r428" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable" ], "lang": { "en-us": { "role": {
"terseLabel": "Year 5", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment
for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current
statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r428" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable" ], "lang": { "en-us": { "role": {
"terseLabel": "Year 4", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment
for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current
statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r428" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable" ], "lang": { "en-us": { "role": {
"terseLabel": "Year 3", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease
payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from
```

current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r428"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.lnmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.lnmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Year 1", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } } }, "auth_ref": ["r844"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.lnmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable"], "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r428"] }, "us-gaap_LesseeOperatingLeaseOptionToTerminate": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseOptionToTerminate", "presentation": ["http://www.lnmedpharmaceuticalsinc.com/role/LeaseObligationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Termination period", "label": "Lessee, Operating Lease, Option to Terminate", "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": ["r425"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.lnmedpharmaceuticalsinc.com/role/LeaseObligations"], "lang": { "en-us": { "role": { "terseLabel": "LEASE OBLIGATIONS", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r420"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.lnmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.lnmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r11", "r40", "r41", "r42", "r43", "r44", "r45", "r46", "r149", "r227", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r377", "r378", "r379", "r408", "r536", "r613", "r656", "r829", "r846", "r847"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.lnmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.lnmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Shareholders\u2019 Equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r53", "r84", "r464", "r641", "r801", "r817", "r841"] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.lnmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.lnmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r42", "r121", "r149", "r227", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r377", "r378", "r379", "r408", "r641", "r829", "r846", "r847"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.lnmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": ["http://www.lnmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Non-current", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } } }, "auth_ref": [] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligationsAbstract", "lang": { "en-us": { "role": { "label": "Lease Obligations [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": ["http://www.lnmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r273", "r274", "r275", "r278", "r347", "r629", "r827", "r828"] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": ["http://www.lnmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } } }, "auth_ref": ["r223", "r631", "r642", "r645", "r833", "r858", "r860", "r861", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.lnmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } } }, "auth_ref": ["r274", "r275", "r276", "r277", "r304", "r347", "r402", "r447", "r485", "r487", "r501", "r528", "r529", "r588", "r591", "r592", "r593", "r594", "r603", "r604", "r626", "r630", "r632", "r636", "r637", "r638", "r639", "r643", "r831", "r848", "r849", "r850", "r851", "r852", "r853"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } } }, "auth_ref": ["r726"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } } }, "auth_ref": ["r726"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.lnmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } } }, "auth_ref": ["r274", "r275", "r276", "r277", "r304", "r347", "r402", "r447", "r485", "r487", "r501", "r528", "r529", "r588", "r591", "r592", "r593", "r594", "r603", "r604", "r626", "r630", "r632", "r636", "r637", "r638", "r643", "r831", "r848", "r849", "r850", "r851", "r852", "r853"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r746"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r754"] }, "dei_NameChangeEventDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventDateAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event Date [Axis]", "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type." } } }, "auth_ref": [] }, "dei_NameChangeEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event [Line Items]", "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table." } } }, "auth_ref": [] }, "dei_NameChangeEventTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event [Table]", "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period." } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://www.lnmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } } }, "auth_ref": ["r223", "r631", "r642", "r645", "r833", "r858", "r860", "r861", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } } }, "auth_ref": ["r727"] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": ["http://www.lnmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperations"], "lang": { "en-us": { "role": { "terseLabel": "CORPORATE INFORMATION AND CONTINUING OPERATIONS", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } } }, "auth_ref": ["r98", "r108"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.lnmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.lnmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Total cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment, borrowing money and repaying amounts borrowed, or settling the obligation, and obtaining and paying for other resources obtained from creditors on long-term credit." } } } }, "auth_ref": ["r144"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.lnmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.lnmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.lnmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Total cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r144"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype":

```
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Investing Activities", "label": "Net Cash Provided by
(Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } },
"presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Total cash used in operating
activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including
discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } },
"auth_ref": [ "r64", "r65", "r67" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Activities", "label": "Net Cash Provided by
(Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": {
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow",
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement",
"http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperationsDetails",
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Loss for the period", "netLabel": "Net loss", "label":
"Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the
parent." } } } }, "auth_ref": [ "r61", "r67", "r88", "r119", "r136", "r137", "r140", "r149", "r154", "r158", "r159", "r160", "r161", "r162", "r165", "r166", "r172", "r227", "r279",
"r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r365", "r374", "r401", "r408", "r469", "r560", "r581", "r582", "r654", "r829" ] }, "us-
gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain
members defined in one or many axes to the table." } } }, "auth_ref": [ "r112", "r113", "r114", "r115", "r116", "r117", "r153", "r154", "r155", "r156", "r157", "r160", "r167",
"r178", "r224", "r225", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r262", "r263", "r267", "r352", "r353", "r354", "r355", "r356", "r358",
"r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r380", "r381", "r382", "r383", "r384", "r385",
"r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r406", "r407", "r417", "r418", "r419", "r430",
"r431", "r432", "r433", "r434", "r435", "r452", "r453", "r454", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r503" ] }, "us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us":
{ "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of
accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the
expected or actual impact." } } }, "auth_ref": [] }, "dei_NewEffectiveDateForPreviousFiling": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "NewEffectiveDateForPreviousFiling", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "New Effective
Date for Previous Filing" } } }, "auth_ref": [ "r697", "r698", "r699", "r700" ] }, "dei_NoSubstantiveChanges462c": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462c", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": {
"label": "No Substantive Changes, 462(c)" } } }, "auth_ref": [ "r771" ] }, "dei_NoSubstantiveChanges462cFileNumber": { "xbrltype": "fileNumberItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": {
"role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "auth_ref": [ "r771" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label":
"No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] },
"ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure
Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r726" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label":
"Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r681", "r692", "r708", "r734", "r743" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO
NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r717" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r716" ] },
"ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r734" ] },
"ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
"terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r754" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-
us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r754" ] }, "us-
gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract",
"presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other Income (Expense)",
"label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "inm_NortonRoseFulbrightCanadaLLPMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "NortonRoseFulbrightCanadaLLPMember", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Norton Rose Fulbright Canada LLP
[Member]", "label": "Norton Rose Fulbright Canada LLPMember" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label":
"Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly
related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-
gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Expenses", "label": "Operating
Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable" ], "lang": { "en-us":
{ "role": { "terseLabel": "Present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease
payments from operating lease." } } }, "auth_ref": [ "r422" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet":
{ "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet",
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of lease
obligations", "negatedLabel": "Less: Current portion of lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's
discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r422" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofMinimumLeasePaymentsTable" ],
"lang": { "en-us": { "role": { "terseLabel": "Lease obligations, net of current portion", "verboseLabel": "Non-current portion of lease liabilities", "label": "Operating Lease,
Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } },
"auth_ref": [ "r422" ] }, "us-gaap_OperatingLeasePaymentsUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeasePaymentsUse", "crdr": "credit", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Obligated to pay", "label": "Operating Lease, Payments, Use", "documentation": "Amount of cash outflow from operating lease to bring another asset to
condition and location necessary for its intended use." } } }, "auth_ref": [ "r423", "r426" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order":
4.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow",
"http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of ROU assets",
"label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right of use
asset from operating lease." } } }, "auth_ref": [ "r798" ] }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Minimum Lease
Payments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Corporate
Information and Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "dei_OtherAddressMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "OtherAddressMember", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label":
"Other Address [Member]", "documentation": "Other address for entity" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType",
```

"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r127"] }, "us-gaap_OtherCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents (in Dollars)", "label": "Other Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r726"] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r672"] }, "us-gaap_OtherResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Other Research and Development Expense", "documentation": "Amount of other research and development expense." } } }, "auth_ref": ["r836"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r679", "r690", "r706", "r741"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r682", "r693", "r709", "r744"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r682", "r693", "r709", "r744"] }, "dei_ParentEntityLegalName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ParentEntityLegalName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Parent Entity Legal Name", "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity" } } }, "auth_ref": [] }, "inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "PatentsAndIntellectualPropertyCostsPolicyTextBlock", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Patents and Intellectual Property Costs", "label": "Patents And Intellectual Property Costs Policy Text Block" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r715"] }, "us-gaap_PaymentsForFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForFees", "crdr": "credit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fees paid (in Dollars)", "label": "Payments for Other Fees", "documentation": "Amount of cash outflow for fees classified as other." } } }, "auth_ref": ["r4"] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRent", "crdr": "credit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Rental rate", "label": "Payments for Rent", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": ["r4"] }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of short-term investments", "label": "Payments to Acquire Short Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": ["r63"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r725"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r725"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r717"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r734"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r727"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r716"] }, "dei_PhoneFaxNumberDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PhoneFaxNumberDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Phone Fax Number Description", "documentation": "Description of Phone or Fax Number" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r718"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r763"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r717"] }, "dei_PostEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "auth_ref": ["r658"] }, "dei_PostEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }, "auth_ref": ["r658"] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": ["r665"] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": ["r667"] }, "dei_PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "auth_ref": ["r658"] }, "dei_PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } }, "auth_ref": ["r658"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares, issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r47", "r288"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares, outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r47", "r538", "r557", "r890", "r891"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Prepaids and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r791"] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": ["r784"] }, "inm_PrivatePlacementIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "PrivatePlacementIssuanceCosts", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Private placement issuance costs", "documentation": "The cash outflow of private placement issuance costs.", "label": "Private Placement Issuance Costs" } } }, "auth_ref": [] },

```
"inm_ProceedFromIssuanceOfShareCapitalAndReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "ProceedFromIssuanceOfShareCapitalAndReserves", "crdr": "debit", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds (in Dollars)", "documentation": "Amount of proceed from issuance of share capital and reserves.", "label": "Proceed From Issuance Of Share Capital And Reserves" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the private placement", "label": "Proceeds from Issuance of Private Placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromSaleOfShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfShortTermInvestments", "crdr": "debit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of short-term investments", "label": "Proceeds from Sale of Short Term Investments", "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r16" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Equipment and Rou Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPropertyEquipmentandROUAssetsTable",
"http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r7", "r429" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNet" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY, EQUIPMENT AND ROU ASSETS, NET", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r72", "r102", "r105", "r106" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPropertyEquipmentandROUAssetsTable": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPropertyEquipmentandROUAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r73", "r124", "r467" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPropertyEquipmentandROUAssetsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Property, Equipment and ROU Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r429" ] }, "us-gaap_PropertyPlantAndEquipmentNet": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": {
"http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 },
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPropertyEquipmentandROUAssetsTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet",
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPropertyEquipmentandROUAssetsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Property, equipment and ROU assets, net", "terseLabel": "Property, equipment and right of use (\u201cROU\u201d) assets, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r7", "r429", "r458", "r467", "r641" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Equipment and ROU Assets, Net", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r7", "r102", "r105", "r465" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Equipment and ROU Assets", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPropertyEquipmentandROUAssetsTable",
"http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r73", "r429" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful lives", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ecd_PvpTable": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r715" ] }, "ecd_PvpTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r715" ] },
"srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r274", "r275", "r276", "r277", "r303", "r304", "r334", "r335", "r336", "r347", "r402", "r445", "r446", "r447", "r485", "r487", "r501", "r528", "r529", "r588", "r591", "r592", "r593", "r594", "r603", "r604", "r626", "r630", "r632", "r636", "r637", "r638", "r639", "r643", "r648", "r825", "r831", "r840", "r849", "r850", "r851", "r852", "r853" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r274", "r275", "r276", "r277", "r303", "r304", "r334", "r335", "r336", "r347", "r402", "r445", "r446", "r447", "r485", "r487", "r501", "r528", "r529", "r588", "r591", "r592", "r593", "r594", "r603", "r604", "r626", "r630", "r632", "r636", "r637", "r638", "r639", "r643", "r648", "r825", "r831", "r840", "r849", "r850", "r851", "r852", "r853" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r674", "r685", "r701", "r736" ] }, "dei_RegistrationStatementAmendmentNumber": {
"xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "RegistrationStatementAmendmentNumber", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Registration Statement Amendment Number", "documentation": "Amendment number to registration statement under the Investment Company Act of 1940." } } }, "auth_ref": [ "r658" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r439", "r440", "r845" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r226", "r564", "r565", "r568" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "inm_RelatedPartyTransactionsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "RelatedPartyTransactionsDetailsTable", "presentation": [
"http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "RELATED PARTY TRANSACTIONS", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r436", "r437", "r438", "r440", "r441", "r513", "r514", "r515", "r566", "r567", "r568", "r586", "r587" ] }, "us-gaap_ReportableSubsegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportableSubsegmentsMember", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Reportable Subsegments [Member]", "label": "Reportable Subsegments [Member]", "documentation": "Identifies division of a component of an entity that
```

engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Research and development and patents", "negatedLabel": "Research and development patents", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r349", "r606", "r620", "r854"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expense [Member]", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Costs", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r348"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r675", "r686", "r702", "r737"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r676", "r687", "r703", "r738"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r683", "r694", "r710", "r745"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet", "http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r50", "r77", "r463", "r495", "r500", "r512", "r539", "r641"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r114", "r150", "r151", "r152", "r155", "r162", "r164", "r166", "r231", "r237", "r263", "r352", "r353", "r361", "r362", "r363", "r366", "r373", "r374", "r383", "r386", "r387", "r390", "r399", "r418", "r421", "r491", "r493", "r516", "r890"] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": ["r109", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r607"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Sales", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r89", "r90", "r141", "r149", "r179", "r188", "r189", "r210", "r216", "r220", "r222", "r223", "r227", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r408", "r457", "r620", "r829"] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Recognition of ROU asset and corresponding operating lease liability", "label": "Right of Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right of use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r427", "r640"] }, "inm_RightofuseAssetsleasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "RightofuseAssetsleasesMember", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPropertyEquipmentandROUAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "ROU Assets (leases) [Member]", "label": "Rightofuse Assetsleases Member" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r754"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r754"] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue Benchmark [Member]", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r223", "r779"] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilitiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofDilutedNetIncomeLossPerSharesTable"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r20"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Diluted Net Income (Loss) Per Shares", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r20"] }, "inm_ScheduleOfDilutedNetIncomeLossPerSharesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "ScheduleOfDilutedNetIncomeLossPerSharesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Diluted Net Income Loss Per Shares Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfImpairedIntangibleAssetsTextBlock", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets", "label": "Schedule of Impaired Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported." } } }, "auth_ref": ["r823"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r13", "r54", "r55", "r56"] }, "inm_ScheduleOfPropertyEquipmentAndRouAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "ScheduleOfPropertyEquipmentAndRouAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Property Equipment And Rou Assets Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPropertyEquipmentandROUAssetsTable"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r7", "r429"] }, "inm_ScheduleOfReportableSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "ScheduleOfReportableSegmentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Reportable Segments Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable"], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": ["r28", "r29",

```
"r30" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reportable Segments", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r28", "r29", "r30" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Warrant Activity", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r34" ] }, "inm_ScheduleOfWarrantActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "ScheduleOfWarrantActivityAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Warrant Activity Abstract" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r659" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r663" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r662" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r668" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r89", "r90", "r91", "r92", "r179", "r184", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r202", "r210", "r211", "r212", "r213", "r214", "r216", "r217", "r218", "r223", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r260", "r269", "r270", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r617", "r620", "r621", "r627", "r644", "r858", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887" ] }, "inm_SegmentInformationDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "SegmentInformationDetailsTable", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Information (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformation" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT INFORMATION", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r92", "r179", "r183", "r184", "r185", "r186", "r187", "r199", "r201", "r202", "r214", "r215", "r216", "r217", "r218", "r220", "r221", "r223", "r615", "r618", "r619", "r620", "r622", "r624", "r625" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable", "http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Reportable Segments [Line Items]", "terseLabel": "Segment Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Segment reporting", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r219", "r222", "r616", "r617", "r623" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and Administrative Expenses [Member]", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Share based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r633" ] }, "inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares Under Warrants, Exercised", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were exercised during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period" } } }, "auth_ref": [] }, "inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Exercised", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares Under Warrants, Expire/Cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r326" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Expire/Cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r326" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares Under Warrants, Warrants Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r324" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average
```

Exercise Price, Warrants Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r324"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofWarrantActivityTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Shares Under Warrants, Balance beginning", "periodEndLabel": "Number of Shares Under Warrants, Balance ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r321", "r322"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofWarrantActivityTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price, Balance beginning", "periodEndLabel": "Weighted Average Exercise Price, Balance ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r321", "r322"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r80"] }, "inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisable", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofWarrantActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares Under Warrants, Warrants Exercisable", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) warrants exercisable, that were exercisable during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Exercisable" } } }, "auth_ref": [] }, "inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceWarrantsExercisable": { "xbrltype": "perShareItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceWarrantsExercisable", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofWarrantActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Warrants Exercisable", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of warrants exercisable outstanding and currently exercisable under the stock other than option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Warrants Exercisable" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofWarrantActivityTable", "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-Based Payments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r306", "r307", "r309", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r333", "r334", "r335", "r336", "r337"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercisable options, weighted average exercise price (in Dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r330"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested and exercisable options (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r329"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of common stock issued and outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share based payment arrangement." } } }, "auth_ref": ["r309", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r333", "r334", "r335", "r336", "r337"] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payments", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r305", "r312", "r331", "r332", "r333", "r334", "r337", "r342", "r343", "r344", "r345"] }, "inm_ShareBasedPaymentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "ShareBasedPaymentsDetailsTable", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payments (Details) [Table]" } } }, "auth_ref": [] }, "inm_ShareCapitalandReservesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "ShareCapitalandReservesDetailsTable", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"], "lang": { "en-us": { "role": { "label": "Share Capital and Reserves (Details) [Table]" } } }, "auth_ref": [] }, "inm_ShareCapitalandReservesTablesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "ShareCapitalandReservesTablesTable", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables"], "lang": { "en-us": { "role": { "label": "Share Capital and Reserves (Tables) [Table]" } } }, "auth_ref": [] }, "srt_ShareRepurchaseProgramLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramLineItems", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables"], "lang": { "en-us": { "role": { "label": "Share Capital and Reserves [Line Items]" } } }, "auth_ref": ["r832"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding intrinsic value (in Dollars)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unvested options (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unvested options, weighted average exercise price (in Dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReserves"], "lang": { "en-us": { "role": { "terseLabel": "SHARE CAPITAL AND RESERVES", "label": "Shareholders' Equity and Share-Based Payments [Text Block]", "documentation": "The entire

disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": ["r76", "r79"] }, "us-gaap_ShippingAndHandlingCostPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShippingAndHandlingCostPolicyTextBlock", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Shipping and Handling", "label": "Shipping and Handling Cost, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": ["r85", "r86", "r790"] }, "inm_SignificantAccountingPoliciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "SignificantAccountingPoliciesDetailsTable", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r68", "r148"] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": ["r666"] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable", "http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationDetails"], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r89", "r90", "r91", "r92", "r118", "r179", "r184", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r202", "r210", "r211", "r212", "r213", "r214", "r216", "r217", "r218", "r223", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r260", "r265", "r269", "r270", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r617", "r620", "r621", "r627", "r644", "r858", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r110", "r129", "r130", "r131", "r149", "r170", "r171", "r173", "r175", "r181", "r182", "r227", "r279", "r281", "r282", "r283", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r408", "r508", "r509", "r510", "r511", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r538", "r561", "r583", "r595", "r596", "r597", "r598", "r599", "r778", "r800", "r806"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails", "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r10", "r48", "r51", "r52", "r114", "r138", "r139", "r140", "r150", "r151", "r152", "r155", "r162", "r164", "r166", "r180", "r231", "r237", "r263", "r294", "r352", "r353", "r361", "r362", "r363", "r366", "r373", "r374", "r383", "r385", "r386", "r387", "r388", "r390", "r399", "r410", "r411", "r412", "r413", "r414", "r415", "r418", "r421", "r435", "r470", "r491", "r492", "r493", "r516", "r583"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r150", "r151", "r152", "r180", "r421", "r450", "r504", "r527", "r530", "r531", "r532", "r533", "r534", "r535", "r538", "r541", "r542", "r543", "r544", "r545", "r547", "r548", "r549", "r550", "r552", "r553", "r554", "r555", "r556", "r558", "r562", "r563", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r583", "r649"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r150", "r151", "r152", "r180", "r226", "r421", "r450", "r504", "r527", "r530", "r531", "r532", "r533", "r534", "r535", "r538", "r541", "r542", "r543", "r544", "r545", "r547", "r548", "r549", "r550", "r552", "r553", "r554", "r555", "r556", "r558", "r562", "r563", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r583", "r649"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r678", "r689", "r705", "r740"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockCompensationPlanMember", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cost of Goods Sold [Member]", "verboseLabel": "Share-Based Payment Arrangement [Member]", "label": "Share-Based Payment Arrangement [Member]", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": ["r807"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Private placement (in Shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r10", "r47", "r48", "r77", "r508", "r583", "r596"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of pre-funded warrants (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r10", "r47", "r48", "r77", "r318"] }, "inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "StockIssuedDuringPeriodValueIssuedForPrivatePlacement", "crdr": "credit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Private placement", "documentation": "Stock Issued During Period Value Issued For Private Placement.", "label": "Stock Issued During Period Value Issued For Private Placement" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "negatedLabel": "Share issuance costs", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r10", "r47", "r48", "r77", "r516", "r583", "r596", "r655"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of pre-funded warrants", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r10", "r48", "r51", "r52", "r77"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet", "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "totalLabel": "Total Shareholders\u2019 Equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r48", "r51", "r52", "r70", "r540", "r557", "r584", "r585", "r641", "r656", "r801", "r817", "r841", "r890"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 Equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Share Capital and Reserves [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reverse stock split, description", "label": "Stockholders' Equity, Reverse Stock Split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": ["r78"] }, "us-gaap_SubordinatedBorrowingInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubordinatedBorrowingInterestRate", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Borrowing rate, percentage", "label": "Subordinated Borrowing, Interest Rate", "documentation": "Stated interest rate of the subordinated debt." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsAxis", "presentation": ["http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable"], "lang": { "en-us": { "role": { "label": "Subsegments [Axis]", "documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",

```
"localname": "SubsegmentsDomain", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofReportableSegmentsTable" ], "lang": { "en-us": { "role": { "label": "Subsegments [Domain]", "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r416", "r443" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Member]", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r416", "r443" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r416", "r443" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r416", "r443" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "inm_SubsequentEventsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "SubsequentEventsDetailsTable", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r442", "r444" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTARY CASH FLOW INFORMATION:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r733" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r725" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r732" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r93", "r94", "r95", "r814", "r815", "r816" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r753" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r755" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r756" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r757" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r757" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r755" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r755" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r758" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r756" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r375" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r752" ] }, "us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedLossOnForeignCurrencyDerivativesBeforeTax", "crdr": "debit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized foreign exchange loss", "label": "Unrealized Loss on Foreign Currency Derivatives, before Tax", "documentation": "Amount of unrealized loss recorded in accumulated other comprehensive income pertaining to the decrease in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments to the extent that a cash flow hedge is determined to be effective." } } }, "auth_ref": [ "r81" ] }, "inm_UnvestedOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20240930", "localname": "UnvestedOptionsMember", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unvested Options [Member]", "label": "Unvested Options Member" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r25", "r26", "r27", "r99", "r100", "r103", "r104" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r721" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofDilutedNetIncomeLossPerSharesTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofWarrantActivityTable", "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants [Member]", "verboseLabel": "Warrant [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r646", "r647", "r650", "r651", "r652", "r653" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r160", "r175" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r168", "r175" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average outstanding Common Shares", "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WorkersCompensationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WorkersCompensationLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employee
```

compensation, benefits and related accruals", "label": "Workers' Compensation Liability, Current", "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r41"] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": ["r769"] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r719"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479910/205-30-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-14" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r116": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r173": { "role":

~~"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4",~~

"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name":

```
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r293": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r296": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r297": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r298": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-
80-50-5" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/718/tableOfContent" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r307": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-
10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r324": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r325": { "role",
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r326": { "role",
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r327": { "role",
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r328": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r329": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r330": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r331": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r332": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r333": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r334": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r335": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r336": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r337": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r338": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r339": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r340": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r341": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r342": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
```

~~"Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",~~

"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",

```
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r454": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r455": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942",
"SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r459": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r460": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r461": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r462": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r463": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r464": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r465": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r466": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r467": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r468": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r469": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r470": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r471": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r472": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r473": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r474": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r475": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r476": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r477": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r478": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r479": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r480": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r481": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r482": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r483": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r484": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r485": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r486": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r487": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r488": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r489": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r490": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r491": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r492": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r493": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r494": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r495": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r496": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r497": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r498": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r499": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r500": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r501": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r502": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
```

"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r618": { "role":

"http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "Global LEI Foundation" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "249", "Section": "308", "Subsection": "a" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "j", "Paragraph": "a" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":

"SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Number": "249", "Section": "308" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form F-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-3" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-4" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-6" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form S-3" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Investment Company Act", "Number": "270" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "i", "Sentence": "A" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "313" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-X", "Number": "210", "Section": "2", "Subsection": "2" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "413", "Subsection": "b" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "b" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "c" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "d" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "e" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "a" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "b" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Section": "8", "Subsection": "c" }, "r778": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"

```
}, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org/705/tableOfContent" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" },
```

"r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 71 0001213900-24-098445-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-098445-xbrl.zip M4$L#!!0 (.N!;EEOTF0TS?\ (8("0 7-96P,CY-S%YANWX<"!L/TS/ME-MCFREL;IDR:T%<50FC=@*TE,C(B,O;X^?^^C"SVQ%W/=.Q?M_J=X6O@?QNV^8YCVXR__T^J>=SK_\W_/_P'%!(;_^LCR;.C[X\^?/CT_/Y_VX1JO;[K<?6;WPX!=.T^L6&'%YN=2Z7.ER![NSUFI4*J(RX<^_F.VMYG^\$ &GBQWW1-||

*M7;]BCQ\{X]XL9XJ+LCO<\#W^SKEF?:?02<[BLT MRX7P7L^IE(KU^<"5"H7R)WE%>,/+HFN+<*UMF3;_]]>[J^AR?_{UT:6??+7# MN@\T@B 6\H52OEB*/20/BT\}2"%CV7.*U7RA$<.H7/E]R4KQZY[N<76YYT:P M#W2O1U?"APGD!U[^4=?'LQ?*+Z8OQLWVYEY-WR0O7T0U &[S$WRK+L0OC"E2 ME-? 5/HDOXY>;RI;.]GS=[H=(>+&67/SO*T!9=.4T>L_+=&FQV6Q^HF_#2[UY MU\$CBY_^_>V]VQ_RD9Z?@<0SU[\K,3S(\B?(^EPWSG(,__>S;_H6/V,_?Q*_ MY'(_C[BOL[YC^]P&8O#YB_^),B0IE.=_!N;3+R?GXOO\/>S@R2=XYB?QT)\[_MCC$Y^]DPGYCG3RS^R\D KOS,BH6QS^[_$?:?8-7]F=|Y(MS7Q@<:ZW#4')W07 M-O)? _X\5@\8Z>ZC:7IF\;CBTWCJ*A1ZER:W0.3=!1,/W^J/'.5;' +Q@+SO MO.$A8_\+DQ_T'.]W1O*S9]/PAPAGX:>3&?CSGOD7*CB#P53_MJZ?WO MK 1+\QS+. {OU9/%]T7U_HV4\;JX5R@A M7+#"%X.[GM0TCM[N.[^#D9P:U]{BA;_C@]^.>G#(6OK(W@S:_.? M+YP^7&/{)".8"4>[^.?*4KQ7*Y9.S8B'_SY_)9YT]HY1MQQEX@!']"A_[GG M.%9/MRS'[SDO\S#ZST!WX<'6Y(Z/"==/(+>"BVO6*[4OT_AEL(/_?&C=W:?O MKO[#[M]W-W?W[/;AKOO0NKYG]S<,6.P>^"\A7++.:.U:L?C ^LIM+=O],F\6X M+.^2\UOD]? EULEBOO>.N ZAV7^4/._E189V.XW3% J3= <4^_N9\-4,[S({A@ MB'N:_-1)?L)U-|_M>;M\2V]fV\8%W);8X^K)69>/?3[J<9>5"UH.5:@?B)UZ M9XY[8&FO5GC EZ:GJX'YPHW\ (P>/E< HY5@HH4P1U[4I+RHS)47]W>MZVX' MI<+V D.@\$>3&GZ(?'4V!BZ8[/_ |=\)X>8B#YYMS@Y=T8CTI.W'"*B]\%F= M.2#!/]=7*=HVF"D3O%?<&E%RM0EO\,.ZK6 G$ S>=URRC3\'(*Q=-)Q/SL!\ MRI>;M4;UYT|XQ]D/)3G3(FG-/;GCCZ:'M.Y?PS<)"5,_:>MFLT%%[)[_:5CP*W 0WU"\[3D;A1VC QF(U^LE!JE>G,5.N$?=RDA^\XX M2<5S$; (SX#\0"3+0'!Q0'5SV1^":.GF'V27L R?1SS_UT!G(H1K1TL?NHV^9? M//?'<+U3&[\&C>OYD9W3N]/N*6N/QI8S@56*526)A%T[IXFER*WZ1%)/2L). M[.Y6(} [L4^U83V]T#,/EGB=_7(%&4DSH% VP@_,3>*58]519GC4:5?;[*?N5-M R^8.NOZ+N?^ ,]K2]E@1[S.4F*=H 7^2P=^#V"O9Y:SKMXLWW(.O]ZX][ZS M'7]5!<3PU]/SZ9> <[AUGZVWJ^G'I/YNO7_F>_DJE(LU'9\POZK=L[*[<,:.UXEGO HO77A'NL7:+[P? M^.839S<#.'ZK]P-4.ACAIM\G$?DV|%=412V7*XG&0:$81&0##\^S]3[:1+] MY0"AWPX=>\95 <\%852K ?/U4[$^RSF'MW\CX_T??VN4BO4O'EQG\3%"SVP" M7T.UTPI0X_22=$$@H($&CQ&^ ,Z"^3\.7"} IX#OP+.,$3EXL M?>A]S($X04]?]^_? FV$O#7M= @Z7!Y!@\?8SK.KC\,7E4N;'Y^[/.SN,3$" MCPRN]X>L;.^F>ESCXI@__)4M:5X]X"]AQ=20SUIV,>H[U_0_/##<2-]?2H4B$ MPU_Z0]U^A)L!L##)*5W&L4)5@@K>G1!TS60%QWW_.O.^7F[?7F90[*_M>XI)43@IEGK$!SC0%QWA&!P YW2&<+W"EI;."O[K(GW0KX.GZQ:.6TM*B1 ME"\(/X.7ZJ[)69WK;X= <_TZE QR+Z[IM@4]FK3M%AVW)1=-!ADKY!_C`,_0_M9S2VKN\ YW_3W>_<9U=7YPN8,?]J\Q^!YYN#R.&TF?!U'=M KQK'%./^D ,R MX* [O((0X.1E1=8E'"KD/O8]L]'ML8%]@\.B6!5]BT!AUH3\#$S4A4(\Z7%X MSPR5H3(Z(T446*1$,4U*[1R]2?@U!H"9_=_"X8&7CEW>YW24%$LYR!'PV =X M'M \P(0E] [0P;B+B]+Z0]V?@IT]ZTDH$41QLUS#1XWIML$^E,0:>T!E\'WO M#U@!7D^7PDT(A7P.QL^]W$ &<|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|[3+;*.KITG M46=3K&A4/]_RH"P".B2+&K@<+W"EI;"

*BM1_$2DF]\8O{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{6>?CA3\1DMLQFM_C$IEZ%FE;=H G/H@]JS2<7'' 'MP0.*FIUL+(CO9D.K;SZ)XI6.X13DM+G HE 6S77R0/@/T;O4;G?>K1>PN*L1]FF.3:?B)6)L:U+O/:RM^AS!ET)M1$9QM2=E?Z)L@TAL@F0&HOEW4YS.8!"D%G# MKVXP[=#6O13]B# .;]XBU[C42D86%P@9@HE OSC$5B,%/D%K4;#HSB4<=SPMP M(`.X%9@YU8A)Y7FU$ _=*%M9F?ND,= _1YFL4CYTCKE.0%>9+ -#' DQF7.U(M%P^,/$A.T:G2(S%0\//EORAR:_MRKE!?P^QOQ%0:T[2CVDHYY$KO7OS#* +XG\X6.@)F(Y2]3W?.?L^_"+EFTD M/XA=*>:,93BUQ.V<=,V BA3ZMB)H%N1PD[V_:USZDMYGGN?Y K>%#5 M01T]%]9WI55>VP^4A1C?78BQ^W![>T53"5MW_XF&$K+.]>7 W;?6?>?F.NLF M]E9#C[0MW.]FP2XBKXJP.E$L9AO[]E&S=&!?U$V.FD_?ZR\;N<./H]K-3*O: ME5,7UDE;3^TD?0,.:T_K8W 9UC?50}YHB<5M.$EVU,RY:1 K-C(LV1%UE<0.P MO7)1[JL? AQ[PRL5Q26W^HM,]O[KI/MRU<>#X]\;[S:)LS,X*$F]!QX:@;.[9!<8ZP MR-ZBF*MJ,X7WUFQ0*LX X<<8]=|\V=VYXQT M6Q.?:*P4)2+QG\^@]&KQCM^;D _"W.'43'7#0$L_$D!* W:T2PBEPCN\7SX M@$JA3G>_G/TA"NA]YIG>]YIGER:WC, L5G\$:NSR/P N]SD^_PO[EVX%^"O+ MY^6-Q'"BWAB1BO?D?6<,%Y>0U.0GBOQ^-FJ._)1FN!['8V!UA$:!PUL4U-$,0\E\?AQ75$6[E_BJ5_=!+ ^^G\+*/E_ M_J2?[97O?^Z!Z]A]X,:>"![8&R#7)')\AWR6YTJT MX& ^15+E44B77#:7*?L!AP4*Z?U5T#!8O'*/OSC;XU2]?"%+]`?BU]RCDOR3WYU+C0R^>5`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{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dH_$71*27D-2 MDWOD-G(1CX?J!*>H+4/GI\A\$A]ZL?.I%YY/ M;.71E#R\U3Z@L$*)ILU65B#YS^^'B)#LCW[G9*.W;&-I4[G:$O(MG9Q53V=G M#"B9D%M$MW V@8G90T4$;0\3352@6CS1XN<94"J7&>B "WJ>P>EY&,T66I.%EB^] MTC='LII/#&;'/[[DV]D.\ GH'@%?,[IV@NL[[,VL-+*Z,"M:?9$6\#_TT?A+ M. /+PYAY0$/ GS%[?!%DBNYFL2;D@V!I[]2BPKGDZ8^&G<>0l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{EA/E#&TU81SBQMJ50'@%"WF):9N.G5D>@<!*E,/,L',.FUT!3X(FBY4YH7G&R>D'&R7" RZF6_@ */@ MX/ 7>?J$>YFHVPE\=*$9(EV$ O)=&9#OP0G%B& .P.:4"F'7Y8B(>?R=?V:57 M=O&5850^UZ)S#9YK3322)E,/%W Z%%Q'6:&[KDY2(Q:$B-(_8@>*)M@)KICA M?$78Z[*32'(D1L!7!#=(X+:4:9!+[K1*%CX482@I*<-W.P<4STGEK[O@6$ MNJ+!RAU/NK9:H62_B*63IM3#UWUN7"/'8?<'T\BGH?/VK(UO+'"VV*E#8/-< M^#)1GP5F%.$RZ325/#HG|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|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

*E;/MRAD]" M5]%<54,=5S/%OEXVPBC0PB2=CA.(\9Q2'N[M 4DXCV_]~$?' L: <*OB)Z&9G&8RL (<,.CC%%BXCX](@8M)F+B_209@X!M6; MK+/>%A[..('7BI+F^+BY7'S< M'!R)CZX^\F0/_]!%U6@=4GU#]\#CHMF<[%$3:0T+!]D!BWN.,7,KH19K8240 M-G' @\X0?=YDJ6CX.,=]U&U9#NJI8A[F!9@FAT;%W?(!>HEA>/+(5+.BX<]P M#M(D)^9ER%%Y6=7/+JM^.EG5SVS53RFK^ME_U<\F53O5]9(437OTWULQ[5F. MN YG.M_*D^F0#:=N8^.NX\ R!6WN!9_Q6V_TP1K8 MJ28.]-2^>VQ>>1H4L"9BWT&?555,])Q%*QHV#!_++GL%+)HN&RLPQP+;.G+ M$&X#&X9BH,K>, S@,7Y,YU1?)>4MB-^,2Q"S&WO:E MJE @01(4KZ+Y,..R1)565EYSR^+5ZJ'ME,1/+D10.&LI0Q /+ &9)6 KV$ MD6<6#GA+Z?]RCZSX/X#RCF]^='OCH(.?82(/R_9&49]V=89EDJV>BXEFUR=G*'TEEL4USE"G:M9\>!WI.CH M@((@Q:$WB%5 @Y24T&@ 9'!/^]"66/*C MG]P)?!:L#(K3B0@'>\BO\+'([[T%Z)E5F6 7Q[S\5' P/ &Z$+8[N8XHI4D' M2EYW"! <,%FG$6 M+3&/0D'#7#"Q0""/H=180@T/E,]'(*9BT#0KF[6+]OHQ8D@G'3Q^$]#GF!0O MH$D1\ +A\('DT82W^_Y>"/LF3 086]I]9F6' M6HI7'4Q..F\W_(\GC]* M_P;S$9%O;!^WEL73U9=Rj*41SF1-0D*<5!!89G)OT"AB7J8CB,T.;*(51P> M=2308 9M-0 _]9: _,KP1WT%7MJ=KN.#SX9Q>+$QSE=-=K<4H*K$F\QFB[*/ MP@_1&&K<'XB:1?]Y Z$&KY.*@5XF+34@)*XQ@#[;%!O?CROAYW0?2^QI%+A M=X.11/1SY<=0+X4)@UJZ X2-TCGR0>Z&;"/.!!;LX60/ZJ3$AYW;ORLDN G) M;):7+/JN2N*JG?6.:G(2)SI!Q%.'3N:E.B3 MUPQG"Q>>F1MY]"+R9LV/XVT&(?L3)09GW!E!<>;!5A%O5>;.SB<8S=1A3VB0 M>@:1QCH8D /H;3.C/:8N=C@(06)+ CCJI(.;FL P(3*..#%4'PDQ#W%#P>(2 M/|&0P=2"QA!#7 $$AQ|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|Z#\'VK\6.*8:.K[IO:^.KE]>M\H2]>A)?REZR%:>N3:^ M[&N6)#&VY$!0K MC0+3>KCFMBPV2>1V(T]DG_Q%&?\]:%VS@ M62@7YCZD^+#V<1%P.]?!=]Y.]2.]C[8<7(3EL' +]KT/FFV"]U>G&6(]5YO. M=3EP[Z98^35Z8OK= <^VL+U[@Q6"N\XBKXP:!W<0E4_3Z'U-I. MM7."[-WY]5[/]M!KO/G8:>+^W=%];!.DF^%0C'"'\<*N;N+DWHA@S=9H#$'_9 MJ=4J3J6]%N5\W_ M""*6=(/!U;]2CSH*%X? O0:.=PO=3H/&_83OO] =?K^Z>_BG8U_] M!/KGP<W^V>P=6CNLO?U).MG+72?53?%9YL87I(@)5*?$@.GQ. L.7(* M#]P2 VLE!E#MLR9YS^TE'|Y"W+K9>.U2.5? +_!Z%)4]'?0T+BI5IW6Q/!IP M)*F"YL5>28ZY&:.=:,SJ=:G6 :8./>O7[C'&W*OL|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| M=A'Z*5F%800WBMDH'5NRTD81C?O,Z0'ZX;B>@5 @&D_9NG,7^]=BM-N KUFM M72]:2H/H-DN0#20$&!6!0,BYGO\&$K76N6W[L,WNZO^0K^K_O8!R8R1V&YR M!A\|^^9&?XK$OAW"D>.)=1\C(6C^CSV@*&UW"'F^S:NHY1Y_"OS!!:YOT7O4 M]^1[B%63\%'.%R*2L+2!W))X3VJQ(VY*+WK8!(@%:837),'EOSOY_:<(1E(8K+U%[X M"&*".5&$R>^%+]D0$74<{'0&8H=G'4/GLQWF<'+@Q2/<;/]OENVS&X.S'L M*8&;2L_)/B_#Z=ZH!]21+P$)$CL64]^.T_%8?HM$"HX=BN%?4GPPY Q=OMXD M1U!Y%^5N/Z?$&ZS4!'+,.D0-5LWC ;^/UWB.?]'T"'@*?]C6]L :39/F7;+M' T<[3$!+NC0RX"W(2)4'QV&]%\P'5&;JWX@IQR;;$[V)?Y27+8?X. M2 /0:)&@!= @Z0!1+ ^"24]4 6X7CL0\W&64+6*8I*+HPFH!A2_Y2,\YLN(4 MGCU0[W6P4P&\./O)2%@]IC!QM+43\@KR!{\#STT0^ M,P+E@<^C\>0?C-YANB[,=^K&X*|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l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|& 3A2- CO01S&'RQI4*B4&M/=_M_2GBO#7Q! 0<"#9$!-N%!=1"VZ_'R([5UF_7 9BL]G?P<4>NI#$]7OXY.VD1 MR0KA&1#RC3Z69UIS;G..!^%4SNTNL'V*;$SDIY?U1H58.6=? D@+G K5IDT]=&^Q!C!.X=%P\/D#=(2 .38] '4T!>Q "f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| [\NZ6BTMM-JKB4TW^3M7\O!7Y/LG0KW,=>&L8)YL@'G86 MU)M.I,V6!'V38F_^V03E&^QA=)QV@6CCH\JL,)%_^\^=D=8J_]OKN?G^,HX M @+3+]ZL)?/9V 0RA+')4GP ?BHBM91P4P]=_]UCPJO+.?!(FQ=K^,)O4E:M MH6K7I3@XLLVkTVPO)_J1VRQK$A)>C82L =Z>$[*.L;(NU:IXX4]&R@XI7B,^ M[=27UTT<]873KVZJC20_2?.JZ].G!^HE-B65:!O M'FJ4YJ%7T.S-V0JO)2^"]P&++Z SCIWL.(WF\LDJ!US?4CNV:[HU9:X)1FJ5 M9J1##D*\=B2#L@\4S"RCWQ$J&R/?31/AN,8PK&-^7&LHNFNBE")A*36!48^V M4[E8GA9]U5">MWQ>985G?;/3 A?>\VU0<0UAO/;#MVQ5K74U.NM>C34(^_9N MR[8LM{6.\ *.X'IK>S/'WO*!E15OC9 XVZIX6\,87>_N -"J5M>_&[GMS7E&S MPDNV EO!+>QBF_1[%"%SD6[X{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{SV//A0.)4:>,2-?C'/_3KO#G!<(Q*/(9POF1]6,MW0^B:U078- MVA?2K,I"4"HR OK+"]QH @0&XU+@"::)IQ*$G/A@T>M1]11*, KZ,N XPI)[! M/2#CB%TA/$;T0' B:\!.02:63^]$;IR'9'8%M2"&H< MHA>"UN,P34!XS;P6O)PT\#T0>V+PF_T4OH I%>4=H3XUPB7^Q'H*_4%LS#^W M'R5:GN^'1O21QI]P 9"3:FN#3/'EQ]F_:/+VH<*@NNO,X_CU[DDM#V2=_?@I= M&U]"+PA,5_P*\#_I65#E6()O$\F00Q*U!NY_2Y]+@!F]53Q^!8Y(TF8)3Z'I!.'C1QE.M%]C/:2 *&CF>I'_ ,_R6'.M +$0WPAD#[C!_3ZQT^.;Y>+V^^7\>B"(HII'01;2@3]+(K<<#. MUO[&^8ZOX%[/3?1]S@+'%E?=?!J,H .O]J^7]UZGO?[VHB+N]N%T?2O#A. MP=V/T|[_@/2VB:,.? 4SBY.)I8%#@&U@%?:HQ_6IP_;JT1.O;=. +X=_N%&J.UN MHSL,M("+ DH'YSZ3W@"'>NH1{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

Copyright © 2026 Google LLC. All rights reserved.

[MY2:8!Y"54<@MXY6SFAL)%MM_W/NC,@""\ M%_+'YD+_08N4EA1,[;AZ:C9LYK;:.YR>MO.Z^T%RIH=BO:,]LB1"]FK_7A2E:@2M;DW26Z+WTA:"$O_+FC5#4$ P>W[%{'I?)($.@G>2.Q\+U MR5AVHYZ7<&S:./FN\=MN'YR4ZL5%U7Y_"[Y0Y(4?)! Y6U1_#[/Z1WX&=WMN M7$MD9^0N^,2S]QC"IF_0NX-A5UC6]4I@!.#MP*
{A.4YCLT$0_K#)V*/(L@8_M8W/C$,/)UO3$N.6N@@.6*4\@V=*@M9[(OA7\%$Q+BS_"P<"L9AGD0(GH([M>,.HARY6.R^NH\(KEC[<.TP3]HN0 6WC]-
[GRS2F[KI\NCH:8,%I-I/%2$@,_MZ1>,:H6UY!!8< 08C70I 9Z6O[,O!BSZG1Z M@1L,K,%E5?TXDN=4U5^BJK]V %7]=U=?NP]7G^WOW;N'?]H/=]V;.^^[EP_7M MS0Y*^I?
O)'1@L7'>WD=D.1=:,X11+C27KIQ!$$4A#BXOA>"]HRUC#^2'E"26(:QS^1GH8LS/Z?,7K]\U#//[FIHLNE#ZW/]>1DL0<[:92>,P7H\$V)WOA1A\$)<%%K[Z MQ_G]^?22+?]S+-
\MRUT>!.IDEB^R^7)#=7 TPD5@V),5D>Y6D+GJ+$&\.*!W ML0:6T5=\\Q=1:G1\HXHP;F#[5ANSV*C,B,NK.R[60!%:..;&U"@$O=ZJSH1LS M]1AAG@D?
"&.&&+>>A&4EF2N>IU'0)-5T _#5]_^/3 M_=72?US=/-A7_\ 6O!UIYX/^QE9 2Z)PKH6]HR({26P5!'V$[FFG(=2&53 M1]L6"7+3ND&04E$[UN]0.@]D'ZS]|+^GW$0=|
9DZO_UN6]S$_X#-;]!6+++H M5R]AZ@^4GP,^&&&Y&Y[TP$S[0!K;6BVG@@GN%^^]CV 43?4QIE)D8SJ4]HWL< M4/T3R,Y$^E @A4'C9^DF]N&M
4B0R.NA6!1 ^^*T,9#KP+X11+GC7LMF'!O3Q2]Q M"L;22K#[5Z54!0(2[!$S?;)2@^Q7]_JO\O7?(G"T;4L2+@=\]+N$Q+?_M)4P |+-[]K:,3.!<4HH[G 9=0C$1F=
[L/WWZ!T!A8]5F/3*.HSH/++2@Z=H>U MAV#WT"G8]V/?(WL%PSQYG]$N6I)?\.^URED2GF'N/W('6L2(J>_ 3S=N/'#_ MA3^Y=HQ/V.I@)?3Q;;#'I@Y@37=VB.7?
6XOLA6JE>J,?8#;P))\V!2"-203 MN4'Z VTOQU*U=Q^[,.6NQ*F2]%T4$,7A;IU;Q8[EWH93FR6#K!^,>B1 *=6) M53WFA[ARD=@S3$"4!50(-?NH.$VP>8A#A?A8$+
!!K,H/IYO<092U5M5I]G4 M*^,@D_&1=K7C5,JU_$O.9PS#K1N+KX_T+$HO-D[IQ9GT8JUR2B^N&=V<>6NA MH?C*I2SUD.C_7))4[O^K(&3;?
_Z'^ UA"A<_.R2KA^NOMFU<_M;]Z,[^Q4B M8L@DU[W]^?K^\L?]_?7M#6%DP >^_O/^^MZ^_6) N;[IWEQ>=[!,E[!P$_"?'<-) M$!PQ%.!5\< 4 FJA4])+8]#9.?=W8(.
(ZZ>^&SG6"SPOB4)L";!!?L)G43#A MZRFOA:ODGO(Y+\H<$5BBI,T=?,;^XE),5447Y3%3P#+GHW%CS*)OHHOJ#3U^_MQ360TZYVS[7#[_<4=H,|QAIYV?
P?|@W1,K&IS9YS[JAEC]R _Z4X)W'8U>6Y MQ6&T>5OMTW'(3F!N4V:,BNR1@0<69V0KS!98C\STAU1='?X/ Y\ 7\&Q^!ZS M'1[_/MAR;0$.R_GA_EW% 1?
<.,2KW5!4{3EDSG3Q\RW]?$<&^\U!*%/0 ME$7EW>]2=#YC#A_G[6'4I+PR'=.+DB4K=)3':Q;9 J4P@0NFVW&+51,'9YY}
M9:E@]=!B=HDQ@$O^!SB5I"&W8@)7&0&')1$&%5J@YDUV{J=Z 95%'W%*$0^: M1 R8[4D((H0"PUD,98Q\ES##?<$.XZH.)^61BF(WIO=[^=V5[,*9>L7F=7FSNF
YV807B]).X*WPG[.%(2""#Q)5U8CB]^N@V!BX"A))WJ\7=CI7[^(Z=^DL6.F;^1O@0#]MQ'6.Z/FH_28 MWT'OC=R^2"E0&^_P"
[I3.V;U7=^L'EZNKN^#C/)!Y^D>/F*#@8ULC)Q*RMXB M!N4/QNJ$U:D.LJ.4LJAW_+2[?<;TC'@Y9IOV#T"[]KCW W!4(=L&B0$JZ' M&GMC
6:%0.@KA"F)\)%@=CD>8:/I*$/3!5O4% TSU,<*!XL> F!K3K92500C> MY5(&Y5E, !:&01Q^"@"A)^[_%4EN=/-.HG'".N<:WZ>P$AD[ZQV4.91 M -`#8__DE-
M3"H1!V25<[!.9\T!8&P6 "&7%6 9L(@ ?/ B]@1U/8C3 V+Q$ MW9&2;E!"DHK ^&V]<#!1-CC7&W*Y%*],$07\PY$(\0YZ?:SU4Y8W+BZ_** P M'*(-`HD?]NG*2F.R%
{D2\@FC#=B7$@"O LDL7B9UL\ K9_?I!<^A_\Q/&H6# M5+,V!B* 0K#X?7?$)C]O8#1"?2@W@9USMVF4@3R)(6P),4 B.\MX="RHHP#(
M*,G.WH[!Y#T^@5P9P2='5(N&BQ8#;,>3N7?^7%8DB0872.N0-2PR##7Z!HG] M9Q"^G#V%+[@+(@T5-I@1*ISB,BVH*N $4CI@C:-QJQ-TJL<#H<)GPT".'93NZ(IP6-
[HSC3C+K4O]) MUYA(/T%PLX^P?>~"A(IMQP U8!=1L2GN 5RA'3YR.65?B;QQ93X_CA6'Y0 MG6L+Z)ZPE<\Y(8!5%BR5T&7L6_*YB7G8?0 @XOI8'
MVJA8PSA*9Y%$H=B$"H",!<;R$7?" @+YWE!0I>D9?N29SD!K \W>W[MWFOFR MI0#S/KVXDW(,!%":PI$N9^&F$ @B)+_=Q9S0%?B&(R#OM4D>P"1U>I7/AJ-N"[=;JZ'RJ
MZQTO'B!I,_AG(ON..26FD|(XRD;K^8E0K9^$IX',E0R84;E/|$O,:\F/1T@-_M O](@M7T.XM5X%R.+X"WJ/HJ!OD;?Y#7Z;%PC?9STZ6^?C4JS$441W,:! 6W)% M$4FGC.?
#L3{2)^&/,9&!+7KHM1&/#RFLA(RKSN'XU179#6C%^H+P)M %A+M0 MRT0N80#BN2);M9M_^[W6_?X'BI",8)'I@"'ZT&MRAT+"]' !#P3/Z$ ^(H/ >Z M(I,1W
_1K*,%V$A?)";UT5|HJNH8?[V1 372)%"\8 P$OM"$NU'\6ANY IA,! M$}?&8YSTS$M0 >,M4'A%:K>\051#;>,)@P2R^ >NC_E-,C(1N]@2Q2O-LM7(MBA6Z W3UBR=I3SE{CG A-
A*(###*O@?WC)V\,/(MA!]P&\&3-@EH8O%.85+_Z-MDFK&=`/8E;Y<\9\<#.&8RO&:8G.M9(S[Y*Q=T)MC#5]C*7RD!)/Y$C/3,(<9 M?R?.C)T.-!@);J((Y]183J$[%!%]C*318*Y%O.
[WD$I%5]A&!_,/_3%3T]B'<$'P+"G+@U,L2!^,(*(GVDL"@LDZU-(=U0" M8[*#@G ?'G;1T+_&C//U74$3($4*,,>AI^N4O$@&AV%!*6H\?5!:&1I?3RHY
M8<6<5/^C95.?:I],CXJ(=?QAFMGQ:$F(BQ&^$D"@$X^[IY$[HN=@:FK@,=__M"==/>)+;'W"< 85ZR).QM+,..!_YA[|^/PDI?)T26++#LSMG=99N74BU31~|
M%1',%A%43T4$!9C'Q@!6KG,#[FV"*'GV^Z]Y^-2^^ GH8BZ M(=_A!WYC(D&@V6-)V111ZO*[&PB?9%11&9N*0A\K),H8!Q'/'O=G1I24R1H>_M5:
{$G28"4;.[%T6U@!H^Y25"H+2 $)\]T6)[1D,U'\W=4?NK/,9P06FPJFB.+ M_72WM%F^3 FO1P+P1!=%@T&"Z]AV&&N*;'&/Af$,:N5@1C@%!>,;K3W5EFSM
M,9&*KGY*A7J9/>,[/<,8LD!X,X3/K3\D>WEHW5K[*MB:GC>0T%&YZ;6D!H% MUU9LJ\L='88 I<_"XSU=!JFH>(>^:K/9K+QW/[RO?,#.K7R3;__DH2&!;\=/
M9^&J]<4.)MSOK(Z@$0.] PNW)C?O;'H"ET]9$4QVG[/_H^.8\)#56=(.M?B98>FQPS^MSQ<=Q.[9?1"A=8\"9.0/|O>#Z6;YU&LS29%%\&+/,2:LT/%&29
M:L*A5;O/KL=]U>P;Q\7\,<@:.SN;SF(`E#C\.P??N@[U$1]^T)AE#2 JIF(04 M5, ^T_9"H658/1S#P1\W /+ M(0^KJ0\NSLJ77E0">T"]0!6\9C7$V99J+,4ESD-
:YLZX:5X,%M\5PB*:TB7F M1.3?9/>N"\O/GR5^%+'-]=H!]3V3I$9CH06R$@A9L%3ZI>\KUBU0@3&,1"-AB MV2G&:4\A7&)Z*.]$BVN!@1BYG77Y5W?\(1U66D@M-
N.R]=+B5/L!C]"A<@B] M!&1F$A?\34M_TVAT+R*2HBX*CO?>.!U:J_/^+9"X)AO>>]\'D957. $?NX^N+ MQ2WM+C]I0A&>]\#M%21C\G2:X:
I*^8K(9THFEOY9D6'-609TLQ100O+\!UP M#!.3=*+/@)9: CL*@$%2G9K8AHD1I[_^M AH5GN:#6C6?IZIY"XU&X5LM#D-3O!=N"MU*A
M)GQ7FG3N7+)CX2)V_2$$C(=HZ6B=R#NFF7.&22SF:Z*?FX)G[R,.!&X7K3!O M@)COY{O*,4VXLAA?1/2CJ1UI)T(8T\85AM+Z68% G>!#=HAIFQIDT<;__V#
M*C]F/:JETD<.^L' (_#0"D(]5"4 >7B] 4^/#9["P"[JHY4[3#$U+<7H/*6O MT..(IT))6E/7ALL^$'BQX,9BG)4!;RK]08YIA#3K*E,S] M5_3;&4B WXYV0\:P5H=Y/ (RY5Q?
89I277(]+Q 8(WQL\@_C+TZ_)3OP4H& MN!9)/G-)V9G,$):*P569-]DBU"R (GX@ID[$6!A3.RO7X7NMJ&_2GLT(CC?._ML(=.Z%H$'<7H"D,R6D@R">"_<"(D)?
@EH#G^5*3=:/ZK@>$MU4M2>92*NGK8 M'3SO*0Z4B\G:MA,9 4CB6G.BCODGD&WB(=ZG^E8>)F0P&F2;[:_ +3F4:3 MFOZ&. \9^2P2R^ ^NC_E-,C(1N]@/22O-LM7(MBA6Z W3UBR=I3SE{CG A-
M;

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{* ZMFEP2,T-M8M3[^ /R^7]@2/1DI\)8> ^^,/:T!8CQQ3_9+(E08)0JR[$(^5> '8S/:40E-F MO"FQS2P'P[7D_ZID?I:$,DG_TR4YM$NB\MI4KQ3GH^K J3+;,"(=N3SEPBAK MS.Z!PF'*65:..>D&&VT<>,XYXP4X8*@E!@VL60(F?@W^,@X'T\N3!57KA3& D M^@+K8HSWC+'2U_5/]^MTO_;L3$]=K'$DQB[?CB&H*'DG@%MCT4^)=WF*%[(P M*''*EDY3:4E\0 =P"3G,3OEH"G"/@WH&V@6>-X4 GZL'CR!.)BSX[)ZLY:C64 MQ3%4.E+T]3,X5ER>U?==;W125;>KM*>K1 "W,?=AQEFUA;Y4PG[,B2GKK+ M%!8=3 ^}$C/)0N%3NCX^)\18V^_G=)GZ)5?+1 1TR_!EA>FY]6 ")36FE:.) MQYLO&^5;J %>/*ZP5Z7UI^MVNF[{UERZ]BK3/XZ$FU;*)5&=-,4]". .,/2] M\#?\PHFE3RR]-Y9>7/X{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

*MSGD1A1L1^R2,S%KHB*ZWW]OOA.7<#&1QS*A!^X0Y\>!VN)(#W#)R,'2M;N>L_M>_$PE+%T['|_]Z"S=P:S;Y]CPD043IA6]\WU+]]_?M]JM_SU M!]O3\}\GUWYQTO^F1GWA^(];.Z;RZ-Y&I&]}XI1_PM^[?S:89D^L)5[-PP"C+_M\?%':6EMB*A.OS?K5@W7ED6+H.UU5SS;/3B2O?)@2F1$T(>;ZW[=SYV.YU)-MC[_EJ6|KY9\B-|sRKN[_:V;//GMBPTH/-S7O9:_SY6# CQE),1(K(D99]++D!-M2VK*[L1(&_!0L__:Y.BTY'@N"Q^0]O;(3#=K_^'?U._M_=/=./+S!=G&YS/'Y\$+Q><9MR)M-A!_^93=%WJB1#H040A3$X(SU1BRT{XE-MZ,UEP7@Q967A3"F8==R\',1 4D02$282TW-M4VJ2\WN(!11C,:C%S1368$Y%FEI)"DND2"]+ >+(#>&A'4&Q;'H:=P3,=H_$4RT+/&TOA!;]%SE>H?_M.?0$RV2!V"9.%K$<@;N4.3PM=>>RW" <(1&31:+*%,(!7FIQ&P$V26(S0K@3 M]H2P4@L6*PILH&\O-GA/)8T<49-2@2<J$&)G\|Z@O)NARQ3>F)G=!HQD-89 MR@@YW0R&P\RH!IF=6?/$W"UFKQ*S=R^$69]*D$5(_FCLYU*?V_JD*I$G0= 9-M*AKV0FE.S'&I(BDC7[;2)TK9$/[))HU7@ M9V1T(E+,0#'*WD,>ZQ!JAN">LRA@7D$25_:)#":6$,58KF7+G+8VM3"4WDCR0-M(:_UHE_02*5E2#7]CF1]8NH545N8 H6$!%,O$;<8*Q4C*8=CWHI%THHN(06N MI^[X+1;4$&*+_B+=BNMK)3C^;Q"\MD8] 7E]=5N+9U"L;1,8RY0PY587G(2< M6S!.A2.QRTTZPPAD2QY+)=V4$ME5\]*VXHGS.(4-8:EIK?#T^<)#|*C9&)5F M!)RM3[V31)O46^!KT{$HD-K0(TG8D3;!35!@1W Q;8B1L+;,O=WDA=']_M&'-5DCZ%PDJD&9W>CQ&/=D4Q \^\^{JP%##II C#Z%K97"EOZ4CH9HIA@ M>\0#':=6]9E_LA*Z[U!'2EYUDI2&@KZ6*#X=M=G(",T*(-Q&.1S>"\1AAAR M.\^!29P\FB+UNNV-KR1URI2\%ZHZPWW4/EK7GV;C2PZ=L"V.K_1,Z.C_=2;D MW^2E,XZCA8*0HN7;.@0MO26OB0E)T3?0)4OF.?&3LG)N&T=IZ,2Q\RS4W\"8 M>2Z=$^(K@AUKY+GT/4PT_R!A!#'BW1+WY2@8OY]SS@ZFCFM$! (9P9"$2'>A1W]WN(F.[\ATZ_?MP[F=E83SG:#6/'DGN\W'L%N?X,^ M22CVI-[21WU+:%+ 29>+CW:3GVCK6NGUFTVN;]USN8KN/BR MEC92^C8Z?"Q-WU3_!5!+ P04_" #K@6Y9M#)?.XT# !U#P &P &5A,# {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|+F>SN_)09.V^=FO=\L=(0I=F,E/^3!I7N7#Y(P13|P MGW1?D_+)0??XU8.55 %5=5]R3N($ZRO_6=E#!RZ?I9Q6OWMC*N]RiT12>2L^"G+,F&8EH X*AQ0Z'KU]YO!fA. ^?48YKCXBA&9PQSXEWZ M.#:_']'P[=&A&LOELSK^CS>?V9U!+ P04 " #K@6Y9BSQY M4/ X$ M#0 &EM86=E7S P,2Y]<&>=EF=4T]V6QO\A]"H0D-Z[..D(B/2BB'2D*\(S M(0(OO2A$05"0CH "2N\$!0E-FI0@O83>BU217D("R<7WWCOS96:6S#QG/9_V M7F>MW]YKGWT(DX1%X(JAKH$N *[(?+ Q!F "V G)24C)2$G(R.C(*"G) (: M0D_147-RL:(!^%DX^;B9,/@X!&0%.;A$^?GX!!1%!67OBXG)\OS/]9A%: GAQX"%2"07P $3T(3 \B=_#<_M-B ?TMX%|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| M2<[4KNKG>ONE&/7V,K6&_(:(;E&W&.\F99\M4KUEG2"/V$4"P(7!3*LTF=3 MAXSZ)%0'%.,M=!:E5LWQXH ->/B6!SN,_960VI66OQ3#Y"_N'8+A30MA=W9E2 M.IF'7E1jL:%> ^,.YN?7-)N%GJ-76F@"\JNPX&Q&I+/(^=,ELD[!]9&1G";.M0RGVIK+9T.NIZ98.5O_U%K[A;C?8-7A&OTT-2EVI'Y%59"QYGB<;.> +K:O&1 MH_F[5PQ';F!%.ID2LZM_=.Z%18MD$UV:CG6, /$TKR, GPKO?F], M]3+'.0Y/9I%X[X@]_+"0582:*,9+]PJf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}.FZ MMKZON;5_<'AT?'**_ MV70."%[Y,7() _2'*%FX/YG8)?UG2/R=%% [F))90&Y)*SU_)'/1W1VP4-M[Y>5TH0_&6R3U;M:2-_9!^:. ?G628C?.DI*4;P7SG(")T@TGG&IVG:3.!8.% MSPD '>Z$ "Q9BOLA%$T3\Y -!DXF2>$*QNPVT3UZFP]J3;^ >.KC&,1&B=6 M2[S]'13][3%KF:,)58+U.G;CW_:94UQD->2WQ.M.4S0<6^S T?%XAGY&//SU M!0Z^E]=N8B.9Y7'2(IT8H/_[]_!>%;/[&_K3?K:.5O>O^)>Y>CVL5),.AJ% M6$F[^],-O&($Y=KQF[B.$&8DT2.STP"WO-T.^%O.GD^A*AI MBLK5:AGG">5&BT(@)CK ?V>?Z6RH^UV M[W7!2JH@CWF_;_!JE1#RY?+- VOTM&\KD[!O77O2Z47:PK_DYDMDF&,C"TJT M*FTI"FBW^QB4]EA=68Z X{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|[!YR%T2)U^B>=?%XWIMQ0)%/US*_>>ON=BHP^^W4/_]89]-6SR6E M!5RFCCN7+3'0T('<(Y-8X;XZA;FF;Z1[,A\T8] MEO#R8P2C@=#$XW*I1'B'\ MIE*V1/R+ZE:.OK5N?U*=@-_YM0@,C@#PJ65=P(OP+XY'SB4(0!(L%S[!3 "&-MIDM[4W\NV')&0$Q,IYGH0$"Z6 2""1+V[`TI.J[A2HC&MMN+O;Y;@+R:.6B(M"H68%BT<[Z@K]A^LC? C]TS3YH9N9;NB1MWVE)=Z8DI*_#L$,OI/59'+,_M0,L2ZH!G6EU@0[Z-A=]A5=D+UPS8=((2X=&Z2Y_+T. Y>:"%>D2S,_%X)8GK MX.(;S^]Y;2+8%]DF$/-H%- X(\&_NFCWG&UG?:X[U,V;=NOVM)[&Q_.CP(?IB M;&4?DK3]'K%3[@A+%VP)PXL'N]%&@4HJF0&E^9F]OM!\MF/N]'G5FY0CCM$__M^+=]GH[_2@]]EYVX+=\]9T='(37 Z6QY\8K4=N%#7N(L;+ILN+KMCT!\#'R'B3/<"/F Q$G.U*[]MYWK[I1CU]C*UAOR&B&Y1MQCO)F6?+5*]99T@C]A% L"%P4_"K`)GX4>, ^B14 M!Q3C+706I5;- \>*#7CXE@<[C/V5D_J5EK\4P^0O[AV"X4T+87=V94C*9AUY4 M:K&A7O@##N;GUS2,A9ZC5UIH @?;L,(*Z:A"SR/G3).)_.;61D5@FD,I]]:R MV=#+[>F6&U;_]1:^X6XWV#5X1K]_'Y=]!^1560L>9XG&S'BZVKQD:/YNU<, M1VY@13[9$K.K373NA46+9!-=FHYUC #\]*\C)\'+]{1@3B\:A$!]']+RO/ M:FL0'*A!=P':^(? RPD%6$FBC&2ZL*M6 A\[LLK^$K8UT;[14XI5)13>LR$UUOI G7> M41=_V;_:!_VM@>;!X1 M-:2+*BN4RR4%W(1?9)..TC^I(@#HKW3=! ![S(V2$-H9M!YNM'Y<_G*/) (OOP#;)!3'7&M8#_GOJXLXIZ,H7\$&'?G_A ^**5P[\]%9)Z82:R8'!B50F6U!.UTUVC MV@=VLF3:6,:'-,GF&>+ -]EV$%*OR0\]VMO9Z@N^%:?7 BGVSL4AK\6?)&V<^?V, ^BI10Q$=UC=7LR*LE%HR;75>P8G*QG;8TS,U3PVWT]L);T]JUNEPY?BZY70>DQLE0'C)CI7++:K/E&\;N,% M3>9PND&7K1H_|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

*M@V#!8QD#5=4)U#!.G7F-(%U%B"0Y^{'4\4J=0MU8I=.(G/UX4:=5XH_7[IBV M30[U2OT;$*W:/VT2]!^V3>D__#<67(#=2I10G67O+NR.B8=I+%-*
!B+KD"M)!JM^)AGUT1SZE\K-V5S?]C M"30*HXPH4,I]>8[^8T"(#T/5 [V_:*8/@\=T"(88S6F]/#3I A#<>Q]7T')L*
MFGCA1YF*$YIQY.@8O!L'_Z(@MZ)C:"!O_;FZECY9DS=)S!+@P47L,81>_%'8D MLN5.G1!#VH.9M6T,:_^:)M0]7S.C!\X:!Q>.7.(':]^DHOV-8U==[SHX9I#
ML*ZNJPN=!7GFF=]PNOS&)FYX.S/:$NO^& Z69WR^L&F>J!^28'B,YE Z;]\P MN8/TTA/FM@"'+YC:>7)G++CA3B(V2AK69W3&', Y.!T>FH0;TE[#JM,4?Z%1 M]XF?
{NT7.P;8 [6CO'P2=EG8.N5T^X_"IH+NO8:.X#]0#*X2(#=PR)DW@_AR MIMEG+B^9'C[0N8D(R3PN D+X7'NVS]%MOVGB. ^9!?0S2=T>8F\(C
M%H0>4(_8UQ#F"U_<0[MATO&WPR)_%/X?((4Y022F9.U8W3(6O[5P8,BT35M\ M?J(4RS,AFB$T(-)A!AYK6T>!\5AQ) (7#H5SNX4+C)1E7B,6+*K."M*FNT$:
M0.F09DC8L:)LX6P29]F-WWK^\S*?ET6'*VF1[YT2>RL+B7BZH.E@'])^+/8! MO#O%D+ ^XA-A2U>SGA0HIKXZPIWQ?7'1>X&>F.B^.Z)6D MSW10;3O4"C=3LP7-
CAO.T_15%65..W[Y&QV*9JZ2N)FSF'YUI"BZ9DI9E,1 MX?)DX&UL[5U9<^*X%GZ?7^'+ M?;FWNF@(64EU>HI R_"=%;)/374)6X 2+[1LL^37CV0,L8D788XQI/ML,K31 M.;?
H^G=62=J+G2%.E :8F,?2CW;,G8D["NFPH1.\>Y6Y;^4]KVFCD_OP)2?]\ M^4\^+YUB'5 D845]CZ6]H?5:,I%N* + CD$UZ7^6]G\I+_4LJW]8* R'P\|R M>|:4"
<6F85,9F_P#*9]G TZ'K%+,!SR4;GJV=&$,I*T=::M\6"H=[FO)MS=5 MJ50L[4R^\L<7E>@O;61BB>FMFT7JK7"X7G'^=/6J2H ?
9L%N%A_.SEMS#&LH3W;20+G,!)CDTG0 /#!E9 M#I*Q>DFA3 #_RT\?R ,/\ENE_/;6YY&IY";X2=(7:]BXB3N2H_FA >{CHYQ) MM+[*%7(^ZU'<.QE9. MX@/?-
AN^*31T#2O]'[(:DK%M$1FI)M%ESF6!/U\(':[P%5[?!EN@&FY9[&_MZQ JSX]82 /F*C)[==48 N@[&VJB*(2F?%4KMHJ-3D.?. P,2K!Y@]K\ZXGT MC1B0:PV]\A4U^IA:XY.?
NES!I&N-"]O*Z;)+:]\ (B 6NM>Y)B8+F@TXE M>%1P4DY&?2Q;9D4S]$5>';_(/I)-##_-N/'!)U219+2B4116.62=TAU<;.HHO)6Y+1/_:.GN\7@3Y_<)PJF
MK6G.:'G"HOKT^QUJ;#'L6<;"R!E4P92ESSEIBSFW9_$_V=22< 7J_7=V@ZG&-MHZ9I.58"3$V@B(+'!-2BF!@7.1+<\@GM6;7[S;QC!G9S#==8"LEXXX2Y;/U
MM60C&BF7E>UY5!)P,LT>QQ<8F@/?T.ONBOPXN CO 'B<*XK[B"AN[L2\W:75 MPS3-P"8B<>W]D1!L+DV[0.[)&3R5+,.M\60'=[" ?"<1S/M F!71:U%VQ!-%B M%,Z*.WA?
$REJ3?Q\#*/@B@_";T?[*E.DX&9S%H!"7:0F"&A<=$EM[G+WJ8)W$:-E IXW2(BQ&6=3(H1E4<M8K"UJD>G]+Q!MEXW8(I>O!>Q@*3A+IC2[$)?
K+QU"UBF&6MH&IFTKWAGT= Y6%B7X>TX2E+&W8YPSGS=URBH M 'NN7(ZA.SJET@J?'SY3IRH.O1\28*NM* KAFB+U"A&EH5=1GUA(]R]/6.#98J>$.D0ET#!00N
E$B> & M6B5Z!#A%*=^=17$/ZR89X.D.ES/#Y$V"R\X &L&77@M)WX@ M#"D(?W>)?.[M%OO23W)BQ65.F"@<(05"5&6P69.*>BHD-O.,%86Y'15?4]MF\6Y;GA="[TZ+
M) 9P2IF=75&C QYNO",G -4F'F#=!L ?9\ F7O,%H.\/==/Y Y??5< DGM4= M'CPK]XZ][A#/(?'>X/.) \VL8G=?94(OX_?C+Y&+FIB!RK?DU!@4]N&\B7+'
M!;> ^*%G99["AE/FM,A{LR%[OP9?2 RIO3BD9T8S#MYJ?P.6)]\I=1 MS$6F05R(D(P[$,N1%08<<%?"OW^KR4>\{#!%G2W. 6>M4]T >R!^P_WEXG #
MGOQZ:XIP;WVIS[51:IB2@=.7=!-0^%T#23388(>;'"#8.V2S8X3WE.VR9@RA M?6^ @ VWT2#(7%+V *R0Y4N4&W\-3_[.T$7V_.-77$F4R+9AM"RMR7!WJ=^'
M.=P\KP.O_RF2K7MB]:JV:.%4FLYV4:=.>K3T2?[D7-KU]_WYW=X_?S_(27OT MJ.^6E=?]0?=QK_6[.'I/BWO?R\]W]Z,375_(+\6U6J6P6KA;Z_[VR^C+?G,
M*C[5ZZ76]\)@=%Q]+ Z4%GTZ:%NG][L_SZ_O?KZ>F1VR??!Z9Y_[INU0KT^ MW+_=,4KDX+Q;^=DZ[^{U1\,^/M:V2]<[CZ-/U9/GZW.=WC^]=N5/?]'G[Z\[
M]=/*WN[UY>ANT*]VVX5A'5\)>R_5LE94=Z[VGFX'S\1ZVFM73H_EY_$G_5ZK M%7:O7+FVG\O5F^HW!3TU\3"63_O.>?+W=*9.&UOB^5SXGS^7KU]+N+BD5'YZ* M>
[NUX<%NY46G;_T=_+5;[C^U'DZ]>_W[+4/N5RK5W<;%P\[VOW%;IC]UN=.MAT[OY6]_5*I4AP:Z4ZS.8[OV<$"N<:ESC[3*SN/\^#XH7MT](4,37=6](^ MD('%+&
{7L@[@>E5S\D.,)Z1N5F%R-SB560!WPKB[-0$ MIU1(Z,8G.F+03KLZ1; WJ'.+R7-C7.]VZ97UL=(9'XI3SK8"WN# D.:_$,_ MQPR%A&Z\&8!!.Z4T^)T"1+CDLT*6U]^W=NT
MLD+2(_)#Y3U!D$Z)?+?'"/#-VB0L9_!F+4AP8]_#'I[U].HR#]M0H.22' RA62NY[L?42;%8(4\%1"B M<)WH2)O,*4&,I\7C6[R(S]T4-Z%S?9=$XZ'2Q#V^6*E<]Z367#U=P>
M(>$$/&9]6\ XY?+T-T[OP$4\ZM1EVFDO&\SZC@e5_MFAH#?B&;PL <-_%((E?FM45^EBC$ERCWDHC(!0[ML_]4_ "WSP#$7AXT+'QK<]SW]PM+P]?$BELX/^:-
'O^H6%9R6.C=/3TKFW>)%Z(F%+/+@]>^?D@#(I\5! M"2$LA&38S")"GB?*I7CR+X$"6>>**7 ;BG66AYD7^('1U>0**55C+!T[.H] MBA<.LYLA5@?XW-
"MW@KS(1%EUC#(U,%\!4AW7. M>$*"8GX$ >_ Z@1*.9^CM@4FUR#/ZKH3T"=XAS@?]LR\S[[GC*NQ"] N8 U^(GN%5!>Z5B8K@7O?DT^ OES](<<'U_U M"Z]Y \\HZ,
S?"VU@:\/N 0$;RA2\$HFY).4<8&4@.6(WSWT8PBT>=15*/*B M:)%-I&+C9%ZX)&1D :3"*A8 (U]_7Q(TYFW&HC"@N]XP=3TWD25\B^$BDC. MNDAS4B'[(:\E"(:],RDZBY3?
G216(\)/7SZDO24#@(9.242W2:!\O+C ;.MLH] M&(]OG:=M['DUSA<6__%]O)LV%1X(?GPK=.%Q?\Z9.?TS-.D.\UF>3(=?@:O:GA;OE(974EP(7W6:C\^CW+U!_P04 "
#K@6Y9NO8N\ TQ #!^ (% M &EN;2TR,#(T,#DS,%]D968N>&\U[[5WK<]LXDO^^?X4O]^6NMCS..Y.IR5W) MS_6N;7ED.YG)UM4434(R$XK4@*1LYZ_@_^)I$@0
+L)T+,@>/ZLP_/;]YV1U<'IZ?/_O=_=G;^ M]NM_[.[NG!"?4"LBSL[MX\Y!,%][..;7_?W]S_9[#.A[5(2!C&U2>?'^ MEYES]^_2C[!XOW[!WO)7U[+U[NOGKQTT/H
MK%ADGW&B%9GB & _VTC\^X.+:V?F5\AZ9D.E.,5?<^ L=.<+CW.>_.Z. MDNF'9ZX_W^6?2?O[^'ZC_9+_ZD?QX&?AAXKL,AVK<]W.K.T2%9SM\X)O)
M;6FNI_Z<.(L[B\XMF\21:UM>Z/HV!WV/?WZO<;@]KA&(_/YY:5'B1WKH&+,Y9>MR3]XB]O.GY@A7?'7G /(.+54*EL83BEBX#,X%.?V]S$X%B^PZA&KA\S
MPSU>Z4<>)'(IL,8DYH=LF$:+M$=Q:B.,%6Z*F_M9$LGH/I\%D< 4N9+&C"$HD> ^5!9\;3/T)D$\"D.2A1?:QKMU6# ##F0# "9,>)N1LED*QVFQD[C>@O)M&
{8+9J0CR^TS,/D'DE M_"1DV5WP;QP..L>ZBF]#\E?,A*"T[+*.JL/ VM;"7KW_F/STV,VBU@T(M;1$ MGL8U-
^.H/DPV.IQG6?!$.G&].0[88FMS03KQ+3DXC+6K^B8=)5X[&)C89;R2 M3A-0(.!{2MUT6+HM6.&84":\ZB-T8KEA.#@Q;_@+*W23<-!S8_FC?$2?V2#] M=+V8.<5LY:6KRE,
G^90O/(&/.8 MD 73:CY\MJ$!S.)I7*@CNO3-\"&)++?#0XLR(4"41*>N:O.2&KJG6^!N,Y$= M'>ZBO:RG=>. ^.33 R\K4T!'U1$/"]C^&S>D (S7C@?'<_40TXWCIM& M&/C M!-
1OHWC03XZ MZD=C7TK0 #69"FF]5N$V@.%H+)_P7 8R#S/:=$U?BM&Z!@.5 $G AF=TfFMX0]2K?T MU95MP.#2\CPUWO@75APQ/64G"FX+SACMC /^.:"{J=(\R4 $?
(#PX+:#Y]SSKEG@?GL7A[LRR%G^NHH#&TV.7N=JV:WF709CP/[H-(\K. MVJ88PUP:4RN\3422C;?'3=@>|:(P_TUBU!*Q*I%,5[GR=%*O[B"F/"P+B?]Z
M&BN&U_B/)EUIBXY*YGF]*!]]NTI#+>9Z$$9!U]QP"ZA#ZX=E5]!5?]2QB>P'S MX3X]BVAR1@G(4K++4'L
M;LL0(:H#PQ0:"@K:Z*$A;>W9Q6W@VSTXS35DUC9V8(YSG<@D]GP]^Y,>N5]Z M_/W -=U9W[_#[BY4-FSYS9I:MFHBB:$=<:K/"XS:T8/MQ3RO[B0(G'N77RT
M.P02),T=3E5 DY_>TAHK6.0UM\!8U=,8!C@-\FEWH#OL2BA[D$%Y"W5L'=F(FD)K$0NIWWLY"A45W($.[Q7X.R6=>@79WKK@2D)-]^
M!+5VFS2,Q9\E3\XYW4<<'%N(&3VGJB'7)C:L.S?TI;9U*TI.0<7&$>G$6B"$ M?FP5TQK@V;5%>*W7,CGD]SS3R\(,^#7U@/\+9(2=9,.A^>)25)4K2O##)L_H/H?A
MTY,.2G7R:.KJ?/1(:J^S>B!,1KWOE*.QU5#MR=/9& MN^>]*Y=Q@H>D.TDA[<'Y22)|@R\0?XT M#&-\!#(JIAT^(,ARF;4_W;J.O= MX.KIQ1&6QD;R[9JH=+!2$[(D?
@S^0+$:UJQJM\!2ONI)!2'CHNE9FY.ML8P. MN'DICCT8H5=$@N53G5!>K8T&4_+S^+(YCPD!8F71(&33+5Z!.RR)TI(D:]A.
MQ^BI0P$,@:10;AYY*1HV$YZ5>LC6G!/1X/"8=0+11"! MD1)1VHJH#QFZ M\D5*^ 2/"&6_ ;^Q:"!CT !)*VRU*$*]O!!S4_ .A&/&?UU%U7TR978X_=RU
M]4#"]P*]36 ^07=C+?8;@-Y$2V./!H.*2#++)OX66?![RE[V.M(GDRC60,.HX*8#1++9*2@N93^QP?L=(C):.ZYB1BYA/9#$=>*9]-/)NNGQ M.)BM2%/$&>0 0V]92NR81-
KLXTRGA;$ /U)>=0,/F7G!CFA116[R\@P,]F:1 MRV7VH,?!B!J]% ^5?BZCN&#,&",>)<198\6H(=_@]5Z E;7U0?E\"VUB)? =:Z M2%E#: <&%N6$B[((.HU5X$=,,XZ\Y%,?
GH5I(PO8:X@5%ZE^\MR6#COTA5:AUG+!5AOOY8&UNEKHWV$$ V18I,\ M_7HYH?@ M;3^?.X7*D@[^F8+$CQ@N+!Z",.8_+[DG\%'%Y^4^&T;.Q"+[T! Y MG(L%IU1N?
>HU"A1B6@9O]*11:9%63SG]*. T$!G$8FD24&NL#%+F.<[JD:9K M\")6>B')"U&B?!=4@1MP%WKKDLSESC]-"I9")A7* *0KQ5 M7TI(KS2\[C"GO(DJH&Z1IGNFOCP-
Z2=TE8__2L^Q2TI"@\!:#>N M0F; 6H ZB MPC5NF_EIQ$MHJ[IL_P=\92!$=PE*3E1]6)E(GW]&KT)S*RIPZ&\T2U7G$4 HT M_J$%\1]M18D+?WHHQ;HZA
M^1%2UA66^F@R*?YD?,ESIH,7@<-ERSKUNO\L,A.BDFL:%$U)H2=5D(W(E>$ M+EV;]"HT(78P2T4+?I_5#]=#4)3>$,Q4\'V+"O9:-H'W+SWV@GO10W'"VE@Y
M":Q,82&I+]DO).+C7=)@Z3)9[# >A+I.S.Q"K[9F1'[C(MC8:4"Z/.P'9LEP+. M*Q9.6< H+PG?R\:IK]'M&ROTVT[!)G.CZMMN4F-M3?DZ.+LZ45CB(FKYOZ K=)
MOEBO+N4>%!,>KSF>,LZ3%GU%C<(IIZ%,WNR&WY<6]*."5@LBSZ?,@OWO&.UK M0N?K#_DT198+22)?A_*((L V@/2NC@%G]/8KY2S."3)6Y,+V$FS=>&+[.MP M\/0=
2U<)%ZI="LD^.S/CY^H&Y'#X&]:/Z@&A+!+TL_TW)RB11ZV:W4[[E'}+T MOP5NLYL[O&*=LH2WXM51\E"G(D^]O8]B;#.0:\!=]!34S+;**VHEZ+42R)$*L$
MZB;92TH6ENOD=8IP7"\IHL8S3T:AK)%FJ3VB1-H@5 M.CRNF8'-KA;HH :0.%II%Q30.GFBE'YM)BUJJMX;N$(FGM "EA,Z7M&W*C^\ M0!7G_I,;W1TPYY^Y^735MA4=?
3%UDUXQ.,XM?L[^53H/AU# MWBC9UE@!W, #8P$'@SK4JLA3XE(2$ +T3M1@+(F(@:,<02R(4<.M&K(.TX\ F MQ$D*1%Y9'N%U2#9NP*$7KB31K8P^D5@#1.:!EY8L2EL(
?@\52G%HED1/GO<4JAK@V M7U?\?:..+K1LR$L)!>@^0Y]N8-7T*&V6M/"5]+VO5,F#T^?]XS80EFER]&:![L9,T*;'O+']&)DPJ11,I =]D>V9^4!MT
MW\"V9MGUKIW:I&P&;T1!51R05#>M8.YXL4BK5%I>/HM3?QK0N577SA@]NEN2 MZH!R Z0%F:L0L !L!_7ER6^4^,/'KHAIQC]3!56$"4?WG>2 M?WKI?
2LNB/I\&&WVI(1O!UFC5,S+LLFKQ0=P%ZL4S>%@*BG#UCI;NK'JZ6:* MBUDSG6V(29($2B-LF;[O.OBP%>WPL*:DO/QF2?+RT0H(*SF:PUE?DC)$:>O. M[F.;|
+3R8N\&WX]H,1Q(_X3O O32&DX6 GEA5*@9I5 @F\ :\D.QNMO%I1$ M.W30Y!%]$8W:U.$*2/"Z@"X>$82A5IMM>VT+2<267)D!>7 M(FRBW(D])$OB!075 C>C.C2'
Z.D#',$!5>,I MCYTZ0EF6,)>^\R83;"CPDOZ5O7P 873T7B0P%55:8YLK W,CQ>>SSEW1&PK]&:-M"0T%,9&L]>0E6..(G31Y",+ M^HPF+Y.,Y$;@
MA&;2CKK55[.5RP5S&K]5B?LMXD16=.DVNC)@[Q4^W(#H8"|)=T4 M80X@&\U.F]>6IJ?AXB;B:\RTA/+*.0*^>+D@]P4Z-)!. M$NJRS4$6-7$V7E+TFC]-
"W.$OK.8Z2OfCC@Q[QDY8N,ZKA=SI_2*V#%-RKRD-MK4V(DU[?S:!=Q7H6Y>FA!V];@&1R.5<5 9RL*C!1*F[8LR>^CN.D;Z-7 6=&F M1#SXBZN%K-'#FFS-
4WDA;DGN6EL9%U+;=ZDX]BV8K((]BBIT,H=8]P M>7P/Q4X+EC)Y22<;Y'K8<5HIFSTO=;Y^JB1DE-[LQUQB) F}])(>S?FM2MIN
M(KO(1/4T.K$R[']XW5"0ZUB[%>5Q$8SQCP*Y&P=!"19Z.C-HL+(-CSZ@I7*[M-;.=U04:ZN6VW16I*')(2]-"50-P9_WZ'!NI,__^=/[O[?_]^%-P9_WZ'!NI,__^=/[$3_\X;I(YWO[MYS]
M\>C?',,W)^_H^W?_>OGEYOHQ]-XMI6_/O7]&>)$5^>>W=Z^^/KRPSZ+GGX^/ M7U[]:V_YL'_PQ_.ENC^?ST9_79W/WBX>[A=D?_[JY6^O_WCX^\'1E]_.??KI\[>9_?=_
MT"__^O;Z^&3TILUOXX>/RZN#V!N]^V.RW1^.O??SY][KR[>?.Y9?W.CSV]O1.MR;[JY?'O_J?YX=X.8H]^B[^\/[@^_^*=C?9Z\LX\67][:OIV:OG=/YZ?_>OO^ MS/WR_K=O+]^\
<5\'__WS\[=O#N]_?C/Z.]+SY?_7YT\';QZ45@ M+T:C@_GYGIQ9=W\T]C^CKV7DQ_G]Y]O7SW[N'G=X?W"]_>[UGC^=FW]_M[M[TI<;Q_'G^>S@+[X].*W#Q_^;^?@:K*
[VV5O7.POk.!W!]0RMXI"A7KAK>97?9EE.M]&$][0%W]2P_P* M>6J?AZ@%0LI928(R^%V!))_&K^KO8)2[>7 M2>O]OE=.G1$TE\USRA*=PX_W_!.;@-^NM1#.SA4@]
';Q(=SUS:R[7@>)YU] M#\F"$MM.GB;8SQ[}]A$6\Q ;F81^9()B:RN7]_@)"0P1F94.NM#AKZ>$[,R^_M&@.O_\I4F#321U.V<:URK+$> 15(JYK99 LNI7AOE)Z4 M<4);1C!
[;ZN.W.HY:9.,UMU$@7!6%Q3#1VFB8M9NZ0+6*CN94RMTI0IDV.K) MF5QN+9HK65]BC!AT3*^HIL7:N2DZ,?TAV,2 T0.###^B-LFU=F%@[MH&=VFCH M2S?
##*B=1N<.:/3J{O#2-W5RM!MQ5%*R XSB^DR"Z*B=(KF.G5D"\%XF:01=. MYM?WQ%N2\\"/[GK<+668V9*]5%N3]&LY,>*"%LBMQM@?Q*+7]X%1/XIL%"1LR1_#,A:%
{00KES>UCX5RXVQ%NRE=@!3$A18U M4^2_E7]O=1=6=4TUGV>U]A@$]"NA8;'1ZJHP(@YP,A0'4^M:.*.49&5^6Z27 M8#W\'\NP@%K,+*R{{-95Z[5G0P
MT$HPK.W#/>*$9R1-YUA_A$DQ:9=T;U$F0)QD2@"&-+?) *PW$N]:P^.T9V MI8 0TMMJ8S(E'/S%52>2I)D2^+4<(:14-M/9@D3*=@5O!5$^81(.)I1,21$E
MPQ406W6U%26%TH7 *($G0K;B9+1>(1144BF//PK8-;N!+$H:CO?8=]#K1WES3 M;B&G/O-KXZ2G^*#BZ(_3ZSO+3NH?A1> O2<@+G,<(P/;'M]G"'^"B^3X^@0R=)
M]SB%3X0O4.*.EH1;,W+"5^.A%9%CRZ4?+2\&+VBR#5,R>6]Y6&67T!302]-5 M*R^4:>7=GXX>F.ONAB]!T7KCYPD990-@0M_V(D^AO+]REF9!+ZMIDZW15D5>S
M'NF@%%E5"W!B]?.FF.P.X:Z.;@:./(Q+2IL&XS2&IK]4_6]_6I_JS7VZ;C+ MJO/ZX3,CZDQK?-SV."KYGN34&_&>79%-;GXX&QV0S/3P'8P[T1/[BC;9E(9* MFM@?
J@N,?:,3/P_%13X.Z)2X49.!W6*78I/S'TY#)]PSU7T(^A%/H,8DN!] M=L!^LM*D?AP,D90E?V%I*[_48U#8.1MN'L^3]N;9S-M31G06;+F3>I;@DU'/ M"1_&6(4E5*EK'^&%;>
S2A/"%P+3A?'TV T9.CQE#'C&'1@QZ\%I*DIQO7GQ7HHE-BWDXB+;.)BK M27/M0*'R6*118=K!H1ZO0->@0]P]6" (=>H0: M$,KDOX^MH"1PB1=?=.3AT_F5R7!?
R8N6=$!%'K.:@QX/WXT.*=M0%4$0IB;.MC=3I$6V!2@X{$_X#CMH\ 0RXAP]\(:?*/VD!7AXVFN]62?MCT4_UOTK/E"O.M-=94!@]FH_C:WT$@X<)>)FVTA-G0SW":+UO<
F"O&%>&+P+?[O+% [ZFNPZ)(.MM_!2>T(6 8WX+?95FOW9=J6M]0*5#IW28A(Z]:U55M, M 97]Q^R/N%UBY3GH/<%9 ?3Z?K$*TC63VWP565'Z*!.S]<4\I7P (>0WBVEA
MW3I]M(I57A,E\,42Q>K)DE%!R7R{R) M@<'4Y6X(H"4L7\6W(:+Y]HR^!449H$Q656YHO8@*$'LU<;XANLQ.*AD@_2Q M+525$KR5]I>_66.E 0&XB>*QI:?^.7$NDS.=
/=S>\8CKBMJHO]%,,OAYMR&2VNO$*'PD$)@3HA]I.7QJIG.G F*7SM'-M[1+@@-9&S?CNKHQ:]_QD*LQ](5?LFUYIEPZ,FHB240] $S.AY%KC3+3:@P24 MN#,_?
6ZS'Z^IY8>6S0F>L$F>!6%XXU-B>>XW IV4I41Z@&933;1R[4(T^L3R M2D:<_U/?#N:$_]F[#? 6#:2&2!NS2)#BOZX(!FE,_ANVN6QA^DA5N2#D]QZ M8(7"

*'_X7E<2\M++GRB XO21\8L1@:?',TA;F22TI1)}D2/!#@(*)N=%9'" MY"S&>^"S&<>,V2RL(?##0Q)9KK>>,52V&YU9?K;/.{)AX+E.[@-<,M(#9)?|
MD^<>,=;X'<[J!27RH#X4EU-3K$_?.(R9VG4=H9+HP(SXP<3TN_$DPW)/9/ MLV#)],9-9\I^6$]0@83)E0>J$WQIJH@6M+O2|[;-@2,GW@?A'}DFW,KYQ#FR
MJ,_,7SBRI7@>>XQ%=OZ?NK8+,6LD")K,*9> M<5\@.?_6BG\AW3@SM>B>'4+WZ'L>PN/++AE(+M+UWYT2R^*B'\FNC*^GI/
MTF.AK;W&2$DPO%=UF.0%UV_@9$BC/\^M+P$]B,.({>54.M2(?,.@JNQ?:S5M M&-1@A)&6\G+PFN0#WO:%$[JPYLSY+9&3#RMJP:-Y;$,A16+-RV4O$ GHJ4!(
M2RZNJ!L 1F**.F(@%5:DN>4RJ\O6=/1XZ?'UZB?5C!9IN:-K]G6$@$@9BD,T M84H210ED;:3,Z.($3LI01$Q5DXJE5-!P*1B+PD2Y,9&@#!Z!*0FDP7A,/!@Q*

MS2L[1]J,6'K#-G'#KVAF540)S?7-MZ9" 4I4X $!#D.=2";^-(?Q1&[MR*")Y9E"&)M+/U8!VE!-I^IP@+ M)IZYE"&)[Z;(K*:"ALL!J6A'L9"$-Z>26)]UJHAPHN4SUFP%^\2W[^86_=J/ MXUDF|[2\SXHHD>K!;1+.R?;CAU;);9\S6JO28NRJ(NS/+:V0QO=-:_';-@>U

M,X0(KB[_B)UPXPWT/K,>;W!.9D44H('HJ['E4P1E!-U#LFOK8\N&]1DB=3_MNS(^R$M*5:*&'DYDY(GF2_'8#)_]^9&'KN;!(./;D/$>,M-D^BO8ER]#%6#MX5$JI[]F+V40)'..AF_X838Q%URDX>"8",9DY!)^1I%N)K%A5:1R&*:D.6% M?1 (!9UZ&N:2_720:9 3SHDR>X[>X!,%G39]6X23V-:UB@WE^9"W+XHC0E/FDZ1:*_@L(F;-/FNHO$AITDQ.N#KE='/NUSE?M&MC\CAE+(Q4__MF.M]S41A:[P4B5S?!\K27'}G0-(L3!36B)2(\!X_ZO(L?,M(B6X|@1;GBKG=M>?,+99D6OF1@U|,2:'&>P'522F3KJTC[\HRAC_)IN/,#K%!+XVVE4,LSQHHH3+K+]EJO0(:BT7X4H&E$ M2G+&BI-B9&|\UP^9)^Z@]/^IHV#P3(F"8*T4<0K-;=SP7!+*?V'-R OLI|XB M*;.W+S@H"D7;ZEW!//KP6GAT"5Y#4T#(W"4""HHBD. MFJDA\ 078)T848K2-=Y>W81D&GMG[A3.LY&A^/0\&RDY(Q6F.^;R8^PMB7/* M;+@_R%,DG9F[EQ"Q1V$[OC9T3.ITO+)?R>,:!)T!GXWME Q&0!*

*M$10HFX0IT>2PGTHAN3E9F1'+=R9!G/ =7I"HO5@(Z&:!5!BMG1Y0Z5Q@ODM# MFUPZ')A}!2@I1YR[F"+[)$L[H]30(\0UWC\X(\2(YOM 10X D7[M1+C5)\W#&$#NA,KPU[FW5! *J90M"\NXFR9'VCPQ<0&#F^+).4B#? K M1[*_D0-KX4:6QX>"V3TO4A'M0S(EE.D\#^%DGF.:44 I/VMSI_23&]V=^HZ[M=)W8\A+6]ID'ZN2MS3>.WF#'+B"VM)$Q!!(5XZ4& 5IQVRL& D-]ZIPI(S$ MNI>,U%)Q'KPYGA9FB9#$74_#:,JBO X7C62#L% B[0M4>$';?B|"WUK|L-'[!MB4!6I6XXA5NHQ:5M3E6J6)E(BHR)W5K 6PTQOL+8[D\;ZW #<*P_'T4T(^ M&M/D:@]C2$8C'=.E+O7,K$!N: T*:FGBE,,04#)=";--85M1PBXFU$P3ONQ%M&TYF*UX 087257QT?3Z:44*4$M%]OF0P:%#3_.%I&,;@K2T%A,S=+&.I/@ M.(Y"'G/@^K,>|"Q2^WY +2:@)%Z^R=|WD+C!5$2SZB$16:ZO}/OML]I7GE6!M_T@_:1F[7W)ZFW|M=,FX/SN_M+;\D0J1G?&WA;T'J M>L6=%9_NM1!NZ^2M]&;?/$#?S_5PL)8>Z@42ZK>M8S[/M$'SJAOL&?\PGRC\ M0Y*(DN%"ZU*Z6\XL%$@-ME!2"TF45R0QK1XQ&@]>D2045@(I^;2 @Q+KCXUX.8=D\"JR0:H> TKIADV|!IH_W^'Y*

M/;Q2$XII1&'1K$6MU7NE|X46+$AO9AC,@IML-"TR:NF-!): .?TKXK%?STZ(MSPZ_+YZY,R93,.DH,N29/E^.!&2:K2-WCM+ ^:4E)5"3*XZ'QM|>V"3O&/E#MLB1>D"2"9K11Q6A."P@I62($_QX-%]XP2,AR>M@>E>% EHS':-08?I)180% M8L99E@FAXIPXCS@65D#)9+&!OJ 52AHZV9*?.6[\)0DCXF0WRJ*1>_7?>\H0M":0%7>*X|VWGNJ3=>%IX+$BT*RLKNBW7VS*L;K5:*=TX]X,L4A?05>!/%BR2 MQO]D\)2(.CT*(>:G_/+($+]1*DK[!UW87\F)A17NV%^:4V M^_$ZX+\J:/1%C.%>],7VDU.]_@ 'CB-$GL#1 S/(;L@O:"M/\=E?R"5UP6VA MXKO@C%; M63TG(;?GT(K(L>52C 8%/3+ ^>)$UI3YC++'[J/3E!R=^)4R\CG+*-DD3-9I;@ M*(VLO-OK"VLW0!'>F@,C+4'PR9T?9(0L48&XTZL$.R,S=ZM^?BN|DTPEO [8 MX;KX]X,@C"Z"Z \238@=S'SW6Y;/EMDMK!<.5)Z?

VN;3$]*9GK['<==UD)+|\M'S|R\"K@*'5.05EI;GH'BUM^>RNL+84>J9\45A[?>NXLF0Q.G>*SP)_Q}(1# M7FE722(6*%8EKU_0BUGAZ9OG0J<>%@8V^>NMA6"[>M!815L&,0]fD MA(!W/ZN./G! -H2%\?)\Q*S>G#O]JZ(IG&F)[^>&+YH]&.D+720+G.9R5_$M M&]CU.<'}@-+@GFT_IWY$*-N))NRWT+Y#*[VA8J<@T?9G#=4%=, (D7 1)*\G MY88(9ZYUZWIN]"BQG*2&,7F5VFUIR4FI]0:^>Q^0W*C>(#?*-(9^#XD$!, MJ0,MCY2$(2%EPNG!*

*[SK@DTG6.+0C*D5SF$M04:ZM5[JI)"FG&9VG_C1@GTFB M;9&2E%-"$[+@A=CYCK&BN"'>! MAER"IDVC<)+#I&/Q +TG&BM LTHE;I&! MF53B5>CX?LS4G"W#C,T0{9].3 OK4ELNN4Y*0N& $HAV5/_G#B7R?:<$9,.2F_|\MJMFTD+H%G>\9S;,%[3# 2>U;CXP6B,/8^?=J/$OEGL%!,D77.);[LRW83TWC?"L$0&RZT7M$-*P%.URDO7J94?"\I"-'GX[-NLK)$EQ=';P,_GW:=DP_@(9^-C^?2TMH_Z] MHL[6.OKU$D3R,BO$4/S[>AI8S^]J/K](74M!'?5R0FG_5$L+,_30B,IV' 4Z M 2-;"JAC!AI*\O'F^";O7(7VH2$K#.7LL*831H%S4++*94 M2P_K"J*5G%8+D!:AR=Y#2 V#YNTUWD'(0I3?1,A) Z"M,*3"(=Q#B"B9+5JL MHJ_EJET"V2'=0#301+F)$-,R6VE30F\EH,*M72PD"GY#T8Z6T:L*2,!0:A=S M2W 1T"CP)VR@<BJ[I=Q'/++|\R[':SBZEG]XD!C%ZQ)(R{?GN)2,1G-5S1F.6 MA]!J:CVNP?B1H"2MW7X47?Q;4C^BOD%Y)++(- ;1#'TO$L'RA1O)Z,1Y M-PA&.K!.]'4LM6V.JVL!8!5+!)YPT@(<+H#U(1>F;J!@O3R^AAY6DB'IIH=Q. MUU##":%KI-.+6R1Z61-K9PLT"C%UL/C !]B)$#+YP : CYRWVBE,(+L&3=Z3 M,$,(-NC@K1\<\|8L,*0^'$5"*+:MAL#VQ @WZ67-%7Y)0E@&;9,6N"5KP&,, M@@3TT, S7|]7;$"S)>@:&"RN>,4AJ^E8;"42)O#*=C0%>#0JW:0]OD.RXV^ M"_H C$T|/Z MXTC3W=[;L]PH,3UUCJ22I9)[/(Z)"8I$2;199)ED:?&O?TB .P$0!$F W?=] MF'%+(H#!N@1QXD?A7_]XMV?WGZ!<.A&GA_>__6+VYO#Q'9,)\RN,8PX0_H/7#'EU&C^C= MU^C=^Q^^_/*'K]^AV_4Q^O+MEU^S(?_K+X$?_G;G)@1N,/DKU|45GJ^BX,_ M1?'JFR_?OOWJ3?!A%^S+'Y[A%[7OG[ZB7?]H[__]&_K7XM/$YWU(IGWWYA\7 MYS?N]XZAWZ8I$[HP@*)_T-"?WD>N4Y**=D)%Q)^ 3|=YI|=P]\.WWUY^-6[M/STGWA>,;@C]\8X"?(TWB$++^0_JRPW_]O&WNP HK]IB/&&#T@0QV]@_)L0 MI[# >UC@W;>PP'^07YT[=SCXL$?M]=+(2[OBSG8@#=_&Q6R>Q"*-G3TUWTA MK QZ4U P@) /"3P95/"MA'%T]DQ,*ICAYQ2''BXY S-';NV; ,0BBO.!=,& _M?K%/#N\=9 ?O19+@-#G>QS$.TS:)$@(-A63C)'<4G&S&&]@7;W"0)OEO#N$W ME$[\N1GN.9 10W,?(]^T8,@:90Z0<:.;NS^'=P%=)>1KT#!X/#P]N:+OZUA*

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|_O.W<04KD.B4%!*! MHF6?HO);] M_2^[VE:)?W7G.O[S7CV$D>KN+HT?>P=_1RFV!O&>19> MA86;^H]3/+3V6-B\UT@=./EK/9D#[?#YZW=$HXKR"=(@[-*YUG?DAL2@O2R5MX M-M+) .Y;.G?9)! IO44O7LO0C;&3X!/_GOZ[9[C[XYN ^$=?B:6"BGFPUV MQW;S&P9^@LM2UW8QBZ%@R^4CX22@&|_;Q[#3^)Y"&Q19 A>*=_F4?DXCW]Y_N75?_PJO5B^X9C=8#MLW"=:,]4/_^BJSO0M3A-'M! MLM#(EH!,OL50"(3VQK\/_8WO.F&*RL$H'\T54BLI6YU\K*5QRB%A$$SQ]30FI2 MH*=#0[CJ@-0.:+Y_F)C#TPO?+5--#'I]772YQ.I,ZY2XQOR,M$ MGP>"0&;S3T4:VTHPI)A'}2A& 9:Z'H2FIX*YSC/J3"8M*FN.[L ^62X\"2"*C MP'W WC[<)_K$"T[8;,]#&X$S"]21#L$O93E"?61A8>1ZO+=.LBNJEF3X1-;W8M3F)6YNU M2@+7H,,HZFY\$T*ZE(U$&AE G4H.UY7(C@]1Y+#WY M04"F789HDS9*7[B)VX0)?L83V01]5O;[.'4"S;A126MG4[S<7)K<;V67]^; M//I>EOKT1.:+D) "BJF<+3V6-OFXV ,_|+MT$|Q-4N;R|)R%"-+9^=RYITW72!UZ\E634X.0J]*R*[@*:&N[>WK%F(+JL]" M"8ANH%1%K.GKFJENT]5I$X6#*7@R(I>/0Y.FE0J)9$Z9SM4[# ME&< M9I$Q6>F;B6RE0."8->V'@*I@3<$(E]A0U5E0-LU,'K;&D!O%PT^-HKJ7 \G" MX[NU.A:SD!8AATB6.60|)TB-<8HR5G5?#0C=2ZZ<%P)LU5>T)]EV&JJHP]>EQ'<5,78R M,9Y-MX7AL034&|U29LMWM,TRA**H72_\(1B:KN89N0R* Z*,#$(#+-2_V5V1T_YWX]=:-DK=W3#) 7'&7Y.)0-1*?/:'-!!*.K MV'>]O("C[7/6\M8PK%K46#Q)(1O!)Z2\KS#45G FX?C_R_>,Q1O_4REX\!) MDM4F,XI6\36L-D&*B'@=LRX'(1RB>BCP/=B0V0@4Q8B.F4,Z2"?S:I5_I)CK MRD|9D;O:5/?-0Z@7_EQE*0)W0)WE2TP50;S0&",IC8/@U7FRSJDV@;E0V83 M&#Z.]%1%>@0:.H9-0I;8&L?;$WP'KZ.9]_ <$K)7=X%_SZHC323F/1*D+/_2W^VV^&T[V4ST-]%W=_MJ/KM"9S"PWHV&#'QE6I?FZT, ^XD"M]%A#Y+!JE>><)!C7%\P?REX]:XVM6%67 MM1"/IPJ;M*;WGESF$OH0"6^K5%!Y+ZPV-&M/CM=T:A_2:+]fX7N8YQKO(-PT MO)_J/56TC-%>+P(@1%]0?5ZK&#F;(N+;[7KO SO :%N147(HWWBAT1:LX4F M[1C$7)')1XC0*LMHI2,8W;J<@(Y.M!ZO/\?L32%=?,"W/EQ.G+.G;"\-K&3.<5Z5S.Z/VR"QJ! M&&;#$!V']@/G8U&|\K4J=4KDT+PL4A7[^YY(I.GCA,YEX3)&;2H!$+(#DWZ. MV/=5<4=T\:QUA(IP'I*0A.\ILHMJ4|^MHQT!V;7UA<%T=_31L^317KLQ/$+ M,9*FB/]26]-\7H<27'T[+=E]*^_#W6;"#52C+R]'W%|%XW$)FD7)/]/4QZ? M+-UQ)F>5?KS,S4,4I_"QUJ9TGO4V(8F;PD+]59X< CC#LBGAV3&;=;'=FM] MO\L850_A$F Y-./_&KN8B.!=@*'-Z*11GMREILCK5$'T'Y '4E<@9%V/0]P G M">L]F\!CPB;*D1MCST]1$)&3GP9D_9_09^E:_^?;;P^^^^X;:)UY0X0"TZC_ MK]X>(* 7_>*_]R$N?G- 5DJ@C(K_B(.7UU9[H2B("B^)4$A>[=!Z[LPFI-6\ M3.[^7U>$*/QK?6K/-1I4ME M10N'])8PBK1=*1S1TL!M9N]?5K5G\CHZHF4L M.7]4B]^0#P_;5WV1+EWW%8C4R+(6,E<@R5PFK MC^A]0A{M?C6])BM%)0B.G,84[UC,@MJ20R27'T2# 7#*/9K^\9:T)\#P__PYC#\UY#T.\/2,@C0>&HSX5/ ZHH5'3,Y-%R8ES@F.DPFN3GPAG>X:U;F>#8]W)U32)+?*24(+TH/^M0D8P7RB D2H9T3HT<8<8#V M8>"3[8L]Y.S3ARCV_R#_3.BG/Z!OQ_WNX.V[KZBB^OKK;P[>?_W] 7+HRWS_ M5_@#Y"<)U/NE;UW[-$F=5MDA6^J.)R5-'=>B]"B">>7$]YBFE'ETYBL<4T9- M)ZO'"%2WX,!3 D@MUD@EU(=`5IWE$S![VQ6N[88GJ[!8(G90X0U+-LOF9;E@4 M&N VUPK3B;%X28MJ5B4FA3RE*EM2TZ5PP+)DU-D%!7(EEC2PV%J>%% M$,"B)EGLO]D).BN1JO--*D45A&WX!23P|+P!-UR26[=1!E!]R U_X7D^.$2<MX,KQO668%36JK#9V]$WW@N;C<#IA$@49%@,11$=&5A0%96-M6[_J?*V%ZJ@1 M8H#@^1JGCA]B[!2)H?)NLG#=_79/$TQ^,9W_?%3BSL7-"YOW3")@UKS#Y'' MOK3[1*[.SGI&L1+^PQJ4Y3/2Z'*IL,!CC!QPFY,ZZ#-UHB\^C!#H$KC9KYWEL M'==S=2N]?_I_""".691K=1[DTXFLJT(]66B$6?U505Z[:=[*&BZVF15C7X=]LYMYQ)4@4!X]4GH(VE2 M8[<5]YO#BK]MW<1F/ VM'EO3@H*,"_HE]IW,3%^Z#KFY%(^?63["5-4@Q.O8 M#(9K B.*!L^_SSN-VXX)[V(:]WF;BZQ^::,$$X@AV?B$2&(0[>"-,UMB]%-7 MMI:%>X<$'&%5(S:&/N]XY2CZ\X|HL!DDG2NQM'ZD=Q%BS$-47>5WPL4[H0<MXG@GLV#.6UW;^@,.B48)H(&GM_5#'!0)/&).I_F[5C/1'M(!CV#_9Z-89]?: M.*MO;XJLK,J5"OXC'NGJNUX!,-Z^KW)F(>",G2T_#7/>#G$(G6!R87=]UN.' M++*%,,_Z(\C;WO92N8=/1)H1$Z=RB?9D5).8?/.IL#"6H.1#LS'4K_]^[P# MQ(FZ#,25FV-GEX_)#OZS/911&^4V!^>+R#/5I+H3=Z]GPP'1")*M+!9ATVA3R_]JKS8LS&Q51O13.9WH MY-*#P8;<:4':U:K]10I6RK1Z:T$SLBE$"F=_4T#G(Y]=3%>04"E=M>KZ9^>&697"R./.3?4PF(F:"[%4)?;KLRB^BOU')\57@>/2]FEU(2734,%[M^_ZKMU3X].(A'-_PZAC;L8'V[VH4=.|"9KW1F)LX)@**M@N4#K92[^NL]Z?]PC0>):/E[%'F1LX#"AS\U5 M6*ZAQU'BI_@&QX^^BQG,U]B-[D-_@N@04U!;Z2!B!C=9S9S#.YB;IB'E*)BC/P 6 MCJ3^4';FY1#;!M3^C)0"_]0(}$HIP]LA]#U:?.5,AMP'=D5[4E M)";/SX6 MH@"6%&\3%%8IBD'K@0E#*R#^8/EA>4I9$YX88Y)ZI+A=\N\ FPW@%2YI.D9" M!:A! ;V69+L/?T71I%)ZZ(=4\(VCL:_$_$7,/[7P =&UM6U<8]7LJK>-%**]MF5A4+\1[#8\SJPW1C;2I354DI\DTZKV_6K;W4"J.+-H@ZY7M^UN1_8K.*O+ M@+B@LR*-M"]?MV&,G0"JO\'1O@K/HAC|JR%K5>"'^G&#Z3N _XN0(;\C?QB^4 MH@.!Z9-7 T:!Z)8S0>M)F 3A9_>!?(0\'*M=)^ .::B*L"ZY],HB-D.R9]? M/L9^BD^BI[/:,X"-A1H&PQA('[V(7[*+P\]\JE=V1*SJ!E\ST'01DU!/BB\ M#*"T>L9&WQRB-:%<(MAM8:^29=)<=PHTA%3O(-3*&<^T$L_]6+HZ9/W(B3TB/ MAK]T!,D@1[;1?!39A+1ZUZEP\4/=1&N+_ OKXMB+3)|&?'N5O,/R ME?,"FQBNF*X,|\GO5!U>@C:40BB).\083>]=# M!G@Q6M (XM- W506O MB2P]V.*[M R_:,Q+2Z"4?%F33^-=6D$&%-ZENTBD^RY-UG$Q]I(S@@K4586T ME2A.USC>EKGM8QNLBHO:<)JH@28I3$N+:*00[+6EERRBD%VU6@_1E^ LB)Z6X2:*MZR(UD1],Q57-9];H@:8Z"R_O:HZ/[TXO5POKG|&QXN;OZ.S M\|5'M+P\6UU?+-,+U>4/MC5F3X,78AIZ$$?#?02)?U0-.WX6W+]^R&*|SZ*8 M+XGPVII0B?SN9"""D8@-I0J.#8;WW1^L!)[W8U2>TZE( ]U#E<4/ MKIUGG,]XWMN:K-,L,,:(@ON;3('OW,,E:"@!\-1TL+(WWVLR)J,!$QYT9G M?WUV*^RO@=!1'|^V^XW+C#KOV^AH-R/-SB+H24_^6;H|0H]CPI_XB1M$R7ZR M GF#P3%N]0R%6,D<.EG>')^O;FZO3]'J#%VN+@^I@;2|_.GT9KV_(6ER?HM;'FYN#RF/QVOES\MU\O3&ZL/RF/)5JU%R1CD'M(?KO[SM|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}6DUIHH&[QZO+ M]?+R%B)W5U>GU_0/-[,/0S'_:MF??.SU8S;\^] G.MT)T\Q7!B_T44"T/$[6 M^#D](N-_&SMH0VU1*WW$E$ 3A6TL/UPNSY;'B\LU6AP?KVXO::SXU>I\>;P\ MO;$=P=&+U;40#G6BZNB^X"]/23?+\CT'C1N)/KQ!KOI$:6GSZ[P=[#'N27 M@@=K=IU3\5YMF!^C)A'9\ "T4M1X=*=%6R!8*[V|>,O02|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|X%?S1137+_'$%HH6R>5%EXID\|NN+ MCR"S5(^FVO68ZLNM8\?#60,+M'|]M)YE{($&I&I 9^@'?O>;]"X L\DZK6% MJD89RTPDKW%"C [W@0CI"7[$040#X?(ZU0K1&FKSF/31*D,E+HA#%56<#;;: MRRN\YZUF;):Y[,6]/*Q#G2C:[MB&H!I10[/10'+E4V1\$,%BU98A\J6O1-(SLJ*UHPR!3 $HC5Z7871 "\8*N^6M8P_0'6LGQ:HKB 7.@KSUX'E5^%0I-,"*:IAHDRDOP3IV\KU\8#J.QGLB7;$3 M4.%RO"VDL*50#.L1\PY'.TI-SLV&7I-00?MZ"H4P']+ (TR #(/TA1RX])=' M3@*165F-\JFNI'V7MQ*LW1-(T=WS[XOK4W2\N%]N%^_TY03Z)^N%,'1E MH':OU*'1" 4S:+W@VKJ748H_.G'LD.56,>V^:R#-H"\<-DMZ]815P962C459M@^\7VS[#P?+!=YGH$$[3YBRW3M666,!*]S3.]^BEM;L63T!L,;B6(3G]JG3+ MT6*BZPRRNZW-!(\ ME[V#XE^(3H<]RZ5N#(MOZR@RQ:D!]U^FX/R(02UA;_%

*(K.%[3/|X0FY:9XX? MT^Z]GZ@.Z,;+PB$[%]Q%=6]R<2@;B$Z?<>SZ"497L>}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|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{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|%Y@-7T6O'FK]11[2\N=8H^E(W$M(*[QRQ]GMJ$\%P91-M(X?L6Y1],/?]TTGYW!06H]@SVA@F6Q)I\: {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`44YD)"@N: M=&QW@Z-PLG?W*)S1N:[.<26]R\&3:F:RD!DZ2K#8?'0AG2U?Q-3SS3G(.RU8R M:GQ* !%%8| ((S+EL#{J@?2_AZ4V!A;6LU@[T=?M#\Z:=XE"5+&3PP58_M17\9:EWF9R-%PE.R_VQ6R14@FV/7LI/LECU.=G", 9% LAT,K;:7 M0[''K4]? BH.]>$#=4&A80/DK.I@^#CI!UMV7H3?L!>P>B;VAT7S+)"=Z>W^BY MW5I>%D+%ON-75Y?G,=^2NN%Q M@U-&OAD+-ZA"8/"'[@Z=P%\WCP8O)4&6V M WHPYA'CL_*/!82OJND'RG':\!166?H+(42+P'/]:G/A_!K%>25$]4.V(S!(/+<1,TL*0E?U2LY1 M:SCLIY,S><"/:,]&2K636DR8&1)C7W"I%#F/F\GREP,-Z@3@Y M_KJNM >X,2[#LNW&:9+Z1(GAZ41*94F3{C4%>$0B1H!T3?!4R3.B.BLJT9K1:F*DJ 5ZF>XY&C[!*#H_@:.MI'BT6E21F^&1_NDZ +K"3[.,L3<.N1 @XD-M)3;PTZ@/<^/>A MOR%XAVFEA12TB_)Q*"M*.M6'T&I34+*S^OT@<)U2E-0:H"%&@35,2?X:7!]#0F%60S<=!5! MT4CL%%H-AI5K3Y9U)'?RK 7-J^T)WN X%C[3?_33AV7H^8^^MW>"UI-],I7= M,!8Y@L"?R:,_^Q\"_ ?+5*Q10E\;:?6G:AX*.T2R>P*2]+(1" M(7(U'R8WDFW8R)W,]9G'/UJ- X)/]"]/J0HDUA;KHIH"5#B%]45IY01]'U.F,0XVG.-69S!5(4X1(W*TR'TV='[7QLJUO>.:?WY MLKD'<71?&Z"B1FWFJ9QDDH4,AB>))H= 2L?FD*7? SL:JS.LB@[Z&]QH&3@ET3 MIR^5]X-)++O3RM4S>$*60"-L1T3&(#D*543.Y<2MQLMZ#]{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}?S(B:$89OP"' <)QC2"/6$NUTZ3CPTY0&R0W%-KX_ 18\0] M>KH(8%(!-JYHES2F)XNC359ES "Y5_MNEYG0NE1?%B%";$)4F1'*E9(YY^*\ MU" ($C[T#*&K6$NP%Z)@LM_N6U0OMP0RV<+NJYZ$09OEP$;2>=\GAQT8=TF&H M')<|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~K6(VK3=.FL-11*D:Q'HN-EQ#+,# Y2K+@O_PIT,%SF6U)IL"OR MJ[5*/L3*XT$;M#6(E#*H307Y,E")=M"L\-]IK3N0#%ZUBY6AK@2'P=&$C(K#.O[]7),(YWI*#G+!X^67#$H)=/ M-H7@Z7-.CY\-7'N\?G*I9#@\G :GU;VMW2$)>8!>PQLM"CRP%Z0G0HS')!52 M&%&6]'Z+(>_(#*&S95 **%^]\!FH_<8)\YOD>I{XWCXU]]6;]V\#Q/DG)80V* M6F[TYA_"8=9.GS==P[H)=97D$K3,:C&B0BMO@'$4DG^R,CE)+T<5G#7E1*@^ MTURW2U_D>9M&CX!FF7R"-SB.A4F]'_WT81EZ_J/O[9V@'1]VWM4+-I]? G'7\ M1)9 Y1H'@N"[(S+C-,1L O;;(RK05.;T!0NYVL(?&\YMJG M!0@.4#[$L@N4CP2_GBC#V>YS*@WE%>>:-.8ZW)95B AV"MU,6'TOF.82)4&4F MNW:H.L:*+Z)2>AGM?#-9#<2S*-Y@/]T3B&V6DO0,NI M,T$A1@ R*I_!{,=D6^<;]YH\"\B,*T4*,);I4.0FB^2:26'1I5%\;],"Y2+ M8[$4].5*G1KGG2*VN+ ^/L;W1*#((1OI8>*[5*HJB4+V558:(RJ S#,-*G:^ MJD5Q1F"14#M9%1F3.BEW@^4]PKIR04M78#YB1D\]0FRX2DJ.NMEDCJ+0RPV^ M:]FYSNO@+\--%&^I"!*Y8W_L54LG&X.*&5%ER@,J9[(O9,5T[%,3Z444[HX> M0E]CM7SSBI_>@N@)S"")M\+PD?QK5'R.X'M[3D0^_$U/H@Q+T\'[T{(EBE^N MG;<+ E'L.X'P0EI\?(#(YZCXOAEN:,U)T,)$Y"$0H&S8,BNKAT"]C578]#=R M@FDA=)]] MXAI#DVJBC:N/WNSM])UN8GLQ9RU^(']MVMAMWJD> (GO$#W30U:'\!=]N :GLG M $_761)5<[>+K,S.IQY!6&"]BDS(S-4$5>NH=*'3(9*@LOT0!7'Y]-B@Y9- M8/.1UGJ?C=\:!]IU1EVRS[]"TE NOS&*C7LL,JBP*R{) {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

ZFTG6$;S.5OY^'"7!993^C%-B)T?W(01C4 = =KU1B00N M;K;E=:K2V;+9\A)6)'|-T0N&T+Y\T8-FN3D;+WLF*.[]*33'2N.M+1,H8NT$-MRJUU'Q$&P19TJS#
<4:5V55A$^/&XW$7)4R?*J#/EMN=X\>P88^)R-V+7[WH-MUZC\'&?7V^_NW4)!^*0H0-.$>SF)TW]?D%-EN]_*72_91VUWBT'RMH"M4E2
MBEPC<@%B$XOCSVW"'S> MCT!-M6.RGE!'VZ&D94#1HP1_XCIHH#M$O-7 M,29*V,OS5NA]NV=[^6R*(HGG@#VPSPKW5##EDKJ9%LT0*@@ZS;G^TC
MV!3IN4>V6;X;KM1:[]*|<-W]=A] 3M8)WOBNN%!TNT7U]\[@E(U^,5EPNO'C M!YJI4<6@E=X^U/+|\+4ELI>#$KXRT?DQ(L%([VUMDF,M;0OY >[)GU3H?
8BQT M'_=]26"53V'&^95?SJ2S%394FGLV?S8#U/J>*2S4#0 M*^Y;L^FP!0=5Y597LN,-D(^\Q-D;,H M/L-B-5=4!=U$<29Z\+EE5=8 GJ>ON/@9CVBC)2G
ID@>L$??++!7*<.3?LT?. M=AT.NY4X:MB(PMA$>)L\XQ>>>Y\-&= *X9BS#8V?GLT?QW TN?,\L1M(;"MPR
ML|\0H%"^"=CF23>&W.=.1;H8]0=D(M,C|C/;+#/MP2;"2+IA1"__G[Y/F)YY-MR3*KT_$)%$5E -,7I:R?1]_*J)^:;[DG"\WZGK7DRVC]8&:.K*,LCK!/S>C" M"$LCE
WOKA5MU3"3HBDSUQ3H8[]&-!,ZV]##)7#YC_B*\"L+W-*,B>Q(7IB- M*I'BKK[I%4AHO/\:>ZH%H^@22\KI9^_6S'=]^NP&>XB@R"U$6]TM_^B 6_+$
M=DF]&IZR5^L:*8S>G3Y&\6\X3JH24SC1.Q+@LZ%9?%;-2JB\/S2SX2TP0@%' M'G.426,VA4[W:,\.\)]8[''+HY=WQUA'\JA*B5+XJ3V09%K8?@X4&%Q>]^LC)
M^Q/:T"5$GWHX04_2CVK1;;'=Y%5H?Q?%9^UX}3^*XCAZHC5UF5Z\)K>5I(86 M-U$QLNRY@E"PY0O1.69F&UN=']9[%'/QHF?N$$$_>35?
3NH'"3HRVC3K\/!2.K;$5+ L-N? M4\=%H;6#J{(-7&*A.]#BWCA5*%&_@R@UKZ:/2D5(=BGD2QV]!R<%Z@/T'Y<&LJMP_#BI=# M57H8-%ORT]UPF4[!K/I]
[],$]>P:QSL\S$'B(YB=F\^#OH7IW8OK#*<^!N[MBP;&56XE7I\ 5.DBU'&7;60S4-,4&RBUJKK94;Y=" H4L!I=[++S:@]/8R9Q4 MJfNCM<3&@A3]$KK9=B/.-
:909>N22[QHP<5ZE=HT(F@PI0$*9T1]XNH3M& M8%]A>[-%[GDJ;O.L*B1'5;F;7=:-KR:D-4(K5+5G%FVH$4QY& MFT,R*3/C4#XMA!OD$[. NV[?
E)U$)'VR\/@_F,ISN&'1*#VQ(2^]8S4B_.9T MR:*@];IF50CQ.3Q!5(?6BS=G03Z*8SCH^4J224XWV21EL3Bf*^WX.:Y-F49])S6X_;+)G-PXVDL18*8M95I;X;"C=>J
MKRV/CN-6%9]93+<2@CQV];"T>#&>OEGN>)]EKSF.#*M[%(6>RLEN!J,,\QJ M8I40\!7]M%L/,4UH'GTY6!EN)X-O.)6[3>XE\B)W!F1.XNN!A+$N(++10>S
M1===H=&], ;GVD]^.8^SY*?Q+7."S,@3!EP>(C+H@ NPZD$<+MU@GD]@09@-@(5 Z9P85(B$CS7M2!L>F"
MO0&-1L(>WYG1T;.ALUYWNVN#E6VGA"1W4_4@C^TJF.7E++LLHZ6K$***B+5=Y] MLWD$C<1G42A+A#,_]* ?Q6905X;SF#ZPE3(O#&$V/3?
[4V%88(+-5LK\9/J. M%FKU^@*'97V!V5SXI'AQ-6PW(2S7LF/>^G4$2:4TDZ%W_3HV SRY%'/,KM5- M"TL>LWJ0Q^AU,7"29+7)? E9T7"6 +3:W& 7>NZ0[7[L!
'H@V9U<>&5$]:% M^NVY5R4OSYXG<-'|L7TB,T/^K9=T-WVOAQ((NY5= RJFS6: ^A19A'>+42M5 MPH0V'U#[{(^J +H)6&.R1C)$?EA-J,)IL3]P--(5\B MGZ=T?
2 R$R)394'@<\]>Z,7A=B*%.LW,9;U,7Q\N+ULRGS*"R[SLC3V1,D?V MECB:YKC9L,,LBK%,'[+(@8O=E3=.!*R*X"^,ANHS\&%&/5EES9A"B?$56GI$[;
MZJ0]_GL;]8)UJ<([70>2> 8,"TY9UX$."UY!W+D[+"14Z.&PZ*2E48>%jN6W MV*0XIN:?_SA;I7<')LVL:#+\M{"[/G8088DMS*&I8\XL[EU9?E#)G^"512N1G
M'#SBBRA,'X2WZXZ2\$6@:OUQC\K *K1>+V\83;C*?P0JFSP!>]8OB+>Z;5;V M2#CH2B8P=+>X).(0A==1@L_VP5T,[I1C)W0\Y_S\2NY!9B,1#$7%6,0&HV*T
MI6<>-=2:9K9@R.5,4(!#) ME^UX TOAUP74S5TA0.MSZ15';DH;3((+VHW8;N7? J2R^*_MO$ICU.<&%)IF MOM$7)W)?@_\!K(!.@&E<-@'8!Y,5_@ .R-
HO*E\RH)OA"$5%I#QY$R=9C&9D^/>A MO_%=".5D:2)$>JB/I, <*K*)\'/9&)4&&XSBWTO1_E/*IZ!,YP@&VE M/4HB'>&'+-
$G4"64KL8H)%M&",'\@EWG_$Y+I"#M>.2.75\1(M4G+KN=NS MFJUIA*Z<>#[ID4+-D\;R 6[@T.TB3_#8V.HY%Q2DL9MIIDL(ABW_(A$)5+M3P=Q8T5L)*.
MV\W(>CYN!P7.IBO4*PS"A==UXSWV\C4,>.W?Y]3-3-Y\W=ERACE5]%O((D-/1Q_V#L0 M?X_|;9YW1EOVMV0MK'C,UR&:4K8(8A&/]
MBD8SZ&DE1ZI'*,9QJXZ1!4=/EL/&>D-.$@7\ ]#;ZQ[_6,S!!\L803RF2K MDEDO(O$=*GJD-JHYKS%U*EXY1$BKZ3\]?"O9%(C.4<^I4O"F6'D&5L:9_P;<
MDV1F'ZQ U9SX,=$_%P3,V'<"L=T/Y;C9MRC_V/9UN@T^WV[G(VDXW+3(\UZ$ MJ_YP1[Z@>5'"%A<%3.,0$?N4J92?'/JQ"%<^(E&H.J@^VDJS[,F)DOUK6HU
MB'RU/"2C6 \&Y2N"=LV,TU_6U!,Z(R_G^/3DZN6)N&8T_HI8& 24#SC$,36^ M%]I6#_V$UFE\Q%G.3M)1*9=-P,$]VDHGZ=Q[M%PYC&P M+|\5,A]##JR84GR?
++.=0X]3JIVTYKKV7'TRTKUPT]E#CFH5&X)O*HS"UW M-"NZ?0B)N*;:*&0W6)*M##U+UI&@6AP_UZ1Z];O&O^_IQ$^)81$_^BXNPMRB
M^]"7A00NKI;'!_Q;<[70*5OFH,R@ /\!F,6HLH9M>3)$2JXCS207/Y$L-_I_M/[']MQS!Y-Z%WAU7TR99K)ZA]4AE]',IQC ,BVUM^@&" M+VP?
>P6HW#M.'0]#3]D'9S2-TV:_/HOBJ]A_=%)\%3@NSBOS<^N\T4W%AB$V M79[022?,_T2F1-F?';%X5KMLUHRK9HU1,,MFK:PZ=(T&Q9PZ3LKE MDMKMG_.L?
=\E=\QV"K7],+YN[+L#^U0I^(E<^3IK6U3LNT;SUVN|=?R0MCAG MF:Y])X';ZT(#$%SIDPK0G!;"!>"H CFMA&_=,IP5'T>],TPG: .:+8B_#"X(5
MP6_K9(ER\A>T90BMH1 ;@?+\0>LUS41H-*U9.;J?1D_T3KF[C*C'&7L-J?L M4?8GQ'8[<_RXR%?M:K\XK5XK8.5H-0HO H 10-S,'/Z(M)DZT\PJL;["9-)!
MTJ^>)PW^Z"Z9+;N9FM1JZ^2A K*XDMG73.U3A2=;PZEL5*]*P/T01XE>L5RB MJ>A@VJ94%W(]^5ZA)T#6=I=(E7SCGATC5;.Y[5I'>]3@L78(40VZG:.C[G-
!05&D13,<]HM#S-?,)Q45]HXP3-/]\T_VQE#-DI M$L+#@LE+ *$WJ3\53:9I*+A .FI4J?J1VA6K9EL$4%+ JC?!S/47F\Z-D#>! MS^04$+?=O3@'"55@LGG9-
$K\YCW6 Y2MQ$R=9C&9D^/>A MO_%=".5D:2)$>JB/I, <*K*)\'/9&)4&&XSBWTO1_E/*IZ!,YP@&VE M/4HB'>&'+-
$G4"64KL8H)%M&",'\@EWG_$Y+I"#M>.2.75\1(M4G+KN=NS MFJUIA*Z<>#[ID4+-D\;R 6[@T.TB3_#8V.HY%Q2DL9MIIDL(ABW_(A$)5+M3P=Q8T5L)*.
MV\W(>CYN!P7.IBO4*PS"A==UXSWV\C4,>.W?Y]3-3-Y\W=ERACE5]%O((D-/1Q_V#L0 M?X_|;9YW1EOVMV0MK'C,UR&:4K8(8A&/]
MBD8SZ&DE1ZI'*,9QJXZ1!4=/EL/&>D-.$@7\ ]#;ZQ[_6,S!!\L803RF2K MDEDO(O$=*GJD-JHYKS%U*EXY1$BKZ3\]?"O9%(C.4<^I4O"F6'D&5L:9_P;<
MDV1F'ZQ U9SX,=$_%P3,V'<"L=T/Y;C9MRC_V/9UN@T^WV[G(VDXW+3(\UZ$ MJ_YP1[Z@>5'"%A<%3.,0$?N4J92?'/JQ"%<^(E&H.J@^VDJS[,F)DOUK6HU
MB'RU/"2C6 \&Y2N"=LV,TU_6U!,Z(R_G^/3DZN6)N&8T_HI8& 24#SC$,36^ M%]I6#_V$UFE\Q%G.3M)1*9=-P,$]VDHGZ=Q[M%PYC&P M+|\5,A]##JR84GR?
++.=0X]3JIVTYKKV7'TRTKUPT]E#CFH5&X)O*HS"UW M-"NZ?0B)N*;:*&0W6)*M##U+UI&@6AP_UZ1Z];O&O^_IQ$^)81$_^BXNPMRB
M^]"7A00NKI;'!_Q;<[70*5OFH,R@ /\!F,6HLH9M>3)$2JXCS207/Y$L-_I_M/[']MQS!Y-Z%WAU7TR99K)ZA]4AE]',IQC ,BVUM^@&" M+VP?
>P6HW#M.'0]#3]D'9S2-TV:_/HOBJ]A_=%)\%3@NSBOS<^N\T4W%AB$V M79[022?,_T2F1-F?';%X5KMLUHRK9HU1,,MFK:PZ=(T&Q9PZ3LKE MDMKMG_.L?
=\E=\QV"K7],+YN[+L#^U0I^(E<^3IK6U3LNT;SUVN|=?R0MCAG MF:Y])X';ZT(#$%SIDPK0G!;"!>"H CFMA&_=,IP5'T>],TPG: .:+8B_#"X(5
MP6_K9(ER\A>T90BMH1 ;@?+\0>LUS41H-*U9.;J?1D_T3KF[C*C'&7L-J?L M4?8GQ'8[<_RXR%?M:K\XK5XK8.5H-0HO H 10-S,'/Z(M)DZT\PJL;["9-)!
MTJ^>)PW^Z"Z9+;N9FM1JZ^2A K*XDMG73.U3A2=;PZEL5*]*P/T01XE>L5RB MJ>A@VJ94%W(]^5ZA)T#6=I=(E7SCGATC5;.Y[5I'>]3@L78(40VZG:.C[G-
!05&D13,<]HM#S-?,)Q45]HXP3-/]\T_VQE#-DI M$L+#@LE+ *$WJ3\53:9I*+A .FI4J?J1VA6K9EL$4%+ JC?!S/47F\Z-D#>! MS^04$+?=O3@'"55@LGG9-
$K\YCW6 N?G4<-2M9B.O)#E7.M3]Z+-TU/|2&;V M-74?2AS'6 ZXFC\/R/'OAB198*R,3,I22U&A_MRVH&\X52E!],(KR-'9YM0 MP1,3OZ.)H(GH+!Z7I-BKO2HI$-
#4P_AB?5$4/>VH_%[YTO[#>;!ONYHDGPLR@= MZ=Q1_$)D('67";%YU>] BK<#E,A@NGT/Z^#6[-NF9BW04@3 'D[#O6Y+P5+! M@4YLN=X:=3*94EG-M*^\4"9-
#1(7$&VDQY551.DX>QU?I>@TE9H"[H9K(X>0 MP:J[!Y+F,L,4)\;V87)O,":VTCRP:9'+Z2/*8H=I>TZH_6@5!'H?4"6/8$AA8G8[
MOP^%^VND(H('B"UC>4>.0BJNSW0\'AC6S\1.Y$4//.IT<98F-)M2'_ 7M>96'R(\B^MU9)OP=PT" 5(M&7X*;#2[ZU'4N-4+L+N6\0S:
"!6,%:FBI!E0/2@:Z/C96^/Z(2NT=1;%2M7W M8&C^1$L&X\5(H/Y(:ZN8#N7KQ*RY=51!8?1"U3S9%!T2/(MAKF\6'2BJ6/=S MJ//!?.>!8[!!
[Q1MY3P%+PN*=,']. 92UGH^D=BY,.3Z"D4;9GB2T0_M/?3(MJ:.?@YK \U|\^"@:ML]< !IL T0BQ2]SQNI-]AXYPZ#YLG9C,]=Z&Y<5#
M@FMKB;&U_F!*0R:@+!F]6:YMFP?9*&4!+N4D68:PS4<%1435WD0E-#)XHV^4 M&\B#@T_ -8&SEC*5 BLB'K:*2C2CM.N5=;+IK1XU/3'G,56+>"9CK=E%#"'*4
M;O9W";N<=<25E$-09L)E9N!VY_AQN^A"OTS*;!).*9)Y51WI@3?7;.A+-N.7"Z$7@\' MFS2P4:%QV)R"&A7=;OW)9M#": H8L579,P32S0!$'JPE&'\@O1/EO=0#CI
S@;2 MMQ9!$#U1IP/M)T$TCY\BR(?DY4!8S8+@(QCf#5M9%MLG4FY:!R#Z Z M'J5-%]6!(S\[A.RF*%E MG:MELBZIHROG9Q9=F_48+==^^6)6S?
\)B2AXI9N69X.5!K\ @\JO9\LO M$&K%)T0HSL?WTB[>3=OZD/6U_'\-"?2;?I>N\Y(9%K+N=]:I.CKB^DBJD%% M7S@8\A;OW9V0\B]MWMM;8/-8(,"M
173WSH?!B M60O&^>C96-=]N%PO#:5(&K.ZO14$NMBGY"[F_X&]VS#PMT1'"4M]\8)@43G^ M -!4SH%_._&=:'2I}[<;^J^#+#8Y\ZG6:1^;Y(CYTX?
B&Z3=]C1Y+Y[]0HGZ+9 M-&\-++E\4R>/42^MK(:8X/%11;Z:I.?%7N749(@;]?9A5!%.]<#==1%%X6^Q#/X3IS97](#75AV*3="'"^MGP;=^ MK$46*&/8?
CN099Y=J._)!*U?L+!([X@(O<@=--I=:5?A99;INI2@7OX#J*H MZ=M]5D^R59A*L3-/NSK73#(!.Q#C:E856IA^@U(1)M:IVX/LJ3-R!#@!;*JQ M-
F@Q.?:,PO1TT]I\9>I3I7O#2F@\EU:.92AUSV113N"Y]<3L:B0%3I"K*Q#%> M_B%)5YENB+9SF4-6AXDGO7]"A^N0PPUH.%=P$
M@3PJ!#'<',W[=9]%W*TCL@T)C[-]BCC1=81K:X31X^^A[VCE]L$[K"%1EZX MJ?_(O!E=(7/E6G"(%:M5@TRS ¦_R9U:D*%L5FFF]@H6)1GQ=.1W+Q>?C&YJ"
MI%QG^F2L,QY*1L. P*+I"/^BWS4R-^5%;A50B^.M&H@9K(_',]D?3WD]X7\ MXZ+;2J,BO/$Z>1S8FU=V"8(F7_)8JC%]V(]/_&07)4ZPVIQ'Q% %5Q]S\"D^
M3I1S0?W(?#8X]V"'^S(N:AQVK/5W8V!H;%.'N'VW*FN1_]4R'JC70>U]9K]N MZHLSO)^EM_S;TR.4>+HS8
M.WV&!#MYO6859TIU3L0F;99GGIL+142&WMX3.3T-%SCC]C03)SMQ^NJ6_<]8 MP#\-:K+?8X6/&8]9,AH8-6KR_%7^@X@\-F99)/ B49C,7,-CE/#FV_K*!#/5
M6.7(>;G GN\Z6=UB^0V ?(W8YR@OXFR]*Q0?@^0]0(:G84*2OD3)SMQ^NJ6_<]8 MP#\-:K+?8X6/&8]9,AH8-6KR_%7^@X@\-F99)/ B49C,7,-CE/#FV_K*!#/5
M6.7(>;G GN\Z6=UB^0V ?(W8YR@OXFR]*Q0?@^0]0(:G84*2OD3)SMQ^NJ6_<]8 MP#@.QX4AP(7KAI#B;=25D.7@0U0G>QXBVS%^%&
MPY_UKLU\FJT(/*7"#J(Y3)W:G9 H5&{(1N:N\1?KU?R56=2NRR"C0JG2,L3. MR1S9[\AOR]WQ)0&QOU_4$L#!!0 (.N!;EG)4LEOR
M]>C$MCRRG4FRM96B24C&#$4J(^E;\^M?@*0DDN(% !MLT9X/V\1C2^C&TXU& MH]'=^/E_'F?NWH^P@/K>+R]>__#]O1]Q;-^AWO27%[??+P?71\/AB__Y[fV]
M?_S\'R]?[IT1CS K),[>W7+OR)_-KVVZ=\,L+YCX;+;WG^'LO_9>[MV'X?RG M_?V'AX]F_MH[])?[+U^M_?Z MX*O=U???!%\LF?'L4O!M_^O7!P<%^_-?U1P-
:JD$^L.O]WR_.K^LI/M_K>4B\(!+<\6! +Z4Q# _\MRWK3!&I\OO1'0V=P5#,6_NV=D\LL+ZLU>"@'!?';Q] M)4;X?_P7?
[&_CGPO\%WJ"..0/+5=,Y/J>D/#%GACX=CS,36'HS8@SO[?8S+)) M%%+;<@/JV4*6^^+S^Y7#[?^W67[_NK(8\<)[DC %S'YQ=!.S&?+E-B/7(?]Y MQFD!S*
XXCZ4TEQS!LB][SK<7IS\'=%P><.'>..SMYI?EO];5XLZL>$6]%#;\&7CL_T^&MC ,$+ZI/@57UM+B M@W.8^&]81)QS:MU1EX;ZVB U--
T8]MZ9,UI*+8R9TP"PA;ZZZUB-" +(48_MY(Z.PY$1NM>*S?Q ,!R>$S[HZ,ZE'TU;&=VL8*&&3J9AMQJ3K K@]$ R_)0P
MHV$LDO5N,^6'#/W%5#.)%+_,DQ=2.^%?.5GT1*SOT@N"(LEG$" MD^X<5$C SZMHGUO/8FM](UU3.'4-(]N,]:N]20D2)@018GA!I!'V:C@0CEY MG!,[#
8SGX7T6[P6Q:^\@.!,HVE\| E)[T*MIR9/"7R2GRW&8G\RI L12 69 M3^F@<}]IAM -%]>@LFL6;UNH #S.%ZI%-S&-,YERKO?#IA@8TBZIQH8[HTI'A
M8Q):M,5%BS(A0"G5G;K:S4MJZ(ZBP.UF(CLZ7*]OZ>UX[YJ-,!@Y?8IH*7] MU*JY/,$5(QDO'@^.Y>(AIQW"5:$#:L76":8EOY7B0EXZ5D=2VAKYQ8"@+
M4A59;3>!IE&A_+="N+6ERE2,IJC@@F3 :<9Y*0&Q?YCZBWV'T'TQ ?%#)-X M%K; (&R;VZUOQNPYOAT)E>#;(;ZE'HI08,RBREP-(H<6[S]B]N;\T"YV0O'+
M<\Y-RI/X-E":3&[FY#$DGD/29!_! >?!]>WP;&]Y5WY Q0P&=T'(N#;70#NQ@KLX(2D=+\&7N&&P^LT& M:"62B2(J3R?9S(\B)K)Q#/%?3F/-
<%8'IBS/O,7I%3/AQRVUR*=WI9_8G\>1 M12_M>^HZ]V!/F#_3$V+H-Z+E,X>P7UZ\$CE^?#83PO_NG"= 5W(;LQH2%/#X MD[H"%/DR RI.FQ&.Y<)RA7D:A$?\?
+GD.\-OEAO5K74=@RL M3"4!A)*QGM&YYT?4&\)F(FX8A.EM/JR1*2.QWD=V7(.E^*0B>]U:9)L;Q2ID M-28VX7K%CT[\E)?.!MS&UI'*36&7Q5@/6"K.-
^W%J2/,5<1^>4F@A9<;NB=6 M,P]'*IJW*,;QBI&Y19TTT,U-^2B\)RPW$V"|R5#LB^F40B^5[SLT2VI0F&5B MPY.;@C)7.J:MG!4_M-QVZS$-
:/J>W<&IIII3,AN_>G2S*0 /T8O2L:Q*UOG)% M!-YSUM%K^'VPEA3VPFS2ZKQ-K<,,\{18C.)SADX>;3<256EGON\\4-<%]VXD M2&(& U0D*X-;ZA7_"W-2+R!&')
(0$W&3-+]\=7*5RREQOE9&# QF& MC$<(ZFGU;DS0 ![8';4V)H[A#32PUZQ4NHN879+3BDH\8-"BMPPWJ3DMWD?I>S)V1_)SB\+BR:]+=XBK,
(X.YW0T<)]8QKFT6=89>FDR> M81(Z9M!,$-EO51&F#'S(EG4L\G@]XIQ8S./V/AC8=C2+X@3E8S*A-H6VL(($ M->R1A&?BPH^A;EN)
M&BMR,@]\0*Z()L:XDO"-Y<;ZQ$^"*A$'==Q4ES>]LBB MI@EMS\VX[X1^_%239QE"+;PD@,_,YES%?7+C$FPDA[TZ6P>-*E!,I?P>(B3X
M\WZQ[*.K6H^MCJ59F7PO_9!*3^XB+[F71\D*M%|+/S9^--?\$8NGYL3'IE5' M%',']RTJ*R+=3;*/"UH. M2\S4A2T.AT$0F1=P2@7?
=P62ZPHUN,LQ$&&.HE"TN1>9@Z8EFB7U9,2:PP^N M0*%S#W:K2WVEUZ]7\)L;W9";6D6EQ58W)@OB1>"75NMAL==!@V#R0;85%'"Y M5+I&+-.#K-
N4'W&&IEQ^Z1>]@8/N(9TQT1&3^!#QTG1T9T^-3D$T.C\:^'$ L M:WTIG=9V!89L<34=Y).9@MAJL$*-(8L64GS"HE_ ,5_OKA]7.1,@N]4=;10
M[X@:53F_>]5BAIL>G#RZY8H,9F=&/2]F$=(%,2/2)FH[D?V0JSK>MU_+6Y$P[3'U:MR7@0%W9ZLC] MTO?\%4>)O[?]9&#&V6VFUZ.#1 1XV(TX-
OV5$@:"A^7_P8\GE1!!M7*2BMW ML5%..6*X?0!6V3FG?(IE3:(/R83O$\GG;JQ'$IP\|CERGJEGL>60:W-C):I>FN,AH,>6659%"W;P6Q5>.4 M2O
CQJ9=Y.K0"JAM6'0)#]". ^SX1.[SD7@P5WLJ;D,IK=$3:.;&4AQ,IFR*+]\8 M>@6+]PERJA<_ M8IV'E=C&U GLR[]6BTA;49#;=E?PFEHUTVE@]M1QHYZF%.0:=-
@*\1//)8_$4 M<@4<-UPP;WSVMCIWK&6Y0X?UYS(TM8,,Z^'3I^/,)Y[AE"?1ZXD) [8F.)S M0P#;45!2M7S)6EZ@^FO9;>L*K%E)N!;%D+X7=Y-XI.9$6$IK-
SH;Y998JB70"[@RR1T[,9UF#RYS1-&W.6Z,X.SS[.I1=4*4[..AX;_-":,_^ MPRFS$+:F];F70=;*4*KH4<--:RO-F*.DKO8X8N)!GC N%H^-^?6ISZX87?!)
M7KF6G:MLK'FU5V_<'?':2B6IB128!Z=M4[=Y3C3PDCS$?X(/:4@1[<>ZE440 MT%V#E'2LG1T+ND!SE]>T(GH:.;L5>5G0(H[_-IK'B8,GCX39-_!/2U"GOQNA
M%&W)5X#:HL56ZPR&6G.$] 1U#.Q*&R%].U^O"#HY@.VW]N>3I"DGP/+\3(WL MQ@5A=WY;Z0R<+\U'Z>O6-7Q&C7>6U$4?
$#X@7Q*!F=6U,^&DOH"&Y)FQ!;9+H MY)C8_M2C!BH@N^^Z'QK5F0RQ4Y^VXPM_O>HF]K+C&E .3"JN]W#^HG7S@^L M"R6
"ZXQ]++C(FP':Q5YT0ZD9:79?5 '"YO I&?:UUC.[!#NDCZZ!HJ9U5G8%?\Y!JI%QPN98A1 MLK_W-'K6*[.;C[*UCY)SOH3WY-DT;MR[8?'&QUWR1EC YN"I:Đ@'L
*7; ,KC?UY^9C0DQ_X#M-=20N#Y6)1M;#&OC?GTF-@- MCTGRW\R$THL,<^WD90GO2)Z(Y%%7!5'D9Q.W65VI)_Q+TO6TL)O&**Z!>GGG M0&P3' /HV+3-
W14C/-&H#M5^Z,2[^$)/+C$[]"2+T,4M^JER#NH01G$.BFRL&!1O*!>V@-(&(??2[!< &[!W,K-&G,T(_XT
M=O)21%L\.P*QDPL^Q?]$.>.'"SCB^PP^,VJGU60#S\G_(O/)I':U&,XZ>;3= MR(D?+K3O+6]*QAR]D\F$@'L!'3/?,P^B:]&V*%O..W+G>KQ+:KD;#0*[4+'V
ME=/Y-F<8%A"^CKJM[CP7 P5?K*VI/]?1?.[&T[;5*\#A]K+@<^'_ WH+G1L;T.-?4N?<]RA1-<;5Z;TAK\"_?0#=70 MK$;OL[@*,,%5UNGNSX)
fD6/'?]R$0SVGY$!U3 /;]8/(V N8K=GIE45N#_Y* M>7 :.GA;*_49W25O]H;^7^3$F7WD2[,BF4TM+RUNW30)2HKFKS+S&TU205KNVCZ8NKB! MX4D[U&F%7#-
'DVW,H4*:VP2P0]>@6I"+3XV)E8=]EBU"TZI4#"5-^9:D*Z76;K@+KAV!SR[W^%/N'*$<5>7LUBS9UP M)9$$/2F97TDE!80P+U6N"V?Y0<1826H)"8
RZHTG9&]%U)+"7A=UDBLMC2[% MJU^^WA7S^5X8+D68^[SQ0U^68 M%0D9#S.IT6ZS754-;FI?;|(:'#S5$GPAA-J,*FRG.O.+K5#1:-45DL(L0)D:
MRJ.T[MIS,D781@]6^NQHOQX@0=C\PM7E GDQ0RE1X=U./8'T[%P7]UI,*QJM M^#*>L$5]; 3FP8%+/S2ULS80:]GZ,_^^O>=LNE6NZSI,Q4M4R6.?$.6DOM7Z
M4PGA?IT?MZ<^O+(V1FDTR;9'9/X$>(X{3GFXB|+A;&5V)(9[1ME:;J=K-NV MW& O8QB5RC5Z,BN?OGG6\0WGZ,ZETZ:+0!UU/_>]J2@?/"9WPL-)M_,B34-K
M7)&XY@7%.>''+)*_,3:V8!N((;N[>M+.,+K\F_%75T:;*IG&53>;"WAP!S:A M,"9ST4[:FYIR7:O(:+\'7!C0_"%2AB)VZER#,',>J0R /3OTB2>R:%)FODY4 MF1*OX5)
<]^6RE-*@0,E\'I\2[1;E!:3)T3*TV1>*8I2=:NE!\V4T%Z-YM8ZG[M>V6Q<'G#+.X4VXUI8WI)DQ6$#*W$1G+:.][V]DPZN@O(WQ$?ZV11'X31JQ?
*CVZL0*B"C+:O6!C0F(=820?,+VP07+Z2J1*L MGGF#VVEJA\OXIR7LLNAQ>N2A%=!@-"D,G*)D:IE($L7>7-32(V61Q"TDNV+4
M9^MWNUTK".*4SAC5!8,BQR2P&9T;>/U-F7R_=$ =?=SZM-N C"8G04AGW"_"MKBY"H?S%KF6E+]6HOU]+7H4 NP[@IO:N5.+IX3_]-- M@MUFQ:W/!_)
fG4J.T)MU):U.1N)8G<;LP9 BF:?I"^)(EC+>MW"B\0Y,"O= M:C]fD>@F*=(:N,#:2&I:=FY-')%3%S^ML_W*2O[T"215.9]!6K.2*+;H/P=@ MG7W/)N(5C#B]@P9?
CSAQ&HJ?X)VR2D!]DFHM8BTZL,'8W[B0R[SY+273H[-1 M-53Z'=% 3DF5I4)F92I-ME<[K#R8+?J8M7\+MJ;8Q:S4%0CWR4*KX G7QTS3

M9,@INOV5H]DG@DBC"-4+2D_5L;E$6MW¥BQS28 M^X'ECB8B6_"<+HC3Q8+78J%7Fj"%\4HQL.)HG.7?+#8XK']DS)|5J231?EUWR2*¥ MDG?
fH)F>Q$\LYG'>1)/^N [*K*B;J/5G#3?BMA(L3@1M4].6K7H;S=-F?<,X M\L<=21%0"(PGU9VI#QY%-R;N0B1H=BK,)P4A*OL ME$XC<%=6F%8KB);;KDOL,++
<5=@P+G.MM>SE[VBI#]J#R+D.5"N9(@77BJ5A M79RIY6CV*:0BB>)*UDC!M:1D-JF4-2OA.D!]DFLM8BMI(D7$+LE#9C+,]_B/ MR<-
]01>+6)E\OPY9ZNBNU*%]J*RK J+;+K\B^Z*ZINB9U4YN"T@5X,D/F5V$ 6^7@JV_E:'L.^%= V]<%N7$??VV%7#MYY M#M:.Q E@6U_E8;71G:DY]#W.F-\XZ0-
LD6N@VVLD3+VR:YU(VPEF""]0O4T M&.K1D,1Y.D46!S,1>TI>4$KCQD8=G5:L]+UU>CLYP)4"[TY/=2,V_GMK]:WS MK00+'9UO-
%C9C2LYT";K{43LS8K%9W6FT]*S[#A>BU6\?]+W)-*#*)O? M8 MF(P\)O.(V?=60/@99,JL&=<,,@S)3*1#!!\F@RS_UP95&0K8;J-\9W<94>KO
MZ>YV)6J';,BKJ4!"2G,@H&BW2Y;+]K/%&#]A:R,6O^S;P=E)E0^V?OC'4A:$SF!TNTS]VL"LJ<8'=3U.ES[HNT#W;#U?S]"?'XJJ=.)>$ M+S_^9W+N!^N[]
(+WV'85;L"M)5J^*L/5XHCHB>;/:\;=RAQ1/.NO\P5A=WI;*_XT;&9$^OFOL0/P'8N\ "Q_GB]\^_-___FI/H\<_O/<'SK>/B^D?2^_V.'HX^\@./O[ZYLOM
MS3)P/R[L;Z_/;[\^OK;/PU=_GIZ^N?YU?_%X>/3'JX5SS?[\ M\2X\^_S^[XM/O_W][3R8T+=GWWZ++O[X&!SOGYX^?+Q]Y{^A/UY,!W]?7TP_ MS!\?YN1P]O;-
IW=_//[SZ.3+IPN/??[SV]3^YI_8EU^_O3L]&WQX_VGT^-OB M^NCN;O_AE(P.OR/W8/;*??UX<_;Q1<:_OGA;G!V:']9_M/[/#O>?T_LP:?H MR\'1S=&_'>O^4?
!9/[E@_WI[>2_#F?#7S\^/1\,CKY=D%?#RR\?9Y\'[%WD MOI[\/KG_>O7QU>MWT\M?%V?A_:>
[P]OAA]OE!QO'#:ZYL$\HJ5E!4!Z[TZB=L)D+OQR3Y[]#+T#-64"%#LT5?OK0>8&P]7%A%}3)!Y(GT79 $RP'-!&T%>$I/U=;T76@Q/BZ==?'&-CG9M5EIZ M-KK-
5,L8N#;,(CK(U+MI79O)C=CZV]RZ/LKHA5@#60/]RTW=84D01#G8:.IF M^>54DY:@A>\K&3M57D5;7^F7!+9G#/;BY-/:G:&O
M)D#WYC/F@P>^&HCMJIK7WA,T 8C[YO7 MJ-9Y%HA<8X))V_3&%'^LTO2_KG9 M\NS*R4#?/4&QM:,^1?W-$IA,--R0@T2W/#(5]-L%RRLY@P_5U9+"3ML -
AS9 M2)Z.MY*+Y'5^9UC2Z ;ZXC!/@L.5W,IRAV/=QL+4 ;$":=55E>^@L=4L6<9O M,!@!O<&;NN!B?[O&,#BK#;]9)FUR8P"U=X8+]U/@S:(V3EG6^>I.UE4,
(!MM&/%7H@OHP9KS)A"\".2, MGG9670Y3*_^W^\MJT<3,KNYK!NONUJRJTRB,XDS#(AN&W-]6K)BQVML$+SG@-M-P_$79 +WPOO.]RM99C9F;U<6Y?
TF_YM2V9'''<)WO\@%KMY\%&5;<4#MM./ MJT5K28#=P76D/5QGH%-S=+G8'9\22X&282!="">KS?>I'T+>]FDR@WL;A*U B M"+!]S:[4AW\67WT$$\]=?
6)!I.H#\#Z2>?493#C-G="A/"?/6)$*(DFUJ?VC MY-#:!'\;V$#L^;@WV:M"G5?,D0,ITFW484,J*EVO\?NFMZP:*)"Z899#TJ'- M3BI':2?
>3M,1>"%OHQI*E++%=!JU;R47(F"E-\=RX^S D^&Z(10$"CFOMS#) M3I;I4UZAQ<79_]"OU; &9U_Y*G'Z]?19LV(6(8B=GUN4S
M@U_9%72>AK!K<(0[2AMW*?%<2?2; S-6OA[L%L=BW)+HM#O7P [I8M61O/(< MI%< 72"A5?)<-89V).'(M8)@/6[Z5H*)PN8:0KH5VG$7-
BL@3G9#&HCQIR0I MF-E\A&MO7-?]8#&NN&;JG $8PG#ZI34T:Q7]J ;T+1H =390XEQ-!WGS;U// MC5*$+&#^WH)2751[J#20U0B!;?4)W##8%*?84P^0#%?
YWN5LF+1D./V^)(_#(8 MA?>$W=Q;7M(W-KCTO04)1&_UR,""Z8YO[)808.X$B,;JBUW?(,P)H[YS'5HL M,)7EU<%D/Q-A(((@SX$;,FI(S836.K9"
<6I3]9KD1>#^>79@2;K2PMPM#0E?T MO9RR-:/Q0J<1!%9/WYT\$F;30.6QS\[XP7:]8+6Z8UE"1=AW1%WSZS2=*;EB MU"8[I\]*O*(^>-(7%5>5/^ 5PVZY.?
$6%0R]JWASZ8TK4V ;MW=,S[R5HL@! M[U9V6;>?CA^O.J_OSKQ1K0%+S-P-WVBU&3KEFT+'WL\V-[ ]&RT9:F215E1B M[YB:*MIU+/V5,M/?%1M0ZJG&?
WQR?LVISR:$AE46>H<]EVW.O_LF+26?:OF/ M:!TVC,\VXGKQ=)QW14E]/]<:4Y=TW1P\N=VA<$OWUZO>+(V2Z]GOR]\O]=5-
MD_;U[(G7LH'H+MRX]5'_)4,ZW_<&0_JR6CG:E[2YE=-Y9O$%|>@LFIV+)PU2 ME!K*+'46]XA/E7/M36,Z.>EK2GI%]3@RU:M*E;IVNO(Y"0)"\N36)2@K2F,B
M'N;@2C.:G-* BT:4;0//N 4CV-9"4U6RIJ&-& #?:#6F07SZACN;;;.!Z89U MI3FE*-VH))EVU3O*77Z](?5#A7%3(,IXTIBH+>4,OGGLA'E($?.'5%B&+[Y
MCS+YYZ8CP*VBC.](R2Y1>CP\(VUIWP*X$)7E6DD)<$N[>A0+> .1('KP:WG M\&.8[.4FSLFC>#9^.,!_ZE(!*GEXZI:C&GR-BW% RU'!KM'XT(,*$Y!Z)8 .
M5\&03D0%7V;.8C00Z[_Y;T)3X_ZR\MX?4-J7OF=W*? ,O:>[M+.@MKC5VZK" M[OA>8DSF/@O%1<0UF4K<2BAJYJ:KQ#8AK=8G-<.TN/A?#Y\.FE#A,A]Z$Y^C
M*_7*9_--$718<#W?+<:@);%X%0LY,AB=OTI%D]B.@H#TDM#2^(#*Y'NI=E6 Q?N&3XM31C& M=4QBGD//]F=DZ/%A^6^
I5Y)II<2K@:M1>H4A#0O2;'[JN/7$ (MKJ>'UI'&"H1S)_XC*@X7EAN'&,(CB[$EGY2)3@1R-/NYZ4KBJ9_75-YWWGS. MPY'/.!1\]Y\\@8?
&)^AZ')^(S2Q.]"\X]J%%W0T\(*69;&IY]??":0:^2YV5 M9W.5F;.HD^-\B4#_ ^I*@(E6B??X,"$^JUSD.H7^=<-!%<;"="H43$16_HTGN M5S73#8C]P]1?
!//!DIGR'S835""!NTI!M4(L8Q5P49]/?'[;++B,Z_=AG0AY MZY3SL;"8'G%.+.9Q4QH,;#N:1:XX9QV3";4IM.F2((A;^VA*Z#)(HSZ]*3R' MHO?@.=?WW VY(6RV\?
O!7V.2)_S$C+X.], /=':0LTJG'N4*'C]-%M=0F,R0.?LT>1DAU=Z>$B"5Y*^6)]U*C]7FL/V0&9OY'Q_13A1] MQ(!N18^9H9?]!%<).G?)UA$&S'-HR\]N//M:H[-Q.U!Y-
>D\.S5@X5\7UA>? M'45!R)T;)IU=Q+ ^9D3' UT:^%8,B"4MYE0]95>$"("!5\5Q:,WZ:R#$CGT'4 M(*7JL7$V]7!U7 FF!I%\ I$*U*N11AZ15G?
<_@[&M5XS:"5S0\DM7?%Q\^ K M8[SYSFYCG)D;RLE@S8=HT**.M.@<&[I//"0N75ZYPGKRXR^0\:4-YP[]N M(!%=AF*?
_$@E)"'2TT"%+%@SDJTN0Q'Y;*>@^U*"SF*I[Z5N,B=G\X@O\?7P M1A+C:?0'+U.J.!5V/^2ATEG(79RDVI M!0Z@S 5*GL8_R M]L7+21#2F142_S/2Y$:NLIC&-
T%?'X!-R9V:60,)!M>ABIJ%I"N*0A!3/+8%[M(6?O M?F:QK]VXMGER3_ +4"H'W_%=W+7G'7CZ1;)[9R[6ZKL]=(M(@CC^*9Z%XR) M3>A"Z)H1HUM):M?
*;@BF&C! DZK7EL7B1CXM0+\D9J*HY31V[+S2*, *I%#N MN,5=VEAL]D#)2INQ>G/(*$"@7\:G=W6T)B^_8F1DL .9!UMZE4.[H/9:KGQ\
M$YQTQ05#+S\>TM59+7R%&<,9?O5TQT=8Z'/C[23T^1G#W;?TPU0"IC_K5]^V MNZ&/7_/LM.I6AB+R#3U8.GNN ;D,TLCO*0KV;CWJ!1$G:.^1!D3(*J*<.([(N
MQ1%G8ZKTS*(s[^PIN2UZ0! EA1VAH<9>=>"BUK'MQV#%+VTV.*\NU\-(M<'@J'A;&Y1)N:+)\NFX/M\!1'<2QTC0[^"$ZI35B?U]BLSMC9?EN>,_2B>
M6W!)PL:2>^B-RE#Q?3.]%@LKV\(2F._]"OZ'F]1 MI(!M^B)^9,A>]M$VX:(&8R)R)[@B997FBC#].] A*5TND \V6@HBY[*T(
E;'N,#CK0\;^1(VM.0\L5A^$T[EUG&J;]+_F1XUT63$1[A&G MF,\TO!]Z#EU0)[+!2=!,L58-)>0ZK28M;A0A9'5L.K*1 M_28_-
O:=@!+N!5CT+5]E>LSNFP^X0PC<25KOQC:E&/O],:/!, @B\'?O:@AA MQE>A#Y/Y9*)[;%';REC;!2%@4@3H-ZT \EG]3TG\)>=0QNW+XL]FOF=ZU5=1 MP=
!O3,J]$EE]O[*X4:H(_(KY-B'.*9^_8,3R;/&,?6;7&VQV/8G3FM)P3U', M:GB"[>Y:=CZ=QZG/3@EX3F!Q=.0K#Z.FO @D5,MJK?L%P?N=X+UBJH?+S4=2
MS@A\VS/U2>?6::A4OP=5J-:>)%4W)-PH8E7NZ!-[F[-.M]:DZ[KN%,ER!07<7]3FL3=RQ;Y(81I.LD,8D?DWQR__"8,O&F7H"KB4SRK&;.M2HB5;N>K!]!U-
]77C:DK>0"&4&TP%V_D'DN/BP-MAK^WJJ.$U'U$:AGGBU-KT-HU&1]YN:JGA>K12ZBRA"PKKJ^TS#%Q^;^G9\3C M'H:(2@R<&7BZ%6ZOFQL<*YZCME 1.(H[
,^<1! ME0^ZF8+GB%(!\4RID3W5"(NH6W'IBE ZX6M)!2+EY&0V=_TE(?'U41(U,&*G MJ^D@6^=&V=4@I+'5'B3+W"-A^\"C8"BK3T(_S'A7-91P\
[>:5UX=2#@7I+?> M@@3\/)W&Z*3S5LN_MZO+IV*6\(VK=MHO@ A1H5[I:D]@TYQN-,F$H>/UF'9T MW97HFPRKR$4R8)%.$.64DBUJQEDF)R;-
DDA28)$"4=ISPX[K-?[SQQ:\R:^0R,N&?=<7V$U32 M!D2.7*UN:*(GCWPSH(%P@ I7S.E?R!6CX/85>3*8MW2]6@;2V@'EY'::X);.
M_=)/SSK)2D^S,XU<+AO@\LEZMB8D"I6'B:NGA:5X)]JKCJV0G%J4F7B-H4/& MGZAE[DCJ4+F46M=*;OQWXI3#:*:9HB11[+H",YHEBSA_
MI05SJ;DT=>]EE.>GM^MU).M4HW]$.W;H !?_GSA=B2;C1CJ9@K+V])035G*I M#A[THM-[W(YY=.?2;3R6J;;%Y]XW%>4(Q^1.M(Q.P\=%XH;RZQ6)Z_J[C%BC
MR;GE0== 9P9&OAS6DV*^G=0&),!NP6VK6\<$,VZXNB]%]T67%@=]TZXN9V) M8\ZZAY:8F$3"1<47,?WG) @(R3.8G)AO?#'IV+) ^]Q2-'"O
MJMH+71+9GE5@DZG0W:$W\?EGXJ(R$UW.$RIC,A>-XKVIJ?[F5614+^TJ49$N MFJX?0+]*+S_!S/A;,0]#F);21(T2->A67-+<($^0/
M]$#4H;7D'/&=3E46%5]$M6VR4JB;-'#7R-TV#%*;(UC(1/OY7?&F*G34>#TN M]N6V@GNR]0QN @NLT3#O/XLT>1K&;]+BIPH_?CR8>#9M?
BY(UV/(D!P429I^ M$U*-MKKQ;H93U@.7':G-4=L/@MS IGSP&D*8NY.6(B91,DDI[X)?GO1I$W?% MOF?:+R^EA6+2%1=BJ8-
>CAR,3+52D/+\&.F/4$YC)WS(.D7.9> ^4PY1O6-"R MKL](I?OV^-BOHRDB7P(0X'L9?;(A=5LKUHL[?A >4T;L\(*+E5'+!5??+0+8 M48!F#R>OOML(P?GS.C);7Z
&M]SI9F>1)?+FB7BG5N0>QJE=]QMUZ$U=C3;Z ME9B*H!5AW69SG6^?F5] V> MQ"#86ZJ$]@HIR<
!W*.IOSH+QOO0O0P@4\LU\'#69ES4]SW9S3.?,+>&!+C\ MHX.\N.@N(']'(GBW(!+ODNC>,A3(F$],JR*CG!A7#HMT6ES=U[4/:85133ET ME61P[]P;-"A.?
ZN5&ML;$ 6V#'4EKZ"'UH=48@D5"D+*48*0&Y#8S+0:KZ2# M'"QMT-L&X54U (>0A9D&TJ4T4*\TM04 GA:?7+K<@C8[&-WXF\PJVZ""'M(&7; M5PT4GJ>?
Y<6(X2LA@'UL;=38DIA_#B 0:_=L$PBD4 =)'BA_XF#W#47E$4#_ M\]&E=YL^_1WDW_[.2 E8>9OIH1N1AG-:K@%!,W10.07MYSON?9=S$"39/6.R M$*/&?
fB>NQ3\""]!<;?\XEKY2@$(ZJ6UBAG%))B_S#U%_L.H0D5Q[?CIWOW MC_S%9C,JQ(;2YCX 5 :10[,%$=4$]_[Q\[[XDV@K*?[U_P%02P$'"% ,4 M" #K@6Y9;])D-
,W_ "&" D %P @ $ 96P,CY-S#,Q+3%?:6YM960N:'1M4$L! M A0#% @ ZX%N6;(&15]!P 6BT !L (!> X. 0!E83 R,3DW-S0P,65X,S(M,5]I
M;FUE9"YH=&U02P$'"% ,4 " #K@6Y9M#)?.XT# !U#P &P M @ &]$@$ 96P,CY-S#,R+3)?:6YM960N:'1M4$L! A0#% M @ ZX%N68L]>0-U#P .! T (!@Q8!
&EM86=E7S P M,2YJ<&=02P$'"% ,4 " #K@6Y9BSQY W4/ X$ #0 M@ $C)@$:6UA9V5?,# R+FIP9U!+ 0(4 Q0 (.N!;EGJHV/?]0T -^* M 0 " <,U 0!I;FTM,C R-#
Y,S N>'-D4$L! A0#% M @ ZX%N6:GR5(@>#0 Y9X !0 (!YD,! &EN;2TR,#(T M,#DS,%]C86PN>&UL4$L! A0#% @ ZX%N6,KV+O ,0 P?@" !0 M (!-E$!
&EN;2TR,#(T,#DS,%]D968N>&UL4$L! A0#% @ MZX%N66Z&UL4$L! A0#% @ ZX%N6=RU*8AT,0 GR$# !0 M (!'? ! &EN;2TR,#(T,#DS,%]P&UL4$L%!@ , P
)0, ' ,,A @ $! end XML 72 ea0219774-10q_inmed_htm.xml IDEA: XBRL DOCUMENT 0001728328 2024-07-01 2024-09-30 0001728328 2024-11-14
0001728328 2024-09-30 0001728328 2024-06-30 0001728328 2023-07-01 2024-06-30 0001728328 2023-07-01 2023-09-30 0001728328 us-
gaap:CommonStockMember 2024-06-30 0001728328 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001728328 us-gaap:RetainedEarningsMember
2024-06-30 0001728328 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001728328 us-gaap:CommonStockMember 2024-07-01
2024-09-30 0001728328 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001728328 us-gaap:RetainedEarningsMember 2024-07-01
2024-09-30 0001728328 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001728328 us-gaap:CommonStockMember
2024-09-30 0001728328 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001728328 us-gaap:RetainedEarningsMember 2024-09-30 0001728328 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001728328 us-gaap:CommonStockMember 2023-06-30 0001728328 us-
gaap:AdditionalPaidInCapitalMember 2023-06-30 0001728328 us-gaap:RetainedEarningsMember 2023-06-30 0001728328 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001728328 us-gaap:CommonStockMember 2023-07-01
2023-09-30 0001728328 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001728328 us-gaap:RetainedEarningsMember 2023-07-01
2023-09-30 0001728328 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001728328 us-gaap:CommonStockMember
2023-09-30 0001728328 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001728328 us-gaap:RetainedEarningsMember 2023-09-30 0001728328 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001728328 2023-09-30 0001728328 inm:CustomerOneMember us-
gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001728328 inm:CustomerTwoMember us-
gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001728328 inm:CustomerThreeMember us-
gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001728328 inm:CustomerFourMember us-
gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001728328 inm:CustomerOneMember us-
gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001728328 inm:CustomerTwoMember us-
gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001728328 inm:CustomerThreeMember us-
gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001728328 inm:CustomerFourMember us-
gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001728328 inm:CustomerFiveMember us-
gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001728328 inm:CustomerOneMember us-
gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001728328 inm:CustomerTwoMember us-
gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001728328 inm:CustomerThreeMember us-
gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001728328 inm:CustomerFourMember us-
gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001728328 inm:CustomerOneMember us-
gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001728328 inm:CustomerTwoMember us-
gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001728328 inm:CustomerThreeMember us-
gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001728328 us-
gaap:InventoryValuationAndObsolescenceMember 2024-09-30 0001728328 us-gaap:InventoryValuationAndObsolescenceMember 2024-06-30 0001728328
us-gaap:ComputerEquipmentMember 2024-09-30 0001728328 srt:MinimumMember inm:LabEquipmentMember 2024-09-30 0001728328
srt:MaximumMember inm:LabEquipmentMember 2024-09-30 0001728328 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001728328 us-
gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001728328 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001728328 us-

gaap:WarrantMember 2024-07-01 2024-09-30 0001728328 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001728328 inm:RightofuseAssetsleasesMember 2024-09-30 0001728328 inm:RightofuseAssetsleasesMember 2024-06-30 0001728328 us-gaap:EquipmentMember 2024-09-30 0001728328 us-gaap:EquipmentMember 2024-06-30 0001728328 inm:FurnishingMember 2024-09-30 0001728328 inm:FurnishingMember 2024-06-30 0001728328 inm:ATMAgreementMember 2024-09-30 0001728328 us-gaap:WarrantMember 2024-09-30 0001728328 us-gaap:WarrantMember 2024-06-30 0001728328 us-gaap:WarrantMember 2024-07-01 2024-09-30 0001728328 us-gaap:WarrantMember 2023-07-01 2024-06-30 0001728328 2017-03-24 2017-03-24 0001728328 2023-12-19 0001728328 us-gaap:EmployeeStockOptionMember 2024-09-30 0001728328 us-gaap:EmployeeStockOptionMember 2024-06-30 0001728328 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-09-30 0001728328 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0001728328 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001728328 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001728328 us-gaap:StockCompensationPlanMember 2024-07-01 2024-09-30 0001728328 us-gaap:StockCompensationPlanMember 2023-07-01 2023-09-30 0001728328 inm:UnvestedOptionsMember 2024-09-30 0001728328 2024-07-29 0001728328 2024-07-29 2024-07-29 0001728328 2023-10-05 2023-10-05 0001728328 2023-10-05 0001728328 inm:InMedPharmaSegmentMember 2024-09-30 0001728328 inm:InMedPharmaSegmentMember 2024-06-30 0001728328 inm:BayMedicaSegmentMember 2024-09-30 0001728328 inm:BayMedicaSegmentMember 2024-06-30 0001728328 inm:InMedPharmaMember us-gaap:ReportableSubsegmentsMember 2024-07-01 2024-09-30 0001728328 inm:BayMedicaCommercialMember us-gaap:ReportableSubsegmentsMember 2024-07-01 2024-09-30 0001728328 inm:InMedPharmaMember us-gaap:ReportableSubsegmentsMember 2023-07-01 2023-09-30 0001728328 inm:BayMedicaCommercialMember us-gaap:ReportableSubsegmentsMember 2023-07-01 2023-09-30 0001728328 inm:InMedPharmaMember us-gaap:ReportableSubsegmentsMember 2024-09-30 0001728328 inm:BayMedicaCommercialMember us-gaap:ReportableSubsegmentsMember 2024-09-30 0001728328 inm:InMedPharmaMember us-gaap:ReportableSubsegmentsMember 2023-09-30 0001728328 inm:BayMedicaCommercialMember us-gaap:ReportableSubsegmentsMember 2023-09-30 0001728328 2021-03-11 0001728328 us-gaap:CommonStockMember 2021-03-11 0001728328 inm:NortonRoseFulbrightCanadaLLPMember 2024-07-01 2024-09-30 0001728328 inm:NortonRoseFulbrightCanadaLLPMember 2023-07-01 2023-09-30 0001728328 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001728328 us-gaap:SubsequentEventMember 2024-11-14 2024-11-14 shares iso4217:USD iso4217:USD shares pure utr:sqm 10-Q true 2024-09-30 false 001-39685 INMED PHARMACEUTICALS INC. A1 98-1428279 Suite 1445 - 885 W. Georgia Street Vancouver B.C CA V6C 3E8 (604) 669-7207 Common Shares, no par value INM NASDAQ Yes Yes Non-accelerated Filer true true false false 718032 5583039 6571610 43203 43064 66775 284695 352838 1220073 1244324 148882 477749 7279892 8689585 1343009 1249999 1742205 1783198 100000 100000 10465106 11822782 1011619 1654011 424260 317797 1435879 1971808 633783 644865 2069662 2616673 667013 667013 445948 445948 84198673 82784400 34821829 35368899 -110753627 -109075759 128569 128569 8395444 9206109 10465106 11822782 1264638 901862 771225 880620 493413 21242 771180 1292093 1421926 1298731 54579 54832 19310 -48457 2228375 2694113 57094 136043 -1677868 -2536828 -1677868 -2536828 -2.71 -2.71 -15.24 -15.24 620127 620127 166410 166410 445948 82784400 35368899 -109075759 128569 9206109 186364 1030063 1030063 191824 191824 34701 576034 -576034 -1677868 -1677868 28964 28964 667013 84198673 34821829 -110753627 128569 8395444 166410 77620252 35741115 -101400209 128569 12089727 -2536828 -2536828 25191 25191 166410 77620252 35766306 -103937037 128569 -9578090 -1677868 -2536828 54579 54832 28964 25191 90401 94532 519 538 5270 2018 0 92930 -24251 -390329 -328867 -283018 -3118 -68143 -94549 -642392 -562484 -16171 -106506 -98709 -1826810 -2174213 21324 21317 21324 21317 1030063 191824 838239 -988571 -2174213 6571610 8912517 5583039 6738304 187223 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">1.</td> <td style="text-align: justify">CORPORATE INFORMATION AND CONTINUING OPERATIONS</td></tr> </table>   Business   InMed Pharmaceuticals Inc. (“InMed” or the “Company”) was incorporated in the Province of British Columbia on May 19, 1981 under the Business Corporations Act of British Columbia. InMed is a clinical stage pharmaceutical company developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry.   The Company’s shares are listed on the Nasdaq Capital Market (“Nasdaq”) under the trading symbol “INM”. InMed’s office and principal place of business is located at Suite 1445- 885 West Georgia Street, Vancouver, B.C., Canada, V6C 1B4.   Going Concern   In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued.   Through September 30, 2024, the Company has funded its operations primarily with proceeds from the sale of the Company’s common shares, no par value per share (the “Common Shares”). The Company has incurred recurring losses and negative cash flows from operations since its inception, including net losses of approximately $1.7 and $2.5 million for the three months ended September 30, 2024 and 2023, respectively. In addition, the Company had an accumulated deficit of approximately $110.8 million as of September 30, 2024. The Company expects to continue to generate operating losses for the foreseeable future.   As of the issuance date of these unaudited condensed consolidated financial statements, the Company expects its cash, cash equivalents and short-term investments of $5.6 million as of September 30, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements through the end of the first quarter of calendar 2025, depending on the level and timing of realizing BayMedica revenues from the sale of bulk rare cannabinoids in the ‘health & wellness‘ sector as well as the level and timing of Company operating expenses. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued.   The Company expects to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s existing shareholders.   In connection with the Company’s assessment of going concern considerations in accordance with Subtopic 205-40, management has determined that the Company’s liquidity condition raises substantial doubt about the Company’s ability to continue as a going concern, which is considered to be for a period of one year from the issuance of these condensed consolidated financial statements. These unaudited condensed consolidated financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts of classification of liabilities that might result from the outcome of this uncertainty. Such adjustments could be material. 1981-05-19 -1700000 -2500000 -110800000 5600000 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">2.</td> <td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES</td></tr> </table>   Basis of Presentation   These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles as applied in the United States (“US GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for financial information.   These unaudited condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended September 30, 2024 and 2023 are not necessarily indicative of results that can be expected for a full year. These unaudited condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the fiscal year ended June 30, 2024.   On November 14, 2024, the Company effected a reverse stock split of the Company’s issued and outstanding Common Shares, by a ratio of 20-to-1 (the “Reverse Stock Split”). Accordingly, all Common Shares, stock options, warrants, as well as per share information, for all periods presented in the condensed consolidated financial statements and notes thereto have been adjusted retrospectively to reflect this Reverse Stock Split.   Reclassifications   Certain prior year amounts in the unaudited condensed consolidated financial statements and the notes thereto have been reclassified where necessary to conform to the current year’s presentation. These reclassifications did not affect the prior period’s total assets, total liabilities, stockholders’ deficit, net loss or net cash used in operating activities. During the year ended June 30, 2024, the Company adopted ASU 2023-07 - Improvements to Reportable Segment Disclosures which has required prior periods to reflect the change in presentation. Refer to

discussion on Recent Accounting Pronouncements below.   Use of Estimates   The preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported. It also requires management to exercise judgment in applying the Company's accounting policies. In the future, actual experience may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these unaudited condensed consolidated financial statements are the application of the going concern assumptions, determining the fair value of share-based payments, income tax provisions, write-down of inventories to net realizable value, and the assumptions used in the determination of research & development accruals.   Actual results could differ from those estimates.   Basis of Consolidation   These unaudited consolidated financial statements include the accounts of the Company and its subsidiaries, including subsidiaries: InMed Pharmaceutical Ltd;, BayMedica, LLC; Biogen Sciences Inc.; and Sweetnam Consulting Inc. A subsidiary is an entity that the Company controls, either directly or indirectly, where control is defined as the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. All inter-company transactions and balances including unrealized income and expenses arising from intercompany transactions are eliminated in preparing these condensed consolidated financial statements.   Foreign Currency   The functional currency of the Company and its subsidiaries is the U.S. Dollar. These unaudited condensed consolidated financial statements are presented in U.S. Dollars. References to "$" and "US$" are to United States ("U.S.") dollars and references to "C$" are to Canadian dollars.   Cash and Cash Equivalents   Cash and cash equivalents include cash-on-hand, demand deposits with financial institutions and other short-term, highly liquid investments with original maturities of three months or less when acquired that are readily convertible to known amounts of cash and subject to an insignificant risk of change in value. As of September 30, 2024 and June 30, 2024, the Company held $1,964,203 and $1,939,482, respectively, of cash equivalents in a money market fund that is considered Level 1 in the financial instruments hierarchy due to the readily available quoted prices in active markets for identical instruments. Short-term Investments   Short-term investments include fixed and variable rate guaranteed investment certificates, with terms greater than three months and less than twelve months. Due to the short-term nature of these investments the fair value of the investments approximates the current value. Guaranteed investment certificates are convertible to known amounts of cash and are subject to an insignificant risk of change in value.   Accounts Receivable   Accounts receivable are recorded at invoiced amounts, net of any credit losses. The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in existing accounts receivable.   The Company evaluates the collectability of accounts receivable on a regular basis based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience.   Concentration of Credit Risk and Other Risks and Uncertainties   At times, cash balances may exceed the Federal Deposit Insurance Corporation ("FDIC") or Canadian Deposit Insurance Corporation insurable limits. The Company has not previously experienced any losses related to these balances. The uninsured cash balance as of September 30, 2024 was $1.6 million. The Company does not believe it is exposed to significant credit risk on cash and cash equivalents.   The Company's customers are primarily concentrated in the United States.   As of September 30, 2024, the Company had four customers with an accounts receivable balance representing 25%, 23%, 22%, and 20% of total accounts receivable. As of June 30, 2024, we had five customers with an accounts receivable balance representing 32%, 20%, 15%,15% and 14% of total accounts receivable.   For the three months ended September 30, 2024, the Company had four customers that accounted for 22%, 20%, 18%, and 15% of revenue. For the three months ended September 30, 2023, the Company had three customers that accounted for 34%, 20%, and 11% of revenue.   Inventories   Inventories are initially valued at weighted average cost and subsequently valued at the lower of weighted average cost and net realizable value. Costs included in inventories are the purchase price of goods and cost of services rendered, freight costs, warehousing costs, purchasing costs and production and labor costs related to manufacturing.   In determining any valuation allowances, the Company reviews inventory for obsolete, redundant, and slow-moving goods. As of September 30, 2024 and June 30, 2024, the Company had $103,434 as a valuation allowance to reduce weighted average cost to net realizable value. During the three months ended September 30, 2024 and 2023, the Company recorded an inventory write-down due to net realizable value of $0 and $92,930, respectively.   Property, Equipment and ROU Assets, Net   Computer equipment, lab equipment and furnishings are recorded at cost, less accumulated depreciation and accumulated impairment losses. The initial cost of computer equipment, lab equipment and furnishings comprises their purchase price. The computer equipment, lab equipment and furnishings are reviewed at least once per year for impairment. Equipment and furniture are depreciated using the straight-line method based on their estimated useful lives as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">●</td> <td style="text-align: justify">Computer equipment — 5 years</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td style="text-align: justify">Lab equipment — 6 - 10 years</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">●</td> <td style="text-align: justify">Furnishings — 5 years</td></tr> </table>   Computer equipment, lab equipment and furnishings, acquired or disposed of during the year, are depreciated proportionately for the period they are in use. The ROU assets are initially measured based on the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, less any lease incentives received. The assets are amortized to the earlier of the end of the useful life of the ROU asset or the lease term using the straight-line method as this most closely reflects the expected pattern of consumption of the future economic benefits. The lease term includes periods covered by an option to extend if the Company is reasonably certain to exercise that option. In addition, the ROU assets are periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability (see Note 2 Lease (i)).   Intangible Assets, Net   Intangible assets are comprised of acquired intellectual property, which consists of certain patents and technical know-how. The intellectual property is recorded at cost and is amortized on a straight-line basis over an estimated useful life of 18 years net of any accumulated impairment losses. There was no impairment

loss during the three months ended September 30, 2024 and 2023.   In-Process R&D   In-process R&D ("IPR&D") is classified as an indefinite-lived intangible asset and is not amortized. IPR&D becomes definite-lived upon the completion or abandonment of the associated research and development efforts. All research and development costs incurred subsequent to the acquisition of IPR&D are expensed as incurred. Indefinite-lived intangible assets are evaluated for impairment on an annual basis or more frequently if an indicator of impairment is present.   Impairment of Long-Lived Assets   The Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or assets. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured as the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets classified as held for sale are reported at the lower of the carrying amount or fair value, less costs to sell.   Fair Value Measurements   Financial Assets   Financial assets are initially recognized at fair value, plus transaction costs that are directly attributable to their acquisition or issue and subsequently carried at amortized cost, using the effective interest rate method, less any impairment losses. No financial assets are elected to be carried at fair value through profit or loss, or where changes in fair value are recognized in these consolidated statements of operations and comprehensive loss in other comprehensive loss.   Short-term investments are subsequently recorded at cost plus accrued interest, which approximates fair value due to their short-term nature. Accounts receivable are reported at outstanding amounts, net of credit losses. Financial Liabilities   To determine the fair value of financial instruments, the Company uses the fair value hierarchy for inputs used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 72px">Level 1 -</td> <td style="text-align: justify"> Unadjusted quoted prices in active markets for identical instruments. </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 72px">Level 2 - </td> <td style="text-align: justify">Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 72px">Level 3 -</td> <td style="text-align: justify">Inputs are unobservable and reflect the Company's assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.</td></tr> </table>   The carrying value of cash and cash equivalents, short-term investments, accounts receivable, and accounts payable and accrued liabilities, approximate their carrying values as at September 30 2024 and June 30, 2024 due to their immediate or short-term maturities.   Revenue Recognition   The Company recognizes revenue when the Company satisfies the performance obligations under the terms of a contract and control of its products and services is transferred to its customers in an amount that reflects the consideration the Company expects to receive from its customers in exchange for those products and services. ASC 606, Revenue from Contracts with Customers defines a five-step process to recognize revenue that requires judgment and estimates, including identifying the contract with the customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract, and recognizing revenue when or as the performance obligation is satisfied.   Revenue consists of manufacturing and distribution sales of bulk rare cannabinoids, which are generally recognized at a point in time. The Company recognizes revenue when control over the products has been transferred to the customer and the Company has a present right to payment. Sales and other taxes that are required to be remitted to regulatory authorities are recorded as liabilities and excluded from sales. Limited rights of return, for claims of damaged or non-compliant products, exist with the Company's customers.   The Company has elected the practical expedient that allows it to recognize the incremental costs of obtaining a contract as an expense, when incurred, if the amortization period of the asset that the Company otherwise would have recognized is one year or less.   Revenues within the scope of ASC 606 do not include material amounts of variable consideration. Customer payments are generally due in advance of when control is transferred to the customer. Some of our larger customers are eligible for payment terms up to 'net 30 days'.   Cost of Sales   Cost of sales consists primarily of the purchase price of goods and cost of services rendered, freight costs, warehousing costs, and purchasing costs. Cost of sales also includes production and labor costs for the Company's manufacturing business. Shipping and Handling   The Company records freight billed to customers within net sales. Shipping and handling costs associated with inbound freight and goods shipped to customers are recorded in cost of sales. Other shipping and handling costs, such as for quality assurance, are recorded in operating expenses.   Earnings (Loss) Per Share   Basic earnings (loss) per Common Share ("EPS") is computed by dividing the net income or loss applicable to Common Shares by the weighted average number of Common Shares outstanding for the relevant period. Diluted earnings (loss) per Common Share ("Diluted EPS") is computed by dividing the net income or loss applicable to Common Shares by the sum of the weighted average number of Common Shares issued and outstanding and all additional Common Shares that would have been outstanding, if potentially dilutive instruments were converted. If the conversion of outstanding stock options and warrants into Common Shares is anti-dilutive, then diluted EPS is not presented separately from EPS.   The following table sets forth the number of potential Common Shares that have been excluded from diluted net income (loss) per because their effect was anti-dilutive: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight:

bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">33,724</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">5,107</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">509,602</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">175,826</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 22.5pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">543,326</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">180,933</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   Share-based Payments   The Company follows the requirements of FASB ASC 718-10-10, Share-Based Payments with regards to stock-based compensation issued to employees and non-employees. The Company has agreements and arrangements that call for stock to be awarded to the employees and consultants at various times as compensation and periodic bonuses. The expense for this stock-based compensation is equal to the fair value of the stock price on the day the stock was awarded multiplied by the number of shares awarded. The Company has a relatively low forfeiture rate of stock-based compensation and forfeitures are recognized as they occur.   The valuation methodology used to determine the fair value of the options issued during the period is the Black-Scholes option-pricing model. The Black-Scholes model requires the use of a number of assumptions, including the volatility of the stock price, the average risk-free interest rate, and the weighted average expected life of the options. Risk-free interest rates are calculated based on continuously compounded risk-free rates for the appropriate term. The dividend yield is assumed to be zero as the Company has never paid or declared any cash dividends on its Common Shares and does not intend to pay dividends on its Common Shares in the foreseeable future. The expected forfeiture rate is estimated based on management's best assessment.   Estimated volatility is a measure of the amount by which InMed's stock price is expected to fluctuate each year during the expected life of the award. The Company's calculation of estimated volatility is based on historical stock prices over a period equal to the expected life of the awards.   Research and Development Costs   The Company conducts research and development programs and incurs costs related to these activities, including research and development personnel compensation, services provided by contract research organizations and lab supplies. Research and development costs are expensed in the periods in which they are incurred. Patents and Intellectual Property Costs   The costs of filing for patents and of prosecuting and maintaining intellectual property rights are expensed as incurred due to the uncertainty surrounding the drug development process and the uncertainty of future benefits. Patents and intellectual property acquired from third parties for approved products or where there are alternative future uses are capitalized and amortized over the remaining life of the patent.   Segment reporting   The Company's operations consist of two operating and reportable segments, the "InMed Pharma" segment and the "BayMedica Commercial" segment.   The "InMed Pharma" segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the "BayMedica Commercial" segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry (See Note 10).   Leases   At inception of a contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.   The lease liability is initially measured as the present value of future lease payments excluding payments made at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate. The lease liability is measured at amortized cost using the effective interest method. It is re-measured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Company's estimate of the amount expected to be payable under a residual value guarantee, or if the Company changes its assessment of whether it will exercise a purchase, extension, or termination option. When the lease liability is re-measured in this way, a corresponding adjustment is made to the carrying amount of the ROU asset or is recorded in profit or loss if the carrying amount of the ROU asset has been reduced to nil.   The Company has lease arrangements that include both lease and non-lease components. The Company accounts for each separate lease component and its associated non-lease components as a single lease component for all of its asset classes.   The Company has elected to apply the practical expedient to exclude initial direct costs such as annual operating costs from the measurement of the ROU asset at the date of initial application. The Company has elected to apply the practical expedient not to recognize ROU assets and lease liabilities for short-term leases that have a lease term of 12 months or less. The lease payments associated with these leases is recognized as an expense on a straight-line basis over the lease term.   Recent Accounting Pronouncements   The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in these unaudited condensed consolidated financial statements as a result of future adoption.   In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements primarily through expanded disclosures around significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company has early adopted this accounting pronouncement.   In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires disclosure of specific categories meeting a quantitative threshold within the income tax rate reconciliation, as well as disaggregation of income taxes paid by jurisdiction. This ASU, which can be applied either prospectively or retrospectively, is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this ASU and expects to include updated income tax disclosures in its fiscal year 2026. Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles as applied in the United States ("US GAAP") and pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC") for financial information. These unaudited condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended September 30, 2024 and 2023 are not necessarily indicative of results that can be expected for a full year. These unaudited condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the fiscal year ended June 30, 2024. On November 14, 2024, the Company effected a reverse stock split of the Company's issued and outstanding Common Shares, by a ratio of 20-to-1 (the "Reverse Stock Split"). Accordingly, all Common Shares, stock options, warrants, as well as per share information, for all periods presented in the condensed consolidated financial statements and notes thereto have been adjusted retrospectively to reflect this Reverse Stock Split. Reclassifications Certain prior year amounts in the unaudited condensed consolidated financial statements and the notes thereto have been reclassified where necessary to conform to the

current year's presentation. These reclassifications did not affect the prior period's total assets, total liabilities, stockholders' deficit, net loss or net cash used in operating activities. During the year ended June 30, 2024, the Company adopted ASU 2023-07 - Improvements to Reportable Segment Disclosures which has required prior periods to reflect the change in presentation. Refer to discussion on Recent Accounting Pronouncements below. Use of Estimates The preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported. It also requires management to exercise judgment in applying the Company's accounting policies. In the future, actual experience may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these unaudited condensed consolidated financial statements are the application of the going concern assumptions, determining the fair value of share-based payments, income tax provisions, write-down of inventories to net realizable value, and the assumptions used in the determination of research & development accruals. Actual results could differ from those estimates. Basis of Consolidation These unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, including subsidiaries: InMed Pharmaceutical Ltd;, BayMedica, LLC; Biogen Sciences Inc.; and Sweetnam Consulting Inc. A subsidiary is an entity that the Company controls, either directly or indirectly, where control is defined as the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. All inter-company transactions and balances including unrealized income and expenses arising from intercompany transactions are eliminated in preparing these condensed consolidated financial statements. Foreign Currency The functional currency of the Company and its subsidiaries is the U.S. Dollar. These unaudited condensed consolidated financial statements are presented in U.S. Dollars. References to "$" and "US$" are to United States ("U.S.") dollars and references to "C$" are to Canadian dollars. Cash and Cash Equivalents Cash and cash equivalents include cash-on-hand, demand deposits with financial institutions and other short-term, highly liquid investments with original maturities of three months or less when acquired that are readily convertible to known amounts of cash and subject to an insignificant risk of change in value. As of September 30, 2024 and June 30, 2024, the Company held $1,964,203 and $1,939,482, respectively, of cash equivalents in a money market fund that is considered Level 1 in the financial instruments hierarchy due to the readily available quoted prices in active markets for identical instruments.   1964203 1939482 Short-term Investments Short-term investments include fixed and variable rate guaranteed investment certificates, with terms greater than three months and less than twelve months. Due to the short-term nature of these investments the fair value of the investments approximates the current value. Guaranteed investment certificates are convertible to known amounts of cash and are subject to an insignificant risk of change in value. Accounts Receivable Accounts receivable are recorded at invoiced amounts, net of any credit losses. The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in existing accounts receivable. The Company evaluates the collectability of accounts receivable on a regular basis based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. Concentration of Credit Risk and Other Risks and Uncertainties At times, cash balances may exceed the Federal Deposit Insurance Corporation ("FDIC") or Canadian Deposit Insurance Corporation insurable limits. The Company has not previously experienced any losses related to these balances. The uninsured cash balance as of September 30, 2024 was $1.6 million. The Company does not believe it is exposed to significant credit risk on cash and cash equivalents. The Company's customers are primarily concentrated in the United States. As of September 30, 2024, the Company had four customers with an accounts receivable balance representing 25%, 23%, 22%, and 20% of total accounts receivable. As of June 30, 2024, we had five customers with an accounts receivable balance representing 32%, 20%, 15%,15% and 14% of total accounts receivable. For the three months ended September 30, 2024, the Company had four customers that accounted for 22%, 20%, 18%, and 15% of revenue. For the three months ended September 30, 2023, the Company had three customers that accounted for 34%, 20%, and 11% of revenue. 1600000 0.25 0.23 0.22 0.20 0.32 0.20 0.15 0.15 0.14 0.22 0.20 0.18 0.15 0.34 0.20 0.11 Inventories Inventories are initially valued at weighted average cost and subsequently valued at the lower of weighted average cost and net realizable value. Costs included in inventories are the purchase price of goods and cost of services rendered, freight costs, warehousing costs, purchasing costs and production and labor costs related to manufacturing. In determining any valuation allowances, the Company reviews inventory for obsolete, redundant, and slow-moving goods. As of September 30, 2024 and June 30, 2024, the Company had $103,434 as a valuation allowance to reduce weighted average cost to net realizable value. During the three months ended September 30, 2024 and 2023, the Company recorded an inventory write-down due to net realizable value of $0 and $92,930, respectively. 103434 103434 0 92930 Property, Equipment and ROU Assets, Net Computer equipment, lab equipment and furnishings are recorded at cost, less accumulated depreciation and accumulated impairment losses. The initial cost of computer equipment, lab equipment and furnishings comprises their purchase price. The computer equipment, lab equipment and furnishings are reviewed at least once per year for impairment. Equipment and furniture are depreciated using the straight-line method based on their estimated useful lives as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">●</td> <td style="text-align: justify">Computer equipment — 5 years</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td style="text-align: justify">Lab equipment — 6 - 10 years</td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">●</td> <td style="text-align: justify">Furnishings — 5 years</td></tr> </table> Computer equipment, lab equipment and furnishings, acquired or disposed of during the year, are depreciated proportionately for the period they are in use. The ROU assets are initially measured based on the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, less any lease incentives received. The assets are amortized to the earlier of the end of the useful life of the ROU asset or the lease term using the straight-line method as this most closely reflects the expected pattern of consumption of the future economic benefits. The lease term includes periods covered by an option to extend if the Company is reasonably certain to exercise that option. In addition, the ROU assets are periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability (see Note 2 Lease (i)). P5Y P6Y P10Y P5Y Intangible Assets, Net Intangible assets are comprised of acquired intellectual property, which consists of certain patents and technical know-how. The intellectual property is recorded at cost and is amortized on a straight-line basis over an estimated useful life of 18 years net of any accumulated impairment losses. There was no impairment loss during the three months ended September 30, 2024 and 2023. P18Y In-Process R&D In-process R&D ("IPR&D") is classified as an indefinite-lived intangible asset and is not amortized. IPR&D becomes definite-lived upon the completion or abandonment of the associated research and development efforts. All research and development costs incurred subsequent to the acquisition of IPR&D are expensed as incurred. Indefinite-lived intangible assets are evaluated for impairment on an annual basis or more frequently if an indicator of impairment is present. Impairment of Long-Lived Assets The Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or assets. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured as the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets classified as held for sale are reported at the lower of the carrying amount or fair value, less costs to sell. Fair Value Measurements Financial Assets Financial assets are initially recognized at fair value, plus transaction costs that are directly attributable to their acquisition or issue and subsequently carried at amortized cost, using the effective interest rate method, less any impairment losses. No financial assets are elected to be carried at fair value through profit or loss, or where

changes in fair value are recognized in these consolidated statements of operations and comprehensive loss in other comprehensive loss. Short-term investments are subsequently recorded at cost plus accrued interest, which approximates fair value due to their short-term nature. Accounts receivable are reported at outstanding amounts, net of credit losses. Financial Liabilities To determine the fair value of financial instruments, the Company uses the fair value hierarchy for inputs used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority). <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 72px">Level 1 -</td> <td style="text-align: justify">Unadjusted quoted prices in active markets for identical instruments. </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 72px">Level 2 -</td> <td style="text-align: justify">Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 72px">Level 3 -</td> <td style="text-align: justify">Inputs are unobservable and reflect the Company's assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.</td></tr> </table> The carrying value of cash and cash equivalents, short-term investments, accounts receivable, and accounts payable and accrued liabilities, approximate their carrying values as at September 30 2024 and June 30, 2024 due to their immediate or short-term maturities. Revenue Recognition The Company recognizes revenue when the Company satisfies the performance obligations under the terms of a contract and control of its products and services is transferred to its customers in an amount that reflects the consideration the Company expects to receive from its customers in exchange for those products and services. ASC 606, Revenue from Contracts with Customers defines a five-step process to recognize revenue that requires judgment and estimates, including identifying the contract with the customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract, and recognizing revenue when or as the performance obligation is satisfied.   Revenue consists of manufacturing and distribution sales of bulk rare cannabinoids, which are generally recognized at a point in time. The Company recognizes revenue when control over the products has been transferred to the customer and the Company has a present right to payment. Sales and other taxes that are required to be remitted to regulatory authorities are recorded as liabilities and excluded from sales. Limited rights of return, for claims of damaged or non-compliant products, exist with the Company's customers. The Company has elected the practical expedient that allows it to recognize the incremental costs of obtaining a contract as an expense, when incurred, if the amortization period of the asset that the Company otherwise would have recognized is one year or less. Revenues within the scope of ASC 606 do not include material amounts of variable consideration. Customer payments are generally due in advance of when control is transferred to the customer. Some of our larger customers are eligible for payment terms up to 'net 30 days'. Cost of Sales Cost of sales consists primarily of the purchase price of goods and cost of services rendered, freight costs, warehousing costs, and purchasing costs. Cost of sales also includes production and labor costs for the Company's manufacturing business. Shipping and Handling The Company records freight billed to customers within net sales. Shipping and handling costs associated with inbound freight and goods shipped to customers are recorded in cost of sales. Other shipping and handling costs, such as for quality assurance, are recorded in operating expenses. Earnings (Loss) Per Share Basic earnings (loss) per Common Share ("EPS") is computed by dividing the net income or loss applicable to Common Shares by the weighted average number of Common Shares outstanding for the relevant period. Diluted earnings (loss) per Common Share ("Diluted EPS") is computed by dividing the net income or loss applicable to Common Shares by the sum of the weighted average number of Common Shares issued and outstanding and all additional Common Shares that would have been outstanding, if potentially dilutive instruments were converted. If the conversion of outstanding stock options and warrants into Common Shares is anti-dilutive, then diluted EPS is not presented separately from EPS. The following table sets forth the number of potential Common Shares that have been excluded from diluted net income (loss) per because their effect was anti-dilutive: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">33,724</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">5,107</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">509,602</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">175,826</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 22.5pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">543,326</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">180,933</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> The following table sets forth the number of potential Common Shares that have been excluded from diluted net income (loss) per because their effect was anti-dilutive:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">33,724</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">5,107</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">509,602</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">175,826</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 22.5pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">543,326</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">180,933</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 33724 5107 509602 175826 543326 180933 Share-based Payments The Company follows the requirements of FASB ASC 718-10-10, Share-Based Payments with regards to stock-based compensation issued to employees and non-employees. The Company has agreements and arrangements that call for stock to be awarded to the employees and consultants at various times as compensation and periodic bonuses. The expense for this stock-based compensation is equal to the fair value of the stock price on the day the stock was awarded multiplied by the number of shares awarded. The Company has a relatively low forfeiture rate of stock-based compensation and forfeitures are recognized as they occur. <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt

0.25in; text-align: justify">The valuation methodology used to determine the fair value of the options issued during the period is the Black-Scholes option-pricing model. The Black-Scholes model requires the use of a number of assumptions, including the volatility of the stock price, the average risk-free interest rate, and the weighted average expected life of the options. Risk-free interest rates are calculated based on continuously compounded risk-free rates for the appropriate term. The dividend yield is assumed to be zero as the Company has never paid or declared any cash dividends on its Common Shares and does not intend to pay dividends on its Common Shares in the foreseeable future. The expected forfeiture rate is estimated based on management's best assessment. Estimated volatility is a measure of the amount by which InMed's stock price is expected to fluctuate each year during the expected life of the award. The Company's calculation of estimated volatility is based on historical stock prices over a period equal to the expected life of the awards. Research and Development Costs The Company conducts research and development programs and incurs costs related to these activities, including research and development personnel compensation, services provided by contract research organizations and lab supplies. Research and development costs are expensed in the periods in which they are incurred. Patents and Intellectual Property Costs The costs of filing for patents and of prosecuting and maintaining intellectual property rights are expensed as incurred due to the uncertainty surrounding the drug development process and the uncertainty of future benefits. Patents and intellectual property acquired from third parties for approved products or where there are alternative future uses are capitalized and amortized over the remaining life of the patent. Segment reporting The Company's operations consist of two operating and reportable segments, the "InMed Pharma" segment and the "BayMedica Commercial" segment. The "InMed Pharma" segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the "BayMedica Commercial" segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry (See Note 10). Leases At inception of a contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The lease liability is initially measured as the present value of future lease payments excluding payments made at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate. The lease liability is measured at amortized cost using the effective interest method. It is re-measured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Company's estimate of the amount expected to be payable under a residual value guarantee, or if the Company changes its assessment of whether it will exercise a purchase, extension, or termination option. When the lease liability is re-measured in this way, a corresponding adjustment is made to the carrying amount of the ROU asset or is recorded in profit or loss if the carrying amount of the ROU asset has been reduced to nil. The Company has lease arrangements that include both lease and non-lease components. The Company accounts for each separate lease component and its associated non-lease components as a single lease component for all of its asset classes. The Company has elected to apply the practical expedient to exclude initial direct costs such as annual operating costs from the measurement of the ROU asset at the date of initial application. The Company has elected to apply the practical expedient not to recognize ROU assets and lease liabilities for short-term leases that have a lease term of 12 months or less. The lease payments associated with these leases is recognized as an expense on a straight-line basis over the lease term. Recent Accounting Pronouncements The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in these unaudited condensed consolidated financial statements as a result of future adoption. In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements primarily through expanded disclosures around significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company has early adopted this accounting pronouncement. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires disclosure of specific categories meeting a quantitative threshold within the income tax rate reconciliation, as well as disaggregation of income taxes paid by jurisdiction. This ASU, which can be applied either prospectively or retrospectively, is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this ASU and expects to include updated income tax disclosures in its fiscal year 2026. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">3.</td> <td style="text-align: justify">INVENTORIES</td></tr> </table>   Inventories consisted of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">274,445</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">372,695</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Work in process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,446</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,817</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">927,182</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">840,812</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Inventories</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,220,073</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,244,324</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> Inventories consisted of the following:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">274,445</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right">372,695</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Work in process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,446</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,817</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">927,182</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">840,812</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Inventories</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,220,073</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,244,324</td><td style="padding-bottom: 4pt; text-

align: left"> </td></tr> </table> 274445 372695 18446 30817 927182 840812 1220073 1244324 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">4.</td> <td style="text-align: justify">PROPERTY, EQUIPMENT AND ROU ASSETS, NET</td></tr> </table>   Property, equipment and ROU assets consisted of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">ROU Assets (leases)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,901,692</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,135,811</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">429,092</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">429,090</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Furnishings</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,409</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,409</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">Property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,371,193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,605,310</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,028,184</td><td style="padding-bottom: 1.5pt; text-align: left">) </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,355,311</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Property, equipment and ROU assets, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,343,009</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,249,999</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   Depreciation expense on computer equipment, lab equipment and furnishing for the three months ended September 30, 2024 and 2023, was $13,586 and $13,839, respectively, and was recorded in general and administrative expenses. Amortization expense related to the ROU assets for the three months ended September 30, 2024 and 2023, was $90,401 and $94,532, respectively, and was recorded in general and administrative expenses.</p> Property, equipment and ROU assets consisted of the following:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">ROU Assets (leases)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,901,692</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,135,811</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">429,092</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">429,090</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Furnishings</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,409</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,409</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">Property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,371,193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,605,310</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,028,184</td><td style="padding-bottom: 1.5pt; text-align: left">) </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,355,311</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Property, equipment and ROU assets, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,343,009</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,249,999</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 1901692 2135811 429092 429090 40409 40409 2371193 2605310 1028184 1355311 1343009 1249999 13586 13839 90401 94532 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">5.</td> <td style="text-align: justify">INTANGIBLE ASSETS</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-indent: 1.2pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 1.2pt">The following table summarizes the Companies intangible assets:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-indent: 1.2pt"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Intellectual property</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,736,420</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,736,420</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Patents</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,191,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,191,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,927,420</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,927,420</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,185,215</td><td style="padding-bottom: 1.5pt; text-align: left">) </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,144,222</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Intangible assets, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,742,205</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,783,198</td><td style="padding-bottom: 4pt; text-

align: left"> </td></tr> </table>   Acquired intellectual property is recorded at cost and is amortized on a straight-line basis over 18 years. Acquired patents consist of patents related to the development of cannabinoid analogs. This intangible asset is being amortized over an estimated useful life of 18 years. As at September 30, 2024, the definite-lived intangible assets had a weighted average estimated remaining useful life of approximately 11 years. Amortization expense on intangible assets for the three months ended September 30, 2024 and 2023 was $40,993 and $40,993 respectively. The Company expects amortization expense to be incurred over the next five years as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Twelve months ending September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">162,746</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">162,746</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">162,746</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">162,746</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">162,746</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">928,475</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,742,205</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> The following table summarizes the Companies intangible assets:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Intellectual property</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,736,420</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,736,420</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Patents</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,191,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,191,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,927,420</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,927,420</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,185,215</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,144,222</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Intangible assets, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,742,205</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,783,198</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 1736420 1736420 1191000 1191000 2927420 2927420 1185215 1144222 1742205 1783198 P18Y P18Y P11Y 40993 40993 The Company expects amortization expense to be incurred over the next five years as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Twelve months ending September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">162,746</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">162,746</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">162,746</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">162,746</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">162,746</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">928,475</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,742,205</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 162746 162746 162746 162746 162746 928475 1742205 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">6.</td> <td style="text-align: justify">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accounts payable and accrued liabilities consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">$</td><td> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Trade payables</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">448,995</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">626,190</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">238,412</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">242,066</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Inventory related accruals</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,004</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Employee compensation, benefits and related accruals</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">236,691</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">488,278</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">85,521</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">256,473</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black

4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,011,619</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,654,011</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> Accounts payable and accrued liabilities consist of the following:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Trade payables</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">448,995</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right">626,190</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">238,412</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">242,066</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Inventory related accruals</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,004</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Employee compensation, benefits and related accruals</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">236,691</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">488,278</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">85,521</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">256,473</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,011,619</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,654,011</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 448995 626190 238412 242066 2000 41004 236691 488278 85521 256473 1011619 1654011 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">7.</td> <td style="text-align: justify">SHARE CAPITAL AND RESERVES</td></tr> </table>   Authorized   As of September 30, 2024, the Company's authorized share structure consisted of: (i) an unlimited number of Common Shares; and (ii) an unlimited number of preferred shares without par value. No preferred shares were issued and outstanding as of September 30, 2024 and June 30, 2024.   The Company may, from time to time, issue preferred shares and may, at the time of issuance, determine the rights, preferences and limitations pertaining to these shares. Holders of preferred shares may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding up of the Company before any payment is made to the holders of Common Shares.   On June 27, 2024, the Company entered into an amendment (the "ATM Amendment") to its At-the-Market Offering Agreement, dated April 7, 2022 (the "Original ATM Agreement" and together with the ATM Amendment, the "Amended ATM Agreement"), pursuant to which the Company may offer and sell Common Shares, from time to time, in "at the market" offerings through the Agent. The ATM Amendment amends the Original ATM Agreement to reflect, among other provisions, updates to certain sales settlement provisions and reimbursement terms, and to supplement the representations being made by the Company to the Agent. During the three months ended September 30, 2024, the Company issued 186,364 Common Shares for gross proceeds of approximately $1.0 million. This amount has been offset by financing fees of approximately $192,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Common Share Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company did not grant any warrants during the three months ended September 30, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A summary of the Company's warrant activity and related information for the periods covered were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of
 Shares
 Under
 Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted
 Average
 Exercise
 Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Balance as at June 30, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">544,303</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20.40</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-left: 9pt">Warrants Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 9pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(34,701</td><td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Expire/Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Warrants Outstanding as at September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">509,602</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">22.60</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Warrants Exercisable as at September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">509,602</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">22.60</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   As of September 30, 2024 and June 30, 2024, the warrants exercisable and outstanding have an intrinsic value of $nil and $184,539, respectively, with a weighted average remaining life of 4 years and 6 years, respectively.</p> 186364 1000000 192000 A summary of the Company's warrant activity and related information for the periods covered were as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of
 Shares
 Under
 Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted
 Average
 Exercise
 Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Balance as at June 30, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">544,303</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20.40</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-left: 9pt">Warrants Granted</td><td> </td> <td

style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 9pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(34,701</td><td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Expire/Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Warrants Outstanding as at September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">509,602</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">22.60</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Warrants Exercisable as at September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">509,602</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">22.60</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 544303 20.4 34701 509602 22.6 509602 22.6 184539 P4Y P6Y <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">8. </td> <td style="text-align: justify">SHARE-BASED PAYMENTS </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in; padding-left: 4.5pt; text-align: justify; text-indent: -4.5pt">a)</td> <td style="padding-left: 4.5pt; text-align: justify; text-indent: -4.5pt">Option Plan Details</td></tr> </table>   On March 24, 2017, and as amended on November 20, 2020, the Company's shareholders approved: (i) the adoption of a new stock option plan (the "Plan") pursuant to which the Company's Board of Directors may, from time to time, in its discretion and in accordance with applicable regulatory requirements, grant to directors, officers, employees and consultants of the Company, non-transferable options to purchase Common Shares, provided that the number of Common Shares reserved for issuance will not exceed twenty percent (20%) of the issued and outstanding Common Shares at the date the options are granted (on a non-diluted and rolling basis); and (ii) the application of the Plan to all outstanding stock options of the Company that were granted prior to March 24, 2017 under the terms of the Company's previous stock option plan. On December 19, 2023, the Company's Board of Directors approved the reservation of an additional 35,000 Common Shares under the Plan.   As of each of September 30, 2024 and June 30, 2024, there were 34,224 stock options immediately available for future allocation pursuant to applicable regulatory requirements. The maximum number of options issuable under the terms of the Plan equates to 20% of the then issued and outstanding shares. The option price under each option shall not be less than the closing price on the day prior to the date of grant. All options vest upon terms as set by the Board of Directors, either over time, up to 36 months, or upon the achievement of certain corporate milestones.   The Company did not grant any stock options during the three months ended September 30, 2024.   As of September 30, 2024 the Company had 10,804 vested and exercisable options with a weighted average exercise price of $163.00 and 22,919 unvested options with a weighted average exercise price of $8.40   Total expenses arising from share-based payment transactions recognized during the three months ended September 30, 2024 and 2023 were $28,964 and $25,191, respectively, of which $17,564 and $15,431, respectively, was allocated to general and administrative expenses, $11,180 and $9,761, respectively, was allocated to research and development expenses, and $220 and $0, respectively, was allocated to Cost of Goods sold.   Unrecognized compensation cost as at September 30, 2024 (which related to unvested options) was $78,685, which will be recognized over a weighted-average vesting period of approximately 1.3 years. </p> 0.20 35000 34224 34224 0.20 10804 163 22919 0.4 28964 25191 17564 15431 11180 9761 220 0 78685 P1Y3M18D <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify">9.</td> <td style="text-align: justify">LEASE OBLIGATIONS</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: -1.2pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company is committed to minimum lease payments as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: justify">Maturity Analysis</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="2" style="text-align: center">$</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Year 1</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">469,668</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Year 2</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">453,191</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Year 3</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">219,261</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Year 4</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Year 5</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">More than five years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Total undiscounted lease liabilities⁽¹⁾</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,142,120</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(84,077</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,058,043</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Less: Current portion of lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(424,260</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Non-current portion of lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">633,783</td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr> </table>   On July 29, 2024, the Company entered into a lease agreement for new office space. This office occupies approximately 2,243 square feet with a monthly basic rental rate and operating charges of an estimated C$12,296 for the two-year term of the agreement. The Company used an incremental borrowing rate of 7% and recognized a ROU asset and corresponding operating lease liability of $205,201.   On October 5, 2023, BayMedica amended its lease located at 458 Carlton Court, Suite C, South San Francisco, California, in order to extend its lease to May 14, 2027.

The Company is obligated to pay $1,295,759 over the three-year period unless terminated before the end of the period. The Company used an incremental borrowing rate of 6.15% and recognized a ROU asset and corresponding operating lease liability of $953,935.</p> The Company is committed to minimum lease payments as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: justify">Maturity Analysis</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="2" style="text-align: center">$</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Year 1</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">469,668</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Year 2</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">453,191</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Year 3</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">219,261</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Year 4</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Year 5</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">More than five years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Total undiscounted lease liabilities⁽¹⁾</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,142,120</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(84,077</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,058,043</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Less: Current portion of lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(424,260</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Non-current portion of lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">633,783</td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr> </table> 469668 453191 219261 1142120 84077 1058043 424260 633783 2243 12296 two-year 0.07 205201 1295759 three-year 0.0615 953935 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify">10.</td> <td style="text-align: justify">SEGMENT INFORMATION</td></tr> </table>   The Company reports segment information based on the management approach, which designates the internal reporting used by the Chief Operating Decision Maker ("CODM"), the Company's Chief Executive Officer and the senior management team, for making decisions and assessing performance as the source of the Company's reportable segments. The CODM allocates resources and assesses the performance of each operating segment based on potential licensing opportunities, historical and potential future product sales, operating expenses, and operating income (loss) before interest and taxes. The Company has determined its reportable segments to be 'InMed Pharma' and 'BayMedica Commercial' based on the information used by the CODM. As such, the pharmaceutical-related research and development carried out at BayMedica is included with the 'InMed Pharma' segment. Other than cash, cash equivalents and short-term investments ("Unrestricted cash") balances, the CODM does not regularly review asset information by reportable segment and, therefore, the Company does not report asset information by reportable segment. The 'InMed Pharma' segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the 'BayMedica Commercial' segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Total assets held in the 'InMed Pharma' segment as of September 30, 2024 and June 30, 2024 were $7.6 million and $9.2 million, respectively. Total assets as of September 30, 2024 and June 30, 2024, held in the 'BayMedica Commercial' segment were $2.8 million and $2.6 million, respectively. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The following table presents information about the Company's reportable segments for the three months ended September 30, 2024 and 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="22" style="text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">InMed</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">BayMedica</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">InMed</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">BayMedica</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-indent: -9pt; padding-left: 9pt">Sales</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,264,638</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">1,264,638</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">901,862</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">901,862</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Cost of sales</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(771,225</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(771,225</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(880,620</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(880,620</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development patents</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(762,874</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8,306</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(771,180</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td>

style="text-align: left"> </td><td style="text-align: right">(1,271,439</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(20,654</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,292,093</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">General and Administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,238,181</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(183,745</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,421,926</td><td style="font-weight: bold; text-align: left">)</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,063,660</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(235,071</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,298,731</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Amortization and depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(53,980</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(599</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(54,579</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(54,241</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(591</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(54,832</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Foreign exchange gain (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,310</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">19,310</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(48,457</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(48,457</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Interest and other income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">57,094</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">57,094</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">136,043</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">136,043</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net Income (Loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,978,631</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,763</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,677,868</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,301,754</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(235,074</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(2,536,828</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Cash and Cash Equivalents</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">4,346,193</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,236,846</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,583,039</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5,886,613</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">851,691</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">6,738,304</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> 7600000 9200000 2800000 2600000 The following table presents information about the Company's reportable segments for the three months ended September 30, 2024 and 2023:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="22" style="text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">InMed</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">BayMedica</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">InMed</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">BayMedica</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-indent: -9pt; padding-left: 9pt">Sales</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,264,638</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">1,264,638</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">901,862</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">901,862</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Cost of sales</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(771,225</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(771,225</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(880,620</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(880,620</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development patents</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(762,874</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8,306</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(771,180</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td

style="text-align: left"> </td><td style="text-align: right">(1,271,439</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(20,654</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,292,093</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">General and Administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,238,181</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(183,745</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,421,926</td><td style="font-weight: bold; text-align: left">)</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,063,660</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(235,071</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,298,731</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Amortization and depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(53,980</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(599</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(54,579</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(54,241</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(591</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(54,832</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Foreign exchange gain (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,310</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">19,310</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(48,457</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td> <td style="font-weight: bold; text-align: right">(48,457</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Interest and other income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">57,094</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">57,094</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">136,043</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">136,043</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net Income (Loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,978,631</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,763</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,677,868</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,301,754</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(235,074</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(2,536,820</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Cash and Cash Equivalents</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">4,346,193</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,236,846</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,583,039</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5,886,613</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">851,691</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">6,738,304</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> 1264638 1264638 901862 901862 771225 771225 880620 880620 762874 8306 771180 1271439 20654 1292093 1238181 183745 1421926 1063660 235071 1298731 53980 599 54579 54241 591 54832 19310 19310 -48457 -48457 57094 57094 136043 136043 -1978631 300763 -1677868 -2301754 -235074 -2536828 4346193 1236846 5583039 5886613 851691 6738304 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify">11.</td> <td style="text-align: justify">COMMITMENTS AND CONTINGENCIES</td></tr> </table>   Pursuant to the terms of agreements with various contract research organizations, as of September 30, 2024, the Company was committed for contract research services and materials at a cost of approximately $422,270, expected to occur in the following twelve-month period.   Pursuant to the terms of a certain Technology Assignment Agreement, dated as of May 31, 2017 (the “Technology Agreement”), between the Company and the University of British Columbia (“UBC”), the Company is committed to pay royalties to UBC on certain licensing and royalty revenues received by the Company for biosynthesis of certain drug products that are covered by the Technology Agreement. To date, no payments have been required to be made.   Pursuant to the terms of a certain Collaborative Research Agreement, dated as of December 13, 2018, between the Company and UBC, pursuant to which the Company owns all rights, title and interests in and to any intellectual property, in addition to funding research at UBC, the Company is committed to make a one-time payment upon filing of any PCT patent application arising from the research. To date, one such payment has been made to UBC.   Pursuant to the terms of a certain Contribution Agreement, dated as of November 1, 2018, between the Company and National Research Council Canada, as represented by its Industrial Research Assistance Program (NRC-IRAP), under certain circumstances contributions received, including the disposition of the underlying intellectual property developed in part with NRC-IRAP contributions, may become repayable. As of September 30, 2024, there have been no triggering events to cause a repayment.   Short-term investments include guaranteed investment certificates, with one year terms, of $43,203 and $43,064 as of September 30, 2024 and June 30, 2024, respectively, that are pledged as security for a corporate credit card.   In addition to the foregoing, the Company has entered into certain agreements in the ordinary course of operations that may include indemnification provisions, which are common in such agreements. In some cases, the maximum amount of potential future indemnification is unlimited; however, the Company currently holds commercial general liability insurance. This insurance may limit the Company’s overall liability and may enable the Company to recover a portion of any future amounts paid. Historically, the Company has not made any indemnification payments under such agreements, and it believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.   Pursuant to that certain Technology Licensing Agreement, dated as of March 11, 2021, between the Company and EyeCRO, the Company is committed to issue, subject to regulatory approval, up to 700 warrants to purchase 700 Common Shares upon the achievement of certain milestones. The exercise price of the warrants will be equal to the five-day VWAP of our Common Shares prior to each milestone achievement and the warrants will be exercisable for a period of three years from the issuance date. On May 10, 2024, the Company delivered a 90-day notice of termination to EyeCRO LLC with respect to the Technology Licensing Agreement, specifying an effective date of termination of August 8, 2024.   BayMedica entered into a patent license agreement (“Patent License Agreement”) with a third party (the “Licensor”) on February 15, 2021. The Company was required to begin making royalty payments to the Licensor based on net sales of licensed products in 2021 in order to maintain an exclusive license. In December 2021, the Company amended the Patent License Agreement, which amendment included the deferral of the 2021 minimum payments to 2022. As of June 30, 2023, the Company had paid $300,000 for the minimum payments due and payable under the

Patent License Agreement. On February 10, 2023, BayMedica received a letter from the Licensor alleging a breach of the Patent License Agreement and asserting a right to monies due thereunder. On April 6, 2023, BayMedica sent a letter to the Licensor disputing the Licensor's interpretation of the Patent License Agreement and asserted that the counterparty's only remedy under the Patent License Agreement to be either (a) the conversion of an exclusive technology license into a non-exclusive license or (b) the termination of the Patent License Agreement. On July 18, 2024, BayMedica received a letter from the Licensor alleging breach of the Patent License Agreement and asserting monies due thereunder. On August 7, 2024, BayMedica responded asserting that the counterparty's interpretation of the Patent License Agreement was again incorrect and that BayMedica, therefore, does not owe any funds under the Patent License Agreement.   To date, the Licensor has not initiated a lawsuit with respect to the foregoing matters. If a lawsuit is ultimately brought alleging a breach of the Patent License Agreement, the proceeding will be subject to final, binding and non-appealable arbitration under the Arbitration Act, 1991 (Ontario) and determined pursuant to Ontario law. BayMedica intends to vigorously defend its position. At this time, it is not possible to reasonably estimate a potential loss due to the terms of the Patent License Agreement, the nature of the legal theory advanced by the counterparty, and the ultimate outcome of any proceeding (including the interpretation by the arbitrator with respect to applicable requirements under Ontario law regarding contract formation). 422270 43203 43064 700 700 300000 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify">12.</td> <td style="text-align: justify">RELATED PARTY TRANSACTIONS</td></tr> </table>   On February 11, 2022, the Board of Directors appointed Janet Grove as a director of the Company. Ms. Grove is a Partner of Norton Rose Fulbright Canada LLP ("NRFC"). During the three months ended September 30, 2024 and 2023, NRFC and Norton Rose Fulbright U.S. LLP ("NRFUS" and together with NRFC, NRF") rendered legal services in the amount of $124,147 and $19,814, respectively, to the Company. These transactions were in the normal course of operations and were measured at the exchange amount which represented the amount of consideration established and agreed to by NRF. No legal services rendered by NRF were provided by Ms. Grove directly. 124147 19814 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"> 13.</td> <td style="text-align: justify">SUBSEQUENT EVENTS</td></tr> </table>   The Company has evaluated subsequent events through the date of the filing of this Annual Report on Form 10-K and determined that there have been no events that have occurred that would require adjustments to our disclosures in the unaudited condensed consolidated financial statements except for the matters described below.   In October 2024, the Company issued 51,019 Common Shares for gross proceeds of $365,473 pursuant to the terms of the Amended ATM Agreement.   On November 14, 2024, the Company effected a Reverse Stock Split of its Common Shares at a ratio of 20-to-1. Trading of the Common Shares on Nasdaq on a split-adjusted basis began as of November 14, 2024. As a result of the Reverse Stock Split, each 20 shares of Common Shares were combined into one Common Share, and the total number of Common Shares outstanding were reduced from approximately 14,361,550 shares to approximately 718,032 Common Shares. 365473 As a result of the Reverse Stock Split, each 20 shares of Common Shares were combined into one Common Share, and the total number of Common Shares outstanding were reduced from approximately 14,361,550 shares to approximately 718,032 Common Shares. false false false false Unlimited Unlimited false --06-30 Q1 2025 0001728328